

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
4 November 2004 (04.11.2004)


PCT

(10) International Publication Number  
WO 2004/094671 A2

- (51) International Patent Classification<sup>7</sup>: C12Q 1/68
- (21) International Application Number: PCT/US2004/012788
- (22) International Filing Date: 22 April 2004 (22.04.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/464,586 22 April 2003 (22.04.2003) US  
60/464,588 22 April 2003 (22.04.2003) US
- (71) Applicants (*for all designated States except US*): COLEY PHARMACEUTICAL GmbH [DE/DE]; Elisabeth-Selbert-Strasse 9, D-40764 Langenfeld (DE). COLEY PHARMACEUTICAL GROUP, INC. [US/US]; 93 Worcester Street, Suite 101, Wellesley, MA 02481 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): VOLLMER, Jörg [DE/DE]; Kohlrauschweg 24, D-40591 Duesseldorf (DE).
- JURK, Marion [DE/DE]; Klosterstr. 4, D-41540 Dornagel (DE). LIPFORD, Grayson, B. [GB/US]; 38 Bates Road, Watertown, MA 02472 (US). SCHETTER, Christian [DE/DE]; Oerknauhof 35, D-40723 Hilden (DE). FORSBACH, Alexandra [DE/DE]; Raiffeisenstrasse N°1, D-40764 Rantingen (DE). KRIEG, Arthur, M. [US/US]; 173 Winding River Road, Wellesley, MA 02482 (US).
- (74) Agent: TREVISAN, Maria, A.; Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA 02210 (US).
- (81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH,

[Continued on next page]

(54) Title: METHODS AND PRODUCTS FOR IDENTIFICATION AND ASSESSMENT OF TLR LIGANDS



WO 2004/094671 A2

(57) Abstract: The invention provides in part novel screening methods and compositions for identifying and distinguishing between candidate immunomodulatory compounds. The invention further provides methods for assessing biological activity of composition containing a known TLR ligand. These latter methods can be used for quality assessment and selection of various lots of test compositions, including pharmaceutical products for clinical use.



GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
(AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,  
GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG).

**Published:**

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

- 1 -

**METHODS AND PRODUCTS FOR IDENTIFICATION AND ASSESSMENT  
OF TLR LIGANDS**

**Background of the Invention**

5 Nucleic acids with immunostimulatory activity have been identified. The first recognized immunostimulatory motif was the CpG motif in which at least the C of the dinucleotide was unmethylated. It has been postulated that mammalian subjects recognize the unmethylated dinucleotide as being of bacterial origin, and thus mount a heightened immune response following exposure. The ensuing immune response includes both cell mediated and  
10 humoral aspects. Since the discovery of the CpG immunostimulatory motif, other immunostimulatory motifs have also been identified including the poly-T and T-rich motifs, the TG motif and the poly-G motif. In some instances, immunostimulation has also been observed in response to exposure to methylated CpG motifs and motif-less nucleic acids having phosphorothioate backbone linkages.

15 The responses induced by immunostimulatory nucleic acids are varied and can include production and secretion of cytokines, chemokines, and other growth factors. The nucleic acids can induce a heightened immune stimulation regardless of whether an antigen is also introduced to the subject. Identification of new motifs as well as of subtle differences between response profiles of different nucleic acids oftentimes can be laborious, and a high  
20 throughput system for screening nucleic acids for their ability to be immunostimulatory as well as to determine the profile of responses they induce would be useful.

**Summary of the Invention**

The invention provides in its broadest sense screening methods and tools for  
25 identification and discrimination of immunomodulatory molecules and assessment and standardization of samples containing known immunomodulatory molecules. The immunomodulatory molecules can be immunostimulatory or immunoinhibitory, and most preferably are Toll-like receptor (TLR) ligands.

In one aspect, the invention provides a screening method for identifying TLR agonists.  
30 The method comprises contacting a cell line endogenously expressing at least one TLR with a test compound and measuring a test level of TLR signaling activity, wherein a positive test level is indicative of a TLR agonist (i.e., an immunostimulatory compound). The positive test

- 2 -

level may be apparent without referring to a control. Preferably, however, it is determined relative to a control (i.e., the TLR signaling activity from a reference compound).

In some embodiments, the reference compound is a compound that induces no response (i.e., a zero response) or a minimal response. In this case, a test level that is greater than the reference level is indicative of a compound with TLR signaling activity. More preferably, the reference compound is a compound that induces a positive response (i.e., a non-zero response) and that is immunostimulatory. These reference compounds are referred to herein as negative and positive reference compounds, respectively. If the reference compound is immunostimulatory (i.e., a positive reference compound), a non-zero test level that is lower than the reference level is still indicative of an immunostimulatory test compound. In this latter embodiment, the test compound is less immunostimulatory than the reference compound (for that particular readout), but it is nonetheless immunostimulatory given the non-zero response induced. There may be one or more concurrent or consecutive assays with a negative reference compound, a positive reference compound, or both. The reference may also be a standard curve or data generated previously.

In a related aspect, the screening method involves exposing the same cell to a positive reference compound and a test compound in order to identify a test compound that inhibits the immunostimulatory response of the positive reference compound (i.e., a TLR antagonist or an immunoinhibitory compound).

In still a related aspect, the screening method involves exposing the same cells to a positive reference compound and a test compound in order to identify a test compound that enhances the immunostimulatory response of the positive reference compound (i.e., an enhancer).

In both of these latter aspects, the assay requires a co-incubation of the positive reference compound, the test compound and the cells. Separate assays with positive reference compound alone and optionally negative reference compound alone are usually also performed.

The positive reference compound is a known TLR ligand. Non-limiting examples include but are not limited to TLR3 ligands, TLR7 ligands, TLR8 ligands and TLR9 ligands.

In some embodiments, the positive reference compound is an immunostimulatory nucleic acid. In some embodiments, the positive reference compound is a CpG nucleic acid, a poly-T nucleic acid, a T-rich nucleic acid or a poly-G nucleic acid. Another example of a positive

- 3 -

reference compound is a nucleic acid comprising a backbone that contains at least one phosphorothioate linkage.

It has been further discovered according to the invention that the RPMI 8226 cell line expresses TLR7 and responds to the imidazoquinoline compound R-848 (Resiquimod) which 5 is known to signal through TLR7 and TLR8. Accordingly, the screening method can be performed using RPMI 8226, Raji or RAMOS cells and an imidazoquinoline compound such as R-848 or R-847 (Imiquimod) as the positive reference compound.

In one embodiment, the test compound is a nucleic acid such as but not limited to a DNA, an RNA and a DNA/RNA hybrid. The test compound may be a nucleic acid that does 10 not comprise motif selected from the group consisting of a CpG motif, a poly-T motif, a T-rich motif and a poly-G motif. The test compound may be a nucleic acid that comprises a phosphorothioate backbone linkage. In another embodiment, the test compound is a non-nucleic acid small molecule. The non-nucleic acid small molecule may be derived from a molecular library. In other embodiments, the test compound comprises amino acids, 15 carbohydrates such as polysaccharides. It may be a hormone or a lipid or contain moieties derived therefrom. In other embodiments, the test compounds are putative ligands for TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10 or TLR11.

In one embodiment, the cell is a RPMI 8226 cell, a Raji cell, a RAMOS cell, a THP-1 cells, a Nalm cell or a KG-1 cell and the TLR is TLR9. In another embodiment, the cell is a 20 RPMI 8226 cell, a Raji cell or a RAMOS cell and the TLR is TLR7. In yet another embodiment, the cell is a KG-1 cell, a Nalm cell, a Raji cell, a RAMOS cell, a Jurkat cell, a Hela cell, a Hep-2 cell, a Hep-2 cells, a A549 cell, a Bewo cell, an NK-92 cell or an NK-92 MI cell and the TLR is TLR3.

In another embodiment, the cell is an RPMI 8226 cell and the TLR is TLR7 or TLR9. 25 In still another embodiment, the cell is a Raji cell and the TLR is TLR9, TLR7 or TLR3.

Depending upon the embodiment, the TLR signaling activity may be measured or detected in a number of ways. In one embodiment, the TLR signaling activity is measured by cytokine, chemokine, or growth factor secretion. The cytokine secretion may be selected from the group consisting of IL-6 secretion, IL-10 secretion, IL-12 secretion, IFN- $\alpha$  secretion 30 and TNF- $\alpha$  secretion, but is not so limited. The chemokine secretion may be IP-10 secretion or IL-8 secretion, but is not so limited.

In another embodiment, the TLR signaling activity is measured by antibody secretion. The antibody secretion may be IgM secretion, but is not limited to this antibody subtype.

- 4 -

In another embodiment, the TLR signaling activity is measured by phosphorylation. The total level of phosphorylation in the cell or the level of phosphorylation of particular factors in the cell may be measured. These factors are preferably signaling factors and can be selected from the group consisting of IRAK, ERK, MyD88, TRAF6, p38, Jun, c-fos, and 5 subunits of NF- $\kappa$ B, but are not so limited.

In still a further embodiment, the TLR signaling activity is measured by cell surface marker expression. In one embodiment, the TLR signaling activity is measured by an increase in cell surface marker expression. Examples of cell surface markers to be analyzed include CD71, CD86, HLA-DR, CD80, HLA Class I, CD54 and CD69. In other 10 embodiments, the TLR signaling activity is measured by a decrease in cell surface marker expression. Cell surface marker expression can be determined using flow cytometry. TLR signaling activity can also be measured by protein production (e.g., by Western blot).

In another embodiment, the TLR signaling activity is measured by gene expression. Gene expression profiles may be determined using Northern blot analysis or RT-PCR that 15 uses mRNA or total RNA as a starting material. The gene expression of interest may be that of the chemokines and cytokines and cell surface molecules recited above. Gene expression analysis can be performed using microarray techniques.

In yet another embodiment, the TLR signaling activity is measured by cell proliferation. Cell proliferation assays can be measured in a number of ways including but 20 not limited to  $^3$ H-thymidine incorporation.

In one embodiment, the cell is an RPMI 8226 cell and TLR signaling is indicated by expression of a marker such as CD71, CD86 and/or HLA-DR or by expression, production or secretion of a factor such as IL-8, IL-10, IP-10 and/or TNF- $\alpha$ . Preferably, in this latter embodiment, the RPMI 8226 cell is unmodified. In another embodiment, the cell is a Raji 25 cell and the TLR signaling is indicated by IL-6 or IFN- $\alpha$ 2 expression, production or secretion. In yet another embodiment, the cell is a RAMOS cell and the TLR signaling is indicated by CD80 cell surface expression.

TLR signaling activity can be measured via a native readout or an artificial readout or both. A native readout is one that does not rely on introduction of a reporter construct into the 30 cell of interest.

The cell line may be used in a modified or unmodified form. In one embodiment, the cell line is transfected with a reporter construct. The transfection may be transient or stable. The reporter construct generally comprises a promoter, a coding sequence and a

- 5 -

polyadenylation signal. The coding sequence may comprise a reporter sequence selected from the group consisting of an enzyme (e.g., luciferase, alkaline phosphatase,  $\beta$ -galactosidase, chloramphenicol acetyltransferase (CAT), secreted alkaline phosphatase, etc.), a bioluminescence marker (e.g., green fluorescent protein (GFP, U.S. Patent No. 5,491,084), etc.), a surface-expressed molecule (e.g., CD25), a secreted molecule (e.g., IL-8, IL-12 p40, TNF- $\alpha$ , etc.), and other detectable protein sequences known to those of skill in the art. 5 Preferably, the coding sequence encodes a protein, the level or activity of which can be quantified, with preferably a wide linear range.

In some embodiments, the promoter is a promoter that is responsive to TLR signaling pathways (i.e., a "TLR responsive promoter"). In some embodiments, the promoter contains a binding site for a transcription factor activated upon CpG nucleic acid exposure, such as for example NF- $\kappa$ B. In other embodiments, the promoter contains a binding site for a transcription factor that is activated by a positive reference compound other than CpG nucleic acids. The transcription factor binding site may be selected from the group consisting of a 10 NF- $\kappa$ B binding site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an 15 SRF binding site, and a TARE, as well as others known to those of skill in the art.

In another embodiment, the promoter contains a functional promoter element from an IL-1 gene, an IL-6 gene, an IL-8 gene, an IL-10 gene, an IL-12 p40 gene, an IFN- $\alpha$ 1 gene, an 20 IFN- $\alpha$ 4 gene, an IFN- $\beta$  gene, an IFN- $\gamma$  gene, a TNF- $\alpha$  gene, a TNF- $\beta$  gene, an IP-9 gene, an IP-10 gene, a RANTES gene, an ITAC gene, a MCP-1 gene, an IGFBP4 gene, a CD54 gene, a CD69 gene, a CD71 gene, a CD80 gene, a CD86 gene, a HLA-DR gene, and a HLA class I gene.

The TLR responsive promoter may be a TLR1 responsive promoter, a TLR2 25 responsive promoter, a TLR3 responsive promoter, a TLR4 responsive promoter, a TLR5 responsive promoter, a TLR6 responsive promoter, a TLR7 responsive promoter, a TLR8 responsive promoter, a TLR9 responsive promoter, a TLR10 responsive promoter or a TLR11 responsive promoter.

In these latter embodiments, the cell line may be transfected with a reporter construct 30 having a promoter derived from a particular cytokine, chemokine, or cell surface marker, and a unique reporter coding sequence conjugated thereto. In this way, the readout from a particular reporter construct is a surrogate readout for cytokine, chemokine, or cell surface marker readout. Measuring readout from the reporter coding sequences described herein is in

- 6 -

some instances easier than measuring cytokine or chemokine secretion, or upregulation of a cell surface marker.

In these latter embodiments, the cell line may be transfected with a number of reporter constructs each having a promoter derived from a particular cytokine, chemokine, or cell 5 surface marker, and a unique distinguishable coding sequence conjugated thereto. In these embodiments, multiple readouts are possible from one screen. In other embodiments, multiple native readouts are also possible from one screen.

In a related embodiment, the cell may be further transfected with a nucleic acid that codes for a TLR polypeptide or a fragment thereof. Preferably, the TLR is one that is not 10 endogenously expressed by the cell. As an example, if the cell is an RPMI 8226 cell which has been shown to express TLR7 and TLR9 according to the invention, then it may be modified to express TLRs other than these (e.g., TLR8) in some embodiments. In this aspect, the RPMI 8226 cell is responsive to TLR8 ligands. In preferred embodiments, the TLR is a human TLR (i.e., hTLR).

15 In another aspect, the invention provides an RPMI 8226 cell transfected with a TLR nucleic acid. In still another embodiment, the TLR nucleic acid is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR8, TLR10 and TLR11. The encoded TLRs nucleic acids can derive from human or non-human sources. Examples of 20 non-human sources include, but are not limited to, murine, bovine, canine, feline, ovine, porcine, and equine species. Other species include chicken and fish, e.g., aquaculture species. The TLR nucleic acids can also include chimeric sequences consisting of domains originating from different species. In preferred embodiments, the TLR is a human TLR.

25 In still another aspect, the invention provides kits including the cells lines (e.g., the RPMI 8226 cell line), the reporter constructs and/or expression constructs described above, and instructions for use.

Other aspects of the invention provide methods for analyzing the biological activity of individual lots of material containing previously identified specific TLR ligands (i.e., specific 30 compounds which are ligands for a particular TLR) intended for use as, or for use in the preparation of, pharmaceutical compositions. The methods permit a qualitative and, importantly, a quantitative assessment of biological activity of individual lots of TLR ligands, pre-formulation as well as post-formulation. Such methods are useful in the manufacture and validation of pharmaceutical compositions containing, as an active agent, at least one specific ligand of at least one specific TLR. The specific TLR can be any known TLR, including

- 7 -

without limitation TLR3, TLR7, TLR8 and TLR9. The specific TLR ligand is an isolated TLR ligand, either found in nature or synthetic (not found in nature), including in particular certain nucleic acid molecules and small molecules. Nucleic acid molecules that are specific TLR ligands include synthetic and naturally-occurring oligonucleotides having specific base sequence motifs. Furthermore, specific TLR ligands include both agonists and antagonists of specific TLR.

These methods are to be distinguished from test procedures and acceptance criteria for new drug substances and new drug products which are classified as chemical substances. Unlike the afore-mentioned test procedures and acceptance criteria, the methods of the instant invention deal specifically with characterizing drug substances and drug products which are classified as oligonucleotides. Oligonucleotides are explicitly excluded in ICH Topic Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances, Step 4 – Consensus Guideline: 6 October 1999, § 1.3.

Further still, the methods of the instant invention are to be distinguished from test procedures and acceptance criteria for biotechnological/biological products. Unlike the afore-mentioned test procedures and acceptance criteria, the methods of the invention deal specifically with characterizing biotechnological/biological products which are classified as DNA products. DNA products are explicitly excluded in ICH Harmonised Tripartite Guideline Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products, Step 4 – 10 March 1999, § 1.3.

In one aspect, the invention provides a method for quality assessment of a test composition containing a known TLR ligand. The method according to this aspect of the invention involves measuring a reference activity of a reference composition comprising a known TLR ligand, wherein the known TLR ligand is a nucleic acid molecule; measuring a test activity of a test composition comprising the known TLR ligand; and comparing the test activity to the reference activity. In one embodiment the method further involves the step of selecting the test composition if the test activity falls within a predetermined range of variance about the reference activity.

In one embodiment, the reference composition is a first production lot of a pharmaceutical composition comprising the known TLR ligand, and the test composition is a second production lot of a pharmaceutical composition comprising the known TLR ligand. This embodiment is particularly useful as a method for developing and applying acceptance criteria for finished pharmaceutical products containing a known TLR ligand.

- 8 -

In another embodiment, the reference composition is a first in-process lot of a composition comprising the known TLR ligand, and the test composition is a second in-process lot of a composition comprising the known TLR ligand. This embodiment is particularly useful as a method for developing and applying acceptance criteria for raw  
5 materials and/or other in-process materials containing a known TLR ligand bound for use in a pharmaceutical product.

In one embodiment according to this aspect of the invention, measuring the reference activity involves contacting the reference composition with an isolated cell expressing a TLR responsive to the known TLR ligand, and measuring the test activity involves contacting the  
10 test composition with the isolated cell expressing the TLR responsive to the known TLR ligand. Further, in one embodiment the isolated cell expressing the TLR responsive to the known TLR ligand includes an expression vector for the TLR responsive to the known TLR ligand. Such expression vector, and likewise for any expression vector according to the instant invention, can be introduced into the cell using any suitable method.

15 In one embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand naturally expresses the TLR responsive to the known TLR ligand. Such a cell can be naturally occurring or it can be a cell line, provided the cell does not include an expression vector introduced into the cell for the purpose of artificially inducing the cell to express or overexpress the TLR.

20 In one particular embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand is RPMI 8226. In another embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand is Raji, RAMOS, Nalm, THP-1 or KG-1 and the TLR is TLR9. In another embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand is RPMI 8226, Raji or RAMOS and the TLR is TLR7. In yet another  
25 embodiment, the isolated cell expressing the TLR responsive to the known TLR ligand is a KG-1 cell, a Nalm cell, a Raji cell, a RAMOS cell, a Jurkat cell, a Hela cell, a Hep-2 cell, a Hep-2 cells, a A549 cell, a Bewo cell, an NK-92 cell or an NK-92 MI cell and the TLR is TLR3.

Further according to this aspect of the invention, in one embodiment measuring the  
30 reference activity and measuring the test activity each comprises measuring signaling activity mediated by a TLR responsive to the known TLR ligand. As described in greater detail elsewhere herein, TLR signaling involves a series of intracellular signaling events. These signaling events give rise to various downstream products, including certain transcription

factors (e.g., NF- $\kappa$ B and AP-1), cytokines, chemokines, etc., which can affect the activity of certain gene promoters. For example, in one embodiment the signaling activity is activity of a reporter gene or reporter construct under the control of a NF- $\kappa$ B response element.

In other embodiments, the signaling activity is activity of a reporter gene or reporter construct under the control of an interferon-stimulated response element (ISRE); an IFN- $\alpha$  promoter; an IFN- $\beta$  promoter; an IL-6 promoter; an IL-8 promoter; an IL-12 p40 promoter; a RANTES promoter; an IL-10 promoter or an IP-10 promoter.

In one embodiment, the known TLR ligand is an immunostimulatory nucleic acid. An immunostimulatory nucleic acid can include, without limitation, a CpG nucleic acid. In another embodiment, the known TLR ligand is an immunoinhibitory nucleic acid. When the known TLR ligand is a TLR antagonist (e.g., an immunoinhibitory oligonucleotide), the method according to this aspect of the invention can further involve measuring the reference activity of the reference composition and measuring the test activity of the test composition, each performed in the presence of a known immunostimulatory TLR ligand.

In various embodiments, the known TLR ligand is a ligand for a particular TLR. Thus in one embodiment the known TLR ligand is a TLR9 ligand. More specifically, in one embodiment the known TLR ligand is a CpG nucleic acid.

In one embodiment, the known TLR ligand is a TLR3 ligand. Such a ligand can include, for example, a double-stranded RNA or a homolog thereof.

In one embodiment, the known TLR ligand is a TLR7 ligand. In one embodiment the known TLR ligand is a TLR8 ligand.

The invention provides in another aspect a method for quality assessment of a test lot of a pharmaceutical product containing a known TLR9 ligand. The method according to this aspect of the invention involves measuring a reference activity of a reference lot of a pharmaceutical product comprising a known TLR9 ligand, wherein the known TLR9 ligand is a nucleic acid molecule; measuring a test activity of a test lot of a pharmaceutical product comprising the known TLR9 ligand; comparing the test activity to the reference activity; and rejecting the test lot if the test activity falls outside of a predetermined range of variance about the reference activity.

In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TGT CGT TTT GTC GTT-3' (SEQ ID NO:1).

- 10 -

In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TGA CGT TTT GTC GTT-3' (SEQ ID NO:139).

5 In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TGT CGT TTT TTT CGA-3' (SEQ ID NO:140).

In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT CGT CGT TTC GTC GTT-3' (SEQ ID NO:141).

10 In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT CGT CGT TTT GTC GTT-3' (SEQ ID NO:142).

15 In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TTC GGT CGT TTT-3' (SEQ ID NO:143).

In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TTC GTG CGT TTT T-3' (SEQ ID NO:144).

20 In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TCG TTT TCG GCG GCC GCC G-3' (SEQ ID NO:145).

25 In one embodiment according to this aspect of the invention, the known TLR9 ligand is an oligonucleotide having a base sequence provided by 5'-TCG TC\_G TTT TAC\_GGC GCC\_GTG CCG-3' (SEQ ID NO:146), wherein every internucleoside linkage is phosphorothioate except for those indicated by “\_”, which are phosphodiester.

Each of the limitations of the invention can encompass various embodiments of the invention. It is, therefore, anticipated that each of the limitations of the invention involving any one element or combinations of elements can be included in each aspect of the invention.

30

**Brief Description of the Figures**

- 11 -

Fig. 1 is a bar graph showing cell surface expression of various markers by RPMI 8226 24 hours and 48 hours following stimulation with CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), LPS and IL-1.

5 Fig. 2 is a bar graph showing IL-8 production by RPMI 8226 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), R-848 and LPS.

Fig. 3 is a bar graph showing IL-6 production by RPMI 8226 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), R-848 and LPS.

10 Fig. 4 is a bar graph showing IP-10 production by RPMI 8226 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), R-848 and LPS.

15 Fig. 5 is a bar graph showing IL-10 production by RPMI 8226 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1), non-CpG nucleic acid (SEQ ID NO: 2), R-848 and LPS.

Fig. 6 is a dose response curve showing fold induction of IL-8 production 24 hours after exposure to CpG nucleic acid (SEQ ID NO: 1) and non-CpG nucleic acid (SEQ ID NO: 2). The EC<sub>50</sub> for CpG nucleic acid is 19 nM and the EC<sub>50</sub> for non-CpG nucleic acid is 263 nM.

20 Fig. 7 is a bar graph showing NF-κB activation in RPMI 8226 transfected transiently with a NF-κB-luciferase reporter gene construct as a function of cell density and nucleic acid amount transfected, following exposure to CpG nucleic acid (SEQ ID NO: 1), LPS and TNF-α. NF-κB activation is measured by luciferase activity.

25 Fig. 8 is a bar graph showing RT-PCR results from RNA isolated from RPMI 8226 using gene specific primers for TLR7, TLR8 and TLR9 genes.

Fig. 9 is a dose response curve showing IP-10 production induced by SEQ ID NO: 1, and inhibition thereof in the presence of SEQ ID NO: 151, a immunoinhibitory nucleic acid.

Fig. 10 is a bar graph showing the results of a TLR9 RT-PCR analysis of a number of cell lines.

30 Fig. 11 is a bar graph showing the results of a TLR7 RT-PCR analysis of a number of cell lines.

Fig. 12 is a bar graph showing the results of a TLR3 RT-PCR analysis of a number of cell lines.

- 12 -

Fig. 13 is a bar graph showing the results of a TLR3, TLR7, TLR8 and TLR9 RT-PCR analysis of the Raji cell line.

Fig. 14 is a graph showing IL-6 production by the Raji cell line upon stimulation with various ODN (SEQ ID NO:1; SEQ ID NO:154; SEQ ID NO:158; SEQ ID NO:160; SEQ ID NO:159; SEQ ID NO:161).

Fig. 15 is a bar graph showing IL-6 production of the Raji cell line upon stimulation with poly I:C and R-848.

Fig. 16 is a bar graph showing IFN- $\alpha$ 2 production by the Raji cell line upon stimulation with CpG ODN (SEQ ID NO: 1), R-848 and poly I:C.

10 Fig. 17 is a bar graph showing CD80 expression (by flow cytometry) by the RAMOS cell line upon stimulation with CpG ODN (SEQ ID NO: 1) and non-CpG ODN (SEQ ID NO: 2).

15 Fig. 18A is a bar graph showing the induction of NF- $\kappa$ B by 293 fibroblast cells transfected with human TLR9 in response to exposure to various stimuli, including CpG-ODN, GpC-ODN, LPS, and medium.

Fig. 18B is a bar graph showing the amount of IL-8 produced by 293 fibroblast cells transfected with human TLR9 in response to exposure to various stimuli, including CpG-ODN, GpC-ODN, LPS, and medium.

20 Fig. 19 is a bar graph showing the induction of NF- $\kappa$ B-luc produced by stably transfected 293-mTLR9 cells in response to exposure to various stimuli, including CpG-ODN, methylated CpG-ODN (Me-CpG-ODN), GpC-ODN, LPS and medium.

Fig. 20 is a bar graph showing the induction of NF- $\kappa$ B-luc produced by stably transfected 293-hTLR9 cells in response to exposure to various stimuli, including CpG-ODN, methylated CpG-ODN (Me-CpG-ODN), GpC-ODN, LPS and medium.

25 Fig. 21 is a series of gel images depicting the results of reverse transcriptase-polymerase chain reaction (RT-PCR) assays for murine TLR9 (mTLR9), human TLR9 (hTLR9), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) in untransfected control 293 cells, 293 cells transfected with mTLR9 (293-mTLR9), and 293 cells transfected with hTLR9 (293-hTLR9).

30

It is to be understood that the Figures are not required for enablement of the invention.

#### Brief Description of Sequences

- 13 -

SEQ ID NO:1 is the nucleotide sequence of an immunostimulatory nucleic acid (TLR9 ligand).

SEQ ID NO:2 is the nucleotide sequence of a non-CpG nucleic acid.

SEQ ID NO:3 is the nucleotide sequence of human TLR2 cDNA (U88878).

5 SEQ ID NO:4 is the amino acid sequence of human TLR2 protein (AAC34133).

SEQ ID NO:5 is the nucleotide sequence of murine TLR2 cDNA (AF165189).

SEQ ID NO:6 is the amino acid sequence of murine TLR2 protein (NP\_036035).

SEQ ID NO:7 is the nucleotide sequence of human TLR3 cDNA (NM\_003265).

SEQ ID NO:8 is the amino acid sequence of human TLR3 protein (NP\_003256).

10 SEQ ID NO:9 is the nucleotide sequence of murine TLR3 cDNA (AF355152).

SEQ ID NO:10 is the amino acid sequence of murine TLR3 protein (AAK26117).

SEQ ID NO:11 is the nucleotide sequence of human TLR4 cDNA (U88880).

SEQ ID NO:12 is the nucleotide sequence of human TLR4 cDNA transcript variant 4 (NM\_138557).

15 SEQ ID NO:13 is the nucleotide sequence of human TLR4 cDNA transcript variant 2 (NM\_138556).

SEQ ID NO:14 is the nucleotide sequence of human TLR4 cDNA transcript variant 1 (NM\_138554).

20 SEQ ID NO:15 is the nucleotide sequence of human TLR4 cDNA transcript variant 3 (NM\_003266).

SEQ ID NO:16 is the amino acid sequence of human TLR4 protein isoform A (NP\_612564).

SEQ ID NO:17 is the amino acid sequence of human TLR4 protein isoform B (NP\_612566).

25 SEQ ID NO:18 is the amino acid sequence of human TLR4 protein isoform C (NP\_003257).

SEQ ID NO:19 is the amino acid sequence of human TLR4 protein isoform D (NP\_612567).

SEQ ID NO:20 is the nucleotide sequence of murine TLR4 cDNA (NM\_021297).

30 SEQ ID NO:21 is the nucleotide sequence of murine TLR4 mRNA (AF185285).

SEQ ID NO:22 is the nucleotide sequence of murine TLR4 mRNA (AF110133).

SEQ ID NO:23 is the amino acid sequence of murine TLR4 protein (AAD29272).

SEQ ID NO:24 is the amino acid sequence of murine TLR4 protein (AAF04278).

- 14 -

SEQ ID NO:25 is the nucleotide sequence of human TLR5 cDNA (AB060695).  
SEQ ID NO:26 is the amino acid sequence of human TLR5 protein (BAB43558).  
SEQ ID NO:27 is the amino acid sequence of human TLR5 protein (O60602).  
SEQ ID NO:28 is the amino acid sequence of human TLR5 protein (AAC34136).  
5 SEQ ID NO:29 is the nucleotide sequence of murine TLR5 cDNA (AF186107).  
SEQ ID NO:30 is the amino acid sequence of murine TLR5 protein (AAF65625).  
SEQ ID NO:31 is the nucleotide sequence of human TLR7 cDNA (AF240467).  
SEQ ID NO:32 is the nucleotide sequence of human TLR7 cDNA (AF245702).  
SEQ ID NO:33 is the nucleotide sequence of human TLR7 cDNA (NM\_016562).  
10 SEQ ID NO:34 is the amino acid sequence of human TLR7 protein (AAF60188).  
SEQ ID NO:35 is the amino acid sequence of human TLR7 protein (AAF78035).  
SEQ ID NO:36 is the amino acid sequence of human TLR7 protein (NP\_057646).  
SEQ ID NO:37 is the amino acid sequence of human TLR7 protein (Q9NYK1).  
SEQ ID NO:38 is the nucleotide sequence of murine TLR7 cDNA (AY035889).  
15 SEQ ID NO:39 is the nucleotide sequence of murine TLR7 splice variant  
(NM\_133211).  
SEQ ID NO:40 is the nucleotide sequence of murine TLR7 splice variant (AF334942).  
SEQ ID NO:41 is the amino acid sequence of murine TLR7 protein (AAK62676).  
SEQ ID NO:42 is the amino acid sequence of murine TLR7 protein (AAL73191).  
20 SEQ ID NO:43 is the amino acid sequence of murine TLR7 protein (AAL73192).  
SEQ ID NO:44 is the amino acid sequence of murine TLR7 protein (NP\_573474).  
SEQ ID NO:45 is the amino acid sequence of murine TLR7 protein (P58681).  
SEQ ID NO:46 is the nucleotide sequence of human TLR8 cDNA (AF245703).  
SEQ ID NO:47 is the nucleotide sequence of human TLR8 cDNA (AF246971).  
25 SEQ ID NO:48 is the nucleotide sequence of human TLR8 cDNA (NM\_138636).  
SEQ ID NO:49 is the nucleotide sequence of human TLR8 cDNA (NM\_016610).  
SEQ ID NO:50 is the amino acid sequence of human TLR8 protein (AAF78036).  
SEQ ID NO:51 is the amino acid sequence of human TLR8 protein (AAF64061).  
SEQ ID NO:52 is the amino acid sequence of human TLR8 protein (Q9NR97).  
30 SEQ ID NO:53 is the amino acid sequence of human TLR8 protein (NP\_619542).  
SEQ ID NO:54 is the amino acid sequence of human TLR8 protein (NP\_057694).  
SEQ ID NO:55 is the nucleotide sequence of murine TLR8 cDNA (AY035890).  
SEQ ID NO:56 is the nucleotide sequence of murine TLR8 cDNA (NM\_133212).

- 15 -

SEQ ID NO:57 is the amino acid sequence of murine TLR8 protein (AAK62677).  
SEQ ID NO:58 is the amino acid sequence of murine TLR8 protein (NP\_573475).  
SEQ ID NO:59 is the amino acid sequence of murine TLR8 protein (P58682).  
SEQ ID NO:60 is the nucleotide sequence of human TLR9 cDNA (AF245704).  
5 SEQ ID NO:61 is the nucleotide sequence of human TLR9 cDNA (AB045180).  
SEQ ID NO:62 is the amino acid sequence of human TLR9 protein (AAF78037).  
SEQ ID NO:63 is the amino acid sequence of human TLR9 protein (AAF72189).  
SEQ ID NO:64 is the amino acid sequence of human TLR9 protein (AAG01734).  
SEQ ID NO:65 is the amino acid sequence of human TLR9 protein (AAG01735).  
10 SEQ ID NO:66 is the amino acid sequence of human TLR9 protein (AAG01736).  
SEQ ID NO:67 is the amino acid sequence of human TLR9 protein (BAB19259).  
SEQ ID NO:68 is the nucleotide sequence of murine TLR9 cDNA (AF348140).  
SEQ ID NO:69 is the nucleotide sequence of murine TLR9 cDNA (AB045181).  
SEQ ID NO:70 is the nucleotide sequence of murine TLR9 cDNA (AF314224).  
15 SEQ ID NO:71 is the nucleotide sequence of murine TLR9 cDNA (NM\_031178).  
SEQ ID NO:72 is the amino acid sequence of murine TLR9 protein (AAK29625).  
SEQ ID NO:73 is the amino acid sequence of murine TLR9 protein (AAK28488).  
SEQ ID NO:74 is the amino acid sequence of murine TLR9 protein (BAB19260).  
SEQ ID NO:75 is the amino acid sequence of murine TLR9 protein (NP\_112455).  
20 SEQ ID NO:76 is the nucleotide sequence of human TLR10 cDNA (AF296673).  
SEQ ID NO:77 is the amino acid sequence of human TLR10 protein (AAK26744).  
SEQ ID NO:78 is the nucleotide sequence of human TLR6 cDNA (AB020807).  
SEQ ID NO:79 is the nucleotide sequence of human TLR6 mRNA (NM\_006068).  
SEQ ID NO:80 is the amino acid sequence of human TLR6 protein (BAA78631).  
25 SEQ ID NO:81 is the amino acid sequence of human TLR6 protein (NP\_006059).  
SEQ ID NO:82 is the amino acid sequence of human TLR6 protein (Q9Y2C9).  
SEQ ID NO:83 is the nucleotide sequence of murine TLR6 cDNA (AB020808).  
SEQ ID NO:84 is the nucleotide sequence of murine TLR6 cDNA (NM\_011604).  
SEQ ID NO:85 is the nucleotide sequence of murine TLR6 cDNA (AF314636).  
30 SEQ ID NO:86 is the amino acid sequence of murine TLR6 protein (BAA78632).  
SEQ ID NO:87 is the amino acid sequence of murine TLR6 protein (AAG38563).  
SEQ ID NO:88 is the amino acid sequence of murine TLR6 protein (NP\_035734).  
SEQ ID NO:89 is the amino acid sequence of murine TLR6 protein (Q9EPW9).

- 16 -

SEQ ID NO:90 is the nucleotide sequence of a consensus sequence for NF- $\kappa$ B p50 subunit.

SEQ ID NO:91 is the nucleotide sequence of a consensus sequence for NF- $\kappa$ B p65 subunit.

5 SEQ ID NO:92 is the nucleotide sequence of an example of an NF- $\kappa$ B p65 subunit binding site.

SEQ ID NO:93 is the nucleotide sequence of an example of a murine CREB binding site.

10 SEQ ID NO:94 is the nucleotide sequence of an example of a murine AP-1 binding site.

SEQ ID NO:95 is the nucleotide sequence of an example of a murine AP-1 binding site.

SEQ ID NO:96 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:97 is the nucleotide sequence of an example of an ISRE.

15 SEQ ID NO:98 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:99 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:100 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:101 is the nucleotide sequence of an example of an ISRE.

SEQ ID NO:102 is the nucleotide sequence of an example of an ISRE.

20 SEQ ID NO:103 is the nucleotide sequence of an example of an SRE.

SEQ ID NO:104 is the nucleotide sequence of an example of an SRE.

SEQ ID NO:105 is the nucleotide sequence of an example of an SRE.

SEQ ID NO:106 is the nucleotide sequence of an example of an NFAT binding site.

SEQ ID NO:107 is the nucleotide sequence of an example of an NFAT binding site.

25 SEQ ID NO:108 is the nucleotide sequence of an example of an NFAT binding site.

SEQ ID NO:109 is the nucleotide sequence of an example of an NFAT binding site.

SEQ ID NO:110 is the nucleotide sequence of an example of a GAS.

SEQ ID NO:111 is the nucleotide sequence of a p53 binding site consensus sequence.

SEQ ID NO:112 is the nucleotide sequence of an example of a p53 binding site.

30 SEQ ID NO:113 is the nucleotide sequence of an example of a p53 binding site.

SEQ ID NO:114 is the nucleotide sequence of an example of a p53 binding site.

SEQ ID NO:115 is the nucleotide sequence of an example of a p53 binding site.

SEQ ID NO:116 is the nucleotide sequence of an example of a p53 binding site.

- 17 -

SEQ ID NO:117 is the nucleotide sequence of an example of a p53 binding site.

SEQ ID NO:118 is the nucleotide sequence of an example of a TARE (TNF- $\alpha$  response element).

SEQ ID NO:119 is the nucleotide sequence of an example of an SRF binding site.

5 SEQ ID NO:120 is the nucleotide sequence of an example of an SRF binding site.

SEQ ID NO:121 is the nucleotide sequence of the -620 to +50 promoter region of IFN- $\alpha$ 4.

SEQ ID NO:122 is the nucleotide sequence of the -140 to +9 promoter region of IFN- $\alpha$ 1.

10 SEQ ID NO:123 is the nucleotide sequence of the -140 to +9 promoter region of IFN- $\alpha$ 1 (point mutation, AL353732).

SEQ ID NO:124 is the nucleotide sequence of the -280 to +20 promoter region of IFN- $\beta$ .

15 SEQ ID NO:125 is the nucleotide sequence of the -397 to +5 promoter region of human RANTES (AB023652).

SEQ ID NO:126 is the nucleotide sequence of the -751 to +30 promoter region of human IL-12 p40.

SEQ ID NO:127 is the nucleotide sequence of the -250 to +30 promoter region of human IL-12 p40.

20 SEQ ID NO:128 is the nucleotide sequence of the -288 to +7 promoter region of human IL-6.

SEQ ID NO:129 is the nucleotide sequence of the IL-6 gene promoter from -1174 to +7 (M22111).

25 SEQ ID NO:130 is the nucleotide sequence of the -734 to +44 promoter region derived from human IL-8.

SEQ ID NO:131 is the nucleotide sequence of the -162 to 44 promoter region of human IL-8.

SEQ ID NO:132 is the nucleotide sequence of the -615 to +30 promoter region of human TNF- $\alpha$ .

30 SEQ ID NO:133 is the nucleotide sequence of a promoter region of human TNF- $\beta$ .

SEQ ID NO:134 is the nucleotide sequence of the -875 to +97 promoter region of human IP-10.

- 18 -

SEQ ID NO:135 is the nucleotide sequence of the -219 to +114 promoter region of human CXCL11 (IP-9).

SEQ ID NO:136 is the nucleotide sequence of the full length promoter region of human CXCL11 (IP-9).

5 SEQ ID NO:137 is the nucleotide sequence of the -289 to +217 promoter region of IGFBP4 (Insulin growth factor binding protein 4).

SEQ ID NO:138 is the nucleotide sequence of the full length promoter region of IGFBP4.

10 SEQ ID NO:139 is the nucleotide sequence of an immunostimulatory nucleic acid.

SEQ ID NO:140 is the nucleotide sequence of an immunostimulatory nucleic acid.

SEQ ID NO:141 is the nucleotide sequence of an immunostimulatory nucleic acid.

SEQ ID NO:142 is the nucleotide sequence of an immunostimulatory nucleic acid.

SEQ ID NO:143 is the nucleotide sequence of an immunostimulatory nucleic acid.

SEQ ID NO:144 is the nucleotide sequence of an immunostimulatory nucleic acid.

15 SEQ ID NO:145 is the nucleotide sequence of an immunostimulatory nucleic acid.

SEQ ID NO:146 is the nucleotide sequence of an immunostimulatory nucleic acid.

SEQ ID NO:147 is the nucleotide sequence of an immunostimulatory methylated CpG nucleic acid.

20 SEQ ID NO:148 is the nucleotide sequence of an immunostimulatory methylated CpG nucleic acid.

SEQ ID NO:149 is the nucleotide sequence of an immunostimulatory methylated CpG nucleic acid.

, SEQ ID NO:150 is the nucleotide sequence of an immunostimulatory methylated CpG nucleic acid.

25 SEQ ID NO:151 is the nucleotide sequence of an immunoinhibitory nucleic acid.

SEQ ID NO:152 is the nucleotide sequence of a sense primer for human TLR3.

SEQ ID NO:153 is the nucleotide sequence of an antisense primer for human TLR3.

SEQ ID NO:154 is the nucleotide sequence of a GpC nucleic acid.

SEQ ID NO:155 is the nucleotide sequence of a CpG ODN.

30 SEQ ID NO:156 is the nucleotide sequence of a GpC ODN.

SEQ ID NO:157 is the nucleotide sequence of a Me-CpG ODN.

SEQ ID NO:158 is the nucleotide sequence of a TLR9 ligand.

SEQ ID NO:159 is the nucleotide sequence of a TLR9 ligand.

- 19 -

SEQ ID NO:160 is the nucleotide sequence of a TLR9 ligand.

SEQ ID NO:161 is the nucleotide sequence of a TLR9 ligand.

#### Detailed Description of the Invention

5       In its broadest sense, the invention relates to screening methods and tools to be used to identify and discriminate between newly discovered immunomodulatory molecules and to compare and standardize compositions of known immunomodulatory molecules. The immunomodulatory molecules are preferably TLR ligands.

Thus, the invention is based in part on the discovery that cell lines expressing  
10 endogenous TLR respond to TLR ligands in a manner similar to the response of peripheral blood mononuclear cells (PBMC). PBMC respond to immunomodulatory TLR ligands by modulating one or more parameters including gene expression, cell surface marker expression, cytokine and/or chemokine production and secretion, cell cycle status, phosphorylation status, and the like. TLR ligands can be categorized and distinguished based  
15 on the cellular changes they induce (i.e., their induction profiles). The ability of a TLR ligand to provide therapeutic or prophylactic benefit to a subject depends on its induction profile. The ability to screen new TLR ligands for a panel of response indicators or parameters allows for rapid discrimination and categorization of TLR ligands. Moreover, the similarity between the cell line responses and those observed after in vivo administration of the TLR ligand  
20 indicates that the cell lines are suitable predictors of in vivo activity. The use of in vitro propagated cell lines additionally overcomes the variability encountered when using freshly isolated PBMC.

The TLR ligands identified according to the invention therefore can be used therapeutically or prophylactically in a more patient- or disorder-specific manner. The  
25 invention allows for the tailoring of TLR ligands for particular patients or disorders.

The invention identifies a number of cell lines that can be used to identify TLR ligands based on endogenous TLR expression such as TLR3, TLR7 and TLR9 expression. As an example, the invention is premised in part on the discovery of TLR9 expression in a number of cell lines including RPMI 8226, Raji, RAMOS, THP-1, Nalm-6 and KG-1. Cell lines  
30 RPMI 8226, Raji and RAMOS have been determined to express TLR7 according to the invention. Cell lines KG-1 cell, a Nalm cell, a Raji cell, a RAMOS cell, a Jurkat cell, a Hela cell, a Hep-2 cell, a Hep-2 cells, a A549 cell, a Bewo cell, an NK-92 cell or an NK-92 MI cell have been discovered to express TLR3 according to the invention.

It is further premised in part on the discovery that RPMI 8226 cells respond to the imidazoquinoline compound R-848. Consistent with this latter finding, it was also discovered  
5 that RPMI 8226 cells express TLR7.

The invention in other aspects provides for screening methods and tools for verifying and standardizing compositions containing known TLR ligands. These compositions may be for example commercial production lots to be used in a clinical setting. Accordingly, the invention provides methods for standardizing lots of known TLR ligands prior to distribution  
10 and use clinically. In this way, production processes can be observed and controlled and substandard production lots can be identified and eliminated prior to shipment.

The methods of the instant invention can be used at any step in the preparation and production of clinical material, i.e., pharmaceutical product. In particular, the methods will find use in characterizing or validating raw materials, in-process materials, finished product  
15 materials (e.g., pre-release materials), and post-production materials (e.g., post-release materials). The methods can also be used to validate existing process methods, as well as to validate new or changed process methods used in the production of the pharmaceutical product.

20 Screening Assays Generally

The screening assays provided herein may be used to identify immunomodulatory agents. Immunomodulatory agents are agents that either stimulate or inhibit immune responses in a subject. Accordingly, as used herein, immunomodulation embraces both immunostimulation and immunoinhibition.

25 The screening methods are used to identify TLR agonists and antagonists. The methods can also be used to identify compounds that enhance the immunostimulation induced by a TLR agonist. This latter set of compounds is referred to herein as "enhancers". A TLR agonist is a compound that stimulates TLR signaling activity. A TLR antagonist is a compound that inhibits TLR signaling activity. Agonists are generally referred to herein as  
30 immunostimulatory compounds because stimulation of TLR is associated with immune stimulation. Antagonists are generally referred to herein as immunoinhibitory compounds because inhibition of TLR is associated with immune inhibition. TLR antagonists include compounds that reduce (or eliminate completely) the immunostimulation induced by a TLR

agonist. In some embodiments, the agonists, antagonists and enhancers are TLR ligands (i.e., they bind to a TLR). In other embodiments, the test compounds with agonist, antagonist or enhancer activity may act downstream or upstream of the TLR-TLR ligand interaction.

An "immunostimulatory compound" as used herein refers to a natural or synthetic compound that characteristically induces a TLR-mediated response when contacted with a suitable functional TLR polypeptide. In one embodiment the immunostimulatory compound is a natural or synthetic compound that induces a TLR-mediated response when contacted with a cell that naturally or artificially expresses a suitable functional TLR polypeptide. Depending on the aspect of the invention, the cell may be an experimental cell or a primary cell such as a PBMC.

Examples of immunostimulatory compounds include the following immunostimulatory nucleic acids, which are discussed in further detail below:

5'-TCGTCGTTTGTCTGTTTGTCTGTT-3'	(SEQ ID NO:1)
5'-TCGTCGTTTGACGTTTGTCTGTT-3'	(SEQ ID NO:139)
15 5'-TCGTCGTTTGTCTGTTTTTCGA-3'	(SEQ ID NO:140)
5'-TCGTCGTTTCGTCGTTTCGTT-3'	(SEQ ID NO:141)
5'-TCGTCGTTTCGTCGTTTGTCTGTT-3'	(SEQ ID NO:142)
5'-TCGTCGTTTCGGTCGTTT-3'	(SEQ ID NO:143)
5'-TCGTCGTTTCGTGCGTTT-3'	(SEQ ID NO:144)
20 5'-TCGTCGTTTCGGCGGCCGCG-3'	(SEQ ID NO:145)
5'-TCGTC_GTTTAC_GGCGCC_GTGCCG-3'	(SEQ ID NO:146)

Imidazoquinolines are immune response modifiers thought to induce expression of several cytokines including interferons (e.g., IFN- $\alpha$  and IFN- $\beta$ ), TNF- $\alpha$  and some interleukins (e.g., IL-1, IL-6 and IL-12) as well as chemokines (e.g., IP-10 and IL-8). Imidazoquinolines are capable of stimulating a Th1 immune response, as evidenced in part by their ability to induce increases in IgG2a levels. Imidazoquinoline agents reportedly are also capable of inhibiting production of Th2 cytokines such as IL-4, IL-5, and IL-13. Some of the cytokines induced by imidazoquinolines are produced by macrophages and dendritic cells. Some species of imidazoquinolines have been reported to increase NK cell lytic activity and to stimulate B cells proliferation and differentiation, thereby inducing antibody production and secretion. Imidazoquinoline mimics can also be tested using the screening methods.

- 22 -

An "immunoinhibitory compound" as used herein refers to a natural or synthetic compound that characteristically inhibits a TLR-mediated response when contacted with a suitable functional TLR polypeptide. In one embodiment the immunoinhibitory compound is a natural or synthetic compound that inhibits a TLR-mediated response when contacted with a 5 cell that naturally or artificially expresses a suitable functional TLR polypeptide.

In addition to the immunoinhibitory nucleic acids disclosed elsewhere herein, immunoinhibitory compounds and TLR antagonists encompass certain small molecules (chloroquine, quinacrine, 9-aminoacridines and 4-aminoquinolines, and derivatives thereof) described by Macfarlane and colleagues in U.S. Pat. 6,221,882; U.S. Pat. 6,399,630; U.S. Pat. 10 6,479,504; U.S. Pat. 6,521,637; and published U.S. Pat. application 2002/0151564, the contents of all of which are hereby incorporated by reference in their entirety.

The invention provides in part methods and tools that utilize cell lines, in modified or unmodified form, as surrogates for PBMC. Immunomodulation by TLR ligands can be assessed using one or preferably more parameters including but not limited to cytokine and 15 chemokine secretion, upregulation of cell surface markers, changes in cell proliferation, phosphorylation changes, and the like. These parameters may be native readouts or artificial readouts as described herein.

The cellular response to immunostimulatory nucleic acids by the cell lines described herein (e.g., RPMI 8226, Raji, RAMOS, and the like) so resembles that of PBMC that these 20 cells can be used to identify and differentiate between immunomodulatory compounds based on the extent of the induced response and the particular profile of that response. The invention provides a number of cell lines each with a particular endogenous TLR expression profile, as described herein.

The cell lines can be used to identify immunomodulatory compounds with particular 25 response profiles. As an example, the cell lines can be used to identify molecules that are mimics to known TLR ligands. The cell lines can also be used to identify TLR ligands that trigger some but not necessarily all of the responses induced by known TLR ligands. For example, the cell line can be used to distinguish between compounds based on individual or group cytokine or chemokine secretion, or based on upregulation of one, a subset or all cell 30 surface markers. As an example, in some therapeutic instances, it may be desirable to use a compound that induces the secretion of relatively high levels of chemokine such as IP-10, yet induces only relatively low levels of one or more other factors. The screening methods of the invention allow for the identification of such a compound with this type of induction profile.

It is to be understood that the screening method also can be used to determine effective amounts of known and newly identified immunomodulatory compounds. For example, the EC<sub>50</sub> value of a TLR ligand for the production of a particular cytokine or chemokine can be determined, thereby facilitating comparison between different nucleic acids.

5 Generally, these assays require the incubation of cells with a reference compound and a test compound, and an analysis of the readout. Depending on the embodiment, the same cells are exposed to the reference compound and the test compound. An example of this latter embodiment is a screening assay for compounds that enhance the immunostimulatory effects of a TLR agonist. Another example is a screening assay for compounds that inhibit the  
10 immunostimulatory effects of a TLR agonist. In both examples, the reference compound is a positive reference compound (i.e., it is itself immunostimulatory).

In other embodiments, particularly those directed at identifying immunostimulatory compounds, separate aliquots from the same cell line (or from the same freshly harvested cell population) are exposed to either the reference compound or the test compound, and the  
15 readouts from each are measured and compared to the other. If the reference compound is a negative reference compound (i.e., it is inert and neither immunostimulatory nor immunoinhibitory), then any test level that is greater than the reference level is indicative of a test compound that has at least some immunostimulatory capacity. Generally, the negative reference compound is used to set background levels of immunostimulation or  
20 immunoinhibition observed in the absence of the test compound. If the reference compound is a positive reference compound (i.e., it is immunostimulatory), then it is possible to compare and contrast the induction profile of the test compound to that of the reference compound.

In some instances, separate reference assays individually containing a positive and a negative reference compound are performed alongside the test assay. For example, if the test  
25 assay is a screen for an immunostimulatory TLR ligand, then reference assays can be a positive reference assay (in which the reference compound is immunostimulatory), a negative reference assay (in which the reference compound is immunologically inert or neutral), or both. A test compound is defined as immunostimulatory if it induces a response greater than that of the negative reference compound. The level and profile of the immunostimulatory  
30 response can be compared to the level and profile induced by the positive reference compound. It is to be understood that a test compound that induces a level of immunostimulation less than that of the positive reference compound may still be considered immunostimulatory according to the invention. Modifications to these screening assays for a

desired readout will be apparent to those of ordinary skill in the art based on the teachings provided herein.

If the test assay is a screen for an immunoinhibitory TLR ligand, then the assay may generally involve co-incubation of the test compound and a positive reference compound.

- 5 The control assay may include co-incubation of the negative and positive reference compounds. As used herein, co-incubation embraces simultaneous or consecutive addition of the reference and test compounds. The test compound may be added before or after the positive reference compound. An immunoinhibitory test compound may be identified by a diminution of the immunostimulatory response induced by the positive reference compound
- 10 when in the presence of the test compound. If the level of the response is less in the presence of the test compound, this indicates that the test compound is capable of interfering with the immunostimulatory effects of the positive reference compound. As an example, simultaneous or consecutive addition of a putative immunoinhibitory test compound can reduce the amount of cytokines or chemokines secreted by cells in response to the positive reference compound
- 15 alone, indicating an inhibition of the immunostimulatory effects of the positive reference compound.

The reference immunoinhibitory compound can be used at one or more concentrations in conjunction with a selected or constant concentration of reference immunostimulatory compound. Under proper conditions, the immunostimulatory effect of the reference

20 immunostimulatory compound will be less in the presence of the immunoinhibitory substance than in the absence of the immunoinhibitory substance. Furthermore, under proper conditions, the immunostimulatory effect of the reference immunostimulatory compound will decrease with increasing concentration of the immunoinhibitory substance.

- 25 The breadth of response by the cell line to immunomodulatory compounds, and its facile manipulation, allows for the identification of novel compounds. The cell line allows the rapid discovery of such compounds given that it lends itself to high throughput screening methods such as those provided herein. These methods and compositions are described in greater detail below. The invention therefore provides screening methods that utilize cell lines that either endogenous express TLRs such as the RPMI 8226 cell line as well as cell
- 30 lines that have been modified to express TLRs. The invention further provides compositions that comprise such cell lines.

The verification and standardization methods of the invention generally involve assays in which an isolated cell expressing a functional TLR is contacted with each of two

- 25 -

compositions, each composition containing a known ligand for the TLR. One composition is a reference composition, and the assay using the reference composition yields a reference activity. The second composition is a test composition, and the assay using the test composition yields a test activity. The two contacting steps can be performed on separate  
5 cells that are alike, and typically will be performed on separate populations of cells that are alike. For example, the separate cells or the separate populations of cells can be drawn from a single population of cells. In typical usage according to this embodiment, the reference and test activities are measured essentially concurrently, although the use of historical reference activity is also contemplated by the methods of the invention. As an alternative, the two  
10 contacting steps can be performed on a single cell or on a single population of cells, usually in an essentially concurrent manner when it is desirable to have competition between reference and test compositions. In one embodiment the known TLR ligand is a nucleic acid molecule.

The assays of the invention are performed under specific conditions so that comparison can be made between reference and test activities or levels. The results of the  
15 comparison can be used as a basis upon which to accept or reject the test material as suitable for its intended use.

The biological characterization of the reference composition will generally entail a series of biological activity measurements of the reference composition using a single assay under defined conditions in order to define a range of inter-test variance. The range of inter-  
20 test variance so obtained using reference composition can be used to define an acceptable range of variance within which a subsequent test measurement must fall in order to satisfy quality standards. Such a range of acceptable variance can serve as a basis for developing predetermined range of variance about the reference activity, i.e., acceptance criteria for a particular test composition or test lot. For example, a particular reference composition can be assayed under defined conditions in a number of independent measurements and found to  
25 yield a result expressed as  $100 \pm 5$  units of activity. Under this same example, a subsequent test measurement of a test composition performed using the same assay and defined conditions is found to yield 97 units of activity. The activity of the test composition under this example thus yielded a result that falls within the normal range of inter-test variance  
30 observed for the reference composition. Accordingly, the test material under this example could be selected on the basis of the test activity falling within a predetermined range of variance about the reference activity. In short, the test material can be deemed acceptable

provided the test activity falls within a predetermined range of activity that is related to the activity of the reference material.

In one embodiment, the methods of the invention provide for comparison between a reference lot of a particular TLR ligand and a test lot of the same particular TLR ligand. Such 5 comparison is useful for quality control assessment of the test lot of material, also referred to herein as validation, e.g., product validation. Such comparison is also useful for process validation.

In another embodiment, the methods of the invention provide for comparison between a reference lot of a particular TLR ligand and a test lot of a different TLR ligand. In a simple 10 example, where a test TLR ligand (T) is expected to have little or no activity characteristic of reference TLR ligand (R), comparison can be made between T and R to confirm the lack of R-like activity possessed by T. In a more complex example, where a test TLR ligand (C) is capable of exerting two different effects, wherein each effect is characteristic of one of two different classes of TLR ligand and is best characterized by one of two different reference 15 TLR ligands (A and B), the test TLR ligand (C) can be compared with either of the two reference TLR ligands (A or B). In this second example, test composition C could be found, for example, to possess 50 percent A-like activity compared with reference A and 70 percent B-like activity compared with reference B. Test composition C could thus independently meet or fail to meet predetermined standards for each of A-like activity and B-like activity. 20 Such comparison is also useful for quality control assessment of the test lot of material, e.g., product validation. Of course test TLR ligand C can alternatively or additionally be compared against reference TLR ligand C, as described in the preceding paragraph.

To facilitate the methods of the invention, certain conditions for carrying out the assays are standardized and used for measurements of both reference activity and test activity. 25 In this way direct comparison between reference activity and test activity can be made readily. Conditions that can be standardized and used in this manner can include, without limitation, readout, temperature, media characteristics, duration (time between introduction of reference composition or test composition and activity measurement), methods of sampling, etc. In some embodiments the methods of the invention can be at least partially automated in order to 30 increase throughput and/or to reduce inter-test variability. For example, robotic devices and workstations with the capacity to dispense and/or sample fluids in a set or programmable fashion are now well known in the art and can be used in performing the methods of the instant invention.

- 27 -

In one embodiment a standard curve of reference composition activity is employed. Typically the standard curve is generated by selecting conditions including concentration of the reference composition such that the dose-response curve is essentially linear (and the slope is non-zero) over a range of concentrations that includes the effective concentration at 5 which activity is 50 percent of maximum (EC50). In one embodiment the standard curve spans a range of concentrations defined by EC50  $\pm$  1 log concentration, e.g.,  $1 \times 10^{-7}$  M –  $1 \times 10^{-5}$  M, where EC50 is  $1 \times 10^{-6}$  M. In another embodiment the standard curve spans a broader range of concentrations defined by EC50  $\pm$  2 log concentration, e.g.,  $1 \times 10^{-8}$  M –  $1 \times 10^{-4}$  M, where EC50 is  $1 \times 10^{-6}$  M. In yet another embodiment the standard curve spans a narrower 10 range of concentrations defined by EC50  $\pm$  0.5 log concentration, e.g.,  $3.16 \times 10^{-7}$  M –  $3.16 \times 10^{-6}$  M, where EC50 is  $1 \times 10^{-6}$  M. The foregoing embodiments are intended to be exemplary and not limiting in any way. One of skill in the art will be able to select, for a given reference 15 composition and without undue experimentation, an appropriate range of concentrations about some middle value in order to generate an essentially linear standard curve with a non-zero slope.

In one embodiment a non-linear standard curve of reference and test composition activity is employed. The standard curve can be generated by selecting conditions including concentrations of the reference composition such that the dose-response curve is sigmoidal and the EC50 value can be determined. Comparison of reference and test activity can be done 20 by comparing, e.g., the EC50 values of both curves. Concentration range is chosen to yield a complete sigmoidal response, e.g., concentration should include EC50  $\pm$  3 log concentration or EC50  $\pm$  4 log concentration. In the case of testing an inhibitory compound the value determined would be the IC50, i.e., concentration where inhibition of the stimulatory signal is half-maximal.

25 The methods of the invention can be adapted to be automated or at least partially automated methods, as well as to parallel array or high throughput format methods. For example, the assays can be set up using multiwell plates in which cells are dispensed in individual wells and reagents are added in a systematic manner using a multiwell delivery device suited to the geometry of the multiwell plate. Manual and robotic multiwell delivery 30 devices suitable for use in a high throughput screening assay are known by those skilled in the art. Each well or array element can be mapped in a one-to-one manner to a particular test condition, such as the test compound. Readouts can also be performed in this multiwell array, preferably using a multiwell plate reader device or the like. Examples of such devices are

known in the art and are available through commercial sources. Sample and reagent handling can be automated to further enhance the throughput capacity of the screening assay, such that dozens, hundreds, thousands, or even millions of parallel assays can be performed in a day or in a week. Fully robotic systems are known in the art for applications such as generation and 5 analysis of combinatorial libraries of synthetic compounds. See, for example, U.S. Pat. Nos. 5,443,791 and 5,708,158.

#### Cell lines

The screening methods may use experimental cells. As used herein, an experimental 10 cell is a non-primary cell (i.e., it is not a cell that has been recently harvested from a subject). It excludes, for example, freshly harvested PBMCs. An experimental cell includes a cell from a cell line such as the RPMI 8226 cell line.

In certain embodiments, the cell naturally expresses a functional TLR. In one embodiment relating to the verification and standardization aspects of the invention, the cell 15 may be a PBMC, preferably a PBMC freshly harvested from a subject.

Cells that would be suitable for identification of TLR agonists, antagonists or enhancers according to the invention may possess one or more particular attributes. These attributes include but are not limited to being of human origin, being an immortalized stable 20 cell line, endogenously expressing at least one functional TLR or a combination of functional TLRs, having intact signaling mechanisms, having intact uptake mechanisms, being able to upregulate cytokines, chemokines or cell surface markers, deriving from normal human B cells or from myeloma or B cell leukemia, deriving from human plasmacytoid and myeloid dendritic cells, and readily activatable by TLR ligands such as TLR7 ligands, TLR8 ligands or 25 TLR9 ligands such as CpG nucleic acids or nucleic acids having other immunostimulatory sequence motifs or small molecules such as imidazoquinoline compounds.

In some embodiments, the cell line is the Raji cell line which expresses TLR3, TLR7 and TLR9. This latter cell line secretes, for example, IL-6 and IFN- $\alpha$ 2 upon CpG nucleic acid exposure. In other embodiments, the cell line is RPMI 8226 which expresses TLR7 and TLR9. Upon CpG nucleic acid exposure, this cell line expresses, produces and/or secretes IL- 30 8, IL-10, IP-10 and TNF- $\alpha$ . It also expresses at its cell surface CD86, HLA-DR and CD71. In yet other embodiments, the cell line is the RAMOS cell line which expresses TLR3, TLR7 and TLR9. This cell line at least induces CD80 cell surface expression in response to CpG nucleic acid exposure.

- 29 -

The cell lines have been observed to respond in a concentration dependent manner to TLR ligands such as but not limited to CpG nucleic acids and some non-CpG nucleic acids including T-rich nucleic acids, poly-T nucleic acids and poly-G nucleic acids. The highest responses have been observed using CpG nucleic acids.

5       The screening methods employ a variety of cell lines as shown in the Examples. These include A549 (human lung carcinoma, ATCC CCL-185), BeWo (human choriocarcinoma, ATCC CCL-98), HeLa (human cervix carcinoma, ATCC CCL-2), Hep-2 (human cervix carcinoma, ATCC CCL-23), KG-1 (human acute myeloid leukemia, ATCC CCL-246), MUTZ-3 (human acute myelomonocytic leukemia, German Collection of Cell 10 lines and Microorganisms (DSZM) ACC-295), Nalm-6 (human B cell precursor leukemia, DSZM ACC-128), NK-92 (human Natural killer cell line, ATCC CRL-2407), NK-92 MI (IL-2 independent human Natural killer cell line, ATCC CRL-2408), Raji (human B lymphocyte Burkitt's lymphoma, ATCC CCL-86), RAMOS (B lymphocyte Burkitt's lymphoma, ATCC CRL-1596), RPMI 8226 (human B lymphocyte multiple myeloma, ATCC CCL-155), THP-1 15 (human acute monocytic leukemia, ATCC TIB 202), U937 (human lymphoma, ATCC CRL-1593.2) and Jurkat (human T cell leukemia, ATCC TIB 152).

As shown in the Examples, each of the afore-mentioned cell lines has a particular endogenous TLR expression profile which dictates its suitability in a particular screening assay.

20       A cell that artificially expresses a functional TLR can be a cell that does not express the functional TLR but for a transfected TLR expression vector. For example, human 293 fibroblasts (ATCC CRL-1573) do not express TLR7, TLR8 or TLR9, and they express very little TLR3. As described in the examples below, such cells can be transiently or stably transfected with suitable expression vector (or vectors) so as to yield cells that do express 25 TLR3, TLR7, TLR8, TLR9, or any combination thereof. Alternatively, a cell that artificially expresses a functional TLR can be a cell that expresses the functional TLR at a significantly higher level with the TLR expression vector than it does without the TLR expression vector. Transfected cells are considered modified cells, as used herein.

30       A cell that artificially expresses an expression or reporter construct is preferably stably transfected.

RPMI

- 30 -

The RPMI 8226 cell line is a human multiple myeloma cell line. The cell line was established from the peripheral blood of a 61 year old man at the time of diagnosis for multiple myeloma (IgG lambda type). RPMI 8226 was previously reported as responsive to CpG nucleic acids as evidenced by the production and secretion of IL-6 protein and 5 production of IL-12p40 mRNA. (Takeshita et al. (2000), Eur. J. Immunol. 30, 108-116, and Takeshita et al. (2000) *Ibid.* 30, 1967-1976) Takeshita et al. however used the cell line solely to study promoter constructs in order to identify transcription factor binding sites important for CpG nucleic acid signaling. It is now known according to the invention that the cell line produces a number of other chemokines and cytokines including IL-8, IL-10 and IP-10. It has 10 also been discovered according to the invention that the cell line responds to immunostimulatory nucleic acids by upregulating cell surface expression of particular markers. Many of these markers, including CD71, CD86 and HLA-DR, are similarly upregulated in PBMCs exposed to immunostimulatory nucleic acids. This has been observed using flow cytometric analysis of the cell line following CpG nucleic acid exposure. In other 15 aspects of the invention, the cell line can be used in similar screening assays that involve secretion of IL-6, IL-12 and/or TNF- $\alpha$ .

It has recently been discovered that R-848 mediates its immunostimulatory effects via other TLR family members, namely TLR7 and TLR8. TLR7 has previously been found expressed on human B cells. It has now also been discovered according to the invention that 20 RPMI 8226 expresses TLR9 as well as TLR7, thus making it a suitable cell line for identifying immunostimulatory nucleic acid and/or imidazoquinoline (e.g., R-848) mimics or other small molecules that also signal through TLR7 and/or TLR9. Incubation of RPMI 8226 cells with the imidazoquinoline R-848 (Resiquimod) induces for example IL-8, IL-10 and IP-10 production.

25

#### Known TLR Ligands

Ligands for many but not all of the TLRs have been described. For instance, it has been reported that TLR1 and TLR2 signals in response to peptidoglycan and lipopeptides. Yoshimura A et al. (1999) *J Immunol* 163:1-5; Brightbill HD et al. (1999) *Science* 285:732-6; 30 Aliprantis AO et al. (1999) *Science* 285:736-9; Takeuchi O et al. (1999) *Immunity* 11:443-51; Underhill DM et al. (1999) *Nature* 401:811-5. TLR4 has been reported to signal in response to lipopolysaccharide (LPS). Hoshino K et al. (1999) *J Immunol* 162:3749-52; Poltorak A et al. (1998) *Science* 282:2085-8; Medzhitov R et al. (1997) *Nature* 388:394-7. Bacterial

- 31 -

flagellin has been reported to be a natural ligand for TLR5. Hayashi F et al. (2001) *Nature* 410:1099-1103. TLR6, in conjunction with TLR2, has been reported to signal in response to proteoglycan. Ozinsky A et al. (2000) *Proc Natl Acad Sci USA* 97:13766-71; Takeuchi O et al. (2001) *Int Immunol* 13:933-40.

5 TLR9 is a receptor for CpG DNA. Hemmi H et al. (2000) *Nature* 408:740-5. Other TLR9 ligands are described herein under "Immunostimulatory Nucleic Acids". Certain imidazoquinoline compounds having antiviral activity are ligands of TLR7 and TLR8. Imidazoquinolines are potent synthetic activators of immune cells with antiviral and antitumor properties. R-848 is a ligand for human TLR7 and TLR8. Jurk M et al. (2002) *Nat Immunol* 10 3:499. Ligands of TLR3 include poly(I:C) and double-stranded RNA (dsRNA). Alexopoulou et al. (2001) *Nature* 413:732-738. For purposes of this invention, poly(I:C) and double-stranded RNA (dsRNA) are classified as oligonucleotide molecules. TLR3 may have a role in host defense against viruses.

15 Reference and Test Compounds

A test and/or reference compound can be a nucleic acid such as an oligonucleotide or a polynucleotide, an oligopeptide, a polypeptide, a lipid such as a lipopolysaccharide, a carbohydrate such as an oligosaccharide or a polysaccharide, or a small molecule. Alternatively, these compounds may also comprise or be synthesized from elements such as 20 amino acids, carbohydrates, hormones, lipids, organic molecules, and the like.

Small molecules in general include naturally occurring, synthetic, and semisynthetic organic and organometallic compounds with molecular weight less than about 2.5 kDa. Examples of small molecules include most drugs, subunits of polymeric materials, and analogs and derivatives thereof.

25 Some specific examples of small molecules include the imidazoquinolines. As used herein, imidazoquinolines include imidazoquinoline amines (imidazoquinolinamines), imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2 bridged imidazoquinoline amines. These compounds have been described in U.S. Pat. Nos. 4,689,338; 4,929,624; 5,238,944; 5,266,575; 5,268,376; 5,346,905; 5,352,784; 5,389,640; 30 5,395,937; 5,482,936; 5,494,916; 5,525,612; 6,039,969 and 6,110,929. Particular species of imidazoquinoline agents include resiquimod (R-848; S-28463; 4-amino-2 ethoxymethyl- $\alpha,\alpha$ -dimethyl-1*H*-imidazo[4,5-*c*]quinoline-1-ethanol); and imiquimod (R-837; S-26308; 1-(2-methylpropyl)-1*H*-imidazo[4,5-*c*]quinoline-4-amine). Further examples of specific small

molecules include 4-aminoquinoline and derivatives thereof, 9-aminoacridine and derivatives thereof, and additional compounds disclosed in U.S. Pat. Nos. 6,221,882; 6,399,630; 6,479,504; and 6,521,637; and published U.S. Pat. Application No. 2002/0151564 A1, the entire contents of which are hereby incorporated by reference.

5       The test and reference compounds may be formulated for pharmaceutical use or not. For example, a test compound not formulated for pharmaceutical use can be a compound (e.g., a lot or batch of the compound) under evaluation for possible use in preparing a pharmaceutical formulation of the compound.

A reference compound, as used herein, is a compound having a known activity in the  
10 presence of a TLR. The reference compound may stimulate TLR signaling (and is therefore regarded as a positive reference compound), or it may be inert in the presence of a TLR (and is therefore regarded as a negative reference compound). If it is a positive reference compound, it need not be the best known stimulator of TLR signaling (i.e., it is possible that other reference compounds and even test compounds will stimulate TLR signaling to a greater  
15 extent). The readout of the screening assay may simply be stated relative to the level of signaling that occurs in the presence of the reference compound. Preferably, the reference compound is analyzed prior to the screening assay in order to determine its level of activity on a TLR. In some aspects of the invention, the reference compound and the test compound will be assayed separately (i.e., in separate wells); in other aspects, the reference compound and  
20 the test compound will be assayed together (i.e., in the same well). These latter aspects are designed to measure the ability of a test compound to modulate the activity of the reference compound. The activity of the test compound and the reference compound combined (i.e., when assayed together in the same well) may be the same as that of the positive reference compound alone, indicating at a minimum that the test compound is not inhibitory; or it may  
25 be less than that of the positive reference compound, indicating at a minimum that it is inhibitory to the effect of the reference compound; or it may be additive or synergistic possibly indicating that the test compound is an enhancer. The effect of an enhance may be due to its ability to stimulate TLR signaling independently of the positive reference compound.

30       A "reference composition" as used herein refers to a composition that includes a reference compound and optionally another agent, e.g., a pharmaceutically acceptable carrier and/or another biologically active agent. A reference compound may be an immunostimulatory compound or it may be an immunoinhibitory compound.

As discussed further below, in some aspects of the invention the reference compositions include both finished products, e.g., finished pharmaceutical products, as well as raw materials and other in-process materials used for the preparation of such finished products, all of which contain a known TLR ligand. As used herein, a "production lot" shall 5 refer to a batch or lot of a completed product prepared for release as clinical material, e.g., a pharmaceutical product. As used herein, an "in-process lot" shall refer to a batch or lot of unfinished product that is prepared in the course of making a production lot; an "in-process lot" shall also refer to a batch or lot of raw material provided for use in the production of a production lot.

10 In some aspects of the invention, the reference compositions of the invention are highly characterized in terms of their chemical, physical, and biological properties. A reference composition will be a specific composition previously determined to have a specific activity, or range of specific activity, of the particular known TLR ligand present in the composition. As used herein, "specific activity" refers to an amount of activity per unit mass 15 or per unit volume of the reference composition as a whole, as determined using a defined assay under defined conditions. In one embodiment the reference composition is a representative sample of a particular lot or batch of a specific TLR ligand. In one embodiment the reference composition is a representative sample of a particular lot or batch of a specific TLR ligand formulated for pharmaceutical use, e.g., a sterile solution of the TLR 20 ligand at a determined concentration or activity.

At least the following parameters are typically very well defined for a given reference composition: chemical formula of the active ingredient TLR ligand (e.g., nucleobase sequence and type of backbone of a nucleic acid; structural formula of a small molecule); concentration; diluent composition; and purity. Such parameters as purity and concentration 25 can be determined using any appropriate physicochemical method, e.g., optical spectroscopy including absorbance at one or more specified wavelengths; nuclear magnetic resonance (NMR) spectroscopy; mass spectrometry (MS), including matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS); melting point; specific gravity; chromatography including as appropriate high pressure liquid chromatography (HPLC), one- 30 and two-dimensional polyacrylamide gel electrophoresis (PAGE), capillary electrophoresis, and the like; as well as other methods known to those of skill in the art.

Reference compositions can also be very well characterized in terms of their biological activity, independent of the methods of the invention, although the methods of the

invention generally include such characterization, at least in part. A reference composition can be very well characterized in terms of its biological activity by characterizing, both qualitatively and quantitatively, the response by sensitive cells to the reference composition under defined conditions. For example, a reference composition can be a specific CpG

5 oligonucleotide such as SEQ ID NO:1 which in a specific assay and under specific conditions of temperature, concentration, duration of contact between the CpG oligonucleotide and a population of TLR9-expressing cells, and particular readout, reliably yields a specific result or range of results. Results can be expressed in any suitable manner, but can include results expressed on a per-cell basis, e.g., picograms of particular cytokine per cell per hour of

10 contact with the reference composition. Reference compositions can be very well characterized in terms of their biological activity according to one or more parameters, for example, according to their capacity to induce each of a plurality of cytokines.

The methods of the invention also involve measurement of a test activity of a test composition containing a known TLR ligand. A "test composition" as used herein refers to a

15 composition that includes a test compound and optionally another agent, e.g., a pharmaceutically acceptable carrier and/or another biologically active agent. A test compound can be an immunostimulatory compound or it can be an immunoinhibitory compound. In some aspects of the invention, the test compound is a known TLR ligand. Test compositions of the invention may comprise known TLR agonist or TLR antagonist

20 compounds, generally but not necessarily nominally the same as the reference compositions against which comparison is to be made according to some aspects of the invention. Thus test compositions may encompass immunostimulatory compounds, immunoinhibitory compounds, known TLR ligands, finished pharmaceutical products, and raw materials and other in-process materials used for the preparation of such finished products.

25 Unlike a reference composition, a test composition is not characterized at all, or is only partially characterized, or is not as well characterized as the reference composition, in terms of its chemical, physical, or (most particularly) biological properties. The methods of the invention permit further characterization of the test composition by comparison with a reference composition. In some aspects, a test composition will be a specific composition

30 previously determined to be a ligand of a specific TLR. In one embodiment the test composition is a representative sample of a particular lot or batch of a specific TLR ligand. In one embodiment the test composition is a representative sample of a particular lot or batch of

- 35 -

a specific TLR ligand formulated for pharmaceutical use, e.g., a sterile solution of the TLR ligand at a determined concentration or activity.

Immunostimulatory and Immunoinhibitory Nucleic Acids

5        Nucleic acids useful as reference compounds and as test compounds in the methods of the invention include single- and double-stranded natural and synthetic nucleic acids, including those with phosphodiester, stabilized, and chimeric backbones. Also encompassed are at least the following classes of nucleic acids, which are described in detail below: immunostimulatory CpG nucleic acids (CpG nucleic acids), including but not limited to types  
10      A, B, and C; immunostimulatory non-CpG nucleic acids, including without limitation methylated CpG nucleic acids, T-rich nucleic acids, TG-motif nucleic acids, CpI motif nucleic acids, and poly-G nucleic acids; and immunoinhibitory nucleic acids. Nucleic acids useful as reference compounds and as test compounds in the methods of the invention also include nucleic acids with modified backbones, including "soft" and "semi-soft" oligonucleotides as  
15      described herein. As will be appreciated from the descriptions below, certain of these various classes of nucleic acids can coexist in a given nucleic acid molecule.

A "nucleic acid" as used herein with respect to test compounds and reference compounds used in the methods of the invention, shall refer to any polymer of two or more individual nucleoside or nucleotide units. Typically individual nucleoside or nucleotide units  
20      will include any one or combination of deoxyribonucleosides, ribonucleosides, deoxyribonucleotides, and ribonucleotides. The individual nucleotide or nucleoside units of the nucleic acid can be naturally occurring or not naturally occurring. For example, the individual nucleotide units can include deoxyadenosine, deoxycytidine, deoxyguanosine, thymidine, and uracil. In addition to naturally occurring 2'-deoxy and 2'-hydroxyl forms,  
25      individual nucleosides also include synthetic nucleosides having modified base moieties and/or modified sugar moieties, e.g., as described in Uhlmann E et al. (1990) *Chem Rev* 90:543-84. The linkages between individual nucleotide or nucleoside units can be naturally occurring or not naturally occurring. For example, the linkages can be phosphodiester, phosphorothioate, phosphorodithioate, phosphoramidate, as well as peptide linkages and other  
30      covalent linkages, known in the art, suitable for joining adjacent nucleoside or nucleotide units. The linkages can also be mixed in a single polymer (e.g., a semi-soft backbone). The nucleic acid test compounds and nucleic acid reference compounds typically range in size from 3-4 units to a few tens of units, e.g., 18-40 units.

- 36 -

In some embodiments the nucleic acids are oligonucleotides made up of 2 to about 100 nucleotides, and more typically 4 to about 40 nucleotides. Oligonucleotides composed exclusively of deoxynucleotides are termed oligodeoxyribonucleotides or, equivalently, oligodeoxynucleotides (ODN).

5 A CpG nucleic acid is an immunostimulatory nucleic acid which contains a cytosine-guanine (CG) dinucleotide, the C residue of which is unmethylated. The effects of CpG nucleic acids on immune modulation have been described extensively in U.S. Pat. Nos. 6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116; and 6,339,068; and published patent applications, such as PCT/US95/01570 (WO 96/02555); PCT/US98/04703 (WO 98/40100);  
10 and PCT/US99/09863 (WO 99/56755). The entire contents of each of these patents and published patent applications is hereby incorporated by reference. The entire immunostimulatory nucleic acid can be unmethylated or portions can be unmethylated, but at least the C of the 5'-CG-3' must be unmethylated. The CpG nucleic acid sequences of the invention include, without limitation, those broadly described above as well as those disclosed  
15 in U.S. Pat. Nos. 6,207,646 and 6,239,116.

In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTGTCTGTTTGTCGTT-3' (SEQ ID NO:1).

In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTGACGTTTGTCGTT-3' (SEQ ID NO:139).

20 In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTGTCTGTTTCGA-3' (SEQ ID NO:140).

In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTCGTCGTTCGTCTGTT-3' (SEQ ID NO:141).

25 In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTCGTCGTTTGTCGTT-3' (SEQ ID NO:142).

In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTCGGTCGTTT-3' (SEQ ID NO:143).

In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTCGTGCGTTT-3' (SEQ ID NO:144).

30 In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTCGTTTCGGCGGCCGCG-3' (SEQ ID NO:145).

In one embodiment the CpG nucleic acid has a base sequence provided by 5'-TCGTC\_GTTTAC\_GGCGCC\_GTGCCG-3' (SEQ ID NO:146).

The oligonucleotides described by SEQ ID NOS: 1, 139-145 are fully stabilized phosphorothioate backbone ODN. The oligonucleotide of SEQ ID NO:146 has a chimeric backbone in which all internucleoside linkages are phosphorothioate except for those indicated by “\_”, which are phosphodiester.

- 5 CpG nucleic acids have been further classified by structure and function into at least the following three types, all of which are intended to be encompassed within the methods of the instant invention: Type B CpG nucleic acids such as SEQ ID NO:1 include the earliest described CpG nucleic acids and characteristically activate B cells but do not induce or only weakly induce expression of IFN- $\alpha$ . Type B nucleic acids are described in U.S. Patents  
10 6,194,388; 6,207,646; 6,214,806; 6,218,371; 6,239,116; and 6,339,068. Type A CpG nucleic acids, described in published international application PCT/US00/26527 (WO 01/22990), incorporate a CpG motif, include a hybrid phosphodiester/phosphorothioate backbone, and characteristically induce plasmacytoid dendritic cells to express large amounts of IFN- $\alpha$  but do not activate or only weakly activate B cells. Type C oligonucleotides incorporate a CpG,  
15 include a chimeric backbone, include a GC-rich palindromic or nearly-palindromic region, and are capable of both activating B cells and inducing expression of IFN- $\alpha$ . These have been described, for example, in copending U.S. Pat. application Ser. No. 10/224,523, filed August 19, 2002. Exemplary sequences of A, B and C class nucleic acids are described in the afore-mentioned references, patents and patent applications, the entire contents of which are  
20 hereby incorporated by reference herein.

- In other embodiments of the invention, a non-CpG nucleic acid is used. A non-CpG nucleic acid is an immunostimulatory nucleic acid which either does not have a CpG motif in its sequence, or has a CpG motif which contains a methylated C residue. In some instances, the non-CpG nucleic acid may still be immunostimulatory by virtue of its having other  
25 immunostimulatory motifs such as those described herein and known in the art. In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid. In some instances the non-CpG nucleic acid is still immunostimulatory despite methylation of the C of the CpG motif, even without having another non-CpG immunostimulatory motif described herein and known in the art.  
30 In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid having a base sequence provided by 5'-TZGTZGTTTGTZGTTTGTT-3' (SEQ ID NO:147), wherein Z represents 5-methylcytosine.

- 38 -

In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid having a base sequence provided by 5'-TZGTZGZTGTZTZZGZTTZTGTGZZ-3' (SEQ ID NO:148), wherein Z represents 5-methylcytosine.

5 In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid having a base sequence provided by 5'-GZGTTGZTZTZZTGTGZG-3' (SEQ ID NO:149), wherein Z represents 5-methylcytosine.

In one embodiment the non-CpG nucleic acid is a methylated CpG nucleic acid having a base sequence provided by 5'-GZZZAAGZTGGZATZZGTZA-3' (SEQ ID NO:150), wherein Z represents 5-methylcytosine.

10 Non-CpG nucleic acids include T-rich immunostimulatory nucleic acids. The T-rich immunostimulatory nucleic acids include those disclosed in published PCT patent application PCT/US00/26383 (WO 01/22972), the entire contents of which are incorporated herein by reference. In some embodiments, T-rich nucleic acids 24 bases in length are used. A T-rich nucleic acid is a nucleic acid which includes at least one poly T sequence and/or which has a 15 nucleotide composition of greater than 25% T nucleotide residues. A nucleic acid having a poly-T sequence includes at least four Ts in a row, such as 5'-TTTT-3'. In some embodiments the T-rich nucleic acid includes more than one poly T sequence. In important embodiments, the T-rich nucleic acid may have 2, 3, 4, or more poly T sequences, such as SEQ ID NO:1.

20 Non-CpG nucleic acids also include poly-G immunostimulatory nucleic acids. A variety of references describe the immunostimulatory properties of poly-G nucleic acids. Pisetsky DS et al. (1993) *Mol Biol Reports* 18:217-221; Krieger M et al. (1994) *Ann Rev Biochem* 63:601-637; Macaya RF et al. (1993) *Proc Natl Acad Sci USA* 90:3745-3749; Wyatt JR et al. (1994) *Proc Natl Acad Sci USA* 91:1356-1360; Rando and Hogan, 1998, In Applied Antisense Oligonucleotide Technology, Krieg and Stein, eds., pp. 335-352; Kimura Y et al. 25 (1994) *J Biochem (Tokyo)* 116:991-994.

The immunostimulatory nucleic acids of the invention can also be those which do not possess CpG, methylated CpG, T-rich, or poly-G motifs.

Exemplary immunostimulatory nucleic acid sequences include but are not limited to those immunostimulatory sequences described and listed in U.S. Non-Provisional Pat.

30 Application No. 09/669,187, filed on September 25, 2000, and in corresponding published PCT patent application PCT/US00/26383 (WO 01/22972).

Immunoinhibitory nucleic acids have been described in Lenert P et al. (2001) *Antisense Nucleic Acid Drug Dev* 11:247-56 and in Stunz L et al. (2002) *Eur J Immunol*

32:1212-22. These inhibitory phosphorothioate ODN (S-ODN) differ from stimulatory S-ODN by having 2-3 G substitutions in the central motif. As inhibitory S-ODN did not directly interfere with the NF- $\kappa$ B DNA binding but prevented CpG-induced NF- $\kappa$ B nuclear translocation of p50, p65, and c-Rel and blocked p105, I $\kappa$ B $\alpha$ , and I $\kappa$ B $\beta$  degradation, Lenert et al. suggested that the putative target of immunoinhibitory ODN would lie upstream of inhibitory kinase (IKK) activation. Stunz et al. reported that replacing GCGTT or ACGTT with GCGGG or ACGGG converted a stimulatory 15-mer ODN into an inhibitory ODN. All inhibitory ODN had three consecutive G, and a fourth G increased inhibitory activity, but a deazaguanosine substitution to prevent planar stacking did not affect activity. Inhibitory ODN blocked apoptosis protection and cell-cycle entry induced by stimulatory ODN, but not that induced by lipopolysaccharide, anti-CD40 or anti-IgM+IL-4. ODN-driven up-regulation of cyclin D(2), c-Myc, c-Fos, c-Jun and Bcl(XL) and down-regulation of cyclin kinase inhibitor p27(kip1) were all blocked by inhibitory ODN. Stunz et al. also reported that interference with uptake of stimulatory ODN did not account for the inhibitory effects of the immunoinhibitory nucleic acids.

In one embodiment the immunoinhibitory nucleic acid has a base sequence provided by 5'-TCCTGGCGGGGAAGT-3' (SEQ ID NO:151).

Immunoinhibitory nucleic acids have also been described in U.S. Pat. No. 6,194,388, issued to Krieg et al. The immunoinhibitory oligonucleotides disclosed by Krieg et al. are oligonucleotides with GCG trinucleotides at or near the ends of the oligonucleotide and are represented by the formula 5' GCGX<sub>n</sub>GCG 3' in which X is a nucleotide and n is an integer between 0 and 50.

The nucleic acids used as either test or reference compounds can be double-stranded or single-stranded. They can be deoxyribonucleotide (DNA) or ribonucleotide (RNA) molecules. Generally, double-stranded molecules are more stable in vivo, while single-stranded molecules have increased immune activity. Thus in some the nucleic acid is single-stranded and in other embodiments the nucleic acid is double-stranded. In certain embodiments, while the nucleic acid is single-stranded, it is capable of forming secondary and tertiary structures (e.g., by folding back on itself, or by hybridizing with itself either throughout its entirety or at select segments along its length). Accordingly, while the primary structure of such a nucleic acid may be single-stranded, its higher order structures may be double- or triple-stranded.

- 40 -

For facilitating uptake into cells, the nucleic acids are preferably in the range of 6 to 100 bases in length. However, nucleic acids of any size equal to or greater than 6 nucleotides (even many kb long) are capable of inducing an immune response. Preferably the nucleic acid is in the range of between 8 and 100 and in some embodiments between 8 and 50 or 8  
5 and 30 nucleotides in size.

The terms "nucleic acid" and "oligonucleotide" are used interchangeably to mean multiple nucleotides (i.e., molecules comprising a sugar (e.g., ribose or deoxyribose) linked to a phosphate group and to an exchangeable organic base, which is either a substituted pyrimidine (e.g., cytosine (C), thymine (T) or uracil (U)) or a substituted purine (e.g., adenine<sup>1</sup>  
10 (A) or guanine (G)). As used herein, the terms "nucleic acid" and "oligonucleotide" refer to oligoribonucleotides as well as oligodeoxyribonucleotides. The terms "nucleic acid" and "oligonucleotide" shall also include polynucleosides (i.e., a polynucleotide minus the phosphate) and any other organic base containing polymer. Nucleic acid molecules can be obtained from existing nucleic acid sources (e.g., genomic or cDNA), but are preferably  
15 synthetic (e.g., produced by nucleic acid synthesis).

The terms "nucleic acid" and "oligonucleotide" also encompass nucleic acids or oligonucleotides with substitutions or modifications, such as in the bases and/or sugars. For example, they include nucleic acids having backbone sugars that are covalently attached to low molecular weight organic groups other than a hydroxyl group at the 2' position and other  
20 than a phosphate group or hydroxy group at the 5' position. Thus modified nucleic acids may include a 2'-O-alkylated ribose group. In addition, modified nucleic acids may include sugars such as arabinose or 2'-fluoroarabinose instead of ribose. Thus the nucleic acids may be heterogeneous in backbone composition thereby containing any possible combination of polymer units linked together such as peptide-nucleic acids (which have an amino acid  
25 backbone with nucleic acid bases). Other examples are described in more detail below.

The immunostimulatory and immunoinhibitory nucleic acids can encompass various chemical modifications and substitutions, in comparison to natural RNA and DNA, involving a phosphodiester internucleoside bridge, a β-D-ribose unit and/or a natural nucleoside base (adenine, guanine, cytosine, thymine, uracil). Examples of chemical modifications are known  
30 to the skilled person and are described, for example, in Uhlmann E et al. (1990) *Chem Rev* 90:543; "Protocols for Oligonucleotides and Analogs" Synthesis and Properties & Synthesis and Analytical Techniques, S. Agrawal, Ed, Humana Press, Totowa, USA 1993; Crooke ST et al. (1996) *Annu Rev Pharmacol Toxicol* 36:107-129; and Hunziker J et al. (1995) *Mod Synth*

Methods 7:331-417. An oligonucleotide according to the invention may have one or more modifications, wherein each modification is located at a particular phosphodiester internucleoside bridge and/or at a particular  $\beta$ -D-ribose unit and/or at a particular natural nucleoside base position in comparison to an oligonucleotide of the same sequence which is composed of natural DNA or RNA.

- For example, the oligonucleotides may comprise one or more modifications and wherein each modification is independently selected from:
- a) the replacement of a phosphodiester internucleoside bridge located at the 3' and/or the 5' end of a nucleoside by a modified internucleoside bridge,
  - 10 b) the replacement of phosphodiester bridge located at the 3' and/or the 5' end of a nucleoside by a diphospho bridge,
  - c) the replacement of a sugar phosphate unit from the sugar phosphate backbone by another unit,
  - d) the replacement of a  $\beta$ -D-ribose unit by a modified sugar unit, and
  - 15 e) the replacement of a natural nucleoside base by a modified nucleoside base.

More detailed examples for the chemical modification of an oligonucleotide are as follows.

The oligonucleotides may include modified internucleotide linkages, such as those described in (a) or (b) above. These modified linkages may be partially resistant to degradation (e.g., are stabilized). A "stabilized oligonucleotide molecule" shall mean an oligonucleotide that is relatively resistant to *in vivo* degradation (e.g., via an exo- or endonuclease) resulting from such modifications. Oligonucleotides having phosphorothioate linkages, in some embodiments, may provide maximal activity and protect the oligonucleotide from degradation by intracellular exo- and endo-nucleases.

25 A phosphodiester internucleoside bridge located at the 3' and/or the 5' end of a nucleoside can be replaced by a modified internucleoside bridge, wherein the modified internucleoside bridge is for example selected from phosphorothioate, phosphorodithioate, NR<sup>1</sup>R<sup>2</sup>-phosphoramidate, boranophosphate,  $\alpha$ -hydroxybenzyl phosphonate, phosphate-(C<sub>1</sub>-C<sub>21</sub>)-O-alkyl ester, phosphate-[(C<sub>6</sub>-C<sub>12</sub>)aryl-(C<sub>1</sub>-C<sub>21</sub>)-O-alkyl]ester, (C<sub>1</sub>-C<sub>8</sub>)alkylphosphonate and/or (C<sub>6</sub>-C<sub>12</sub>)arylphosphonate bridges, (C<sub>7</sub>-C<sub>12</sub>)- $\alpha$ -hydroxymethyl-aryl (e.g., disclosed in WO 95/01363), wherein (C<sub>6</sub>-C<sub>12</sub>)aryl, (C<sub>6</sub>-C<sub>20</sub>)aryl and (C<sub>6</sub>-C<sub>14</sub>)aryl are optionally substituted by halogen, alkyl, alkoxy, nitro, cyano, and where R<sup>1</sup> and R<sup>2</sup> are, independently of each other, hydrogen, (C<sub>1</sub>-C<sub>18</sub>)-alkyl, (C<sub>6</sub>-C<sub>20</sub>)-aryl, (C<sub>6</sub>-C<sub>14</sub>)-aryl-(C<sub>1</sub>-C<sub>8</sub>)-alkyl, preferably hydrogen,

- 42 -

(C<sub>1</sub>-C<sub>8</sub>)-alkyl, preferably (C<sub>1</sub>-C<sub>4</sub>)-alkyl and/or methoxyethyl, or R<sup>1</sup> and R<sup>2</sup> form, together with the nitrogen atom carrying them, a 5-6-membered heterocyclic ring which can additionally contain a further heteroatom from the group O, S and N.

The replacement of a phosphodiester bridge located at the 3' and/or the 5' end of a nucleoside by a dephospho bridge (dephospho bridges are described, for example, in Uhlmann E and Peyman A in "Methods in Molecular Biology", Vol. 20, "Protocols for Oligonucleotides and Analogs", S. Agrawal, Ed., Humana Press, Totowa, 1993, Chapter 16, pp. 355 ff), wherein a dephospho bridge is for example selected from the dephospho bridges formacetal, 3'-thioformacetal, methylhydroxylamine, oxime, methylenedimethyl-hydrazo, dimethylenesulfone and/or silyl groups.

A sugar phosphate unit (i.e., a β-D-ribose and phosphodiester internucleoside bridge together forming a sugar phosphate unit) from the sugar phosphate backbone (i.e., a sugar phosphate backbone is composed of sugar phosphate units) can be replaced by another unit, wherein the other unit is for example suitable to build up a "morpholino-derivative" oligomer (as described, for example, in Stirchak EP et al. (1989) *Nucleic Acids Res* 17:6129-41), that is, e.g., the replacement by a morpholino-derivative unit; or to build up a polyamide nucleic acid ("PNA"; as described for example, in Nielsen PE et al. (1994) *Bioconjug Chem* 5:3-7), that is, e.g., the replacement by a PNA backbone unit, e.g., by 2-aminoethylglycine. The oligonucleotide may have other carbohydrate backbone modifications and replacements, such as peptide nucleic acids with phosphate groups (PHONA), locked nucleic acids (LNA), and oligonucleotides having backbone sections with alkyl linkers or amino linkers. The alkyl linker may be branched or unbranched, substituted or unsubstituted, and chirally pure or a racemic mixture.

A β-ribose unit or a β-D-2'-deoxyribose unit can be replaced by a modified sugar unit, wherein the modified sugar unit is for example selected from β-D-ribose, α-D-2'-deoxyribose, L-2'-deoxyribose, 2'-F-2'-deoxyribose, 2'-F-arabinose, 2'-O-(C<sub>1</sub>-C<sub>6</sub>)alkyl-ribose, preferably 2'-O-(C<sub>1</sub>-C<sub>6</sub>)alkyl-ribose is 2'-O-methylribose, 2'-O-(C<sub>2</sub>-C<sub>6</sub>)alkenyl-ribose, 2'-[O-(C<sub>1</sub>-C<sub>6</sub>)alkyl-O-(C<sub>1</sub>-C<sub>6</sub>)alkyl]-ribose, 2'-NH<sub>2</sub>-2'-deoxyribose, β-D-xylo-furanose, α-arabinofuranose, 2,4-dideoxy-β-D-erythro-hexo-pyranose, and carbocyclic (described, for example, in Froehler J (1992) *Am Chem Soc* 114:8320) and/or open-chain sugar analogs (described, for example, in Vandendriessche et al. (1993) *Tetrahedron* 49:7223) and/or bicyclosugar analogs (described, for example, in Tarkov M et al. (1993) *Helv Chim Acta* 76:481).

In some embodiments the sugar is 2'-O-methylribose, particularly for one or both nucleotides linked by a phosphodiester or phosphodiester-like internucleoside linkage.

In some embodiments, the nucleic acids may be soft or semi-soft nucleic acids. A soft nucleic acid is an immunostimulatory nucleic acid having a partially stabilized backbone, in which phosphodiester or phosphodiester-like internucleotide linkages occur only within and immediately adjacent to at least one internal pyrimidine-purine dinucleotide (YZ). Preferably YZ is YG, a pyrimidine-guanosine (YG) dinucleotide. The at least one internal YZ dinucleotide itself has a phosphodiester or phosphodiester-like internucleotide linkage. A phosphodiester or phosphodiester-like internucleotide linkage occurring immediately adjacent to the at least one internal YZ dinucleotide can be 5', 3', or both 5' and 3' to the at least one internal YZ dinucleotide.

In particular, phosphodiester or phosphodiester-like internucleotide linkages involve "internal dinucleotides". An internal dinucleotide in general shall mean any pair of adjacent nucleotides connected by an internucleotide linkage, in which neither nucleotide in the pair of nucleotides is a terminal nucleotide, i.e., neither nucleotide in the pair of nucleotides is a nucleotide defining the 5' or 3' end of the nucleic acid. Thus a linear nucleic acid that is n nucleotides long has a total of n-1 dinucleotides and only n-3 internal dinucleotides. Each internucleotide linkage in an internal dinucleotide is an internal internucleotide linkage. Thus a linear nucleic acid that is n nucleotides long has a total of n-1 internucleotide linkages and only n-3 internal internucleotide linkages. The strategically placed phosphodiester or phosphodiester-like internucleotide linkages, therefore, refer to phosphodiester or phosphodiester-like internucleotide linkages positioned between any pair of nucleotides in the nucleic acid sequence. In some embodiments the phosphodiester or phosphodiester-like internucleotide linkages are not positioned between either pair of nucleotides closest to the 5' or 3' end.

Preferably a phosphodiester or phosphodiester-like internucleotide linkage occurring immediately adjacent to the at least one internal YZ dinucleotide is itself an internal internucleotide linkage. Thus for a sequence N<sub>1</sub> YZ N<sub>2</sub>, wherein N<sub>1</sub> and N<sub>2</sub> are each, independent of the other, any single nucleotide, the YZ dinucleotide has a phosphodiester or phosphodiester-like internucleotide linkage, and in addition (a) N<sub>1</sub> and Y are linked by a phosphodiester or phosphodiester-like internucleotide linkage when N<sub>1</sub> is an internal nucleotide, (b) Z and N<sub>2</sub> are linked by a phosphodiester or phosphodiester-like internucleotide linkage when N<sub>2</sub> is an internal nucleotide, or (c) N<sub>1</sub> and Y are linked by a phosphodiester or

phosphodiester-like internucleotide linkage when N<sub>1</sub> is an internal nucleotide and Z and N<sub>2</sub> are linked by a phosphodiester or phosphodiester-like internucleotide linkage when N<sub>2</sub> is an internal nucleotide.

Soft nucleic acids according to the instant invention are believed to be relatively 5 susceptible to nuclease cleavage compared to completely stabilized nucleic acids. Without meaning to be bound to a particular theory or mechanism, it is believed that soft nucleic acids of the invention are cleavable to fragments with reduced or no immunostimulatory activity relative to full-length soft nucleic acids. Incorporation of at least one nuclease-sensitive 10 internucleotide linkage, particularly near the middle of the nucleic acid, is believed to provide an “off switch” which alters the pharmacokinetics of the nucleic acid so as to reduce the duration of maximal immunostimulatory activity of the nucleic acid. This can be of particular value in tissues and in clinical applications in which it is desirable to avoid injury related to 15 chronic local inflammation or immunostimulation, e.g., the kidney.

A semi-soft nucleic acid is an immunostimulatory nucleic acid having a partially 15 stabilized backbone, in which phosphodiester or phosphodiester-like internucleotide linkages occur only within at least one internal pyrimidine-purine (YZ) dinucleotide. Semi-soft nucleic acids generally possess increased immunostimulatory potency relative to corresponding fully stabilized immunostimulatory nucleic acids. Due to the greater potency 20 of semi-soft nucleic acids, semi-soft nucleic acids may be used, in some instances, at lower effective concentrations and have lower effective doses than conventional fully stabilized immunostimulatory nucleic acids in order to achieve a desired biological effect.

It is believed that the foregoing properties of semi-soft nucleic acids generally increase with increasing “dose” of phosphodiester or phosphodiester-like internucleotide linkages involving internal YZ dinucleotides. Thus it is believed, for example, that generally for a 25 given nucleic acid sequence with five internal YZ dinucleotides, an nucleic acid with five internal phosphodiester or phosphodiester-like YZ internucleotide linkages is more immunostimulatory than an nucleic acid with four internal phosphodiester or phosphodiester-like YG internucleotide linkages, which in turn is more immunostimulatory than an nucleic acid with three internal phosphodiester or phosphodiester-like YZ internucleotide linkages, 30 which in turn is more immunostimulatory than an nucleic acid with two internal phosphodiester or phosphodiester-like YZ internucleotide linkages, which in turn is more immunostimulatory than an nucleic acid with one internal phosphodiester or phosphodiester-like YZ internucleotide linkage. Importantly, inclusion of even one internal phosphodiester or

- 45 -

phosphodiester-like YZ internucleotide linkage is believed to be advantageous over no internal phosphodiester or phosphodiester-like YZ internucleotide linkage. In addition to the number of phosphodiester or phosphodiester-like internucleotide linkages, the position along the length of the nucleic acid can also affect potency.

5 The soft and semi-soft nucleic acids will generally include, in addition to the phosphodiester or phosphodiester-like internucleotide linkages at preferred internal positions, 5' and 3' ends that are resistant to degradation. Such degradation-resistant ends can involve any suitable modification that results in an increased resistance against exonuclease digestion over corresponding unmodified ends. For instance, the 5' and 3' ends can be stabilized by the  
10 inclusion thereof at least one phosphate modification of the backbone. In a preferred embodiment, the at least one phosphate modification of the backbone at each end is independently a phosphorothioate, phosphorodithioate, methylphosphonate, or methylphosphorothioate internucleotide linkage. In another embodiment, the degradation-resistant end includes one or more nucleotide units connected by peptide or amide linkages at  
15 the 3' end.

A phosphodiester internucleotide linkage is the type of linkage characteristic of nucleic acids found in nature. The phosphodiester internucleotide linkage includes a phosphorus atom flanked by two bridging oxygen atoms and bound also by two additional oxygen atoms, one charged and the other uncharged. Phosphodiester internucleotide linkage  
20 is particularly preferred when it is important to reduce the tissue half-life of the nucleic acid.

A phosphodiester-like internucleotide linkage is a phosphorus-containing bridging group that is chemically and/or diastereomerically similar to phosphodiester. Measures of similarity to phosphodiester include susceptibility to nuclease digestion and ability to activate RNase H. Thus for example phosphodiester, but not phosphorothioate, nucleic acids are  
25 susceptible to nuclease digestion, while both phosphodiester and phosphorothioate nucleic acids activate RNase H. In a preferred embodiment the phosphodiester-like internucleotide linkage is boranophosphate (or equivalently, boranophosphonate) linkage. U.S. Patent No. 5,177,198; U.S. Patent No. 5,859,231; U.S. Patent No. 6,160,109; U.S. Patent No. 6,207,819; Sergueev et al., (1998) *J Am Chem Soc* 120:9417-27. In another preferred embodiment the  
30 phosphodiester-like internucleotide linkage is diasteromerically pure Rp phosphorothioate. It is believed that diasteromerically pure Rp phosphorothioate is more susceptible to nuclease digestion and is better at activating RNase H than mixed or diastereomerically pure Sp phosphorothioate. Stereoisomers of CpG nucleic acids are the subject of co-pending U.S.

patent application 09/361,575 filed July 27, 1999, and published PCT application PCT/US99/17100 (WO 00/06588). It is to be noted that for purposes of the instant invention, the term "phosphodiester-like internucleotide linkage" specifically excludes phosphorodithioate and methylphosphonate internucleotide linkages.

- 5 As described above the soft and semi-soft nucleic acids of the invention may have phosphodiester like linkages between C and G. One example of a phosphodiester-like linkage is a phosphorothioate linkage in an Rp conformation. Nucleic acid p-chirality can have apparently opposite effects on the immune activity of a CpG nucleic acid, depending upon the time point at which activity is measured. At an early time point of 40 minutes, the R<sub>p</sub>, but not  
10 the S<sub>p</sub> stereoisomer of phosphorothioate CpG nucleic acid induces JNK phosphorylation in mouse spleen cells. In contrast, when assayed at a late time point of 44 hr, the S<sub>p</sub> but not the R<sub>p</sub> stereoisomer is active in stimulating spleen cell proliferation. This difference in the kinetics and bioactivity of the R<sub>p</sub> and S<sub>p</sub> stereoisomers does not result from any difference in cell uptake, but rather most likely is due to two opposing biologic roles of the p-chirality.  
15 First, the enhanced activity of the Rp stereoisomer compared to the Sp for stimulating immune cells at early time points indicates that the Rp may be more effective at interacting with the CpG receptor, TLR9, or inducing the downstream signaling pathways. On the other hand, the faster degradation of the Rp PS-nucleic acids compared to the Sp results in a much shorter duration of signaling, so that the Sp PS-nucleic acids appear to be more biologically  
20 active when tested at later time points.

A surprisingly strong effect is achieved by the p-chirality at the CpG dinucleotide itself. In comparison to a stereo-random CpG nucleic acid the congener in which the single CpG dinucleotide was linked in Rp was slightly more active, while the congener containing an Sp linkage was nearly inactive for inducing spleen cell proliferation.

- 25 Nucleic acids also include substituted purines and pyrimidines such as C-5 propyne pyrimidine and 7-deaza-7-substituted purine modified bases. Wagner RW et al. (1996) *Nat Biotechnol* 14:840-4. Purines and pyrimidines include but are not limited to adenine, cytosine, guanine, and thymine, and other naturally and non-naturally occurring nucleobases, substituted and unsubstituted aromatic moieties.  
30 A modified base is any base which is chemically distinct from the naturally occurring bases typically found in DNA and RNA such as T, C, G, A, and U, but which share basic chemical structures with these naturally occurring bases. The modified nucleoside base may be, for example, selected from hypoxanthine, uracil, dihydrouracil, pseudouracil, 2-thiouracil,

- 47 -

- 4-thiouracil, 5-aminouracil, 5-(C<sub>1</sub>-C<sub>6</sub>)-alkyluracil, 5-(C<sub>2</sub>-C<sub>6</sub>)-alkenyluracil, 5-(C<sub>2</sub>-C<sub>6</sub>)-alkynyluracil, 5-(hydroxymethyl)uracil, 5-chlorouracil, 5-fluorouracil, 5-bromouracil, 5-hydroxycytosine, 5-(C<sub>1</sub>-C<sub>6</sub>)-alkylcytosine, 5-(C<sub>2</sub>-C<sub>6</sub>)-alkenylcytosine, 5-(C<sub>2</sub>-C<sub>6</sub>)-alkynylcytosine, 5-chlorocytosine, 5-fluorocytosine, 5-bromocytosine, N<sup>2</sup>-dimethylguanine,
- 5 2,4-diamino-purine, 8-azapurine, a substituted 7-deazapurine, preferably 7-deaza-7-substituted and/or 7-deaza-8-substituted purine, 5-hydroxymethylcytosine, N4-alkylcytosine, e.g., N4-ethylcytosine, 5-hydroxydeoxycytidine, 5-hydroxymethyldeoxycytidine, N4-alkyldeoxycytidine, e.g., N4-ethyldeoxycytidine, 6-thiodeoxyguanosine, and deoxyribonucleosides of nitropyrrole, C5-propynylpyrimidine, and
- 10 diaminopurine e.g., 2,6-diaminopurine, inosine, 5-methylcytosine, 2-aminopurine, 2-amino-6-chloropurine, hypoxanthine or other modifications of a natural nucleoside bases.
- This list is meant to be exemplary and is not to be interpreted to be limiting.

Modified cytosines include but are not limited to 5-substituted cytosines (e.g., 5-methyl-cytosine, 5-fluoro-cytosine, 5-chloro-cytosine, 5-bromo-cytosine, 5-iodo-cytosine, 5-hydroxy-cytosine, 5-hydroxymethyl-cytosine, 5-difluoromethyl-cytosine, and unsubstituted or substituted 5-alkynyl-cytosine), 6-substituted cytosines, N4-substituted cytosines (e.g., N4-ethyl-cytosine), 5-aza-cytosine, 2-mercaptop-cytosine, isocytosine, pseudo-isocytosine, cytosine analogs with condensed ring systems (e.g., N,N'-propylene cytosine or phenoxyazine), and uracil and its derivatives (e.g., 5-fluoro-uracil, 5-bromo-uracil, 5-bromovinyl-uracil, 4-thio-uracil, 5-hydroxy-uracil, 5-propynyl-uracil). In another embodiment, the cytosine base is substituted by a universal base (e.g., 3-nitropyrrole, P-base), an aromatic ring system (e.g., fluorobenzene or difluorobenzene) or a hydrogen atom (dSpacer).

Modified guanines include but are not limited to 7-deazaguanine, 7-deaza-7-substituted guanine (such as 7-deaza-7-(C<sub>2</sub>-C<sub>6</sub>)alkynylguanine), 7-deaza-8-substituted guanine, hypoxanthine, N2-substituted guanines (e.g., N2-methyl-guanine), 5-amino-3-methyl-3H,6H-thiazolo[4,5-d]pyrimidine-2,7-dione, 2,6-diaminopurine, 2-aminopurine, purine, indole, adenine, substituted adenines (e.g., N6-methyl-adenine, 8-oxo-adenine) 8-substituted guanine (e.g., 8-hydroxyguanine and 8-bromoguanine), and 6-thioguanine. In another embodiment, the guanine base is substituted by a universal base (e.g., 4-methyl-indole, 5-nitro-indole, and K-base), an aromatic ring system (e.g., benzimidazole or dichloro-benzimidazole, 1-methyl-1H-[1,2,4]triazole-3-carboxylic acid amide) or a hydrogen atom (dSpacer).

- 48 -

For use in the instant invention, the oligonucleotide reference compounds and test compounds can be synthesized *de novo* using any of a number of procedures well known in the art, for example, the  $\beta$ -cyanoethyl phosphoramidite method (Beaucage SL et al. (1981) *Tetrahedron Lett* 22:1859), or the nucleoside H-phosphonate method (Garegg et al. (1986) *Tetrahedron Lett* 27:4051-4; Froehler BC et al. (1986) *Nucleic Acids Res* 14:5399-407; Garegg et al (1986) *Tetrahedron Lett* 27:4055-8; Gaffney et al. (1988) *Tetrahedron Lett* 29:2619-22). These chemistries can be performed by a variety of automated nucleic acid synthesizers available in the market. These oligonucleotides are referred to as synthetic oligonucleotides. An isolated oligonucleotide generally refers to an oligonucleotide which is separated from components which it is normally associated with in nature. As an example, an isolated oligonucleotide may be one which is separated from a cell, from a nucleus, from mitochondria or from chromatin.

Modified backbones such as phosphorothioates can be synthesized using automated techniques employing either phosphoramidate or H-phosphonate chemistries. Aryl-and alkyl-phosphonates can be made, e.g., as described in U.S. Pat. No. 4,469,863; and alkylphosphotriesters (in which the charged oxygen moiety is alkylated as described in U.S. Pat. No. 5,023,243 and European Pat. No. 092,574) can be prepared by automated solid phase synthesis using commercially available reagents. Methods for making other DNA backbone modifications and substitutions have been described (e.g., Uhlmann E et al. (1990) *Chem Rev* 90:544; Goodchild J (1990) *Bioconjugate Chem* 1:165).

#### TLR expression

The cell lines can be used in their native state without any modification. For example, in the case of the RPMI 8226 cell line, it can be used to identify compounds that signal through at least TLR9 and/or TLR7. In other instances, however, the cell line can be modified to express a TLR that it does not naturally express. In still other instances, the cell to be used in the screening method may express one or more endogenous TLR and yet still be manipulated to express an additional TLR different from those it endogenously expresses. The cell may also be manipulated in order to increase or decrease the level of TLR that it endogenously expresses. The cells may be stably or transiently transfected.

A cell that does not naturally express a protein or polypeptide, but is genetically manipulated to do so is referred to as ectopically expressing the protein or polypeptide.

- 49 -

The basic screening method remains the same regardless of which TLR is expressed by the cell. However, the reference compound and the readout may vary depending upon the TLR(s) expressed. In the most simple aspect, the screening method is used to identify a compound that signals through a TLR such as for example TLR9. In this case, the positive 5 reference compound may be an immunostimulatory compound already known to act through TLR9 (e.g., CpG nucleic acid).

The methods of the invention involve, in part, contacting a functional TLR with a test composition. A functional TLR is a full-length TLR protein or a fragment thereof capable of inducing or inhibiting a signal in response to interaction with its ligand. Generally the 10 functional TLR will include at least a TLR ligand-binding fragment of the extracellular domain of the full-length TLR and at least a fragment of a TIR domain capable of interacting with another Toll homology domain-containing polypeptide, e.g., MyD88. In various embodiments the functional TLR is a full-length TLR selected from TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, and TLR10.

15 To date, there are eleven TLRs known. Nucleic acid and amino acid sequences for ten currently known human TLRs are available from public databases such as GenBank. Similarly, nucleic acid and amino acid sequences for various TLRs from numerous non-human species are also available from public databases including GenBank. For example, nucleic acid and amino acid sequences for human TLR9 (hTLR9) can be found as GenBank 20 accession numbers AF245704 (coding region spanning nucleotides 145-3243) (SEQ ID NO: 60) and AAF78037 (SEQ ID NO: 62), respectively. Nucleic acid and amino acid sequences for murine TLR9 (mTLR9) can be found as GenBank accession numbers AF348140 (coding region spanning nucleotides 40-3138) (SEQ ID NO: 68) and AAK29625 (SEQ ID NO: 72), respectively.

25 Nucleic acid and amino acid sequences for human TLR8 (hTLR8) can be found as GenBank accession numbers AF245703 (coding region spanning nucleotides 49-3174) (SEQ ID NO: 46) and AAF78036 (SEQ ID NO: 50), respectively. Nucleic acid and amino acid sequences for murine TLR8 (mTLR8) can be found as GenBank accession numbers AY035890 (coding region spanning nucleotides 59-3157) (SEQ ID NO: 55) and AAK62677 30 (SEQ ID NO: 57), respectively.

Nucleic acid and amino acid sequences for human TLR7 (hTLR7) can be found as GenBank accession numbers AF240467 (coding region spanning nucleotides 135-3285) (SEQ ID NO: 31) and AAF60188 (SEQ ID NO: 34), respectively. Nucleic acid and amino acid

- 50 -

sequences for murine TLR7 (mTLR7) can be found as GenBank accession numbers AY035889 (coding region spanning nucleotides 49-3201) (SEQ ID NO: 38) and AAK62676 (SEQ ID NO: 41), respectively.

Nucleic acid and amino acid sequences for human TLR3 (hTLR3) can be found as  
5 GenBank accession numbers NM\_003265 (coding region spanning nucleotides 102-2816)  
(SEQ ID NO: 7) and NP\_003256 (SEQ ID NO: 8), respectively. Nucleic acid and amino acid  
sequences for murine TLR3 (hTLR3) can be found as GenBank accession numbers  
AF355152 (coding region spanning nucleotides 44-2761) (SEQ ID NO: 9) and AAK26117  
(SEQ ID NO: 10), respectively.

10 Nucleic acid and amino acid sequences for human TLR1 (hTLR1) can be found as  
GenBank accession numbers NM\_003263 and NP\_003254, respectively. Nucleic acid and  
amino acid sequences for murine TLR1 (mTLR1) can be found as GenBank accession  
numbers NM\_030682 and NP\_109607, respectively.

The functional TLR also is not limited to native TLR polypeptides. As used herein, a  
15 native TLR is one that is naturally occurring. The TLR may be a non-native (or non-naturally  
occurring TLR). An example is a chimeric TLR having an extracellular domain and the  
cytoplasmic domain derived from TLRs from different species. Such chimeric TLR  
polypeptides can include, for example, a human TLR extracellular domain and a murine TLR  
cytoplasmic domain. In alternative embodiments, such chimeric TLR polypeptides can  
20 include chimerae created with different TLR splice variants or allotypes.

#### TLR Signaling Pathways

The screening methods provided by the invention measure TLR signaling activity.  
TLR signaling activity is activity that results from interaction of a TLR with a TLR ligand.  
25 TLR signaling can be measured in a number of ways including but not limited to interaction  
between a TLR and a protein or factor (such as an adaptor protein), interaction between  
downstream proteins or factors (such as an adaptor protein) with each other, activation of  
nuclear factors such as transcription factors or transcription complexes, up- or down-  
regulation of genes, phosphorylation or dephosphorylation of proteins or factors in the  
30 signaling cascade, expression, production and/or secretion of cytokines and/or chemokines,  
changes in cell cycle status, up- or down-regulation of cell surface marker expression, and the  
like. Those of ordinary skill in the art are familiar with assays for measuring these latter

- 51 -

events including but not limited to gel shift assays, immunoprecipitations, phosphorylation status analysis of proteins, Northern analysis, RT-PCR analysis, etc.

The following is an exemplary TLR signaling pathway or cascade. It is to be understood that this is meant to be illustrative and that different factors may be involved in the 5 signaling of particular TLR. One TLR signaling pathway is known to use the cytoplasmic Toll/IL-1 receptor (TIR) homology domain, present in all TLRs. This domain interacts (e.g., binds to) and thereby transduces a signal to a similar domain on an adapter protein (e.g., MyD88). This type of interaction is referred to as a like:like interaction of TIR domains. This interaction is followed by another interaction between the adapter protein and a 10 kinase, through their respective "death domains". In the case of at least TLR4 signaling, the kinase then interacts with tumor necrosis factor (TNF) receptor-associated factor-6 (TRAF6). Medzhitov R et al., *Mol Cell* 2:253 (1998); Kopp EB et al., *Curr Opin Immunol* 11:15 (1999). After TRAF6, two sequential kinase activation steps lead to phosphorylation of the inhibitory protein I kappa B and its dissociation from NF- $\kappa$ B. The first kinase is a mitogen-activated 15 kinase kinase kinase (MAPKKK) known as NIK, for NF- $\kappa$ B-inducing kinase. The target of this kinase is another kinase made up of two chains, called I kappa B kinase  $\alpha$  (IKK  $\alpha$ ) and I kappa B kinase  $\beta$  (IKK  $\beta$ ), that together form a heterodimer of IKK $\alpha$ :IKK $\beta$ , which phosphorylates I kappa B. NF- $\kappa$ B translocates to the nucleus to activate genes with kappa B binding sites in their promoters and enhancers such as the genes encoding IL-6, IL-8, the p40 20 subunit of IL-12, and the costimulatory molecule CD86. The signaling mechanisms of TLRs are not limited to this pathway; other signaling pathways exist and can be used in the screening readouts of the methods provided herein.

The screening assays employ a number of readouts (or parameters). The readouts can be native readouts. A native readout is one that does not rely on introduction of a reporter 25 construct into the cell of interest. The readouts can be artificial. An artificial readout is one that relies on introduction of a reporter construct into the cell of interest. Examples of both are provided herein. In still other embodiments, a given assay may measure one or more native readouts and one or more artificial readouts. Each readout whether native or artificial is related to signaling pathways that ensue after TLR engagement with a ligand.

30 Each cell line described herein will be associated with a particular set of native readouts which the invention seeks to determine in the screening assays provided. As an example, the response of the RPMI 8226 cell line to an immunomodulatory molecule can be assessed in terms of native readouts such as CD71 expression, CD86 expression, HLA-DR

- 52 -

expression, IL-8 expression, IL-8 production, IL-8 secretion, IL-10 expression, IL-10 production, IL-10 secretion, IP-10 expression, IP-10 production, IP-10 secretion, TNF- $\alpha$  expression, TNF- $\alpha$  production and TNF- $\alpha$  secretion. RAMOS response can be assessed, inter alia, by CD80 cell surface expression. Raji response can be assessed, inter alia, by IL-6 secretion.

As described in greater detail herein, the cell line can be used in an unmodified form. In one respect, an unmodified cell line will naturally respond to a TLR ligand through a native readout system. For example, an RPMI 8226 cell exposed to an immunostimulatory TLR ligand may increase expression of IP-10 from the native gene locus. Alternatively, the cell line may be modified to contain a reporter construct that acts as a surrogate for the IP-10 gene locus. For example, the reporter construct may contain the TLR responsive promoter elements that are naturally found in the native IP-10 locus operably linked to a reporter coding sequence that encodes a gene product that is detectable and quantifiable. The structure and variability of suitable reporter constructs will be discussed in greater detail herein.

Readouts typically include the induction of a gene under control of a specific promoter such as a NF- $\kappa$ B promoter. The gene under the control of the NF- $\kappa$ B promoter can be a gene which naturally includes an NF- $\kappa$ B promoter or it can be a gene in a construct in which an NF- $\kappa$ B promoter has been inserted. Endogenous genes and transfected constructs which include the NF- $\kappa$ B promoter include but are not limited to IL-8, IL-12 p40, NF- $\kappa$ B-luc, IL-12 p40-luc, and TNF-luc.

Increases in cytokine levels can result from increased production, increased stability, increased secretion, or any combination of the forgoing, of the cytokine in response to the TLR-mediated signaling. Cytokines generally include, without limitation, IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-11, IL-12, IL-13, IL-15, IL-18, IFN- $\alpha$ , IFN- $\beta$ , IFN- $\gamma$ , TNF- $\alpha$ , GM-CSF, G-CSF, M-CSF. Th1 cytokines include but are not limited to IL-2, IFN- $\gamma$ , and IL-12. Th2 cytokines include but are not limited to IL-4, IL-5, and IL-10.

Increases in chemokine levels can result from increased production, increased stability, increased secretion, or any combination of the forgoing, of the chemokine in response to the TLR-mediated signaling. Chemokines of particular significance in the invention include but are not limited to CCL5 (RANTES), CXCL9 (Mig), CXCL10 (IP-10), CXCL11 (I-TAC), IL-8, and MCP-1.

- 53 -

TLR signaling activity can also be measured by phosphorylation, such as total cellular phosphorylation or phosphorylation of specific factors such as but not limited to IRAK, ERK, MyD88, TRAF6, p38, NF- $\kappa$ B subunits, c-Jun and c-Fos.

5 TLR signaling activity can be measured by changes in gene expression. The expression of CD71, CD86, CD80, CD69, CD54, HLA-DR, HLA class I, IL-6, IL-8, IL-10, IP-9, IP-10, IFN- $\alpha$ , TNF- $\alpha$ , and the like can be assessed as a measure of TLR signaling activity. Gene expression analysis may be performed using microarray techniques.

TLR signaling activity can also be measured by cell proliferation status or changes thereto.

10 TLR signaling activity can also be measured by cell surface marker expression such as the cell surface expression of markers such as but not limited to CD71, CD86, HLA-DR, CD80, HLA class I, CD54 and CD69.

TLR signaling activity can also be measured by antibody secretion such as but not limited to IgM secretion.

15

#### Reporter and Expression Constructs

The cells can be manipulated by the introduction of expression and/or reporter constructs. The expression constructs preferably comprise a TLR coding sequence, as described above. The reporter constructs can be used as surrogate measures of native TLR 20 signaling activity. These reporter constructs are intended to substitute for the "native" readouts capable with the cell line. In order to act as substitutes, the reporter constructs include a promoter element derived from a gene known to be modulated following TLR engagement with a TLR ligand. The reporter construct further includes a coding sequence linked to the promoter. The coding sequence is usually that of a reporter (i.e., a protein that is 25 detectable or quantifiable).

The reporter construct generally includes a promoter, a coding sequence and a polyadenylation signal. These nucleic acids shall include, as necessary, 5' non-transcribing and 5' non-translating sequences involved with the initiation of transcription and translation, respectively, such as a TATA box, capping sequence, CAAT sequence, in addition to 30 promoter elements that are responsive to TLR signaling. The nucleic acid constructs may optionally include enhancer sequences or upstream activator sequences as desired.

The promoter in the reporter construct will include a TLR responsive promoter element, and will therefore be regarded as a TLR responsive promoter. As used herein, a

TLR responsive promoter is a promoter having an activity that is modulated (i.e., either activated or inhibited) by signaling through a TLR (e.g., by TLR interaction with its ligand). In order to be modulated by TLR signaling, the promoter contains sites that are bound by transcription factors modulated by TLR signaling. The factors may be activated or inhibited 5 by TLR signaling. Activation of the transcription factor includes increases in the activity of the transcription factor per se, increases in its ability to interact with other factors or with DNA that serve to increase its activity, and increases in its transcription and translation (i.e., increased mRNA and protein levels of the transcription factor). Conversely, inhibition of the transcription factor includes decreases in the activity of the transcription factor per se, 10 decreases in its ability to interact with other factors or with DNA that serve to decrease its activity, and decreases in its transcription and translation (i.e., decreased mRNA and protein levels of the transcription factor). The effect on the transcription factor is usually the downstream result of other interactions in the signaling pathway. The expression of coding sequences linked to such promoters will therefore be modulated by TLR signaling events, and 15 it is the level of expression of these coding sequences that can be used as a readout of TLR signaling in the screening methods provided herein.

The TLR responsive promoter may comprise a transcription factor binding site selected from the group consisting of a NF- $\kappa$ B binding site, an AP-1 binding site, a CRE, a SRE, an interferon-stimulated response element (ISRE), a GAS, an ATF2 binding site, an 20 IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding site, and a TARE, among others. These binding sites and their sequences are known in the art. Below is a exemplary list of these sequences.

W = A or T, R = A or G, Y = C or T

25 NF- $\kappa$ B Binding site:

Consensus p50 subunit  
5' GGGGATYCCC 3' (SEQ ID NO:90)

30 Consensus p65 subunit  
5' GGGRNTTCC 3' (SEQ ID NO:91)

Example of p65 subunit binding site  
5' AGT TGA GGG GAC TTT CCC AGG C 3' (SEQ ID NO:92)

35 CREB Binding site:  
5'AGA GAT TGC CTG ACG TCA GAG AGC TAG 3' (SEQ ID NO:93)

- 55 -

**AP-1 Binding site:**

- 5'- CGC TTG ATG AGT CAG CCG GAA -3' (SEQ ID NO:94)
- 5'- CGC ATG AGT CAG ACA -3' (SEQ ID NO:95)

5 ISRE :

- 5'- TGCAGAAGTGAAACTGAGGG-3' (SEQ ID NO:96)
- 5'- AGAACGAAACA-3' (SEQ ID NO:97)
- 5'- GAGAAGTGAAAGTGG-3' (SEQ ID NO:98)
- 5'- TAAGAACATGAAACTGAA-3' (SEQ ID NO:99)
- 10 5'- ATGAAACTGAAAGTA-3' (SEQ ID NO:100)
- 5'- TGAAAACCGAAAGCGC-3' (SEQ ID NO:101)
- 5'- AGAAATGGAAAGT-3' (SEQ ID NO:102)

SRE

- 15 5'- TCACCCCCAC-3' (SEQ ID NO:103)  
 5'- CTCACCCCCAC-3' (SEQ ID NO:104)  
 5'- GCCACCCTAC-3' (SEQ ID NO:105)

NFAT:

- 20 5'- TATGAAACAGTTTCC -3' (SEQ ID NO:106)  
 5'- AGGAAACTC -3' (SEQ ID NO:107)  
 5'- ARGARATTCC -3' (SEQ ID NO:108)  
 5'- CCAGTTGAGCCAGAGA -3' (SEQ ID NO:109)

25 GAS:

- 5'- CTTTCAGTTCATATTACTCTAAATCCATT -3' (SEQ ID NO:110)

p53 Binding Site :

- 30 p53 Consensus site:  
 5'- RRRCWWGYYY -3' (SEQ ID NO:111)

Examples of p53 binding sites:

- 35 5'- AGGCATGCCT -3' (SEQ ID NO:112)  
 5'- GGGCTTGCCTC -3' (SEQ ID NO:113)  
 5'- GGGCTTGCTT -3' (SEQ ID NO:114)  
 5'- GCCTGGACTTGCC -3' (SEQ ID NO:115)  
 5'- GGACATGCCGGGCATGTCC -3' (SEQ ID NO:116)  
 5'- GTAGCATTAGCCCAGACATGTCC -3' (SEQ ID NO:117)

40

TARE (TNF- $\alpha$  response element):

e.g. from the COL1A1 promoter

5'GAGGTATGCAGACAGAGTCAGAGTTCCCCTTGAA 3' (SEQ ID  
 NO:118)

45

SRF

- 5'- CCWWWWWWGG -3' (SEQ ID NO:119)
- 5'- CCAAATAAGGC -3' (SEQ ID NO:120)

- 56 -

The TLR responsive promoter element can be derived from the promoter of a naturally occurring (i.e., an endogenous) gene that is activated or inhibited by TLR signaling (such as the IL-6 gene, the IL-8 gene, the IL-10 gene, the IL-12 p40 gene, the IP-9 gene, the IP-10 gene, the type 1 IFN gene, the IFN- $\alpha$ 4 gene, the IFN- $\beta$  gene, the TNF- $\alpha$  gene, the TNF- $\beta$  gene, the RANTES gene, the ITAC gene, the IGFBP4 gene, the CD54 gene, the CD69 gene, the CD71 gene, the CD80 gene, the CD86 gene, the HLA-DR gene, the HLA class I gene, and the like). The afore-mentioned genes are genes that are known to be activated in response to TLR interaction with its ligand.

Suitable promoter regions are described in the Examples. Briefly, the upstream (5') – 10 620 to +50 promoter region of IFN- $\alpha$ 4 or the upstream (5') – 140 to +9 promoter region of IFN- $\alpha$ 1 can be used. In one embodiment, the IFN- $\alpha$ 4 sequence is cloned into the *Sma*I site of the pGL3-Basic Vector (Promega) resulting in an expression vector that includes a luciferase gene under the control of the upstream (5') promoter region of IFN- $\alpha$ 4.

The promoter can also be the upstream (5') – 280 to +20 promoter region of IFN- $\beta$ .  
15 The promoter can also be the upstream (5') – 397 to +5 promoter region of RANTES.

In one embodiment, the RANTES promoter sequence is cloned into the *Nhe*I site (filled in with Klenow) of the pGL3-Basic Vector (Promega) resulting in an expression vector that includes a luciferase gene under the control of the upstream (5') – 397 to +5 promoter region of RANTES.

20 The promoter can also be the upstream truncated (-250 to +30) and full length (-860 to +30) promoter regions derived from human IL-12 p40 genomic DNA. In one embodiment, the truncated IL-12 p40 promoter was cloned as a *Kpn*I-*Xho*I insert into p $\beta$ gal-Basic (Promega) resulting in an expression vector that includes a  $\beta$  gal gene under the control of the upstream (5') – 250 to +30 promoter region of human IL-12 p40. In another embodiment, the truncated 25 full length IL-12 p40 promoter was cloned as a *Kpn*I-*Xho*I insert into p $\beta$ gal-Basic (Promega) resulting in an expression vector that includes a  $\beta$  gal gene under the control of the upstream (5') – 751 to +30 promoter region of human IL-12 p40. In another embodiment, the truncated –250 to +30 promoter region of human IL-12 p40 was cloned into the pGL3-Basic Vector (Promega) resulting in an expression vector that includes a luciferase gene under the control 30 of the upstream (5') – 250 to +30 promoter region of human IL-12 p40. In yet another embodiment, the full length IL-12 p40 promoter of human IL-12 p40 was cloned into the

- 57 -

pGL3-Basic Vector (Promega) resulting in an expression vector that includes a luciferase gene under the control of the upstream (5') -751 to +30 promoter region of human IL-12 p40.

The promoter can also be the upstream (5') -288 to +7 promoter region derived from human IL-6 genomic DNA. The promoter can also be derived from the full-length promoter 5 region of the IL-6 gene from -1174 to + 7 (Accession No M22111, SEQ ID NO:129).

The promoter can also be the upstream (5') -734 to +44 or the upstream (5') -162 to +44 promoter region derived from human IL-8 genomic DNA. Mukaida N et al. (1989) *J Immunol* 143:1366-71.

The promoter can also be derived from the -615 to +30 promoter region of human 10 TNF- $\alpha$ .

The promoter can also be derived from a promoter region of human TNF- $\beta$ .

The promoter can also be derived from the -875 to +97 promoter region of human IP- 10.

The promoter can also be derived from the -219 to +114 promoter region of human 15 CXCL11 (IP9). The promoter can also be derived from the full length (-934 to +114) promoter region of human CXCL11 (IP9).

The promoter can also be derived from the -289 to +217 promoter region of human IGFBP4 (Insulin growth factor binding protein 4). The promoter can also be derived from the full length (-836 to +217) promoter region of human IGFBP4.

20 The promoter response element generally will be present in multiple copies, e.g., as tandem repeats. For example, in one reporter construct, coding sequence for luciferase is under control of an upstream 6X tandem repeat of NF- $\kappa$ B response element. In another example, an ISRE-luciferase reporter construct useful in the invention is available from Stratagene (catalog no. 219092) and includes a 5x ISRE tandem repeat joined to a TATA box 25 upstream of a luciferase reporter gene.

The reporter construct coding sequence is preferably any nucleotide sequence that codes for a protein capable of detection or quantification. The protein can be an enzyme (e.g., luciferase, alkaline phosphatase,  $\beta$ -galactosidase, chloramphenicol acetyltransferase (CAT), secreted alkaline phosphatase, etc.), a bioluminescence marker (e.g., green fluorescent protein 30 (GFP, U.S. Pat. No. 5,491,084), etc.), blue fluorescent protein (BFP, e.g., U.S. Pat. No. 6,486,382), etc.), a surface-expressed molecule (e.g., CD25, CD80, CD86), a secreted molecule (e.g., IL-1, IL-6, IL-8, IL-12 p40, TNF- $\alpha$ ), a hapten or antigen, and other detectable protein products known to those of skill in the art. For assays relying on enzyme activity

readout, substrate can be supplied as part of the assay, and detection can involve measurement of chemiluminescence, fluorescence, color development, incorporation of radioactive label, drug resistance, or other marker of enzyme activity. For assays relying on surface expression of a molecule, detection can be accomplished using flow cytometry (FACS) analysis or 5 functional assays. Secreted molecules can be assayed using enzyme-linked immunosorbent assay (ELISA) or bioassays. Many of these and other suitable readout systems are well known in the art and are commercially available. Preferably, the coding sequence encodes a protein having a level or an activity that is quantifiable, preferably with a wide linear range.

The expression construct coding sequence is preferably a TLR coding sequence 10 derived from the sequences listed herein. Preferably, the expression construct promoter is a constitutive promoter, although in some embodiments it may be inducible. Those of ordinary skill in the art are familiar with such promoters.

As used herein, a coding sequence and the regulatory sequences (such as promoters) are said to be operably linked when they are covalently linked in such a way as to place the 15 expression or transcription and/or translation of the coding sequence under the influence or control of the regulatory sequence. Two DNA sequences are said to be operably linked if induction of a promoter in the 5' regulatory sequence results in the transcription of the coding sequence and if the nature of the linkage between the two DNA sequences does not (1) result in the introduction of a frame-shift mutation, (2) interfere with the ability of the promoter 20 region to direct the transcription of the coding sequence, or (3) interfere with the ability of the corresponding RNA transcript to be translated into a protein. Thus, a regulatory sequence would be operably linked to a coding sequence if the gene expression sequence were capable of effecting transcription of that coding sequence such that the resulting transcript is translated into the desired protein or polypeptide.

25 Methods for nucleic acid introduction into cells are known in the art.

The nucleic acid may be delivered to the cells alone or in association with a vector. In its broadest sense, a vector is any vehicle capable of facilitating the transfer of the nucleic acid to the cells so that the reporter can be expressed. The vector generally transports the nucleic acid to the cells with reduced degradation relative to the extent of degradation that would 30 result in the absence of the vector. In general, the vectors useful in the invention include, but are not limited to, plasmids, phagemids, viruses, other vehicles derived from viral or bacterial sources that have been manipulated by the insertion or incorporation of the antigen nucleic acid sequences. Viral vectors are a preferred type of vector and include, but are not limited

- 59 -

to, nucleic acid sequences from the following viruses: retrovirus, such as Moloney murine leukemia virus, Harvey murine sarcoma virus, murine mammary tumor virus, and Rous sarcoma virus; adenovirus, adeno-associated virus; SV40-type viruses; polyoma viruses; Epstein-Barr viruses; papilloma viruses; herpes virus; vaccinia virus; polio virus; and RNA 5 virus such as a retrovirus. One can readily employ other vectors not named but known in the art.

Preferred viral vectors are based on non-cytopathic eukaryotic viruses in which non-essential genes have been replaced with the gene of interest. Non-cytopathic viruses include retroviruses, the life cycle of which involves reverse transcription of genomic viral 10 RNA into DNA with subsequent proviral integration into host cellular DNA. Retroviruses have been approved for human gene therapy trials. Most useful are those retroviruses that are replication-deficient (i.e., capable of directing synthesis of the desired proteins, but incapable of manufacturing an infectious particle). Such genetically altered retroviral expression vectors have general utility for the high-efficiency transduction of genes *in vivo*. Standard 15 protocols for producing replication-deficient retroviruses (including the steps of incorporation of exogenous genetic material into a plasmid, transfection of a packaging cell lined with plasmid, production of recombinant retroviruses by the packaging cell line, collection of viral particles from tissue culture media, and infection of the target cells with viral particles) are provided in Kriegler, M., Gene Transfer and Expression, A Laboratory Manual W.H. Freeman C.O., New York (1990) and Murray, E.J. Methods in Molecular Biology, vol. 7, 20 Humana Press, Inc., Clifton, New Jersey (1991).

A preferred virus for certain applications is the adeno-associated virus, a double-stranded DNA virus. The adeno-associated virus can be engineered to be replication 25 deficient and is capable of infecting a wide range of cell types and species. It further has advantages such as, heat and lipid solvent stability; high transduction frequencies in cells of diverse lineages, including hemopoietic cells; and lack of superinfection inhibition thus allowing multiple series of transductions. Reportedly, wild-type adeno-associated virus manifest some preference for integration sites into human cellular DNA, thereby minimizing the possibility of insertional mutagenesis and variability of inserted gene expression 30 characteristic of retroviral infection. In addition, wild-type adeno-associated virus infections have been followed in tissue culture for greater than 100 passages in the absence of selective pressure, implying that the adeno-associated virus genomic integration is a relatively stable event. The adeno-associated virus can also function in an extrachromosomal fashion.

Recombinant adeno-associated viruses that lack the replicase protein apparently lack this integration sequence specificity.

Other vectors include plasmid vectors. Plasmid vectors have been extensively described in the art and are well-known to those of skill in the art. See e.g., Sambrook et al.,

- 5 Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, 1989. In the last few years, plasmid vectors have been found to be particularly advantageous for delivering genes to cells *in vivo* because of their inability to replicate within and integrate into a host genome. These plasmids, however, having a promoter compatible with the host cell, can express a peptide from a gene operatively encoded within the plasmid.
- 10 Some commonly used plasmids include pBR322, pUC18, pUC19, pRc/CMV, SV40, and pBlueScript. Other plasmids are well-known to those of ordinary skill in the art. Additionally, plasmids may be custom designed using restriction enzymes and ligation reactions to remove and add specific fragments of DNA.

In general, the vectors useful in the invention are divided into two classes: biological  
15 vectors and chemical/physical vectors. Biological vectors and chemical/physical vectors are useful in the delivery and/or uptake of reporter constructs of the invention.

Most biological vectors are used for delivery of nucleic acids and thus would be most appropriate in the delivery of nucleic acids.

- As used herein, a "chemical/physical vector" refers to a natural or synthetic molecule,  
20 other than those derived from bacteriological or viral sources, capable of delivering the reference and test compound.

A preferred chemical/physical vector of the invention is a colloidal dispersion system. Colloidal dispersion systems include lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. A preferred colloidal system of the invention is a  
25 liposome. Liposomes are artificial membrane vessels which are useful as a delivery vector *in vivo* or *in vitro*. It has been shown that large unilamellar vessels (LUV), which range in size from 0.2 - 4.0  $\mu\text{m}$  can encapsulate large macromolecules. RNA, DNA and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (Fraley, et al., *Trends Biochem. Sci.*, (1981) 6:77).

- 30 Liposomes may be targeted to a particular tissue by coupling the liposome to a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein. Ligands which may be useful for targeting a liposome to an immune cell include, but are not limited to, intact or fragments of molecules which interact with immune cell specific receptors and molecules,

- 61 -

such as antibodies, which interact with the cell surface markers of immune cells. Such ligands may easily be identified by binding assays well known to those of skill in the art. In still other embodiments, the liposome may be targeted to the cancer by coupling it to a one of the immunotherapeutic antibodies discussed earlier. Additionally, the vector may be coupled 5 to a nuclear targeting peptide, which will direct the vector to the nucleus of the host cell.

Lipid formulations for transfection are commercially available from QIAGEN, for example, as EFFECTENE™ (a non-liposomal lipid with a special DNA condensing enhancer) and SUPERFECT™ (a novel acting dendrimeric technology).

Liposomes are commercially available from Gibco BRL, for example, as  
10 LIPOFECTIN™ and LIPOFECTACE™, which are formed of cationic lipids such as N-[1-(2,3 dioleyloxy)-propyl]-N, N, N-trimethylammonium chloride (DOTMA) and dimethyl dioctadecylammonium bromide (DDAB). Methods for making liposomes are well known in the art and have been described in many publications. Liposomes also have been reviewed by Gregoriadis, G. in *Trends in Biotechnology*, (1985) 3:235-241. In some preferred  
15 embodiments, the method of choice for delivering DNA (for transfection) to the cells is electroporation, particularly where a stably transfected cell line is sought.

The present invention is further illustrated by the following Examples, which in no way should be construed as further limiting.

20

### Examples

#### **Example 1. Biological Activity of Production Lot of CpG ODN (SEQ ID NO:1) Assayed Using Cells Stably Transfected with hTLR9 Expression Vector**

CpG ODN (SEQ ID NO:1) is currently in preclinical and clinical trials for a number of  
25 clinical applications. SEQ ID NO:1 has been discovered to induce signaling through TLR9. In order to assess different lots of clinical material, the methods of the invention are employed, using a highly characterized lot of SEQ ID NO:1 as a reference.

In a TLR9 assay, the CpG-non-responsive human embryonal kidney cell line HEK293 (e.g., ATCC CRL-1573) was stably transfected with a hTLR9 expression construct and found  
30 to express full-length human TLR9 constitutively. The cells also contained a genomic copy of a reporter construct with a 6x NF- $\kappa$ B binding site and a luciferase gene reporter cassette. Incubation of the cells with CpG ODN (SEQ ID NO:1) activates NF- $\kappa$ B driven expression of luciferase, while incubation with medium alone (negative control) does not. The cells are

then lysed and activity of the luciferase protein determined by its catalytic activity of luciferin oxidation which is measured in a luminometer. Results are expressed as fold induction above medium control.

Assay set-up includes a reference standard material which is highly pure and well characterized. The reference material is used to create a standard curve within a defined range where the dose-response curve is linear (e.g., in the range of the EC50 value for SEQ ID NO:1, 70-100 nM). The test material is dissolved for testing and assayed at a defined concentration. Activity of the test material is calculated using the standard curve of the reference material. Quality of the tested material is deemed acceptable if activity of the test material compared to activity of the reference material falls within predetermined limits.

**Example 2. Biological Activity of Production Lot of CpG ODN (SEQ ID NO:1) Assayed Using RPMI 8226 Cells**

The assay of Example 1 is performed using RPMI 8226 cells (ATCC CCL-155) in place of the stably transfected HEK cells of Example 1. RPMI 8226 cells naturally express human TLR9. The cells are stably transfected with a 6x NF- $\kappa$ B-luciferase reporter construct. It is to be understood that the assay could also be carried out by measuring a native readout such as IL-10 secretion.

**20 Example 3. Expression Vectors for Human TLR3 (hTLR3) and Murine TLR3 (mTLR3)**

To create an expression vector for human TLR3, human TLR3 cDNA was amplified by the polymerase chain method (PCR) from a cDNA made from human 293 cells using the primers 5'-GAAACTCGAGCCACCATGAGACAGACTTGCCTTGTATCTAC-3' (sense, SEQ ID NO:152) and 5'-GAAAGAATTCTTAATGTACAGAGTTTGGATCCAAG-3' (antisense, SEQ ID NO:153). The primers introduce *Xho*I and *Eco*RI restriction endonuclease sites at their 5' ends for use in subsequent cloning into the expression vector. The resulting amplification product fragment was cloned into pGEM-T Easy vector (Promega), isolated, cut with *Xho*I and *Eco*RI restriction endonucleases, ligated into an *Xho*I/*Eco*RI-digested pcDNA3.1 expression vector (Invitrogen). The insert was fully sequenced and translated into protein. The cDNA sequence corresponds to the published cDNA sequence for hTLR3, available as GenBank accession no. NM\_003265 (SEQ ID NO:7). The open reading frame codes for a protein 904 amino acids long, having the sequence corresponding to GenBank accession no. NP\_003256 (SEQ ID NO:8).

Corresponding nucleotide and amino acid sequences for murine TLR3 (mTLR3) are known. The nucleotide sequence of mTLR3 cDNA has been reported as GenBank accession no. AF355152 (SEQ ID NO:9), and the amino acid sequence of mTLR3 has been reported as GenBank accession no. AAK26117 (SEQ ID NO:10).

5

#### **Example 4. Reconstitution of TLR3 Signaling in 293 Fibroblasts**

Human TLR3 cDNA and murine TLR3 cDNA in pT-Adv vector (from Clontech) were individually cloned into the expression vector pcDNA3.1(-) from Invitrogen using the *Eco*RI site. The resulting expression vectors mentioned above were transfected into

- 10 CpG-DNA non-responsive human 293 fibroblast cells (ATCC, CRL-1573) using the calcium phosphate method. Utilizing a "gain of function" assay it was possible to reconstitute human TLR3 (hTLR3) and murine TLR3 (mTLR3) signaling in 293 fibroblast cells.

Since NF- $\kappa$ B activation is central to the IL-1/TLR signal transduction pathway (Medzhitov R et al. (1998) *Mol Cell* 2:253-8; Muzio M et al. (1998) *J Exp Med*

- 15 187:2097-101), in a first set of experiments human 293 fibroblast cells were transfected with hTLR3 alone or co-transfected with hTLR3 and an NF- $\kappa$ B-driven luciferase reporter construct.

Likewise, in a second set of experiments, 293 fibroblast cells were transfected with hTLR3 alone or co-transfected with hTLR3 and an IFN- $\alpha$ 4-driven luciferase reporter 20 construct (described in Example 8 below).

In a third group of experiments, 293 fibroblast cells were transfected with hTLR3 alone or co-transfected with hTLR3 and a RANTES-driven luciferase reporter construct (described in Example 14 below).

- 25 **Example 5. Reconstitution of TLR7 Signaling**

Methods for cloning murine and human TLR7 have been described in pending U.S. Pat. Application No. 09/954,987 and corresponding published PCT application PCT/US01/29229 (WO 02/22809), both filed September 17, 2001, the contents of which are incorporated herein by reference. Human TLR7 cDNA and murine TLR7 cDNA in pT-Adv 30 vector (from Clontech) were individually cloned into the expression vector pcDNA3.1(-) from Invitrogen using the *Eco*RI site. Utilizing a "gain of function" assay it was possible to reconstitute human TLR7 (hTLR7) and murine TLR7 (mTLR7) signaling in CpG-DNA non-responsive human 293 fibroblasts (ATCC, CRL-1573). The expression vectors

- 64 -

mentioned above were transfected into 293 fibroblast cells using the calcium phosphate method.

#### **Example 6. Reconstitution of TLR8 Signaling**

5 Methods for cloning murine and human TLR8 have been described in pending U.S. Pat. Application No. 09/954,987 and corresponding published PCT application PCT/US01/29229 (WO 02/22809), both filed September 17, 2001, the contents of which are incorporated by reference. Human TLR8 cDNA and murine TLR8 cDNA in pT-Adv vector (from Clontech) were individually cloned into the expression vector pcDNA3.1(-) from  
10 Invitrogen using the EcoRI site. Utilizing a "gain of function" assay it was possible to reconstitute human TLR8 (hTLR8) and murine TLR8 (mTLR8) signaling in CpG-DNA non-responsive human 293 fibroblasts (ATCC, CRL-1573). The expression vectors mentioned above were transfected into 293 fibroblast cells using the calcium phosphate method.

15

#### **Example 7. Reconstitution of TLR9 Signaling in 293 Fibroblasts**

Methods for cloning murine and human TLR9 have been described in pending U.S. Pat. Application No. 09/954,987 and corresponding published PCT application PCT/US01/29229 (WO 02/22809), both filed September 17, 2001, the contents of which are incorporated by reference. Human TLR9 cDNA and murine TLR9 cDNA in pT-Adv vector (from Clontech) were individually cloned into the expression vector pcDNA3.1(-) from  
20 Invitrogen using the EcoRI site. Utilizing a "gain of function" assay it was possible to reconstitute human TLR9 (hTLR9) and murine TLR9 (mTLR9) signaling in CpG-DNA non-responsive human 293 fibroblasts (ATCC, CRL-1573). The expression vectors  
25 mentioned above were transfected into 293 fibroblast cells using the calcium phosphate method.

To generate stable clones expressing human TLR9, murine TLR9, or either TLR9 with the NF- $\kappa$ B-luc reporter plasmid, 293 cells were transfected in 10 cm plates ( $2 \times 10^6$  cells/plate) with 16  $\mu$ g of DNA and selected with 0.7 mg/ml G418 (PAA Laboratories GmbH, Cöln, Germany). Clones were tested for TLR9 expression by RT-PCR, for example as shown in Fig. 21. The clones were also screened for IL-8 production or NF- $\kappa$ B-luciferase activity after stimulation with ODN. Four different types of clones were generated.

- 65 -

293-hTLR9-luc:	expressing human TLR9 and 6x NF-κB-luciferase reporter
293-mTLR9-luc:	expressing murine TLR9 and 6x NF-κB-luciferase reporter
293-hTLR9:	expressing human TLR9
293-mTLR9:	expressing murine TLR9

5

Human 293 fibroblast cells were transiently transfected with hTLR9 and a 6x NF-κB-luciferase reporter plasmid (NF-κB-luc, kindly provided by Patrick Baeuerle, Munich, Germany) (Fig. 18A) or with hTLR9 alone (Fig. 18B). After stimulus with CpG-ODN (2μM, TCGTCGTTTGTGCTTTGTGCTT, SEQ ID NO:1), GpC-ODN (2μM,

10 TGCTGCTTTGTGCTTTGTGCTT, SEQ ID NO:154), LPS (100 ng/ml) or media, NF-κB activation by luciferase readout (8h, Fig. 18A) or IL-8 production by ELISA (48h, Fig. 18B) was monitored. Results are representative of three independent experiments. Fig. 18 shows that cells expressing hTLR9 responded to CpG-DNA but not to LPS.

Human 293 fibroblast cells were transiently transfected with mTLR9 and the 15 NF-κB-luc construct. Similar data was obtained for IL-8 production (not shown). Thus expression of TLR9 (human or mouse) in 293 cells results in a gain of function for CpG DNA stimulation similar to hTLR4 reconstitution of LPS responses.

Figs. 19 and 20 demonstrate the responsiveness of a stable 293-mTLR9-luc and 293-hTLR9-luc clones after stimulation with CpG-ODN (2μM, SEQ ID NO:1), GpC-ODN 20 (2μM, SEQ ID NO:154), Me-CpG-ODN (2μM; TZGTZGTTTGTZGTTTGTTZGTT, Z = 5-methylcytidine, SEQ ID NO:147), LPS (100 ng/ml) or media, as measured by monitoring NF-κB activation. Similar results were obtained utilizing IL-8 production with the stable clones. These results demonstrate that CpG-DNA non-responsive cell lines can be stably genetically complemented with TLR9 to become responsive to CpG DNA in a motif-specific 25 manner.

#### Example 8. Method of Making IFN-α4 Reporter Vector

A number of reporter vectors may be used in the practice of the invention. Some of the reporter vectors are commercially available, e.g., the luciferase reporter vectors 30 pNF-κB-Luc (Stratagene) and pAP1-Luc (Stratagene). These two reporter vectors place the luciferase gene under control of an upstream (5') promoter region derived from genomic DNA for NF-κB or AP1, respectively. Other reporter vectors can be constructed following standard

- 66 -

methods using the desired promoter and a vector containing a suitable reporter, such as luciferase,  $\beta$ -galactosidase ( $\beta$ -gal), chloramphenicol acetyltransferase (CAT), and other reporters known by those skilled in the art. Following are some examples of reporter vectors constructed for use in the present invention.

5 IFN- $\alpha$ 4 is an immediate-early type 1 IFN. Sequence-specific PCR products for the –620 to +50 promoter region of IFN- $\alpha$ 4 were derived from genomic DNA of human 293 cells and cloned into the *Sma*I site of the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') –620 to +50 promoter region of IFN- $\alpha$ 4. The sequence of the –620 to +50 promoter region of IFN- $\alpha$ 4 is provided as  
10 SEQ ID NO:121.

#### **Example 9. Method of Making IFN- $\alpha$ 1 Reporter Vector**

IFN- $\alpha$ 1 is a late type 1 IFN. Sequence-specific PCR products for the –140 to +9 promoter region of IFN- $\alpha$ 1 were derived from genomic DNA of human 293 cells and cloned  
15 into *Sma*I site of the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') –140 to +9 promoter region of IFN- $\alpha$ 1. A sequence of the –140 to +9 promoter region of IFN- $\alpha$ 1 is provided as SEQ ID NO:122.

#### **Example 10. Method of Making IFN- $\beta$ Reporter Vector**

20 IFN- $\beta$  is an immediate-early type 1 IFN. The –280 to +20 promoter region of IFN- $\beta$  was derived from the pUC $\beta$ 26 vector (Algarté M et al. (1999) *J Virol* 73:2694-702) by restriction at *Eco*RI and *Taq*I sites. The 300 bp restriction fragment was filled in by Klenow enzyme and cloned into *Nhe*I-digested and filled in pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') –280  
25 to +20 promoter region of IFN- $\beta$ . A sequence of the –280 to +20 promoter region of IFN- $\beta$  is provided as SEQ ID NO:123.

#### **Example 11. Method of Making Human IL-6 Reporter Vectors**

Reporter constructs are made using the –285 to +7 promoter region derived from  
30 human IL-6 genomic DNA. (Takeshita et al. Eur. J. Immunol. 2000. 30: 108–116.) In one reporter construct the IL-6 promoter region is cloned as a *Kpn*I-*Xho*I insert into pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of

- 67 -

an upstream (5') -288 to +7 promoter region derived from human IL-6 genomic DNA. A sequence of the -288 to +7 promoter region of human IL-6 is provided as SEQ ID NO:128.

The promoter can also be derived from the full-length promoter region of the IL-6 gene from -1174 to + 7 (GenBank Accession No M22111) as shown below as SEQ ID

5 NO:129.

#### **Example 12. Method of Making Human IL-8 Reporter Vectors**

Reporter constructs have been made using a -546 to +44 and a truncated -133 to +44 promoter region derived from human IL-8 genomic DNA. Mukaida N et al. (1989) *J*

10 *Immunol* 143:1366-71. In each reporter construct the IL-8 promoter region was cloned as a *KpnI-XhoI* insert into pGL3-Basic Vector (Promega). One of the resulting expression vectors includes a luciferase gene under control of an upstream (5') -546 to +44 promoter region derived from human IL-8 genomic DNA. Another of the resulting expression vectors includes a luciferase gene under control of an upstream (5') -133 to +44 promoter region

15 derived from human IL-8 genomic DNA.

The promoter can also be the upstream (5') -734 to +44 or the upstream (5') -162 to +44 promoter region derived from human IL-8 genomic DNA. Mukaida N et al. (1989) *J* *Immunol* 143:1366-71. A sequence of the -734 to +44 promoter region derived from human IL-8 is provided below as SEQ ID NO: 130.

20

#### **Example 13. Method of Making Human IL-12 p40 Reporter Vectors**

Reporter constructs have been made using truncated (-250 to +30, SEQ ID NO:127) and full length (-751 to +30, SEQID NO:126) promoter regions derived from human IL-12 p40 genomic DNA. (Takeshita et al. *Eur. J. Immunol.* 2000. 30: 108-116.) In one reporter

25 construct the truncated IL-12 p40 promoter was cloned as a *KpnI-XhoI* insert into p $\beta$ gal-Basic (Promega). The resulting expression vector includes a  $\beta$  gal gene under control of an upstream (5') -250 to +30 promoter region of human IL-12 p40. In a second reporter construct the full length IL-12 p40 promoter was cloned as a *KpnI-XhoI* insert into p $\beta$ gal-Basic (Promega). The resulting expression vector includes a  $\beta$  gal gene under control

30 of an upstream (5') -751 to +30 promoter region of human IL-12 p40. In a third reporter construct the truncated -250 to +30 promoter region of human IL-12 p40 was cloned into the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') -250 to +30 promoter region of human IL-12 p40. In a

- 68 -

fourth reporter construct the full length IL-12 p40 promoter of human IL-12 p40 was cloned into the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') -751 to +30 promoter region of human IL-12 p40. A sequence of the -751 to +30 promoter region of human IL-12 p40 is provided as SEQ ID NO:

5 126.

#### **Example 14. Method of Making RANTES Reporter Vector**

Transcription of the chemokine RANTES is believed to be regulated at least in part by IRF3 and by NF- $\kappa$ B. Lin R et al. (1999) *J Mol Cell Biol* 19(2):959-66; Genin P et al. (2000) *J Immunol* 164:5352-61. A 483 bp sequence-specific PCR product including the -397 to +5 promoter region of RANTES was derived from genomic DNA of human 293 cells, restricted with *Pst*I and cloned into pCAT-Basic Vector (Promega) using *Hind*III (filled in with Klenow) and *Pst*I sites (filled in). The -397 to +5 promoter region of RANTES was then isolated from the resulting RANTES/chloramphenicol acetyltransferase (CAT) reporter plasmid by restriction with *Bgl*II and *Sal*II, filled in with Klenow enzyme, and cloned into the *Nhe*I site (filled in with Klenow) of the pGL3-Basic Vector (Promega). The resulting expression vector includes a luciferase gene under control of an upstream (5') -397 to +5 promoter region of RANTES. Comparison of the insert sequence -397 to +5 of Genin P et al. (2000) *J Immunol* 164:5352-61 and GenBank accession no. AB023652 (SEQ ID NO:125) revealed two point deletions (at positions 105 and 273 of SEQ ID NO:125) which do not create new restriction sites. A sequence of the -397 to +5 promoter region of RANTES is provided as SEQ ID NO:125.

#### **Example 15. RT-PCR Analysis of Cell Lines for TLR Expression**

25 TLR expression was determined using total RNA of cells prepared by standard methods (QIAGEN). RNA was transcribed to cDNA using AMV Reverse Transcriptase (Roche). Quantitative PCR was performed with TLR-gene specific primer sets using a LightCycler Instrument (Roche). Controls for genomic DNA impurities were performed by a similar PCR method using RNA (but without reverse transcriptase).

30 A variety of cell lines was screened for their expression of TLR3, 7, 8 and 9. These cell lines are A549 (human lung carcinoma), BeWo (human choriocarcinoma), HeLa (human cervix carcinoma), Hep-2 (human cervix carcinoma), KG-1 (human acute myeloid leukemia), MUTZ-3 (human acute myelomonocytic leukemia), Nalm-6 (human B cell precursor

- 69 -

leukemia), NK-92 (human Natural killer cell line), NK-92 MI (human Natural killer cell line, IL-2 independent), Raji (human Burkitt's lymphoma, B lymphocyte), RAMOS (Burkitt's lymphoma, B lymphocyte), RPMI 8226 (human multiple myeloma, B lymphocyte), THP-1 (human acute monocytic leukemia), U937 (human lymphoma) and Jurkat (human T cell

5 leukemia).

All B cell lines express, as determined by Real Time-PCR (RT-PCR), endogenous TLR9. In addition, all lines except NALM co-express TLR7. Nevertheless, none of the other cell lines appeared to express TLR7, whereas low TLR9 expression on the mRNA level was observed for KG-1 and THP-1. TLR3 appeared to be expressed in most of these cell lines, 10 with the highest mRNA levels for example in the NK cell lines (e.g., NK-92).

Raji cells contain high levels of TLR9 mRNA and low levels of TLR3 and TLR7 mRNA suggesting high expression of TLR9 protein and lower levels of TLR3 and TLR7 protein.

These results indicate that the cell lines expressing TLR9 can be used to screen 15 potential new TLR9 ligands (CpG ODN, etc.), cell lines expressing TLR7 to screen potential new TLR7 ligands (ORN (oligonucleotides), small molecules, etc.), and cell lines expressing both receptors may be used to screen for "hybrid" TLR7 and 9 agonists. In addition, cell lines lacking TLR8 expression (i.e., all cell lines tested) can be used to confirm the specificity of a TLR7 versus a TLR8 ligand (i.e., the latter should not be able to stimulate 20 TLR7-expressing cells). In contrast, cell lines expressing TLR3 (e.g., Raji cells) may be used to screen for potential new TLR3 ligands (dsRNA, etc.).

#### **Example 16. Screening of Various Cell Lines for Responses to TLR Ligands**

Except where otherwise indicated, the following general methods were used.

25 Cells were plated at  $5 \times 10^5$ /ml in 48 well plates in RPMI medium with 10% FBS. Stimulation was performed by addition of the oligonucleotides or other compounds diluted to the test concentrations in TE. Cells were incubated for 24 or 48h and the supernatants were taken to analyse for the presence of cytokines or chemokines.

The TLR ligands used are as follows:

30 TLR3: Poly I:C

TLR7, TLR8: R-848

TLR9:

T\*C\*C\*A\*G\*G\*A\*C\*T\*T\*C\*T\*C\*T\*C\*A\*G\*G\*T\*T (SEQ ID NO: 2);

- 70 -

- T\*C\*G\*T\*C\*G\*T\*T\*T\*G\*T\*C\*G\*T\*T\*T\*G\*T\*C\*G\*T (SEQ ID NO: 1);  
T\*G\*C\*T\*G\*C\*T\*T\*T\*G\*T\*C\*T\*T\*T\*G\*T\*C\*T (SEQ ID NO: 154);  
T\*C\*G\*T\*C\*G\*T\*T\*T\*C\*G\*G\*C\*G\*C\*G\*C\*C\*G (SEQ ID NO: 158);  
G\*G\*G\_G\_A\_C\_G\_A\_C\_G\_T\_C\_G\_T\_G\*G\*G\*G\*G\*G (SEQ ID NO: 159);  
5 T\*G\*C\*T\*G\*C\*T\*T\*T\*C\*G\*G\*C\*G\*C\*C\*G (SEQ ID NO: 160);  
G\*G\*G\_G\_A\_G\_C\_A\_G\_C\_T\_G\_C\_T\_G\*G\*G\*G\*G\*G (SEQ ID NO: 161).

\* phosphorothioate linkage; \_ phosphodiester linkage.

Increased expression of cell surface markers was determined using cells stimulated as  
10 described above and then stained with different monoclonal antibody combinations specific  
for the cell surface markers. Analysis of the cells was performed by flow cytometry.

Changes in reporter gene activity were determined using cells transfected with a  
NF- $\kappa$ B reporter construct (Stratagene) and a  $\beta$ -galactosidase reporter control plasmid  
(Invitrogen) using electroporation. For NF- $\kappa$ B analysis, a 5x NF- $\kappa$ B-Luciferase Vector  
15 (Stratagene) was used. The amount of DNA transfected as well as cell concentration was  
varied. Stimulation was performed 24h after transfection. Cells were stimulated with the  
indicated amounts of ODN, R-848, LPS, TNF- $\alpha$ , or IL-1  $\beta$  for the indicated incubation times.  
Cell extracts were prepared by lysing the cells in 100  $\mu$ l reporter lysis buffer (Promega) using  
the freeze-thaw method. All data were normalized for  $\beta$ -galactosidase expression.  
20 Stimulation indices were calculated in reference to luciferase activity of medium without  
addition of ODN.

Stimulation of the Raji cell line with a TLR9 ligand (CpG ODN), a TLR3 ligand (poly  
I:C) or a TLR7 ligand (R-848) results in the ligand-specific secretion of cytokines. Figs. 14  
and 15 show IL-6 production of Raji cells upon stimulation with ODN, poly I:C or R-848.  
25 Fig. 16 shows IFN- $\alpha$ 2 production of Raji cells upon stimulation with ODN, poly I:C or R-848.  
In all assays, cells were incubated with Na-Butyrate for 48h before stimulation with TLR  
ligands. CpG stimulation of the RAMOS cell lines can result in the CpG-specific up-  
regulation of cell surface markers such as CD80, as shown in Fig. 17.

30 **Example 17. Inhibition of a Positive Reference Compound Response with an Inhibitory Test Compound**

Inhibition of CpG mediated chemokine production was determined using RPMI 8226  
cells incubated with increasing amounts of SEQ ID NO:1 in the presence of an

- 71 -

immunoinhibitory ODN (SEQ ID NO: 151). IP-10 production was measured 24h later by ELISA (Fig. 9).

Equivalents

5       The foregoing written specification is considered to be sufficient to enable one skilled in the art to practice the invention. The present invention is not to be limited in scope by examples provided, since the examples are intended as a single illustration of one aspect of the invention and other functionally equivalent embodiments are within the scope of the invention. Various modifications of the invention in addition to those shown and described  
10      herein will become apparent to those skilled in the art from the foregoing description and fall within the scope of the appended claims. The advantages and objects of the invention are not necessarily encompassed by each embodiment of the invention.

All references, patents and patent publications that are recited in this application are incorporated in their entirety herein by reference.

15

We claim:

- 72 -

**Claims**

1. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising

5 contacting an RPMI 8226 cell that expresses a TLR with a test compound and measuring a test level of TLR signaling activity,

wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and

10 wherein the TLR signaling activity is selected from the group consisting of CD71 expression, CD86 expression, HLA-DR expression, IL-8 expression, IL-8 production, IL-8 secretion, IL-10 expression, IL-10 production, IL-10 secretion, IP-10 expression, IP-10 production, IP-10 secretion, TNF- $\alpha$  expression, TNF- $\alpha$  production and TNF- $\alpha$  secretion.

2. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising

15 contacting a cell that expresses a TLR with a test compound and measuring a test level of TLR signaling activity,

wherein a test level that is positive is indicative of an immunostimulatory compound, and

20 wherein the cell is a Raji cell, a RAMOS cell, a Nalm cell, a THP-1 cell, or a KG-1 cell.

3. The method of claim 1 or 2, wherein the test level is positive relative to a reference level determined by contacting the cell with a reference compound and measuring a reference TLR signaling activity.

25

4. The method of claim 3, wherein the reference compound is a positive reference compound

30 5. The method of claim 4, wherein the positive reference compound is selected from the group consisting of an immunostimulatory nucleic acid and an imidazoquinoline compound.

- 73 -

6. The method of claim 3, wherein the reference compound is a negative reference compound.

7. The method of claim 6, wherein the negative reference compound is  
5 medium alone.

8. The method of claim 5, wherein the immunostimulatory nucleic acid is selected from the group consisting of a CpG nucleic acid, a T-rich nucleic acid, a poly-T nucleic acid and a poly-G nucleic acid.

10

9. The method of claim 5, wherein the imidazoquinoline compound is selected from the group consisting of R-848 and R-847.

15 10. The method of claim 1 or 2, wherein the test compound is a nucleic acid.

11. The method of claim 10, wherein the nucleic acid does not comprise a motif selected from the group consisting of a CpG motif, a poly-T motif, a T-rich motif and a poly-G motif.

20

12. The method of claim 10, wherein the nucleic acid comprises a phosphorothioate backbone linkage.

13. The method of claim 10, wherein the nucleic acid is a DNA, an RNA or  
25 a DNA-RNA hybrid.

14. The method of claim 1 or 2, wherein the test compound is a non-nucleic acid small molecule.

30 15. The method of claim 1 or 2, wherein the test compound comprises an amino acid, a carbohydrate, a lipid, or a hormone.

16. The method of claim 15, wherein the carbohydrate is a polysaccharide.

- 74 -

17. The method of claim 1 or 2, wherein the test compound is derived from a molecular library.

5 18. The method of claim 1, wherein the cell is transfected with a nucleic acid.

19. The method of claim 18, wherein the nucleic acid encodes a TLR or a reporter construct.

10 20. The method of claim 2, wherein the cell is transfected with a nucleic acid.

15 21. The method of claim 20, wherein the nucleic acid encodes a TLR or a reporter construct.

22. The method of claim 19 or 21, wherein the TLR is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9 and TLR10.

20 23. The method of claim 22, wherein the TLR is a human TLR.

25 24. The method of claim 19 or 21, wherein the reporter construct is selected from the group consisting of a luciferase reporter construct, a  $\beta$ -galactosidase reporter construct, a chloramphenicol acetyltransferase reporter construct, a green fluorescent protein reporter construct, and a secreted alkaline phosphatase construct.

25. The method of claim 19 or 21, wherein the reporter construct comprises a TLR responsive promoter.

30 26. The method of claim 25, wherein the TLR responsive promoter comprises a transcription factor binding site selected from the group consisting of a NF- $\kappa$ B binding site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an

- 75 -

IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding site, and a TARE.

27. The method of claim 25, wherein the TLR responsive promoter is a  
5 promoter region selected from the group consisting of an IL-1 promoter region, an IL-6 promoter region, an IL-8 promoter region, an IL-10 promoter region, an IL-12 p40 promoter region, an IFN- $\alpha$ 1 promoter region, an IFN- $\alpha$ 4 promoter region, an IFN- $\beta$  promoter region, an IFN- $\gamma$  promoter region, a TNF- $\alpha$  promoter region, a TNF- $\beta$  promoter region, an IP-9 promoter region, an IP-10 promoter region, a RANTES promoter region, an ITAC promoter region, a  
10 MCP-1 promoter region, an IGFBP4 promoter region, a CD54 promoter region, a CD69 promoter region, a CD71 promoter region, a CD80 promoter region, a CD86 promoter region, a HLA-DR promoter region, and a HLA class I promoter region.

28. The method of claim 18 or 20, wherein the cell is stably transfected.  
15

29. The method of claim 1 or 2, wherein the TLR signaling activity is measured by cytokine secretion or chemokine secretion.

30. The method of claim 1, wherein the TLR signaling activity is selected  
20 from the group consisting of IL-8 secretion, IL-10 secretion, IP-10 secretion and TNF- $\alpha$  secretion.

31. The method of claim 2, wherein the TLR signaling activity is selected  
from the group consisting of IL-6 expression, IL-6 production, IL-6 secretion, IL-8  
25 expression, IL-8 production, IL-8 secretion, IL-10 expression, IL-10 production, IL-10 secretion, IP-10 expression, IP-10 production, IP-10 secretion, IL-12 expression, IL-12 production, IL-12 secretion, TNF- $\alpha$  expression, TNF- $\alpha$  production and TNF- $\alpha$  secretion.

32. The method of claim 2, wherein the TLR signaling activity is measured  
30 by phosphorylation.

33. The method of claim 32, wherein phosphorylation is total cellular phosphorylation.

- 76 -

34. The method of claim 32, wherein phosphorylation is phosphorylation of a factor selected from the group consisting of IRAK, ERK, MyD88, TRAF6, p38, NFkB subunits, c-Jun and c-Fos.

5

35. The method of claim 1 or 2, wherein the TLR signaling activity is measured by gene expression.

36. The method of claim 1, wherein the TLR signaling activity is measured  
10 by gene expression selected from the group consisting of CD71 expression, CD86 expression, HLA-DR expression, IL-8 expression, IL-10 expression, IP-10 expression, and TNF- $\alpha$  expression.

37. The method of claim 35, wherein TLR signaling activity is measured  
15 by microarray techniques.

38. The method of claim 2, wherein the TLR signaling activity is measured by cell proliferation.

20 39. The method of claim 1 or 2, wherein TLR signaling activity is measured by cell surface marker expression.

40. The method of claim 1, wherein TLR signaling activity is measured by cell surface expression of CD71, CD86 or HLA-DR.

25

41. The method of claim 2, wherein TLR signaling activity is measured by CD71 cell surface expression, CD86 cell surface expression, HLA-DR cell surface expression, CD80 cell surface expression, HLA class I cell surface expression, CD54 cell surface expression and CD69 cell surface expression.

30

42. The method of claim 2, wherein TLR signaling activity is measured by antibody secretion.

- 77 -

43. The method of claim 42, wherein the antibody secretion is IgM secretion.

44. A composition comprising  
an RPMI 8226 cell stably transfected with a nucleic acid encoding a TLR  
5 polypeptide, or a fragment thereof.

45. The composition of claim 44, further comprising a reporter construct  
comprising a promoter and a reporter sequence wherein the promoter is a TLR responsive  
promoter.

10

46. The composition of claim 45, wherein the TLR responsive promoter  
comprises a nucleic acid sequence selected from the group consisting of an NF- $\kappa$ B binding  
site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an IRF3  
binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding  
15 site, and a TARE.

47. The composition of claim 45, wherein the reporter sequence is selected  
from the group consisting of a luciferase sequence, a  $\beta$ -galactosidase sequence, a green  
fluorescent protein sequence, a secreted alkaline phosphatase sequence and a chloramphenicol  
20 transferase sequence.

48. The composition of claim 44, wherein the TLR polypeptide or fragment  
thereof is a human TLR polypeptide or fragment thereof.

25 49. The composition of claim 44, wherein the TLR polypeptide or fragment  
thereof is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6,  
TLR7, TLR8, TLR9 and TLR10.

30 50. The composition of claim 44, wherein the TLR polypeptide or fragment  
thereof is a human TLR polypeptide.

51. A screening method for identifying agonists of Toll-like receptor (TLR)  
signaling activity, comprising

- 78 -

contacting an cell that ectopically expresses a TLR with a test compound and measuring a test level of TLR signaling activity,

wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and

5        wherein the cell that ectopically expresses a TLR is selected from the group consisting of RPMI 8226, RAMOS, Raji, Nalm, THP-1, KG-1 and 293 HEK.

10        52.        The method of claim 51, wherein the test level is positive relative to a reference level determined by contacting the cell with a reference compound and measuring a reference TLR signaling activity.

15        53.        The method of claim 52, wherein the reference compound is a positive reference compound.

15        54.        The method of claim 53, wherein the positive reference compound is selected from the group consisting of an immunostimulatory nucleic acid and an imidazoquinoline compound.

20        55.        The method of claim 54, wherein the immunostimulatory nucleic acid is selected from the group consisting of a CpG nucleic acid, a T-rich nucleic acid, a poly-T nucleic acid and a poly-G nucleic acid.

25        56.        The method of claim 54, wherein the imidazoquinoline compound is selected from the group consisting of R-848 and R-847.

25        57.        The method of claim 52, wherein the reference compound is negative reference compound.

30        58.        The method of claim 57, wherein the negative reference compound is medium alone.

59.        The method of claim 51, wherein the test compound is a nucleic acid.

60. The method of claim 59, wherein the nucleic acid does not comprise a motif selected from the group consisting of a CpG motif, a poly-T motif, a T-rich motif and a poly-G motif.

5 61. The method of claim 59, wherein the nucleic acid comprises a phosphorothioate backbone linkage.

62. The method of claim 59, wherein the nucleic acid is a DNA, an RNA, or a DNA-RNA hybrid.

10

63. The method of claim 51, wherein the test compound is a non-nucleic acid small molecule.

15 64. The method of claim 51, wherein the test compound comprises an amino acid, a carbohydrate, a lipid, or a hormone.

65. The method of claim 64, wherein the carbohydrate is a polysaccharide.

20 66. The method of claim 51, wherein the test compound is derived from a molecular library.

25 67. The method of claim 51, wherein the TLR signaling activity is selected from the group consisting of CD71 expression, CD86 expression, HLA-DR expression, IL-6 expression, IL-6 production, IL-6 secretion, IL-8 expression, IL-8 production, IL-8 secretion, IL-10 expression, IL-10 production, IL-10 secretion, IL-12 expression, IL-12 production, IL-12 secretion, IP-10 expression, IP-10 production, IP-10 secretion, TNF- $\alpha$  expression, TNF- $\alpha$  production and TNF- $\alpha$  secretion.

30 68. The method of claim 51, wherein the TLR is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9 and TLR10.

69. The method of claim 51, wherein the TLR is a human TLR.

- 80 -

70. The method of claim 51, wherein the cell is transfected with a reporter construct.

71. The method of claim 70, wherein the reporter construct is selected from 5 the group consisting of a luciferase reporter construct, a  $\beta$ -galactosidase reporter construct, a chloramphenicol acetyltransferase reporter construct, a green fluorescent protein reporter construct, and a secreted alkaline phosphatase construct.

72. The method of claim 71, wherein the TLR signaling activity is 10 measured by luciferase expression,  $\beta$ -galactosidase expression, chloramphenicol expression, acetyltransferase expression, green fluorescent protein expression, alkaline phosphatase expression and alkaline phosphatase secretion.

73. The method of claim 71, wherein the reporter construct comprises a 15 TLR responsive promoter.

74. The method of claim 25 or 73, wherein the TLR responsive promoter is a TLR1 responsive promoter, a TLR2 responsive promoter, a TLR3 responsive promoter, a TLR4 responsive promoter, a TLR5 responsive promoter, a TLR6 responsive promoter, a 20 TLR7 responsive promoter, a TLR8 responsive promoter, a TLR9 responsive promoter and a TLR10 responsive promoter.

75. The method of claim 73, wherein the TLR responsive promoter comprises a transcription factor binding site selected from the group consisting of an NF- $\kappa$ B 25 binding site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding site, and a TARE.

76. The method of claim 73, wherein the TLR responsive promoter is a 30 promoter region selected from the group consisting of an IL-1 promoter region, an IL-6 promoter region, an IL-8 promoter region, an IL-10 promoter region, an IL-12 p40 promoter region, an IFN- $\alpha$ 1 promoter region, an IFN- $\alpha$ 4 promoter region, an IFN- $\beta$  promoter region, an IFN- $\gamma$  promoter region, a TNF- $\alpha$  promoter region, a TNF- $\beta$  promoter region, an IP-9 promoter

region, an IP-10 promoter region, a RANTES promoter region, an ITAC promoter region, a MCP-1 promoter region, an IGFBP4 promoter region, a CD54 promoter region, a CD69 promoter region, a CD71 promoter region, a CD80 promoter region, a CD86 promoter region, a HLA-DR promoter region, and a HLA class I promoter region.

5

77. The method of claim 51, wherein the cell is stably transfected with a TLR nucleic acid.

10 78. The method of claim 70, wherein the cell is stably transfected with the reporter construct.

79. The method of claim 51, wherein the TLR signaling activity is measured by cytokine secretion or chemokine secretion.

15 80. The method of claim 79, wherein the cytokine secretion or chemokine secretion is selected from the group consisting of IL-8 secretion, TNF- $\alpha$  secretion, IL-10 secretion and IP-10 secretion.

20 81. The method of claim 79, wherein the cytokine secretion or chemokine secretion is selected from the group consisting of IL-6 secretion and IL-12 secretion.

82. The method of claim 51, wherein the TLR signaling activity is measured by phosphorylation.

25 83. The method of claim 82, wherein phosphorylation is total cellular phosphorylation.

30 84. The method of claim 82, wherein phosphorylation is phosphorylation of a factor selected from the group consisting of IRAK, ERK, MyD88, TRAF6, p38, NF- $\kappa$ B subunits, c-Jun and c-Fos.

85. The method of claim 51, wherein the TLR signaling activity is measured by gene expression.

86. The method of claim 85, wherein the gene expression is selected from the group consisting of IL-8 expression, IL-10 expression, IP-10 expression, CD71 expression, CD86 expression and HLA-DR expression.

5

87. The method of claim 85, wherein the gene expression is selected from the group consisting of IL-6 expression, IL-12 expression and TNF- $\alpha$  expression.

88. The method of claim 51, wherein the TLR signaling activity is  
10 measured by microarray techniques.

89. The method of claim 51, wherein the TLR signaling activity is measured by cell proliferation.

15 90. The method of claim 51, wherein the TLR signaling activity is measured by cell surface marker expression.

91. The method of claim 90, wherein the cell surface marker expression is selected from the group consisting of CD71 cell surface expression, CD86 cell surface expression and HLA-DR cell surface expression.  
20

92. The method of claim 90, wherein the cell surface marker expression is selected from the group consisting of CD80 cell surface expression, HLA class I cell surface expression, CD54 cell surface expression and CD69 cell surface expression.

25

93. The method of claim 51, wherein the TLR signaling activity is measured by antibody secretion.

94. The method of claim 93, wherein the antibody secretion is IgM  
30 secretion.

95. A screening method for identifying antagonists of Toll-like receptor (TLR) signaling activity, comprising

- 83 -

contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity,

contacting the cell with the positive reference compound and a test compound, and measuring a test level of TLR signaling activity,

5 wherein a test level that is less than a reference level is indicative of test compound that is a TLR antagonist, and

wherein the cell is selected from the group consisting of a RPMI 8226 cell, a RAMOS cell, a Raji cell, a THP-1 cell, a Nalm cell and a KG-1 cell.

10 96. The method of claim 95, wherein the positive reference compound is selected from the group consisting of an immunostimulatory nucleic acid and an immunostimulatory imidazoquinoline compound.

15 97. The method of claim 96, wherein the immunostimulatory nucleic acid is selected from the group consisting of a CpG nucleic acid, a T-rich nucleic acid, a poly-T nucleic acid and a poly-G nucleic acid.

98. The method of claim 96, wherein the imidazoquinoline compound is selected from the group consisting of R-848 and R-847.

20 99. The method of claim 95, wherein the test compound is a nucleic acid.

100. The method of claim 99, wherein the nucleic acid does not comprise a motif selected from the group consisting of a CpG motif, a poly-T motif, a T-rich motif and a 25 poly-G motif.

101. The method of claim 99, wherein the nucleic acid comprises a phosphorothioate backbone linkage.

30 102. The method of claim 99, wherein the nucleic acid is a DNA, an RNA or a DNA-RNA hybrid.

103. The method of claim 95, wherein the test compound is a non-nucleic acid small molecule.

104. The method of claim 95, wherein the test compound comprises an 5 amino acid, a carbohydrate, a lipid, or a hormone.

105. The method of claim 104, wherein the carbohydrate is a polysaccharide.

10 106. The method of claim 95, wherein the test compound is derived from a molecular library.

107. The method of claim 95, wherein the experimental cell is transfected with a nucleic acid.

15 108. The method of claim 107, wherein the nucleic acid encodes a TLR or a reporter construct.

20 109. The method of claim 108, wherein the TLR is selected from the group consisting of TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9 and TLR10.

110. The method of claim 108, wherein the TLR is a human TLR.

111. The method of claim 108, wherein the reporter construct is selected 25 from the group consisting of a luciferase reporter construct, a  $\beta$ -galactosidase reporter construct, a chloramphenicol acetyltransferase reporter construct, a green fluorescent protein reporter construct, and a secreted alkaline phosphatase construct.

112. The method of claim 111, wherein the TLR signaling activity is 30 selected from the group consisting of luciferase expression,  $\beta$ -galactosidase expression, chloramphenicol acetyltransferase expression, green fluorescent protein expression, alkaline phosphatase expression and alkaline phosphatase secretion.

113. The method of claim 108, wherein the reporter construct comprises a TLR responsive promoter.

114. The method of claim 113, wherein the TLR responsive promoter  
5 comprises a transcription factor binding site selected from the group consisting of an NF- $\kappa$ B binding site, an AP-1 binding site, a CRE, a SRE, an ISRE, a GAS, an ATF2 binding site, an IRF3 binding site, an IRF7 binding site, an NFAT binding site, a p53 binding site, an SRF binding site, and a TARE.

10 115. The method of claim 113, wherein the TLR responsive promoter is a promoter region selected from the group consisting of an IL-1 promoter region, an IL-6 promoter region, an IL-8 promoter region, an IL-10 promoter region, an IL-12 p40 promoter region, an IFN- $\alpha$ 1 promoter region, an IFN- $\alpha$ 4 promoter region, an IFN- $\beta$  promoter region, an IFN- $\gamma$  promoter region, a TNF- $\alpha$  promoter region, a TNF- $\beta$  promoter region, an IP-9 promoter  
15 region, an IP-10 promoter region, a RANTES promoter region, an ITAC promoter region, a MCP-1 promoter region, an IGFBP4 promoter region, a CD54 promoter region, a CD69 promoter region, a CD71 promoter region, a CD80 promoter region, a CD86 promoter region, a HLA-DR promoter region, and a HLA class I promoter region.

20 116. The method of claim 113, wherein the TLR responsive promoter is selected from the group consisting of a TLR1 responsive promoter, TLR2 responsive promoter, a TLR3 responsive promoter, a TLR4 responsive promoter, a TLR5 responsive promoter, a TLR6 responsive promoter, a TLR7 responsive promoter, a TLR8 responsive promoter, a TLR9 responsive promoter and a TLR10 responsive promoter.

25 117. The method of claim 107, wherein the cell is stably transfected with the nucleic acid.

30 118. The method of claim 95, wherein the TLR signaling activity is measured by cytokine secretion or chemokine secretion.

- 86 -

119. The method of claim 118, wherein the cytokine secretion or chemokine secretion is selected from the group consisting of IL-6 secretion, IL-12 secretion and TNF- $\alpha$  secretion.

5 120. The method of claim 118, wherein the cytokine secretion or chemokine secretion is selected from the group consisting of IL-8 secretion, IL-10 secretion and IP-10 secretion.

10 121. The method of claim 95, wherein the TLR signaling activity is measured by phosphorylation.

122. The method of claim 121, wherein phosphorylation is total cellular phosphorylation.

15 123. The method of claim 122, wherein phosphorylation is phosphorylation of a factor selected from the group consisting of IRAK, ERK, MyD88, TRAF6, p38, NF- $\kappa$ B subunits, c-Jun and c-Fos.

20 124. The method of claim 95, wherein the TLR signaling activity is measured by gene expression.

125. The method of claim 124, wherein the gene expression is selected from the group consisting of CD71 expression, CD86 expression, HLA-DR expression, IL-8 expression, IL-10 expression and IP-10 expression.

25 126. The method of claim 124, wherein the gene expression is selected from the group consisting of IL-6 expression, IL-12 expression and TNF- $\alpha$  expression.

127. The method of claim 95, wherein the TLR signaling activity is measured by microarray techniques.

30 128. The method of claim 95, wherein the TLR signaling activity is measured by cell proliferation.

129. The method of claim 95, wherein the TLR signaling activity is measured by cell surface marker expression.

5 130. The method of claim 129, wherein the cell surface marker expression is selected from the group consisting of CD71 cell surface expression, CD86 cell surface expression and HLA-DR MHC class II cell surface expression.

10 131. The method of claim 129, wherein the cell surface marker expression is selected from the group consisting of CD80 cell surface expression, HLA class I cell surface expression, CD54 cell surface expression and CD69 cell surface expression.

15 132. The method of claim 95, wherein the TLR signaling activity is measured by antibody secretion.

133. The method of claim 132, wherein the antibody secretion is IgM secretion.

20 134. The method of claim 95, wherein the cell is contacted to the positive reference compound and the test compound simultaneously.

135. The method of claim 95, wherein the cell is contacted to the positive reference compound prior to contact with the test compound.

25 136. The method of claim 95, wherein the cell is contacted to the test compound prior to contact with the positive reference compound.

137. A method for quality assessment of a test composition containing a known Toll like receptor (TLR) ligand, comprising:  
30 measuring a reference activity of a reference composition comprising a known TLR ligand, wherein the known TLR ligand is a nucleic acid molecule;  
measuring a test activity of a test composition comprising the known TLR ligand; and  
comparing the test activity to the reference activity.

138. The method of claim 137, further comprising selecting the test composition if the test activity falls within a predetermined range of variance about the reference activity.

5

139. The method of claim 1, wherein the reference composition is a first production lot of a pharmaceutical composition comprising the known TLR ligand, and wherein the test composition is a second production lot of a pharmaceutical composition comprising the known TLR ligand.

10

140. The method of claim 137, wherein the reference composition is a first in-process lot of a composition comprising the known TLR ligand, and wherein the test composition is a second in-process lot of a composition comprising the known TLR ligand.

15

141. The method of claim 137, wherein the measuring the reference activity comprises contacting the reference composition with an isolated cell expressing a TLR responsive to the known TLR ligand, and wherein the measuring the test activity comprises contacting the test composition with the isolated cell expressing a TLR responsive to the known TLR ligand.

20

142. The method of claim 141, wherein the isolated cell expressing the TLR responsive to the known TLR ligand comprises an expression vector for the TLR responsive to the known TLR ligand.

25

143. The method of claim 141, wherein the isolated cell expressing the TLR responsive to the known TLR ligand naturally expresses the TLR responsive to the known TLR ligand.

30

144. The method of claim 141, wherein the isolated cell expressing the TLR responsive to the known TLR ligand is RPMI 8226.

- 89 -

145. The method of claim 137, wherein the measuring the reference activity and the measuring the test activity each comprise measuring signaling activity mediated by a TLR responsive to the known TLR ligand.

5 146. The method of claim 145, wherein the signaling activity is activity of a reporter construct under control of NF- $\kappa$ B response element.

147. The method of claim 145, wherein the signaling activity is activity of a reporter construct under control of interferon-stimulated response element (ISRE).

10 148. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of an IFN- $\alpha$  promoter.

15 149. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of an IFN- $\beta$  promoter.

150. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of an IL-6 promoter.

20 151. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of an IL-8 promoter.

152. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of an IL-12 p40 promoter.

25 153. The method of claim 145, wherein the signaling activity is activity of a reporter gene under control of a RANTES promoter.

154. The method of claim 137, wherein the known TLR ligand is a TLR9  
30 ligand.

155. The method of claim 137, wherein the known TLR ligand is a TLR3  
ligand.

- 90 -

156. The method of claim 137, wherein the known TLR ligand is a TLR7 ligand.

5 157. The method of claim 137, wherein the known TLR ligand is a TLR8 ligand.

158. The method of claim 137, wherein the known TLR ligand is an immunostimulatory nucleic acid.

10 159. The method of claim 137, wherein the known TLR ligand is a CpG nucleic acid.

15 160. The method of claim 137, wherein the known TLR ligand is an immunoinhibitory nucleic acid.

161. A method for quality assessment of a test lot of a pharmaceutical product containing a known TLR9 ligand, comprising:  
measuring a reference activity of a reference lot of a pharmaceutical product  
20 comprising a known TLR9 ligand, wherein the known TLR9 ligand is a nucleic acid molecule;  
measuring a test activity of a test lot of a pharmaceutical product comprising the known TLR9 ligand;  
comparing the test activity to the reference activity; and  
rejecting the test lot if the test activity falls outside of a predetermined range of variance about the reference activity.

162. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence TCGTCGTTTGTCGTTTGTGTT (SEQ ID 30 NO:1).

163. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTGACGTTTGTCTGTT-3' (SEQ ID NO:139).

5 164. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTGTCGTTTTTCGA-3' (SEQ ID NO:140).

10 165. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTCGTCGTTCGCTGTT-3' (SEQ ID NO:141).

15 166. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTCGTCGTTGTCGTT-3' (SEQ ID NO:142).

167. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTCGGTCGTTT-3' (SEQ ID NO:143).

20 168. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTCGTGCGTTT-3' (SEQ ID NO:144).

25 169. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTCGTTTCGGCGGCCGCG-3' (SEQ ID NO:145).

30 170. The method of claim 161, wherein the known TLR9 ligand is an oligonucleotide comprising a base sequence 5'-TCGTC\_GTTTAC\_GGC GCC\_GTGCCG-3' (SEQ ID NO:146), wherein every internucleoside linkage is phosphorothioate except for those indicated by “\_”, which are phosphodiester.

- 92 -

171. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising

contacting a cell that expresses a TLR with a test compound and measuring a test level of TLR signaling activity,

5 wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and

wherein the cell is a Raji cell, a RAMOS cell, a Nalm cell, a THP-1 cell, or a KG-1 cell, and the TLR is TLR9.

10 172. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising

contacting a cell that expresses a TLR with a test compound and measuring a test level of TLR signaling activity,

15 wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and

wherein the cell is a Raji cell or a RAMOS cell, and the TLR is TLR7.

173. A screening method for identifying agonists of Toll-like receptor (TLR) signaling activity, comprising

20 contacting a cell that expresses a TLR with a test compound and measuring a test level of TLR signaling activity,

wherein a test level that is positive is indicative of a test compound that is a TLR agonist, and

25 wherein the cell is a Raji cell, a RAMOS cell, a KG-1 cell, a Nalm-6 cell, a Jurkat cell, a Hela cell, a Hep-2 cell, an A549 cell, a Bewo cell, an NK-92 cell or an NK-92 MI cell, and the TLR is TLR3.

174. A screening method for identifying antagonists of Toll-like receptor (TLR) signaling activity, comprising

30 contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity,

contacting the cell with the positive reference compound and a test compound, and measuring a test level of TLR signaling activity,

- 93 -

wherein a test level that is less than a reference level is indicative of a test compound that is a TLR antagonist, and

wherein the cell is selected from the group consisting of a RPMI 8226 cell, a RAMOS cell, a Raji cell, a THP-1 cell, a Nalm cell and a KG-1 cell, and the TLR is TLR9.

5

175. A screening method for identifying antagonists of Toll-like receptor (TLR) signaling activity, comprising

contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity,

10 contacting the cell with the positive reference compound and a test compound, and measuring a test level of TLR signaling activity,

wherein a test level that is less than a reference level is indicative of a test compound that is a TLR antagonist, and

wherein the cell is selected from the group consisting of a RPMI 8226 cell, a 15 RAMOS cell and a Raji cell, and the TLR is TLR7.

175. A screening method for identifying antagonists of Toll-like receptor (TLR) signaling activity, comprising

20 contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity,

contacting the cell with the positive reference compound and a test compound, and measuring a test level of TLR signaling activity,

wherein a test level that is less than a reference level is indicative of a test compound that is a TLR antagonist, and

25 wherein the cell is selected from the group consisting of a Raji cell, a RAMOS cell, a KG-1 cell, a Nalm-6 cell, a Jurkat cell, a Hela cell, a Hep-2 cell, an A549 cell, a Bewo cell, an NK-92 cell and an NK-92 MI cell, and the TLR is TLR3.

176. A screening method for identifying an enhancer of a Toll-like receptor 30 (TLR) agonist, comprising

contacting a cell with a positive reference compound and measuring a reference level of TLR signaling activity, and

contacting a cell with the positive reference compound and a test compound and measuring a test level of TLR signaling activity,

wherein the positive reference compound is a TLR agonist, and a test level that is greater than the reference level is indicative of a test compound that is an enhancer of a TLR  
5 agonist.

177. The method of claim 176, wherein the positive reference compound is an immunostimulatory nucleic acid.

10 178. The method of claim 176, wherein the positive reference compound is an imidazoquinoline compound.

15 180. The method of claim 176, wherein the cell is selected from the group consisting of a KG-1 cell, a Nalm-6 cell, a Raji cell, a RAMOS cell, a Jurkat cell, a Hela cell, a Hep-2 cell, an A549 cell, a Bewo cell, an NK-92 cell and an NK-92 MI cell, and the TLR is TLR3.

20 181. The method of claim 176, wherein the cell is selected from the group consisting of a KG-1 cell, a Nalm-6 cell, a Raji cell, an RPMI 8226 cell, a RAMOS cell, and a THP-1 cell, and the TLR is TLR9.

182. The method of claim 176, wherein the cell is selected from the group consisting of a Raji cell, an RPMI 8226 cell and a RAMOS cell, and the TLR is TLR7.

25 183. The method of claim 1, wherein the TLR is TLR7 or TLR9.

184. The method of claim 172-175 or 176, wherein the cell is unmodified.

1/15




Fig. 1

2/15




Fig. 2

3/15




Fig. 3

4/15




Fig. 4

5/15




Fig. 5

6/15




Fig. 6

7/15




Fig. 7

8/15





Fig. 8

9/15



**Fig. 9**

10/15




Fig. 10




Fig. 11

11/15




Fig. 12

12/15




Fig. 13




Fig. 14

13/15




Fig. 15




Fig. 16




Fig. 17  
SUBSTITUTE SHEET (RULE 26)

14/15




Fig. 18A






Fig. 18B

15/15

**Fig. 19****Fig. 20****Fig. 21**  
SUBSTITUTE SHEET (RULE 26)



ggcagctcag gatctttaaa ctccattccc tcagggctca cagaagctgt aaaaagcctt 300  
gacctgtcca acaacaggat cacctacatt agcaacagtgc acctacagag gtgtgtgaac 360  
ctccaggctc tggtgctgac atccaatgga attaacacaa tagaggaaga ttcttttct 420  
tccctggca gtcttgaaca tttagactta tcctataatt acttatctaa tttatcgct 480  
tcctggttca agcccctttc ttcttaaca ttcttaaact tactggaaa tccttacaaa 540  
accctagggg aaacatctct ttttctcat ctcacaaaat tgcaaattcct gagagtggaa 600  
aatatggaca ccttcactaa gattcaaaga aaagattttg ctggacttac cttcctttag 660  
gaacttgaga ttgatgcttc agatctacag agctatgagc caaaaagttt gaagtcaatt 720  
cagaacgtaa gtcatctgat cttcatatg aagcagcata ttttactgct ggagatttt 780  
gtagatgtta caagttccgt ggaatgtttt gaactgcgag atactgattt ggacacttcc 840  
cattttcag aactatccac tggtaaaca aattcattga ttaaaaagtt tacatttaga 900  
aatgtaaaaa tcaccgatga aagtttggg caggttatga aactttgaa tcagatttct 960  
ggattgttag aatttagagtt tgatgactgt acccttaatg gagttggtaa ttttagagca 1020  
tctgataatg acagagttt agatccaggt aaagtggaaa cgtaacaat ccggaggctg 1080  
catattccaa ggtttactt atttatgat ctgagcactt tatattcact tacagaaaga 1140  
gttaaaaagaa tcacagtaga aaacagtaaa gttttctgg ttccctgttt actttcacaa 1200  
catttaaaat cattagaata cttggatctc agtggaaatt tgatggtgaa agaatacttg 1260  
aaaaattcag cctgtgagga tgcctggccc tctctacaaa ctttaattt aaggcaaaaat 1320  
catttggcat cattggaaaa aaccggagag actttgtca ctctgaaaaa cttgactaac 1380  
attgatatca gtaagaatag ttttcttct atgcctgaaa cttgtcagtgc gccagaaaag 1440  
atgaaatatt tgaacttatac cagcacacga atacacagtgc taacaggctg cattccaaag 1500  
acactggaaa ttttagatgt tagcaacaac aatctcaatt tattttctt gaatttgcgc 1560  
caactcaaag aactttatata ttcctggaaaat aagttgatga ctctaccaga tgcctccctc 1620  
ttaccatgt tactagtatt gaaaatcagt aggaatgcaa taactacgtt ttctaaaggag 1680  
caacttgact catttcacac actgaagact ttggaaagctg gtggcaataa cttcatttgc 1740  
tcctgtgaat tccctccctt cactcaggag cagcaagcac tggccaaagt cttgattgt 1800  
tggccagcaa attacctgtg tgactctcca tcccatgtgc gtggccagca ggttcaggat 1860  
gtccgcctct cgggtgcggg atgtcacagg acagcactgg tgtctggcat gtgtgtgtct 1920  
ctgttccctgc tgatcctgct cacgggggtc ctgtgccacc gtttccatgg cctgtggat 1980  
atgaaaatga tggggcctg gctccaggcc aaaaggaagc ccagggaaagc tcccagcagg 2040  
aacatctgct atgatgcatt tgtttcttac agtgagcggg atgcctactg ggtggagaac 2100

cttatggtcc aggagctgga gaacttaat ccccccttca agttgtgtct tcataaggcg 2160  
 gacttcattc ctggcaagtg gatcattgac aatatcattg actccattga aaagagccac 2220  
 aaaactgtct ttgtgcttgc tgaaaacttt gtgaagagtg agtggtgcaa gtatgaactg 2280  
 gacttctccc atttccgtct ttttgaagag aacaatgatg ctgccattct cattcttctg 2340  
 gagccattg agaaaaaaagc cattccccag cgcttctgca agctgcggaa gataatgaac 2400  
 accaagacct acctggagtg gcccatggac gaggctcagc gggaggatt ttggtaaat 2460  
 ctgagagctg cgataaaagtc ctaggtcccc atattaaga ccagtcttg tctagttggg 2520  
 atcttatgt cactagttat agttaagttc attcagacat aattatataa aaactacgtg 2580  
 gatgtaccgt catttgagga 2600

<210> 4  
 <211> 784  
 <212> PRT  
 <213> Homo sapiens

<400> 4

Met Pro His Thr Leu Trp Met Val Trp Val Leu Gly Val Ile Ile Ser  
 1 5 10 15

Leu Ser Lys Glu Glu Ser Ser Asn Gln Ala Ser Leu Ser Cys Asp Arg  
 20 25 30

Asn Gly Ile Cys Lys Gly Ser Ser Gly Ser Leu Asn Ser Ile Pro Ser  
 35 40 45

Gly Leu Thr Glu Ala Val Lys Ser Leu Asp Leu Ser Asn Asn Arg Ile  
 50 55 60

Thr Tyr Ile Ser Asn Ser Asp Leu Gln Arg Cys Val Asn Leu Gln Ala  
 65 70 75 80

Leu Val Leu Thr Ser Asn Gly Ile Asn Thr Ile Glu Glu Asp Ser Phe  
 85 90 95

Ser Ser Leu Gly Ser Leu Glu His Leu Asp Leu Ser Tyr Asn Tyr Leu  
 100 105 110

Ser Asn Leu Ser Ser Trp Phe Lys Pro Leu Ser Ser Leu Thr Phe  
 115 120 125

Leu Asn Leu Leu Gly Asn Pro Tyr Lys Thr Leu Gly Glu Thr Ser Leu  
 130 135 140

Phe Ser His Leu Thr Lys Leu Gln Ile Leu Arg Val Gly Asn Met Asp  
 145 150 155 160

Thr Phe Thr Lys Ile Gln Arg Lys Asp Phe Ala Gly Leu Thr Phe Leu  
 165 170 175

Glu Glu Leu Glu Ile Asp Ala Ser Asp Leu Gln Ser Tyr Glu Pro Lys  
 180 185 190

Ser Leu Lys Ser Ile Gln Asn Val Ser His Leu Ile Leu His Met Lys  
195 200 205

Gln His Ile Leu Leu Leu Glu Ile Phe Val Asp Val Thr Ser Ser Val  
210 215 220

Glu Cys Leu Glu Leu Arg Asp Thr Asp Leu Asp Thr Phe His Phe Ser  
225 230 235 240

Glu Leu Ser Thr Gly Glu Thr Asn Ser Leu Ile Lys Lys Phe Thr Phe  
245 250 255

Arg Asn Val Lys Ile Thr Asp Glu Ser Leu Phe Gln Val Met Lys Leu  
260 265 270

Leu Asn Gln Ile Ser Gly Leu Leu Glu Leu Glu Phe Asp Asp Cys Thr  
275 280 285

Leu Asn Gly Val Gly Asn Phe Arg Ala Ser Asp Asn Asp Arg Val Ile  
290 295 300

Asp Pro Gly Lys Val Glu Thr Leu Thr Ile Arg Arg Leu His Ile Pro  
305 310 315 320

Arg Phe Tyr Leu Phe Tyr Asp Leu Ser Thr Leu Tyr Ser Leu Thr Glu  
325 330 335

Arg Val Lys Arg Ile Thr Val Glu Asn Ser Lys Val Phe Leu Val Pro  
340 345 350

Cys Leu Leu Ser Gln His Leu Lys Ser Leu Glu Tyr Leu Asp Leu Ser  
355 360 365

Glu Asn Leu Met Val Glu Glu Tyr Leu Lys Asn Ser Ala Cys Glu Asp  
370 375 380

Ala Trp Pro Ser Leu Gln Thr Leu Ile Leu Arg Gln Asn His Leu Ala  
385 390 395 400

Ser Leu Glu Lys Thr Gly Glu Thr Leu Leu Thr Leu Lys Asn Leu Thr  
405 410 415

Asn Ile Asp Ile Ser Lys Asn Ser Phe His Ser Met Pro Glu Thr Cys  
420 425 430

Gln Trp Pro Glu Lys Met Lys Tyr Leu Asn Leu Ser Ser Thr Arg Ile  
435 440 445

His Ser Val Thr Gly Cys Ile Pro Lys Thr Leu Glu Ile Leu Asp Val  
450 455 460

Ser Asn Asn Asn Leu Asn Leu Phe Ser Leu Asn Leu Pro Gln Leu Lys  
465 470 475 480

Glu Leu Tyr Ile Ser Arg Asn Lys Leu Met Thr Leu Pro Asp Ala Ser  
485 490 495

Leu Leu Pro Met Leu Leu Val Leu Lys Ile Ser Arg Asn Ala Ile Thr  
500 505 510

Thr Phe Ser Lys Glu Gln Leu Asp Ser Phe His Thr Leu Lys Thr Leu

515	520	525
Glu Ala Gly Gly Asn Asn Phe Ile Cys Ser Cys Glu Phe Leu Ser Phe		
530	535	540
Thr Gln Glu Gln Gln Ala Leu Ala Lys Val Leu Ile Asp Trp Pro Ala		
545	550	560
Asn Tyr Leu Cys Asp Ser Pro Ser His Val Arg Gly Gln Gln Val Gln		
565	570	575
Asp Val Arg Leu Ser Val Ser Glu Cys His Arg Thr Ala Leu Val Ser		
580	585	590
Gly Met Cys Cys Ala Leu Phe Leu Leu Ile Leu Thr Gly Val Leu		
595	600	605
Cys His Arg Phe His Gly Leu Trp Tyr Met Lys Met Met Trp Ala Trp		
610	615	620
Leu Gln Ala Lys Arg Lys Pro Arg Lys Ala Pro Ser Arg Asn Ile Cys		
625	630	640
Tyr Asp Ala Phe Val Ser Tyr Ser Glu Arg Asp Ala Tyr Trp Val Glu		
645	650	655
Asn Leu Met Val Gln Glu Leu Glu Asn Phe Asn Pro Pro Phe Lys Leu		
660	665	670
Cys Leu His Lys Arg Asp Phe Ile Pro Gly Lys Trp Ile Ile Asp Asn		
675	680	685
Ile Ile Asp Ser Ile Glu Lys Ser His Lys Thr Val Phe Val Leu Ser		
690	695	700
Glu Asn Phe Val Lys Ser Glu Trp Cys Lys Tyr Glu Leu Asp Phe Ser		
705	710	720
His Phe Arg Leu Phe Glu Glu Asn Asn Asp Ala Ala Ile Leu Ile Leu		
725	730	735
Leu Glu Pro Ile Glu Lys Lys Ala Ile Pro Gln Arg Phe Cys Lys Leu		
740	745	750
Arg Lys Ile Met Asn Thr Lys Thr Tyr Leu Glu Trp Pro Met Asp Glu		
755	760	765
Ala Gln Arg Glu Gly Phe Trp Val Asn Leu Arg Ala Ala Ile Lys Ser		
770	775	780

<210> 5  
<211> 2824  
<212> DNA  
<213> murine

<400> 5  
gccccccatg gccatatggg caccggggag cggcggtgg aggactccta ggctcctggg 60  
caggcggtca catggcagaa gatgtgtccg caatcatagt ttctgtatggt gaaggttgga 120  
cggcagtctc tgcgacctag aagtggaaaa gatgtcggttc aaggaggtgc ggactgttc 180

cgtcaaatct cagaggatgc tacagactct ttggcttcc tggatcttgg tggccataac 360  
agtccctttc agcaaacgct gttctgtca ggagtctctg tcatgtgatg cttctgggt 420  
gtgtgatggc cgctccaggt cttecacctc tattccctcc ggactcacag cagccatgaa 480  
aagccttgac ctgtcttca acaagatcac ctacattggc catggtgacc tccgagcgtg 540  
tgcgaacctc caggttctga ttttgaagtc cagcagaatc aatacaatag agggagacgc 600  
cttttattct ctgggcagtc ttgaacattt ggatttgtct gataatcacc tatctagtt 660  
atcttcctcc tggttcgggc cccttcctc ttgaaatac ttaaacttaa tggaaatcc 720  
ttaccagaca ctggggtaa catcgcccc tcccaatctc acaaatttac aaaccctcag 780  
gataggaaat gtagagactt tcagttagat aaggagaata gattttgctg ggctgacttc 840  
tctcaatgaa cttgaaatta aggcatthaag tctccgaat tatcagtccc aaagtctaaa 900  
gtcgatccgc gacatccatc acctgactct tcacttaagc gagtctgctt tcctgctgga 960  
gattttgca gatattctga gttctgttag atatttagaa ctaagagata ctaacttggc 1020  
caggttccag ttttaccac tggccgtaga tgaagtcagc tcaccgatga agaagctggc 1080  
attccgagggc tcgggtctca ctgatgaaag cttaacgag ctccctgaagc tggcgatgtt 1140  
catcttgaa ctgtcgagg tagagttcga cgactgtacc ctcaatgggc tggcgatgtt 1200  
caaccctcg gagtcagacg tagtgagcga gctggtaaa gtagaaacag tcactatccg 1260  
gagggttgcatttcccccagt tctattttttt ttatgacctg agtactgtct attccctcct 1320  
ggagaagggtg aagcgaatca cagtagagaa cagcaaggtc ttccctgggtc cctgctgctt 1380  
ctccccagcat ttaaaatcat tagaattttt agacctcagc gaaaatctga tggttgaaga 1440  
atatttgaa aactcagcct gtaagggagc ctggccttct ctacaaacctt tagtttgag 1500  
ccagaatcat ttgagatcaa tgcaaaaaac aggagagatt ttgctgactc tgaaaaacct 1560  
gaccccccgtt gacatcagca ggaacacttt tcatccgatg cccgacagct gtcagtgcc 1620  
agaaaagatg cgcttcgtga atttgcgttccag tacagggatc cgggtggtaa aacacgtcat 1680  
tcctcagacg ctggaggtgt tggatgttag taacaacaat cttgactcat tttctttgtt 1740  
cttgcctcgg ctgcaagagc tctatatttc cagaataaag ctgaaaacac tcccaagatgc 1800  
ttcggttgc tctgtgttgc tggatgttag aatcagagag aatgcagttaa gtactttctc 1860  
taaagaccaa cttgggttctt ttcccaaact ggagactctg gaagcaggcg acaaccactt 1920  
tggttgcgtcc tgcgaactcc tattcccttac tatggagacg ccagctctgg ctcaaatcc 1980  
ggttgactgg ccagacagct acctgtgtga ctctccgcct cgcctgcacg gccacaggct 2040  
tcaggatgcc cggccctccg tcttggaaatg tcaccaggct gcaactgggtgt ctggagtcgt 2100

ctgtgccctt	ctcctgttga	tcttgcttgt	agggtgccctg	tgccaccatt	tccacgggct	2160
gtggcacctg	agaatgatgt	gggcgtggct	ccaggccaag	aggaagccca	agaaagctcc	2220
ctgcagggac	gtttgctatg	atgccttgt	ttcttacagt	gagcaggatt	cccattgggt	2280
ggagaacctc	atggtccagc	agctggagaa	ctctgacccg	cccttaagc	tgtgtctcca	2340
caagcgggac	ttcggtccgg	gcaaatggat	cattgacaac	atcatcgatt	ccatcgaaaa	2400
gagccacaaa	actgtgttcg	tgctttctga	gaacttcgta	cggagcgcgt	ggtgcaagta	2460
cgaactggac	ttctcccact	tcaggcttctt	tgacgagaac	aacgacgcgg	ccatccttgt	2520
tttgctggag	cccattgaga	ggaaagccat	tccccagcgc	ttctgcaaac	tgcgcaagat	2580
aatgaacacc	aagacctacc	tggagtggcc	cttggatgaa	ggccagcagg	aagtgttttgc	2640
ggttaaatctg	agaactgcaa	taaagtcccta	ggttctccac	ccagttcctg	acttccttaa	2700
ctaaggtctt	tgtgacacaaa	actgtaaacaa	agtttataag	taacatagaa	ttgtattatt	2760
gaggatatta	actatgggtt	ttgtcttgaa	tactgttata	taaatatgtg	acatcaggct	2820
tttag						2824

<210> 6  
<211> 784  
<212> PRT  
<213> murine

<400> 6

Met Leu Arg Ala Leu Trp Leu Phe Trp Ile Leu Val Ala Ile Thr Val  
1               5                           10                           15

Leu Phe Ser Lys Arg Cys Ser Ala Gln Glu Ser Leu Ser Cys Asp Ala  
20              25                           30

Ser Gly Val Cys Asp Gly Arg Ser Arg Ser Phe Thr Ser Ile Pro Ser  
35              40                           45

Gly Leu Thr Ala Ala Met Lys Ser Leu Asp Leu Ser Phe Asn Lys Ile  
50              55                           60

Thr Tyr Ile Gly His Gly Asp Leu Arg Ala Cys Ala Asn Leu Gln Val  
65              70                           75                           80

Leu Ile Leu Lys Ser Ser Arg Ile Asn Thr Ile Glu Gly Asp Ala Phe  
85              90                           95

Tyr Ser Leu Gly Ser Leu Glu His Leu Asp Leu Ser Asp Asn His Leu  
100            105                           110

Ser Ser Leu Ser Ser Trp Phe Gly Pro Leu Ser Ser Leu Lys Tyr  
115            120                           125

Leu Asn Leu Met Gly Asn Pro Tyr Gln Thr Leu Gly Val Thr Ser Leu  
130            135                           140

Phe Pro Asn Leu Thr Asn Leu Gln Thr Leu Arg Ile Gly Asn Val Glu  
145 150 155 160

Thr Phe Ser Glu Ile Arg Arg Ile Asp Phe Ala Gly Leu Thr Ser Leu  
165 170 175

Asn Glu Leu Glu Ile Lys Ala Leu Ser Leu Arg Asn Tyr Gln Ser Gln  
180 185 190

Ser Leu Lys Ser Ile Arg Asp Ile His His Leu Thr Leu His Leu Ser  
195 200 205

Glu Ser Ala Phe Leu Leu Glu Ile Phe Ala Asp Ile Leu Ser Ser Val  
210 215 220

Arg Tyr Leu Glu Leu Arg Asp Thr Asn Leu Ala Arg Phe Gln Phe Ser  
225 230 235 240

Pro Leu Pro Val Asp Glu Val Ser Ser Pro Met Lys Lys Leu Ala Phe  
245 250 255

Arg Gly Ser Val Leu Thr Asp Glu Ser Phe Asn Glu Leu Leu Lys Leu  
260 265 270

Leu Arg Tyr Ile Leu Glu Leu Ser Glu Val Glu Phe Asp Asp Cys Thr  
275 280 285

Leu Asn Gly Leu Gly Asp Phe Asn Pro Ser Glu Ser Asp Val Val Ser  
290 295 300

Glu Leu Gly Lys Val Glu Thr Val Thr Ile Arg Arg Leu His Ile Pro  
305 310 315 320

Gln Phe Tyr Leu Phe Tyr Asp Leu Ser Thr Val Tyr Ser Leu Leu Glu  
325 330 335

Lys Val Lys Arg Ile Thr Val Glu Asn Ser Lys Val Phe Leu Val Pro  
340 345 350

Cys Ser Phe Ser Gln His Leu Lys Ser Leu Glu Phe Leu Asp Leu Ser  
355 360 365

Glu Asn Leu Met Val Glu Glu Tyr Leu Lys Asn Ser Ala Cys Lys Gly  
370 375 380

Ala Trp Pro Ser Leu Gln Thr Leu Val Leu Ser Gln Asn His Leu Arg  
385 390 395 400

Ser Met Gln Lys Thr Gly Glu Ile Leu Leu Thr Leu Lys Asn Leu Thr  
405 410 415

Ser Leu Asp Ile Ser Arg Asn Thr Phe His Pro Met Pro Asp Ser Cys  
420 425 430

Gln Trp Pro Glu Lys Met Arg Phe Leu Asn Leu Ser Ser Thr Gly Ile  
435 440 445

Arg Val Val Lys Thr Cys Ile Pro Gln Thr Leu Glu Val Leu Asp Val  
450 455 460

Ser Asn Asn Asn Leu Asp Ser Phe Ser Leu Phe Leu Pro Arg Leu Gln

465	470	475	480
Glu Leu Tyr Ile Ser Arg Asn Lys Leu Lys	Thr Leu Pro Asp Ala Ser		
485	490	495	
Leu Phe Pro Val Leu Leu Val Met Lys Ile Arg Glu Asn Ala Val Ser			
500	505	510	
Thr Phe Ser Lys Asp Gln Leu Gly Ser Phe Pro Lys Leu Glu Thr Leu			
515	520	525	
Glu Ala Gly Asp Asn His Phe Val Cys Ser Cys Glu Leu Leu Ser Phe			
530	535	540	
Thr Met Glu Thr Pro Ala Leu Ala Gln Ile Leu Val Asp Trp Pro Asp			
545	550	555	560
Ser Tyr Leu Cys Asp Ser Pro Pro Arg Leu His Gly His Arg Leu Gln			
565	570	575	
Asp Ala Arg Pro Ser Val Leu Glu Cys His Gln Ala Ala Leu Val Ser			
580	585	590	
Gly Val Cys Cys Ala Leu Leu Leu Ile Leu Leu Val Gly Ala Leu			
595	600	605	
Cys His His Phe His Gly Leu Trp Tyr Leu Arg Met Met Trp Ala Trp			
610	615	620	
Leu Gln Ala Lys Arg Lys Pro Lys Lys Ala Pro Cys Arg Asp Val Cys			
625	630	635	640
Tyr Asp Ala Phe Val Ser Tyr Ser Glu Gln Asp Ser His Trp Val Glu			
645	650	655	
Asn Leu Met Val Gln Gln Leu Glu Asn Ser Asp Pro Pro Phe Lys Leu			
660	665	670	
Cys Leu His Lys Arg Asp Phe Val Pro Gly Lys Trp Ile Ile Asp Asn			
675	680	685	
Ile Ile Asp Ser Ile Glu Lys Ser His Lys Thr Val Phe Val Leu Ser			
690	695	700	
Glu Asn Phe Val Arg Ser Glu Trp Cys Lys Tyr Glu Leu Asp Phe Ser			
705	710	715	720
His Phe Arg Leu Phe Asp Glu Asn Asn Asp Ala Ala Ile Leu Val Leu			
725	730	735	
Leu Glu Pro Ile Glu Arg Lys Ala Ile Pro Gln Arg Phe Cys Lys Leu			
740	745	750	
Arg Lys Ile Met Asn Thr Lys Thr Tyr Leu Glu Trp Pro Leu Asp Glu			
755	760	765	
Gly Gln Gln Glu Val Phe Trp Val Asn Leu Arg Thr Ala Ile Lys Ser			
770	775	780	

<210> 7  
<211> 3029  
<212> DNA

<213> Homo sapiens  
<400> 7

gcggccgcgt cgacgaaatg tctggattt gactaaagaa aaaaggaaag gctagcagtc	60
atccaaacaga atcatgagac agacttgcc ttgtatctac ttttgggggg gcctttgcc	120
ctttggatg ctgtgtgcat cctccaccac caagtgcact gttagccatg aagttgctga	180
ctgcagccac ctgaagttga ctcaggtacc cgatgatcta cccacaaaaca taacagtgtt	240
gaaccttacc cataatcaac tcagaagatt accagccgcc aacttcacaa ggtatagcca	300
gctaactgc ttggatgttag gatttaacac catctaaaa ctggagccag aatttgtcca	360
gaaacctccc atgttaaaag ttttgaacct ccagcacaat gagctatctc aactttctga	420
taaaaccttt gccttctgca cgaatttgac tgaactccat ctcatgtcca actcaatcca	480
gaaaattaaa aataatccct ttgtcaagca gaagaattta atcacattag atctgtctca	540
taatggcttg tcatctacaa aattaggaac tcaggttcag ctggaaaatc tccaagagct	600
tctattatca aacaataaaa ttcaagcgct aaaaagtcaa gaactggata tctttgccaa	660
ttcatcttta aaaaaattag agttgtcatc gaatcaaatt aaagagttt ctccagggtg	720
ttttcacgca attggaagat tatttgcct ctttctgaac aatgtccagc tgggtcccag	780
ccttacagag aagctatgtt tggaatttagc aaacacaagc attcggaaatc tgtctctgag	840
taacagccag ctgtccacca ccagcaatac aactttcttggactaaagt ggacaaaatct	900
cactatgctc gatcttcct acaacaactt aaatgtggtt ggtaacgatt cctttgcttg	960
gcttccacaa ctagaatatt tcttcctaga gtataataat atacagcatt tgtttctca	1020
ctctttgcac gggctttca atgtgaggtt cctgaatttggaaacggctttt ttactaaaca	1080
aagtatttcc ctgcctcac tccccaaatgat tgatgatttt tctttcagt ggctaaaatg	1140
tttggagcac cttaacatgg aagataatga tattccaggc ataaaaagca atatgttcac	1200
aggattgata aacctgaaat acttaagtct atccaaactcc tttacaagtt tgcaactttt	1260
gacaaatgaa acatttgtat cacttgctca ttctccctta cacatactca acctaaccac	1320
gaataaaaatc taaaaatag agagtgtatgc tttctcttgg ttggccacc tagaagtact	1380
tgacctgggc cttaatgaaa ttggcaaga actcacaggc caggaatgga gaggtctaga	1440
aaatattttca gaaatctatc tttctacaa caagtacctg cagctgacta ggaactcctt	1500
tgccttggtc ccaagccttc aacgactgat gctccgaagg gtggccctta aaaatgtgga	1560
tagctctcc tcaccattcc agcctttcg taacttgacc attctggatc taagcaacaa	1620
caacatagcc aacataaaatg atgacatgtt ggagggtctt gagaaacttag aaattctcga	1680
tttgcagcat aacaacttag cacggctctg gaaacacgca aaccctggtg gtccattta	1740
tttcctaaag ggtctgtctc acctccacat ccttaacttg gagtccaaacg gctttgacga	1800

gatcccagtt gaggtcttca aggatttatt tgaactaaag atcatcgatt taggattgaa	1860
taattnaaac acacttccag catctgtctt taataatcag gtgtctctaa agtcattgaa	1920
ccttcagaag aatctcataa catccgttga gaagaagggtt ttccggccag ctttcaggaa	1980
cctgactgag ttagatatgc gctttaatcc ctttgattgc acgtgtgaaa gtattgcctg	2040
gtttgttaat tggattaacg agaccatac caacatccct gagctgtcaa gccactacct	2100
ttgcaacact ccacactcaat atcatgggtt cccagtgaga ctttttgata catcatcttg	2160
caaagacagt gccccctttg aactctttt catgatcaat accagtatcc tggtgatttt	2220
tatctttatt gtacttctca tccacttga gggctggagg atatctttt attggaatgt	2280
ttcagttacat cgagttcttg gtttcaaaga aatagacaga cagacagaac agtttgaata	2340
tgcagcatat ataattcatg cctataaaga taaggattgg gtctggaaac atttctcttc	2400
aatggaaaag gaagaccaat ctctcaaatt ttgtctggaa gaaaggact ttgaggcggg	2460
tgttttgaa ctagaagcaa ttgttaacag catcaaaaaga agcagaaaaaa ttattttgt	2520
tataacacac catctattaa aagaccatt atgcaaaaga ttcaaggtagc atcatgcagt	2580
tcaacaagct attgaacaaa atctggattc cattatattg gttttccttg aggagattcc	2640
agattataaa ctgaaccatg cactctgtt gcgaagagga atgtttaaat ctcactgcatt	2700
cttgaactgg ccagttcaga aagaacggat aggtgcctt cgtcataaat tgcaagtagc	2760
acttggatcc aaaaactctg tacattaaat ttattnaaat attcaattag caaaggagaa	2820
actttctcaa tttaaaaagt tctatggcaa atttaagttt tccataaagg tgttataatt	2880
tgtttattca tatttgtaaa tgattatatt ctatcacaat tacatctttt ctaggaaaat	2940
gtgtctcctt atttcaggcc tattttgac aattgactta attttaccca aaataaaaaca	3000
tataaggcacg caaaaaaaaaa aaaaaaaaaa	3029

<210> 8  
<211> 904  
<212> PRT  
<213> Homo sapiens

<400> 8

Met Arg Gln Thr Leu Pro Cys Ile Tyr Phe Trp Gly Gly Leu Leu Pro  
1               5                                   10                           15

Phe Gly Met Leu Cys Ala Ser Ser Thr Thr Lys Cys Thr Val Ser His  
20               25                                   30

Glu Val Ala Asp Cys Ser His Leu Lys Leu Thr Gln Val Pro Asp Asp  
35               40                                   45

Leu Pro Thr Asn Ile Thr Val Leu Asn Leu Thr His Asn Gln Leu Arg  
50               55                                   60

Arg Leu Pro Ala Ala Asn Phe Thr Arg Tyr Ser Gln Leu Thr Ser Leu

65	70	75	80
Asp Val Gly Phe Asn Thr Ile Ser Lys Leu Glu Pro Glu Leu Cys Gln			
85	90	95	
Lys Leu Pro Met Leu Lys Val Leu Asn Leu Gln His Asn Glu Leu Ser			
100	105	110	
Gln Leu Ser Asp Lys Thr Phe Ala Phe Cys Thr Asn Leu Thr Glu Leu			
115	120	125	
His Leu Met Ser Asn Ser Ile Gln Lys Ile Lys Asn Asn Pro Phe Val			
130	135	140	
Lys Gln Lys Asn Leu Ile Thr Leu Asp Leu Ser His Asn Gly Leu Ser			
145	150	155	160
Ser Thr Lys Leu Gly Thr Gln Val Gln Leu Glu Asn Leu Gln Glu Leu			
165	170	175	
Leu Leu Ser Asn Asn Lys Ile Gln Ala Leu Lys Ser Glu Glu Leu Asp			
180	185	190	
Ile Phe Ala Asn Ser Ser Leu Lys Lys Leu Glu Leu Ser Ser Asn Gln			
195	200	205	
Ile Lys Glu Phe Ser Pro Gly Cys Phe His Ala Ile Gly Arg Leu Phe			
210	215	220	
Gly Leu Phe Leu Asn Asn Val Gln Leu Gly Pro Ser Leu Thr Glu Lys			
225	230	235	240
Leu Cys Leu Glu Leu Ala Asn Thr Ser Ile Arg Asn Leu Ser Leu Ser			
245	250	255	
Asn Ser Gln Leu Ser Thr Thr Ser Asn Thr Thr Phe Leu Gly Leu Lys			
260	265	270	
Trp Thr Asn Leu Thr Met Leu Asp Leu Ser Tyr Asn Asn Leu Asn Val			
275	280	285	
Val Gly Asn Asp Ser Phe Ala Trp Leu Pro Gln Leu Glu Tyr Phe Phe			
290	295	300	
Leu Glu Tyr Asn Asn Ile Gln His Leu Phe Ser His Ser Leu His Gly			
305	310	315	320
Leu Phe Asn Val Arg Tyr Leu Asn Leu Lys Arg Ser Phe Thr Lys Gln			
325	330	335	
Ser Ile Ser Leu Ala Ser Leu Pro Lys Ile Asp Asp Phe Ser Phe Gln			
340	345	350	
Trp Leu Lys Cys Leu Glu His Leu Asn Met Glu Asp Asn Asp Ile Pro			
355	360	365	
Gly Ile Lys Ser Asn Met Phe Thr Gly Leu Ile Asn Leu Lys Tyr Leu			
370	375	380	
Ser Leu Ser Asn Ser Phe Thr Ser Leu Arg Thr Leu Thr Asn Glu Thr			
385	390	395	400
Phe Val Ser Leu Ala His Ser Pro Leu His Ile Leu Asn Leu Thr Lys			

405                    410                    415  
Asn Lys Ile Ser Lys Ile Glu Ser Asp Ala Phe Ser Trp Leu Gly His  
420                    425                    430

Leu Glu Val Leu Asp Leu Gly Leu Asn Glu Ile Gly Gln Glu Leu Thr  
435                    440                    445

Gly Gln Glu Trp Arg Gly Leu Glu Asn Ile Phe Glu Ile Tyr Leu Ser  
450                    455                    460

Tyr Asn Lys Tyr Leu Gln Leu Thr Arg Asn Ser Phe Ala Leu Val Pro  
465                    470                    475                    480

Ser Leu Gln Arg Leu Met Leu Arg Arg Val Ala Leu Lys Asn Val Asp  
485                    490                    495

Ser Ser Pro Ser Pro Phe Gln Pro Leu Arg Asn Leu Thr Ile Leu Asp  
500                    505                    510

Leu Ser Asn Asn Asn Ile Ala Asn Ile Asn Asp Asp Met Leu Glu Gly  
515                    520                    525

Leu Glu Lys Leu Glu Ile Leu Asp Leu Gln His Asn Asn Leu Ala Arg  
530                    535                    540

Leu Trp Lys His Ala Asn Pro Gly Gly Pro Ile Tyr Phe Leu Lys Gly  
545                    550                    555                    560

Leu Ser His Leu His Ile Leu Asn Leu Glu Ser Asn Gly Phe Asp Glu  
565                    570                    575

Ile Pro Val Glu Val Phe Lys Asp Leu Phe Glu Leu Lys Ile Ile Asp  
580                    585                    590

Leu Gly Leu Asn Asn Leu Asn Thr Leu Pro Ala Ser Val Phe Asn Asn  
595                    600                    605

Gln Val Ser Leu Lys Ser Leu Asn Leu Gln Lys Asn Leu Ile Thr Ser  
610                    615                    620

Val Glu Lys Lys Val Phe Gly Pro Ala Phe Arg Asn Leu Thr Glu Leu  
625                    630                    635                    640

Asp Met Arg Phe Asn Pro Phe Asp Cys Thr Cys Glu Ser Ile Ala Trp  
645                    650                    655

Phe Val Asn Trp Ile Asn Glu Thr His Thr Asn Ile Pro Glu Leu Ser  
660                    665                    670

Ser His Tyr Leu Cys Asn Thr Pro Pro His Tyr His Gly Phe Pro Val  
675                    680                    685

Arg Leu Phe Asp Thr Ser Ser Cys Lys Asp Ser Ala Pro Phe Glu Leu  
690                    695                    700

Phe Phe Met Ile Asn Thr Ser Ile Leu Leu Ile Phe Ile Phe Ile Val  
705                    710                    715                    720

Leu Leu Ile His Phe Glu Gly Trp Arg Ile Ser Phe Tyr Trp Asn Val  
725                    730                    735

Ser Val His Arg Val Leu Gly Phe Lys Glu Ile Asp Arg Gln Thr Glu

740	745	750
Gln Phe Glu Tyr Ala Ala Tyr Ile Ile His Ala Tyr Lys Asp Lys Asp		
755	760	765
Trp Val Trp Glu His Phe Ser Ser Met Glu Lys Glu Asp Gln Ser Leu		
770	775	780
Lys Phe Cys Leu Glu Glu Arg Asp Phe Glu Ala Gly Val Phe Glu Leu		
785	790	795
Glu Ala Ile Val Asn Ser Ile Lys Arg Ser Arg Lys Ile Ile Phe Val		
805	810	815
Ile Thr His His Leu Leu Lys Asp Pro Leu Cys Lys Arg Phe Lys Val		
820	825	830
His His Ala Val Gln Gln Ala Ile Glu Gln Asn Leu Asp Ser Ile Ile		
835	840	845
Leu Val Phe Leu Glu Glu Ile Pro Asp Tyr Lys Leu Asn His Ala Leu		
850	855	860
Cys Leu Arg Arg Gly Met Phe Lys Ser His Cys Ile Leu Asn Trp Pro		
865	870	875
Val Gln Lys Glu Arg Ile Gly Ala Phe Arg His Lys Leu Gln Val Ala		
885	890	895
Leu Gly Ser Lys Asn Ser Val His		
900		

<210> 9  
<211> 3310  
<212> DNA  
<213> murine

<400> 9	
tagaatatga tacagggatt gcaccataa tctgggctga atcatgaaag ggtgttcctc	60
ttatctaattg tactcctttt gggactttt gtccctatgg attcttctgg tgtcttccac	120
aaaccaatgc actgtgagat acaacgttagc tgactgcagc catttgaagc taacacacat	180
acctgatgat cttccctcta acataacagt gttaatctt actcacaacc aactcagaag	240
attaccaccc accaacttta caagatacag ccaacttgct atcttggatg caggatttaa	300
ctccatttca aaactggagc cagaactgtg ccaaatactc ctttgttga aagtattgaa	360
cctgcaacat aatgagctct ctcagatttc tgatcaaacc tttgtcttct gcacgaacct	420
gacagaactc gatctaatgt ctaactcaat acacaaaatt aaaagcaacc ctttcaaaaa	480
ccagaagaat ctaatcaaat tagatttgc tcataatggt ttatcatcta caaagttggg	540
aacgggggtc caactggaga acctccaaga actgcttta gcaaaaaata aaatccttgc	600
gttgcgaagt gaagaacttg agtttcttgg caattcttct ttacgaaagt tggacttgc	660
atcaaatcca cttaaagagt tctccccggg gtgtttccag acaattggca agttattcgc	720

cctcccttgc aacaacgccc aactgaaccc ccacccata gagaagcttt gctggaaact	780
ttcaaacaca agcatccaga atctctctc ggctaacaac cagctgctgg ccaccagcga	840
gagcactttc tctgggctga agtggacaaa tctcacccag ctgcgtctt cctacaacaa	900
cctccatgtat gtcggcaacg gttccttctc statctccca agcctgaggt atctgtctct	960
ggagtacaac aatatacage gtctgtcccc tcgctcttt tatggactct ccaacctgag	1020
gtacctgagt ttgaagcgag catttactaa gcaaagtgtt tcaacttgctt cacatccaa	1080
cattgacgtat tttcccttca aatggtaaa atatggaa tatctcaaca tggatgacaa	1140
taatattcca agtaccaaaa gcaataacctt cacgggattt gtgagtcgtt agtacctaag	1200
tctttccaaa actttcacaa gtttgcacaa tttaacaaat gaaacatgg tgcacttgc	1260
tcattctccc ttgctactc tcaacttaac gaaaaatcac atctcaaaaa tagcaaattgg	1320
tactttctct tggtaggccc aactcaggat acttgatctc ggccttaatg aaattgaaca	1380
aaaactcagc ggccaggaat ggagaggtct gagaatata tttgagatct acctatccta	1440
taacaaatac ctccaaactgt ctaccagttc cttgcattt gtccccagcc ttcaagact	1500
gatgctcagg agggtggccc ttaaaaatgt ggatatctcc cttcacctt tcccccctct	1560
tgcgtacttgc accattctgg acttaagcaa caacaacata gccaacataa atgaggactt	1620
gctggagggt ttgagaatcc tagaaatccctt ggattttcag cacaataact tagccaggct	1680
ctggaaacgc gcaaaaccccg gtggccgtt taatccctg aagggcgtt ctcacccca	1740
catcttgaat ttagagtcca acggcttaga tgaaatccca gtcgggttt tcaagaactt	1800
attcgaacta aagagcatca atctaggact gaataactta aacaaacttg aaccattcat	1860
ttttgatgac cagacatctc taaggtcaactt gaaacctccag aagaacctca taacatctgt	1920
tgagaaggat gtttcgggc cgcccttca aaacctgaac agtttagata tgcgttcaa	1980
tccgttcgac tgcacgtgtt aaagtatttc ctggttgtt aactggatca accagaccca	2040
cactaatatc tttgagctgt ccactcacta cctctgttac actccacatc attattatgg	2100
cttccccctg aagctttcg atacatcatc ctgttacccac agcgccccctt ttgaactcc	2160
cttcataatc agcaccagta tgctcctgg ttttatactt gtggactgc tcattcacat	2220
cgagggctgg agatctttt tttactggaa tggttcaatc catcgatttcc ttgggttcaa	2280
ggaaatagac acacaggctg agcagtttga atatacagcc tacataattt atgcccataa	2340
agacagagac tgggtctggg aacatttctc cccatggaa gaacaagacc aatctctcaa	2400
attttgccta gaagaaaggg actttgaagc aggcttcctt ggacttgaag caattgtttaa	2460
tagcatcaaa agaagccgaa aaatcatttt cgttatcaca caccattttt taaaagaccc	2520
tctgtgcaga agattcaagg tacatcacgc agttcagccaa gctattgagc aaaatctgga	2580
ttcaattata ctgatttttc tccagaatat tccagattat aaactaaacc atgcactctg	2640

tttgcgaaga ggaatgttta aatctcattg catcttgaac tggccagttc agaaagaacg 2700  
 gataaatgcc tttcatcata aattgcaagt agcacttgga tctcggaatt cagcacatta 2760  
 aactcatttgc aagatttgga gtcggtaaaag ggatagatcc aatttataaaa ggtccatcat 2820  
 gaatctaagt ttacttgaa agttttgtat atttatttat atgtatagat gatgatatta 2880  
 catcacaatc caatctcagt tttgaaatat ttccggcttat ttcattgaca tctggttat 2940  
 tcactccaaa taaacacatg ggcagttaaa aacatcctct attaatagat taccattaa 3000  
 ttcttgagggt gtatcacagc tttaaagggt tttaaatatt ttatataaaa taagactgag 3060  
 agttttataa atgtaatttt tttaaaactcg agtcttactg tgttagctcg aaaggcctgg 3120  
 aaattaatat attagagagt catgtcttga acttatttat ctctgcctcc ctctgtctcc 3180  
 agagtgttgc tttaagggc atgttagcacc acacccagct atgtacgtgt gggattttat 3240  
 aatgctcatt ttgagacgt ttatagaata aaagataatt gctttatgg tataaggcta 3300  
 cttgaggtaa 3310

&lt;210&gt; 10

&lt;211&gt; 905

&lt;212&gt; PRT

&lt;213&gt; murine

&lt;400&gt; 10

Met	Lys	Gly	Cys	Ser	Ser	Tyr	Leu	Met	Tyr	Ser	Phe	Gly	Gly	Leu	Leu
1								5		10				15	

Ser	Leu	Trp	Ile	Leu	Leu	Val	Ser	Ser	Thr	Asn	Gln	Cys	Thr	Val	Arg
									25				30		

Tyr	Asn	Val	Ala	Asp	Cys	Ser	His	Leu	Lys	Leu	Thr	His	Ile	Pro	Asp
								35		40		45			

Asp	Leu	Pro	Ser	Asn	Ile	Thr	Val	Leu	Asn	Leu	Thr	His	Asn	Gln	Leu
							50		55		60				

Arg	Arg	Leu	Pro	Pro	Thr	Asn	Phe	Thr	Arg	Tyr	Ser	Gln	Leu	Ala	Ile
65							70		75			80			

Leu	Asp	Ala	Gly	Phe	Asn	Ser	Ile	Ser	Lys	Leu	Glu	Pro	Glu	Leu	Cys
								85		90		95			

Gln	Ile	Leu	Pro	Leu	Leu	Lys	Val	Leu	Asn	Leu	Gln	His	Asn	Glu	Leu
							100		105		110				

Ser	Gln	Ile	Ser	Asp	'Gln	Thr	Phe	Val	Phe	Cys	Thr	Asn	Leu	Thr	Glu
								115		120		125			

Leu	Asp	Leu	Met	Ser	Asn	Ser	Ile	His	Lys	Ile	Lys	Ser	Asn	Pro	Phe
								130		135		140			

Lys	Asn	Gln	Lys	Asn	Leu	Ile	Lys	Leu	Asp	Leu	Ser	His	Asn	Gly	Leu
145								150		155		160			

Ser Ser Thr Lys Leu Gly Thr Gly Val Gln Leu Glu Asn Leu Gln Glu  
165 170 175

Leu Leu Leu Ala Lys Asn Lys Ile Leu Ala Leu Arg Ser Glu Glu Leu  
180 185 190

Glu Phe Leu Gly Asn Ser Ser Leu Arg Lys Leu Asp Leu Ser Ser Asn  
195 200 205

Pro Leu Lys Glu Phe Ser Pro Gly Cys Phe Gln Thr Ile Gly Lys Leu  
210 215 220

Phe Ala Leu Leu Leu Asn Asn Ala Gln Leu Asn Pro His Leu Thr Glu  
225 230 235 240

Lys Leu Cys Trp Glu Leu Ser Asn Thr Ser Ile Gln Asn Leu Ser Leu  
245 250 255

Ala Asn Asn Gln Leu Leu Ala Thr Ser Glu Ser Thr Phe Ser Gly Leu  
260 265 270

Lys Trp Thr Asn Leu Thr Gln Leu Asp Leu Ser Tyr Asn Asn Leu His  
275 280 285

Asp Val Gly Asn Gly Ser Phe Ser Tyr Leu Pro Ser Leu Arg Tyr Leu  
290 295 300

Ser Leu Glu Tyr Asn Asn Ile Gln Arg Leu Ser Pro Arg Ser Phe Tyr  
305 310 315 320

Gly Leu Ser Asn Leu Arg Tyr Leu Ser Leu Lys Arg Ala Phe Thr Lys  
325 330 335

Gln Ser Val Ser Leu Ala Ser His Pro Asn Ile Asp Asp Phe Ser Phe  
340 345 350

Gln Trp Leu Lys Tyr Leu Glu Tyr Leu Asn Met Asp Asp Asn Asn Ile  
355 360 365

Pro Ser Thr Lys Ser Asn Thr Phe Thr Gly Leu Val Ser Leu Lys Tyr  
370 375 380

Leu Ser Leu Ser Lys Thr Phe Thr Ser Leu Gln Thr Leu Thr Asn Glu  
385 390 395 400

Thr Phe Val Ser Leu Ala His Ser Pro Leu Leu Thr Leu Asn Leu Thr  
405 410 415

Lys Asn His Ile Ser Lys Ile Ala Asn Gly Thr Phe Ser Trp Leu Gly  
420 425 430

Gln Leu Arg Ile Leu Asp Leu Gly Leu Asn Glu Ile Glu Gln Lys Leu  
435 440 445

Ser Gly Gln Glu Trp Arg Gly Leu Arg Asn Ile Phe Glu Ile Tyr Leu  
450 455 460

Ser Tyr Asn Lys Tyr Leu Gln Leu Ser Thr Ser Ser Phe Ala Leu Val  
465 470 475 480

Pro Ser Leu Gln Arg Leu Met Leu Arg Arg Val Ala Leu Lys Asn Val

	485	490	495
Asp Ile Ser Pro Ser Pro Phe Arg Pro Leu Arg Asn Leu Thr Ile Leu			
	500	505	510
Asp Leu Ser Asn Asn Asn Ile Ala Asn Ile Asn Glu Asp Leu Leu Glu			
	515	520	525
Gly Leu Glu Asn Leu Glu Ile Leu Asp Phe Gln His Asn Asn Leu Ala			
	530	535	540
Arg Leu Trp Lys Arg Ala Asn Pro Gly Gly Pro Val Asn Phe Leu Lys			
	545	550	555
			560
Gly Leu Ser His Leu His Ile Leu Asn Leu Glu Ser Asn Gly Leu Asp			
	565	570	575
Glu Ile Pro Val Gly Val Phe Lys Asn Leu Phe Glu Leu Lys Ser Ile			
	580	585	590
Asn Leu Gly Leu Asn Asn Leu Asn Lys Leu Glu Pro Phe Ile Phe Asp			
	595	600	605
Asp Gln Thr Ser Leu Arg Ser Leu Asn Leu Gln Lys Asn Leu Ile Thr			
	610	615	620
Ser Val Glu Lys Asp Val Phe Gly Pro Pro Phe Gln Asn Leu Asn Ser			
	625	630	635
			640
Leu Asp Met Arg Phe Asn Pro Phe Asp Cys Thr Cys Glu Ser Ile Ser			
	645	650	655
Trp Phe Val Asn Trp Ile Asn Gln Thr His Thr Asn Ile Phe Glu Leu			
	660	665	670
Ser Thr His Tyr Leu Cys Asn Thr Pro His His Tyr Tyr Gly Phe Pro			
	675	680	685
Leu Lys Leu Phe Asp Thr Ser Ser Cys Lys Asp Ser Ala Pro Phe Glu			
	690	695	700
Leu Leu Phe Ile Ile Ser Thr Ser Met Leu Leu Val Phe Ile Leu Val			
	705	710	715
			720
Val Leu Leu Ile His Ile Glu Gly Trp Arg Ile Ser Phe Tyr Trp Asn			
	725	730	735
Val Ser Val His Arg Ile Leu Gly Phe Lys Glu Ile Asp Thr Gln Ala			
	740	745	750
Glu Gln Phe Glu Tyr Thr Ala Tyr Ile Ile His Ala His Lys Asp Arg			
	755	760	765
Asp Trp Val Trp Glu His Phe Ser Pro Met Glu Glu Gln Asp Gln Ser			
	770	775	780
Leu Lys Phe Cys Leu Glu Glu Arg Asp Phe Glu Ala Gly Val Leu Gly			
	785	790	795
			800
Leu Glu Ala Ile Val Asn Ser Ile Lys Arg Ser Arg Lys Ile Ile Phe			
	805	810	815
Val Ile Thr His His Leu Leu Lys Asp Pro Leu Cys Arg Arg Phe Lys			

820	825	830
Val His His Ala Val Gln Gln Ala Ile Glu Gln Asn Leu Asp Ser Ile		
835	840	845

Ile Leu Ile Phe Leu Gln Asn Ile Pro Asp Tyr Lys Leu Asn His Ala		
850	855	860

Leu Cys Leu Arg Arg Gly Met Phe Lys Ser His Cys Ile Leu Asn Trp		
865	870	875

Pro Val Gln Lys Glu Arg Ile Asn Ala Phe His His Lys Leu Gln Val		
885	890	895

Ala Leu Gly Ser Arg Asn Ser Ala His		
900	905	

&lt;210&gt; 11

&lt;211&gt; 3811

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 11

acaggccac tgctgctcac agaagcagtg agatgtgc caggatgtgc tctgcctcg	60
---	----

gcctggctgg gactctgatc ccagccatgg ctttcctctc ctgcgtgaga ccagaaagct	120
---	-----

gggagccctg cgtggagact tggccctaaa ccacacagaa gagctggcat gaaacccaga	180
---	-----

gctttcagac tccggagcc cagccctca ccccgattcc attgcttctt gctaaatgct	240
---	-----

gccgttttat cacggaggtg gttcctaata ttacttatca atgcatggag ctgaatttct	300
---	-----

acaataatccc cgacaacctc cccttctcaa ccaagaacct ggacctgagc tttaatcccc	360
--	-----

tgaggcattt aggcagctat agcttctca gtttcccaga actgcaggtg ctggatttat	420
--	-----

ccaggtgtga aatccagaca attgaagatg ggcatatca gagcctaagc cacctctcta	480
--	-----

ccttaatatt gacaggaaac cccatccaga gtttagccct gggagccctt tctggactat	540
---	-----

caagtttaca gaagctggtg gctgtggaga caaatctagc atctctagag aacttcccc	600
--	-----

ttggacatct caaaaactttt aaagaactta atgtggctca caatcttatac caatcttca	660
--	-----

aattacctga gtatttttct aatctgacca atcttagagca cttggacctt tccagcaaca	720
--	-----

agattcaaag tatattattgc acagacttgc gggttctaca tcaaattcccc ctactcaatc	780
---	-----

tctctttaga cctgtccctg aaccctatga actttatcca accaggtgca tttaaagaaaa	840
--	-----

ttaggcttca taagctgact ttaagaaata attttgatag tttaaatgta atgaaaactt	900
---	-----

gtattcaagg tctggctgg ttagaagtcc atcggttggt tctgggagaa tttagaaatg	960
--	-----

aaggaaactt ggaaaagttt gacaaatctg ctctagaggg cctgtgcaat ttgaccattg	1020
---	------

aagaattccg attagcatac ttagactact acctcgatga tattattgac ttatttaatt	1080
---	------

gtttgacaaa tgtttctca tttccctgg tgagtgtgac tattgaaagg gtaaaagact	1140
---	------

tttattataa ttccggatgg caacatttag aattagttaa ctgtaaattt ggacagttc	1200
--	------

ccacattgaa actcaaatct ctc当地aggc ttactttcac ttccaacaaa ggtggaaatg 1260  
cttttcaga agttgatcta ccaagccttg agtttctaga tctcagttaga aatggcttga 1320  
gttcaaagg ttgctgttct caaagtgatt ttgggacaac cagcctaaag tatttagatc 1380  
tgagcttcaa tgggtttatt accatgagtt caaacttctt gggcttagaa caactagaac 1440  
atctggattt ccagcattcc aatttggaaac aaatgagtga gttttcagta ttccttatcac 1500  
tcagaaacct catttacctt gacatttctc atactcacac cagagttgct ttcaatggca 1560  
tcttc当地gg ctgtccagt ctc当地gtct tgaaaatggc tggcaattct ttccaggaaa 1620  
acttc当地cc agatatcttcc acagagctga gaaacttgac cttccctggac ctctctcagt 1680  
tgcaactgga gcagttgtct ccaacagcat ttaactcact ctccagtc当地 caggtactaa 1740  
atatgagcca caacaacttc tttc当地gg atacgttcc ttataagtgt ctgaactccc 1800  
tccaggttct tgattacagt ctcaatcaca taatgacttc caaaaaacag gaactacagc 1860  
attttccaag tagtcttagt ttcttaatc ttactcagaa tgactttgct tgtacttgc 1920  
aacaccagag ttccctgcaa tggatcaagg accagaggca gctcttggc 1980  
gaatggaatg tgcaacaccc tcagataagc agggcatgcc tgtgctgagt ttgaatatca 2040  
cctgtcagat gaataagacc atcattggc tgctc当地ctt cagtgctt gtatctg 2100  
ttgttagcagt tctggcttat aagttctatt ttccacctgat gctcttgc 2160  
agtatggtag aggtgaaaac atctatgatg ccttgc当地 ctactcaagc caggatgagg 2220  
actgggtaag gaatgagcta gtaaagaatt tagaagaagg ggtgc当地cc ttccagtc当地 2280  
gc当地tcaacta cagagacttt attccggc tgccattgc tgccaaacatc atccatgaag 2340  
gttccataa aagccgaaag gtgattttg tggatgtccca gc当地tcatc cagagccgct 2400  
ggatgtatctt tgaatatgag attgctcaga cctggcagtt tctgagcagt cgtgctggta 2460  
tc当地tcat tgc当地tgc当地 aaggtggaga agaccctgct caggcagcag gtggagctgt 2520  
accgc当地tct cagcaggaac acttacctgg agtgggagga cagtgctc当地 gggccgcaca 2580  
tcttctggag acgactcaga aaagccctgc tggatggtaa atcatggaat ccagaaggaa 2640  
cagtggtac aggatgcaat tggcaggaag caacatctat ctgaagagga aaaataaaaa 2700  
cctc当地tgc当地 catttcttgc ccagctggc当地 ccaacacttg ttcaat 2760  
tgctgccaca tgc当地ggc当地 tatgcttaagg gtgagtaatt ccatggc当地 ctatctatgc 2820  
agggctgcta atctcaagga gcttccagtg cagagggaaat aaatgctaga ct当地ataca 2880  
gagtc当地cc ggtggc当地 tcaaccaact cagtc当地gg acccatgaca aagaaagtca 2940  
tttcaactct tacctcatca agttgaataa agacagagaa aacagaaaga gacattgttc 3000  
tttccctgag tctttgaat ggaaattgtta ttatgttata gccatcataa aaccatttg 3060

gtagtttga ctgaactggg tttcaacttt ttcccttttg attgaataca atttaaatc	3120
tacttgatga ctgcagtcgt caaggggctc ctgatgcaag atgccccttc catttaagt	3180
ctgtctcctt acagaggtta aagtctaattg gctaattcct aaggaaacct gattaacaca	3240
tgctcacaac catcctggtc attctcgAAC atgttctatt ttttaactaa tcaccctga	3300
tatattttta ttttatata tccagtttc attttttac gtctgccta taagctaata	3360
tcataaataa gttgtttaa gacgtgcttc aaatatccat attaaccact attttcaag	3420
gaagtatgga aaagtacact ctgtcaactt gtcactcgat gtcattccaa agttattgcc	3480
tactaagtaa tgactgtcat gaaagcagca ttgaaataat ttgtttaaag ggggcactct	3540
tttaaacggg aagaaaattt ccgcttcctg gtcttatcat ggacaatttggctataggc	3600
atgaaggaag tgggattacc tcaggaagtc acctttctt gattccagaa acatatggc	3660
tgataaaccC ggggtgacccatgaaatgaaatgttgcagcag atgtttttttttcagaac	3720
aagtgtatgtt tgatggacccatgaaatctat ttagggagac acagatggct gggatccctc	3780
ccctgtaccc ttctcaactga caggagaact a	3811

<210> 12  
<211> 2845  
<212> DNA  
<213> Homo sapiens

<400> 12	
cctctcaccc tttagcccaag aactgctttg aatacaccaa ttgctgtggg gccccctcgag	60
gaagagaaga caccagtgcc tcagaaactg ctcggtcaga cggtgatagc gagccacgca	120
ttcacagggc cactgctgot cacagaagca gtgaggatga tgccaggatg atgtctgcct	180
cgcgcctggc tgggactctg atcccagcca tggccttcct ctccctgcgt agaccagaaa	240
gctgggagcc ctgcgtggag gtgtgaaatc cagacaattt aagatgggc atatcagagc	300
ctaagccacc tctctacctt aatattgaca gaaaacccca tccagagttt agccctggga	360
gcctttctg gactatcaag tttacagaag ctgggtggctg tggagacaaa tctagcatct	420
ctagagaact tccccattgg acatctcaa actttgaaag aacttaatgt ggctcacaat	480
cttatccaat ctttcaaatt acctgagttat ttttctaattc tgaccaatct agagcacttg	540
gacctttcca gcaacaagat tcaaagtatt tattgcacag acttgcgggt tctacatcaa	600
atgcccctac tcaatctctc tttagacctg tcctgaacc ctatgaactt tatccaaacca	660
ggtgcatTTT aagaaatttag gttcataag ctgactttaa gaaataattt tgatagttt	720
aatgtaatga aaacttgtat tcaaggctcg gctggtttag aagtccatcg tttggttctg	780
ggagaattta gaaatgaagg aaacttggaa aagtttgaca aatctgctct agagggcctg	840

tgcaatttga ccattgaaga attccgatta gcatacttag actactacct cgatgatatt	900
attgacttat ttaattgttt gacaaatgtt tcttcatttt ccctggtag tgtagtatt	960
gaaaggtaa aagactttc ttataattc ggatggcaac atttagaatt agttaactgt	1020
aaatttggac agttcccac attgaaaactc aaatctctca aaaggcttac tttcaattcc	1080
aacaaaggta ggaatgcattt ttcagaagtt gatctaccaa gccttgagtt tctagatctc	1140
agtagaaatg gcttgagttt caaagggtgc tggatctcaaa gtgatttgg gacaaccagc	1200
ctaaagtatt tagatctgag cttcaatggt gttattacca tgagttcaaa cttcttggc	1260
ttagaacaac tagaacatct ggatttccag cattccaatt tgaaacaaat gagtgagttt	1320
tcaagtattcc tattcaactcgaa aaacccatt tacattgaca tttctcatac tcacaccaga	1380
gttgcatttca atggcatctt caatggcttgc tccagtctcg aagtcttgc aatggctggc	1440
aattcttcc aggaaaaactt cttccagat atcttcacag agctgagaaa cttgacccctc	1500
ctggacccctt ctcaagtgtca actggagcag ttgtctccaa cagcatttaa ctcactctcc	1560
agtcttcagg tactaaatat gagccacaac aacttctttt cattggatac gtttcattt	1620
aagtgtctga actccctcca ggttcttgat tacagtctca atcacataat gacttccaa	1680
aaacaggaac tacagcattt tccaagtagt cttagttct taaatcttac tcagaatgac	1740
tttgcttgta cttgtgaaca ccagagtttctgcaatggatcaaggacca gaggcagctc	1800
ttgggttggaaat ttgaacgaat ggaatgtgca acacccatcg ataagcaggg catgcctgt	1860
ctgagtttga atatcacctg tcagatgaat aagaccatca ttgggtgtgc ggtcctcagt	1920
gtgcttgttag tatctgttgc agcagttctg gtctataagt tctatccatca cctgatgctt	1980
cttgctggct gcataaaagta tggtagaggt gaaaacatct atgatgcctt tgatatctac	2040
tcaagccagg atgaggactg ggttaaggaat gagctagtaa agaattttaga agaaggggtg	2100
cctccatttc agctctgcct tcactacaga gactttattc ccgggtgtggc cattgctgcc	2160
aacatcatcc atgaaggttt ccataaaagc cgaaagggtga ttgttgggt gtccccagcac	2220
ttcatccaga gcccgtggtg tatcttgaa tatgagatttgc ctcagacccgt gcagttctg	2280
agcagtcgtg ctggatcat cttcattgtc ctgcagaagg tggagaagac cctgctcagg	2340
cagcaggtgg agctgtaccg ctttctcagc aggaacactt acctggagtg ggaggacagt	2400
gtcctggggc ggcacatctt ctggagacga ctcagaaaag ccctgctgga tggtaaatca	2460
tggaaatccag aaggaacagt gggtagacca tgcaattggc aggaagcaac atctatctga	2520
agagggaaaaaaa taaaaacctc ctgaggcatt tcttgcccag ctgggtccaa cacttggatca	2580
gttaataagt attaaatgct gccacatgtc aggcctttagt ctaagggtga gtaattccat	2640
ggtagcactag atatgcaggg ctgctaattct caaggagctt ccagtgcaga gggaaataat	2700
gcttagactaa aatacagagt cttccaggtg ggcatttcaaa ccaactcagt caaggaaccc	2760

atgacaaaaga aagtcat ttc aactcttacc tcatcaagtt gaataaagac agagaaaaca	2820
aaaaaaaaaaa aaaaaaaaaaa aaaaaa	2845

<210> 13  
<211> 3767  
<212> DNA  
<213> Homo sapiens

<400> 13	
cctctcaccc tttagcccaag aactgc ttg aatacaccaa ttgtgtggg gcggctcgag	60
gaagagaaga caccagtgcc tcagaaactg ctcggtcaga cggtgatagc gagccacgca	120
ttcacagggc cactgctgct cacagaagca gtgaggatga tgccaggatg atgtctgcct	180
cgcgcctggc tgggactctg atcccagcca tggccttcct ctccctgcgtg agaccagaaa	240
gctgggagcc ctgcgtggag acttggccct aaaccacaca gaagagctgg catgaaaccc	300
agagtttca gactccggag cctcagccct tcaccccgat tccattgctt cttgctaaat	360
gctgccgtt tatcacggag gtgtgaaatc cagacaattt aagatgggc atatcagagc	420
ctaagccacc tctctacctt aatattgaca ggaaacccca tccagagttt agccctggga	480
gcctttctg gactatcaag tttacagaag ctggtggtcg tggagacaaa tctagcatct	540
ctagagaact tccccattgg acatctcaaa actttaaag aacttaatgt ggctcacaat	600
cttatccaat ctttcaaatt acctgagttt ttttctaattc tgaccaatct agagcacttg	660
gacctttcca gcaacaagat tcaaagtatt tattgcacag acttgcgggt tctacatcaa	720
atgcccctac tcaatctctc tttagacctg tccctgaacc ctatgaactt tatccaacca	780
ggtcattta aagaaatttgc gcttcataag ctgactttaa gaaataattt tgatagttt	840
aatgtatga aaacttgtat tcaaggctcg gctggtttag aagtccatcg tttggttctg	900
ggagaatttgc gaaatgaagg aaacttggaa aagtttgc aatctgcct agagggcctg	960
tgcaatttgc ccattgaaga attccgatta gcatacttag actactacct cgatgatatt	1020
attgacttat ttaattgttt gacaaatgtt tcttcatttt ccctgggtcg tgtgactatt	1080
gaaagggtaa aagacttttc ttataatttc ggatggcaac atttagaatt agttaactgt	1140
aaatttggac agtttccac attgaaactc aaatctctca aaaggcttac tttcaattcc	1200
aacaaagggtg ggaatgc tttcagaagtt gatctaccaa gccttgagtt tctagatctc	1260
agtagaaatg gcttgagttt caaagggtgc tggatctcaaa gtgatgggg gacaaccagc	1320
ctaaagtatt tagatctgag cttcaatggt gttattacca tgagttcaaa cttctgggc	1380
ttagaacaac tagaacatct ggatttccag cattccaatt tgaaacaaat gagtgagttt	1440
tcagtttcc tatcactcag aaacctcatt taccttgaca tttctcatac tcacaccaga	1500

gttgctttca atggcatctt caatggcttg tccagtctcg aagtcttcaa aatggctggc	1560
aattcttcc agaaaaactt cttccagat atottcacag agctgagaaa cttgaccttc	1620
ctggacctct ctcagtgtca actggaggcag ttgtctccaa cagcattaa ctcactctcc	1680
agtcttcagg tactaaatat gagccacaac aacttctttt cattggatac gtttccttat	1740
aagtgtctga actccctcca ggttcttgat tacagtctca atcacataat gacttccaaa	1800
aaacaggaac tacagcattt tccaagtagt cttagttct taaatcttac tcagaatgac	1860
tttgcttgta cttgtgaaca ccagagttc ctgcaatgga tcaaggacca gaggcagctc	1920
ttgggtggaaag ttgaacgaat ggaatgtgca acacccctcag ataagcaggg catgcctgtg	1980
ctgagtttga atatcacctg tcagatgaat aagaccatca ttgggtgtgc ggtcctcagt	2040
tggtgttag tatctgttgt agcagttctg gtctataagt tctatttca cctgtatgtt	2100
cttgctggct gcataaaagta tggtagaggt gaaaacatct atgatgcctt tgttatctac	2160
tcaagccagg atgaggactg ggtaaggaat gagctagtaa agaattttaga agaaggggtg	2220
cctccatttc agctctgcct tcactacaga gactttattc ccgggtgtggc cattgctgcc	2280
aacatcatcc atgaaggttt ccataaaagc cgaaagggtga ttgttgtgt gtcccagcac	2340
ttcatccaga gccgctggtg tatcttgaa tatgagattt ctcagacctg gcagttctg	2400
agcagtcgtg ctggtatcat cttcattgtc ctgcagaagg tggagaagac cctgctcagg	2460
cagcaggtgg agctgtaccg cttctcagc aggaacactt acctggagtg ggaggacagt	2520
gtcctggggc ggcacatctt ctggagacga ctcagaaaag ccctgctgga tggtaaatca	2580
tggaatccag aaggaacagt ggttacagga tgcaattggc aggaagcaac atctatctga	2640
agaggaaaaaa taaaaacctc ctgaggcatt tcttgcccag ctgggtccaa cacttgtca	2700
gttaataagt attaaatgct gccacatgtc aggccattatg ctaagggtga gtaattccat	2760
ggtgacttag atatgcaggg ctgctaatttca caaggagctt ccagtgcaga gggataaat	2820
gctagactaa aatacagagt cttccaggtg ggcatttcaa ccaactcagt caaggaaccc	2880
atgacaaaaga aagtcttacc aactcttacc tcatcaagtt gaataaagac agagaaaaca	2940
gaaagagaca ttgttctttt cctgagttt ttgaatggaa attgtattat gttatagcca	3000
tcataaaaacc attttggtag ttttgactga actgggtgtt cacttttcc ttttgattt	3060
aatacaattt aaattctact tcatcaactgc agtcgtcaag gggctcctga tgcaagatgc	3120
cccttccatt ttaagtctgt ctccttacag aggttaaatgt cttagtggcta attcctaagg	3180
aaacctgatt aacacatgct cacaaccatc ctggtcattc tcgagcatgt tctatTTTT	3240
aactaatcac ccctgatata tttttatTTT tatatatcca gttttcattt ttttacgtct	3300
tgcctataag ctaatatcat aaataaggtt gtttaagacg tgcttcaa atccatatta	3360
accactattt ttcaaggaag tatggaaaag tacactctgt cactttgtca ctgcgtgtca	3420

ttccaaagtt attgcctact aagtaatgac tgtcatgaaa gcagcattga aataattgt	3480
ttaaaggggg cactcttta aacgggaaga aaattccgc ttcctggct tatcatggac	3540
aatttggct agaggcagga aggaagtggg atgaccttag gaggtcacct tttcttgatt	3600
ccagaaaacat atgggctgat aaacccgggg tgacctcatg aaatgagttg cagcagaagt	3660
ttatTTTTT cagaacaagt gatgttgat ggacctctga atctcttag ggagacacag	3720
atggctggga tccctccct gtacccttct cactgccagg agaacta	3767

<210> 14  
<211> 3814  
<212> DNA  
<213> Homo sapiens

<400> 14	
cctctcaccc tttagccccag aactgcttg aatacaccaa ttgctgtggg gcccgtcgag	60
gaagagaaga caccagtgcc tcagaaactg ctcggtcaga cggtgatagc gagccacgca	120
ttcacaggc cactgctgct cacagaagca gtgaggatga tgccaggatg atgtctgcct	180
cgcgcctggc tgggactctg atcccagcca tggccttcct ctccctgcgtg agaccagaaa	240
gctgggagcc ctgcgtggag gtggttccta atattactta tcaatgcatt gagctgaatt	300
tctacaaaat ccccgacaac ctccccttct caaccaagaa cctggacctg agcttaatc	360
ccctgaggca tttaggcagc tatacgctt tcagtttccc agaactgcag gtgctggatt	420
tatccaggtg tgaatccag acaattgaag atggggcata tcagagccta agccacctct	480
ctaccctaat attgacagga aaccccatcc agagtttagc cctgggagcc tttctggac	540
tatcaagttt acagaagctg gtggctgtgg agacaaaatct agcatctcta gagaacttcc	600
ccattggaca tctcaaaact ttgaaagaac ttaatgtggc tcacaatctt atccaatctt	660
tcaaattacc tgagtatttt tctaattctga ccaatctaga gcacttgac ctttccagca	720
acaagattca aagtattttat tgcacagact tgcgggttct acatcaaatg cccctactca	780
atctctcttt agacctgtcc ctgaacccta tgaactttat ccaaccaggt gcatttaaag	840
aaattaggct tcataagctg actttaagaa ataattttga tagtttaat gtaatgaaaa	900
cttgtattca aggtctggct ggtttagaag tccatcgaaa ggttctggga gaatttagaa	960
atgaaggaaa cttggaaaag tttgacaaat ctgcctctaga gggcctgtgc aatttgacca	1020
ttgaagaatt ccgatttagca tacttagact actacctcgat tgatattatt gacttattta	1080
attgtttgac aaatgtttct tcattttccc tggtgagtgt gactattgaa aggtaaaag	1140
acttttctta taatttcgga tggcaacatt tagaatttagt taactgtaaa tttggacagt	1200
ttcccacatt gaaactcaaa tctctcaaaa ggcttacttt cacttccaaac aaaggtggga	1260

atgcttttc agaagttgat ctaccaagcc ttgagttct agatctcagt agaaatggct	1320
ttagttcaa agttgctgt tctcaaagtg atttgggac aaccagccta aagtatttag	1380
atctgagctt caatggtggtt attaccatga gttcaaactt cttgggccta gaacaactag	1440
aacatctgga tttccagcat tccaatttga aacaaatgag tgagtttca gtattcctat	1500
cactcagaaa cctcatttac cttgacattt ctcatactca caccagagtt gcttcaatg	1560
gcacatcaa tggcttgcac agtctcgaag tctgaaaat ggctggcaat tcttccagg	1620
aaaacttcct tcacagatatc ttcacagagc tgagaaactt gacccctcctg gacctctc	1680
agtgtcaact ggagcagttg tctccaaacag catttaactc actctccagt cttcaggtac	1740
taaatatgag ccacaacaac ttctttcat tggatacgtt tccttataag tgtctgaact	1800
ccctccaggc tcttgcattt acgtctcaatc acataatgac ttccaaaaaa caggaactac	1860
agcattttcc aagtagtcta gctttcttaa atcttactca gaatgacttt gcttgcattt	1920
tgaaacacca gagttccctg caatggatca aggaccagag gcagctctg gtggaaagttg	1980
aacgaatgga atgtgcaaca ctttcagata agcagggcat gcctgtgtc agttgaata	2040
tcacctgtca gatgaataag accatcattt gtgtgtcggt ctcagtggtc cttgtat	2100
ctgttgcattt agttctggtc tataaggctt atttcacct gatgcttctt gctggctgca	2160
taaagtatgg tagaggtgaa aacatctatg atgcctttgt tatctactca agccaggatg	2220
aggactgggt aaggaatgag ctagtaaaga atttagaaga aggggtgcct ccatttc	2280
tctgccttca ctacagagac tttattcccg gtgtggccat tgctgccaac atcatccatg	2340
aaggttcca taaaagccga aaggtgattt ttgtgggtgc ccagcaccc atccagagcc	2400
gctgggttat ctttgaatat gagattgtc agacctggca gtttctgagc agtcgtgtc	2460
gtatcatctt cattgtcctg cagaagggtt agaagaccct gctcaggcag caggtggagc	2520
tgtaccgcct tctcagcagg aacacttacc tggagtgaaa ggacagtgtc ctggggcggc	2580
acatcttctg gagacgactc agaaaagccc tgctggatgg taaatcatgg aatccagaag	2640
gaacagtggg tacaggatgc aattggcagg aagcaacatc tatctgaaga ggaaaaataa	2700
aaaccccttg aggcatttct tgcccaagtc ggtccaaacac ttgttcagtt aataagtatt	2760
aaatgctgcc acatgtcagg ctttatgcta agggtgagta attccatggt gcactagata	2820
tgcagggctg ctaatctcaa ggagcttcca gtgcagaggg aataaatgct agactaaaat	2880
acagagtctt ccaggtggc atttcaacca actcagtcaa ggaacccatg acaaagaaaag	2940
tcatttcaac tcttacactca tcaagttgaa taaagacaga gaaaacagaa agagacattt	3000
ttctttccct gagtcttttgc aatggaaatt gtattatgtt atagccatca taaaaccatt	3060
ttggtagttt tgactgaact ggggtgttcac ttttccttt ttgattgaat acaatttaaa	3120
ttctacttgc tgcactgcagg cgtaagggg ctccgtatgc aagatgcccc ttccattttta	3180

agtctgtctc	tttacagagg	ttaaaagtcta	gtggtaatt	cctaaggaaa	cctgattaac	3240
acatgctcac	aaccatcctg	gtcattctcg	agcatgttct	attttttaac	taatcacc	3300
tgatataattt	ttatTTTtat	atatccagtt	ttcaTTTTT	tacgtcttgc	ctataagcta	3360
atatcataaa	taaggTTgtt	taagacgtgc	ttcaaata	catattaacc	actatTTTC	3420
aaggaagtat	ggaaaagtac	actctgtcac	tttgtca	actgtcattc	caaagttatt	3480
gcctactaag	taatgactgt	catgaaagca	gcattgaaat	aatttgttta	aagggggcac	3540
tctttaaac	ggaaagaaaaa	tttccgcttc	ctggtcttat	catggacaat	ttgggctaga	3600
ggcaggaagg	aagtgggatg	acctcaggag	gtcaccttt	cttgattcca	gaaacatatg	3660
ggctgataaa	cccggggtga	cctcatgaaa	ttagttgcag	cagaagttt	ttttttcag	3720
aacaagtat	gtttgatgga	cctctgaatc	tctttaggga	gacacagatg	gctgggatcc	3780
ctccctgt	ta cccttctcac	tgccaggaga	acta			3814

<210> 15  
<211> 3934  
<212> DNA  
<213> Homo spaiens

<400> 15						
cctctcaccc	tttagccag	aactgcttg	aatacaccaa	ttgctgtggg	gcggctcgag	60
gaagagaaga	caccagtgcc	tcagaaactg	ctcggtcaga	cggtgatagc	gagccacgca	120
ttcacagggc	cactgctgt	cacagaagca	gtgaggatga	tgccaggatg	atgtctgcct	180
cgcgcctggc	tggactctg	atcccagcca	tggccttcct	ctcctgcgtg	agaccagaaa	240
gctggagcc	ctgcgtggag	acttggccct	aaaccacaca	gaagagotgg	catgaaaccc	300
agagtttca	gactccggag	cctcagccct	tcaccccgat	tccattgott	cttgctaaat	360
gctgccgtt	tatcacggag	gtggttccta	atattactta	tcaatgcatg	gagctgaatt	420
tctacaaaat	ccccgacaac	ctccccctct	caaccaagaa	cctggacctg	agtttaatc	480
ccctgaggca	tttaggcagc	tatagcttct	tcagtttccc	agaactgcag	gtgctggatt	540
tatccaggtg	tgaaatccag	acaattgaag	atggggcata	tcagagccta	agccacctct	600
ctaccttaat	attgacagga	aacccatcc	agagtttagc	cctggagcc	ttttctggac	660
tatcaagttt	acagaagctg	gtggctgtgg	agacaaatct	agcatctcta	gagaacttcc	720
ccattggaca	tctcaaaaact	ttgaagaac	ttaatgtggc	tcacaatctt	atccaatctt	780
tcaaattacc	ttagtatttt	tctaatctga	ccaatctaga	gcacttggac	ctttccagca	840
acaagattca	aagtatttat	tgcacagact	tgcgggttct	acatcaaatg	ccccctactca	900
atctctcttt	agacctgtcc	ctgaacccta	tgaactttat	ccaaccaggt	gcatttaaag	960

aaatttagct tcataagctg actttaagaaa ataattttga tagtttaaat gtaataaaaa 1020  
cttgttattca aggtctggct ggtttagaag tccatcggtt ggttctggga gaatttagaa 1080  
  
atgaaggaaa cttggaaaag tttgacaaat ctgctctaga gggcctgtgc aatttgacca 1140  
ttgaagaatt ccgatttagca tacttagact actacacctcgta tgatattatt gacttattta 1200  
attgtttgac aaatgtttct tcattttccc tggtagtggt gactattgaa agggtaaaag 1260  
acttttccta taatttcgga tggcaacatt tagaattagt taactgtaaa tttggacagt 1320  
ttccccacatt gaaactcaaa tctctcaaaa ggcttacttt cacttccaac aaagggtggga 1380  
atgcttttc agaagttgat ctaccaagcc ttgagtttct agatctcagt agaaatggct 1440  
ttagtttcaa aggttgctgt tctcaaagtg attttggac aaccagccta aagtatttag 1500  
atctgagctt caatggtggtt attaccatga gttcaaactt cttgggctta gaacaactag 1560  
aacatctgga tttccagcat tccaaatttga aacaaatgag ttagtttca gtattccat 1620  
cactcagaaa cctcattttac cttgacattt ctcatactca caccagagtt gcttcaatg 1680  
gcatcttcaa tggottgtcc agtctcgaag tcttggaaaat ggctggcaat tcttccagg 1740  
aaaacttcct tccagatatc ttcacagagc tgagaaactt gaccttcctg gacctctctc 1800  
agtgtcaact ggagcagttg tctccaaacag catttaactc actctccagt cttcaggtac 1860  
taaatatgag ccacaacaac ttctttcat tggatacggtt tccttataag tgtctgaact 1920  
ccctccaggt tcttgattac agtctcaatc acataatgac ttccaaaaaaaa caggaactac 1980  
agcattttcc aagtagtcta gcttcttaa atcttactca gaatgacttt gcttgcattt 2040  
gtgaacacca gagtttcctg caatggatca aggaccagag gcagctcttg gtggaaagttg 2100  
aacgaatgga atgtgcaaca cttcagata agcagggcat gcctgtgctg agtttgaata 2160  
tcacctgtca gatgaataag accatcatgg gtgtgtcggt cctcagtgtg cttgttagtat 2220  
ctgttgcattc agttctggtc tataagttct attttccat gatgcttctt gctggctgca 2280  
taaagtatgg tagaggtgaa aacatctatg atgcctttgt tatctactca agccaggatg 2340  
aggactgggt aaggaatgag ctagtaaaga atttagaaga aggggtgcct ccatttcagc 2400  
tctgccttca ctacagagac tttattcccg gtgtggccat tgctgccaac atcatccatg 2460  
aaggtttcca taaaagccga aaggtgattt ttgtgggtgtc ccagcacttc atccagagcc 2520  
gctgggtgtat ctttgaatat gagattgctc agacctggca gtttctgagc agtcgtgctg 2580  
gtatcatctt cattgtcctg cagaagggtgg agaagaccc gatcaggcag caggtggagc 2640  
tgtaccgcct ttcagcagg aacacttacc tggagtggtt ggacagtgtc ctggggcgcc 2700  
acatcttctg gagacgactc agaaaagccc tgctggatgg taaatcatgg aatccagaag 2760  
gaacagtggg tacaggatgc aattggcagg aagcaacatc tatctgaaga ggaaaaataa 2820  
aacacccctg aggcattttct tgcccaacac ttgttcagtt aataagtatt 2880

aatgctgcc acatgtcagg ccttatgcta agggtgagta attccatgg gcactagata	2940
tgcagggctg ctaatctcaa ggagcttcca gtgcagaggg aataaatgct agactaaaat	3000
acagagtctt ccaggtgggc atttcaacca actcagtcaa ggaacccatg acaaagaag	3060
tcatttcaac tcttacctca tcaagttgaa taaagacaga gaaaacagaa agagacattg	3120
ttcttttccct gagtcttttg aatggaaatt gtattatggtt atagccatca taaaaccatt	3180
ttggtagttt tgactgaact ggggtttcac tttttccccc ttgattgaat acaatttaaa	3240
ttctacttga tgactgcagt cgtcaagggg ctccctgatgc aagatgcccc ttccatttta	3300
agtctgtctc cttacagagg ttaaagtcta gtggctaatt cctaaggaaa cctgattaac	3360
acatgctcac aaccatcctg gtcattctcg agcatgttct attttttaac taatcaccccc	3420
tgtatatattt ttatTTTtat atatccagtt ttcatttttt tacgtcttgc ctataagcta	3480
atatcataaa taaggttgtt taagacgtgc ttcaaataatc catattaacc actatTTTtc	3540
aaggaagtat ggaaaagtac actctgtcac ttgtcactc gatgtcattt caaagttatt	3600
gcctactaag taatgactgt catgaaagca gcattgaaat aatttgttta aagggggcac	3660
tcttttaaac gggaaagaaaa ttcccgcttc ctggctttat catggacaat ttgggctaga	3720
ggcaggaagg aagtgggatg acctcaggag gtcacccccc cttgattcca gaaacatatg	3780
ggctgataaa cccgggggtga cctcatgaaa tgagttgcag cagaagtttta tttttttcag	3840
aacaagtgtat gtttgtatgga cctctgaatc tcttttaggga gacacagatg gctgggatcc	3900
ctccccctgtta cccttctcac tgccaggaga acta	3934

<210> 16  
<211> 839  
<212> PRT  
<213> Homo sapiens

<400> 16

Met Met Ser Ala Ser Arg Leu Ala Gly Thr Leu Ile Pro Ala Met Ala  
1 5 10 15

Phe Leu Ser Cys Val Arg Pro Glu Ser Trp Glu Pro Cys Val Glu Val  
20 25 30

Val Pro Asn Ile Thr Tyr Gln Cys Met Glu Leu Asn Phe Tyr Lys Ile  
35 40 45

Pro Leu Arg His Leu Gly Ser Tyr Ser Phe Phe Ser Phe Pro Glu Leu  
 65                    70                    75                    80

Gln Val Leu Asp Leu Ser Arg Cys Glu Ile Gln Thr Ile Glu Asp Gly  
85 90 95

Ala Tyr Gln Ser Leu Ser His Leu Ser Thr Leu Ile Leu Thr Gly Asn  
100 105 110

Pro Ile Gln Ser Leu Ala Leu Gly Ala Phe Ser Gly Leu Ser Ser Leu  
115 120 125

Gln Lys Leu Val Ala Val Glu Thr Asn Leu Ala Ser Leu Glu Asn Phe  
130 135 140

Pro Ile Gly His Leu Lys Thr Leu Lys Glu Leu Asn Val Ala His Asn  
145 150 155 160

Leu Ile Gln Ser Phe Lys Leu Pro Glu Tyr Phe Ser Asn Leu Thr Asn  
165 170 175

Leu Glu His Leu Asp Leu Ser Ser Asn Lys Ile Gln Ser Ile Tyr Cys  
180 185 190

Thr Asp Leu Arg Val Leu His Gln Met Pro Leu Leu Asn Leu Ser Leu  
195 200 205

Asp Leu Ser Leu Asn Pro Met Asn Phe Ile Gln Pro Gly Ala Phe Lys  
210 215 220

Glu Ile Arg Leu His Lys Leu Thr Leu Arg Asn Asn Phe Asp Ser Leu  
225 230 235 240

Asn Val Met Lys Thr Cys Ile Gln Gly Leu Ala Gly Leu Glu Val His  
245 250 255

Arg Leu Val Leu Gly Glu Phe Arg Asn Glu Gly Asn Leu Glu Lys Phe  
260 265 270

Asp Lys Ser Ala Leu Glu Gly Leu Cys Asn Leu Thr Ile Glu Glu Phe  
275 280 285

Arg Leu Ala Tyr Leu Asp Tyr Tyr Leu Asp Asp Ile Ile Asp Leu Phe  
290 295 300

Asn Cys Leu Thr Asn Val Ser Ser Phe Ser Leu Val Ser Val Thr Ile  
305 310 315 320

Glu Arg Val Lys Asp Phe Ser Tyr Asn Phe Gly Trp Gln His Leu Glu  
325 330 335

Leu Val Asn Cys Lys Phe Gly Gln Phe Pro Thr Leu Lys Leu Lys Ser  
340 345 350

Leu Lys Arg Leu Thr Phe Thr Ser Asn Lys Gly Gly Asn Ala Phe Ser  
355 360 365

Glu Val Asp Leu Pro Ser Leu Glu Phe Leu Asp Leu Ser Arg Asn Gly  
370 375 380

Leu Ser Phe Lys Gly Cys Cys Ser Gln Ser Asp Phe Gly Thr Thr Ser  
385 390 395 400

Leu Lys Tyr Leu Asp Leu Ser Phe Asn Gly Val Ile Thr Met Ser Ser  
405 410 415

Asn Phe Leu Gly Leu Glu Gln Leu Glu His Leu Asp Phe Gln His Ser

Asn Leu Lys Gln Met Ser Glu Phe Ser Val Phe Leu Ser Leu Arg Asn 435	420                    425                    430 440                    445
Leu Ile Tyr Leu Asp Ile Ser His Thr His Thr Arg Val Ala Phe Asn 450                    455                    460	
Gly Ile Phe Asn Gly Leu Ser Ser Leu Glu Val Leu Lys Met Ala Gly 465                    470                    475                    480	
Asn Ser Phe Gln Glu Asn Phe Leu Pro Asp Ile Phe Thr Glu Leu Arg 485                    490                    495	
Asn Leu Thr Phe Leu Asp Leu Ser Gln Cys Gln Leu Glu Gln Leu Ser 500                    505                    510	
Pro Thr Ala Phe Asn Ser Leu Ser Ser Leu Gln Val Leu Asn Met Ser 515                    520                    525	
His Asn Asn Phe Phe Ser Leu Asp Thr Phe Pro Tyr Lys Cys Leu Asn 530                    535                    540	
Ser Leu Gln Val Leu Asp Tyr Ser Leu Asn His Ile Met Thr Ser Lys 545                    550                    555                    560	
Lys Gln Glu Leu Gln His Phe Pro Ser Ser Leu Ala Phe Leu Asn Leu 565                    570                    575	
Thr Gln Asn Asp Phe Ala Cys Thr Cys Glu His Gln Ser Phe Leu Gln 580                    585                    590	
Trp Ile Lys Asp Gln Arg Gln Leu Leu Val Glu Val Glu Arg Met Glu 595                    600                    605	
Cys Ala Thr Pro Ser Asp Lys Gln Gly Met Pro Val Leu Ser Leu Asn 610                    615                    620	
Ile Thr Cys Gln Met Asn Lys Thr Ile Ile Gly Val Ser Val Leu Ser 625                    630                    635                    640	
Val Leu Val Val Ser Val Val Ala Val Leu Val Tyr Lys Phe Tyr Phe 645                    650                    655	
His Leu Met Leu Leu Ala Gly Cys Ile Lys Tyr Gly Arg Gly Glu Asn 660                    665                    670	
Ile Tyr Asp Ala Phe Val Ile Tyr Ser Ser Gln Asp Glu Asp Trp Val 675                    680                    685	
Arg Asn Glu Leu Val Lys Asn Leu Glu Glu Gly Val Pro Pro Phe Gln 690                    695                    700	
Leu Cys Leu His Tyr Arg Asp Phe Ile Pro Gly Val Ala Ile Ala Ala 705                    710                    715                    720	
Asn Ile Ile His Glu Gly Phe His Lys Ser Arg Lys Val Ile Val Val 725                    730                    735	
Val Ser Gln His Phe Ile Gln Ser Arg Trp Cys Ile Phe Glu Tyr Glu 740                    745                    750	
Ile Ala Gln Thr Trp Gln Phe Leu Ser Ser Arg Ala Gly Ile Ile Phe	

755	760	765
Ile Val Leu Gln Lys Val Glu Lys Thr Leu Leu Arg Gln Gln Val Glu		
770	775	780
Leu Tyr Arg Leu Leu Ser Arg Asn Thr Tyr Leu Glu Trp Glu Asp Ser		
785	790	795
800		
Val Leu Gly Arg His Ile Phe Trp Arg Arg Leu Arg Lys Ala Leu Leu		
805	810	815
Asp Gly Lys Ser Trp Asn Pro Glu Gly Thr Val Gly Thr Gly Cys Asn		
820	825	830
Trp Gln Glu Ala Thr Ser Ile		
835		

<210> 17  
<211> 782  
<212> PRT  
<213> Homo sapiens

<400> 17

Met Lys Pro Arg Ala Phe Arg Leu Arg Ser Leu Ser Pro Ser Pro Arg		
1	5	10
		15
Phe His Cys Phe Leu Leu Asn Ala Ala Val Leu Ser Arg Arg Cys Glu		
20	25	30
Ile Gln Thr Ile Glu Asp Gly Ala Tyr Gln Ser Leu Ser His Leu Ser		
35	40	45
Thr Leu Ile Leu Thr Gly Asn Pro Ile Gln Ser Leu Ala Leu Gly Ala		
50	55	60
Phe Ser Gly Leu Ser Ser Leu Gln Lys Leu Val Ala Val Glu Thr Asn		
65	70	75
		80
Leu Ala Ser Leu Glu Asn Phe Pro Ile Gly His Leu Lys Thr Leu Lys		
85	90	95
Glu Leu Asn Val Ala His Asn Leu Ile Gln Ser Phe Lys Leu Pro Glu		
100	105	110
Tyr Phe Ser Asn Leu Thr Asn Leu Glu His Leu Asp Leu Ser Ser Asn		
115	120	125
Lys Ile Gln Ser Ile Tyr Cys Thr Asp Leu Arg Val Leu His Gln Met		
130	135	140
Pro Leu Leu Asn Leu Ser Leu Asp Leu Ser Leu Asn Pro Met Asn Phe		
145	150	155
		160
Ile Gln Pro Gly Ala Phe Lys Glu Ile Arg Leu His Lys Leu Thr Leu		
165	170	175
Arg Asn Asn Phe Asp Ser Leu Asn Val Met Lys Thr Cys Ile Gln Gly		
180	185	190
Leu Ala Gly Leu Glu Val His Arg Leu Val Leu Gly Glu Phe Arg Asn		
195	200	205

Glu Gly Asn Leu Glu Lys Phe Asp Lys Ser Ala Leu Glu Gly Leu Cys  
210 215 220

Asn Leu Thr Ile Glu Glu Phe Arg Leu Ala Tyr Leu Asp Tyr Tyr Leu  
225 230 235 240

Asp Asp Ile Ile Asp Leu Phe Asn Cys Leu Thr Asn Val Ser Ser Phe  
245 250 255

Ser Leu Val Ser Val Thr Ile Glu Arg Val Lys Asp Phe Ser Tyr Asn  
260 265 270

Phe Gly Trp Gln His Leu Glu Leu Val Asn Cys Lys Phe Gly Gln Phe  
275 280 285

Pro Thr Leu Lys Leu Lys Ser Leu Lys Arg Leu Thr Phe Thr Ser Asn  
290 295 300

Lys Gly Gly Asn Ala Phe Ser Glu Val Asp Leu Pro Ser Leu Glu Phe  
305 310 315 320

Leu Asp Leu Ser Arg Asn Gly Leu Ser Phe Lys Gly Cys Cys Ser Gln  
325 330 335

Ser Asp Phe Gly Thr Thr Ser Leu Lys Tyr Leu Asp Leu Ser Phe Asn  
340 345 350

Gly Val Ile Thr Met Ser Ser Asn Phe Leu Gly Leu Glu Gln Leu Glu  
355 360 365

His Leu Asp Phe Gln His Ser Asn Leu Lys Gln Met Ser Glu Phe Ser  
370 375 380

Val Phe Leu Ser Leu Arg Asn Leu Ile Tyr Leu Asp Ile Ser His Thr  
385 390 395 400

His Thr Arg Val Ala Phe Asn Gly Ile Phe Asn Gly Leu Ser Ser Leu  
405 410 415

Glu Val Leu Lys Met Ala Gly Asn Ser Phe Gln Glu Asn Phe Leu Pro  
420 425 430

Asp Ile Phe Thr Glu Leu Arg Asn Leu Thr Phe Leu Asp Leu Ser Gln  
435 440 445

Cys Gln Leu Glu Gln Leu Ser Pro Thr Ala Phe Asn Ser Leu Ser Ser  
450 455 460

Leu Gln Val Leu Asn Met Ser His Asn Asn Phe Phe Ser Leu Asp Thr  
465 470 475 480

Phe Pro Tyr Lys Cys Leu Asn Ser Leu Gln Val Leu Asp Tyr Ser Leu  
485 490 495

Asn His Ile Met Thr Ser Lys Lys Gln Glu Leu Gln His Phe Pro Ser  
500 505 510

Ser Leu Ala Phe Leu Asn Leu Thr Gln Asn Asp Phe Ala Cys Thr Cys  
515 520 525

Glu His Gln Ser Phe Leu Gln Trp Ile Lys Asp Gln Arg Gln Leu Leu

530                    535                    540  
 Val Glu Val Glu Arg Met Glu Cys Ala Thr Pro Ser Asp Lys Gln Gly  
 545                    550                    555                    560  
  
 Met Pro Val Leu Ser Leu Asn Ile Thr Cys Gln Met Asn Lys Thr Ile  
 565                    570                    575  
  
 Ile Gly Val Ser Val Leu Ser Val Leu Val Val Ser Val Val Ala Val  
 580                    585                    590  
  
 Leu Val Tyr Lys Phe Tyr Phe His Leu Met Leu Leu Ala Gly Cys Ile  
 595                    600                    605  
  
 Lys Tyr Gly Arg Gly Glu Asn Ile Tyr Asp Ala Phe Val Ile Tyr Ser  
 610                    615                    620  
  
 Ser Gln Asp Glu Asp Trp Val Arg Asn Glu Leu Val Lys Asn Leu Glu  
 625                    630                    635                    640  
  
 Glu Gly Val Pro Pro Phe Gln Leu Cys Leu His Tyr Arg Asp Phe Ile  
 645                    650                    655  
  
 Pro Gly Val Ala Ile Ala Ala Asn Ile Ile His Glu Gly Phe His Lys  
 660                    665                    670  
  
 Ser Arg Lys Val Ile Val Val Val Ser Gln His Phe Ile Gln Ser Arg  
 675                    680                    685  
  
 Trp Cys Ile Phe Glu Tyr Glu Ile Ala Gln Thr Trp Gln Phe Leu Ser  
 690                    695                    700  
  
 Ser Arg Ala Gly Ile Ile Phe Ile Val Leu Gln Lys Val Glu Lys Thr  
 705                    710                    715                    720  
  
 Leu Leu Arg Gln Gln Val Glu Leu Tyr Arg Leu Leu Ser Arg Asn Thr  
 725                    730                    735  
  
 Tyr Leu Glu Trp Glu Asp Ser Val Leu Gly Arg His Ile Phe Trp Arg  
 740                    745                    750  
  
 Arg Leu Arg Lys Ala Leu Leu Asp Gly Lys Ser Trp Asn Pro Glu Gly  
 755                    760                    765  
  
 Thr Val Gly Thr Gly Cys Asn Trp Gln Glu Ala Thr Ser Ile  
 770                    775                    780

<210> 18  
 <211> 799  
 <212> PRT  
 <213> Homo sapiens

<400> 18

Met Glu Leu Asn Phe Tyr Lys Ile Pro Asp Asn Leu Pro Phe Ser Thr  
 1                    5                    10                    15  
  
 Lys Asn Leu Asp Leu Ser Phe Asn Pro Leu Arg His Leu Gly Ser Tyr  
 20                    25                    30  
  
 Ser Phe Phe Ser Phe Pro Glu Leu Gln Val Leu Asp Leu Ser Arg Cys  
 35                    40                    45

Glu Ile Gln Thr Ile Glu Asp Gly Ala Tyr Gln Ser Leu Ser His Leu  
50 55 60

Ser Thr Leu Ile Leu Thr Gly Asn Pro Ile Gln Ser Leu Ala Leu Gly  
65 70 75 80

Ala Phe Ser Gly Leu Ser Ser Leu Gln Lys Leu Val Ala Val Glu Thr  
85 90 95

Asn Leu Ala Ser Leu Glu Asn Phe Pro Ile Gly His Leu Lys Thr Leu  
100 105 110

Lys Glu Leu Asn Val Ala His Asn Leu Ile Gln Ser Phe Lys Leu Pro  
115 120 125

Glu Tyr Phe Ser Asn Leu Thr Asn Leu Glu His Leu Asp Leu Ser Ser  
130 135 140

Asn Lys Ile Gln Ser Ile Tyr Cys Thr Asp Leu Arg Val Leu His Gln  
145 150 155 160

Met Pro Leu Leu Asn Leu Ser Leu Asp Leu Ser Leu Asn Pro Met Asn  
165 170 175

Phe Ile Gln Pro Gly Ala Phe Lys Glu Ile Arg Leu His Lys Leu Thr  
180 185 190

Leu Arg Asn Asn Phe Asp Ser Leu Asn Val Met Lys Thr Cys Ile Gln  
195 200 205

Gly Leu Ala Gly Leu Glu Val His Arg Leu Val Leu Gly Glu Phe Arg  
210 215 220

Asn Glu Gly Asn Leu Glu Lys Phe Asp Lys Ser Ala Leu Glu Gly Leu  
225 230 235 240

Cys Asn Leu Thr Ile Glu Glu Phe Arg Leu Ala Tyr Leu Asp Tyr Tyr  
245 250 255

Leu Asp Asp Ile Ile Asp Leu Phe Asn Cys Leu Thr Asn Val Ser Ser  
260 265 270

Phe Ser Leu Val Ser Val Thr Ile Glu Arg Val Lys Asp Phe Ser Tyr  
275 280 285

Asn Phe Gly Trp Gln His Leu Glu Leu Val Asn Cys Lys Phe Gly Gln  
290 295 300

Phe Pro Thr Leu Lys Leu Lys Ser Leu Lys Arg Leu Thr Phe Thr Ser  
305 310 315 320

Asn Lys Gly Gly Asn Ala Phe Ser Glu Val Asp Leu Pro Ser Leu Glu  
325 330 335

Phe Leu Asp Leu Ser Arg Asn Gly Leu Ser Phe Lys Gly Cys Cys Ser  
340 345 350

Gln Ser Asp Phe Gly Thr Thr Ser Leu Lys Tyr Leu Asp Leu Ser Phe  
355 360 365

Asn Gly Val Ile Thr Met Ser Ser Asn Phe Leu Gly Leu Glu Gln Leu

370	375	380
Glu His Leu Asp Phe Gln His Ser Asn Leu Lys Gln Met Ser Glu Phe		
385	390	395
Ser Val Phe Leu Ser Leu Arg Asn Leu Ile Tyr Leu Asp Ile Ser His		
405	410	415
Thr His Thr Arg Val Ala Phe Asn Gly Ile Phe Asn Gly Leu Ser Ser		
420	425	430
Leu Glu Val Leu Lys Met Ala Gly Asn Ser Phe Gln Glu Asn Phe Leu		
435	440	445
Pro Asp Ile Phe Thr Glu Leu Arg Asn Leu Thr Phe Leu Asp Leu Ser		
450	455	460
Gln Cys Gln Leu Glu Gln Leu Ser Pro Thr Ala Phe Asn Ser Leu Ser		
465	470	475
Ser Leu Gln Val Leu Asn Met Ser His Asn Asn Phe Phe Ser Leu Asp		
485	490	495
Thr Phe Pro Tyr Lys Cys Leu Asn Ser Leu Gln Val Leu Asp Tyr Ser		
500	505	510
Leu Asn His Ile Met Thr Ser Lys Lys Gln Glu Leu Gln His Phe Pro		
515	520	525
Ser Ser Leu Ala Phe Leu Asn Leu Thr Gln Asn Asp Phe Ala Cys Thr		
530	535	540
Cys Glu His Gln Ser Phe Leu Gln Trp Ile Lys Asp Gln Arg Gln Leu		
545	550	555
Leu Val Glu Val Glu Arg Met Glu Cys Ala Thr Pro Ser Asp Lys Gln		
565	570	575
Gly Met Pro Val Leu Ser Leu Asn Ile Thr Cys Gln Met Asn Lys Thr		
580	585	590
Ile Ile Gly Val Ser Val Leu Ser Val Leu Val Val Ser Val Val Ala		
595	600	605
Val Leu Val Tyr Lys Phe Tyr Phe His Leu Met Leu Leu Ala Gly Cys		
610	615	620
Ile Lys Tyr Gly Arg Gly Glu Asn Ile Tyr Asp Ala Phe Val Ile Tyr		
625	630	640
Ser Ser Gln Asp Glu Asp Trp Val Arg Asn Glu Leu Val Lys Asn Leu		
645	650	655
Glu Glu Gly Val Pro Pro Phe Gln Leu Cys Leu His Tyr Arg Asp Phe		
660	665	670
Ile Pro Gly Val Ala Ile Ala Ala Asn Ile Ile His Glu Gly Phe His		
675	680	685
Lys Ser Arg Lys Val Ile Val Val Ser Gln His Phe Ile Gln Ser		
690	695	700
Arg Trp Cys Ile Phe Glu Tyr Glu Ile Ala Gln Thr Trp Gln Phe Leu		

705	710	715	720
Ser Ser Arg Ala Gly Ile Ile Phe Ile Val Leu Gln Lys Val Glu Lys			
725		730	735

740	745	750	
Thr Leu Leu Arg Gln Gln Val Glu Leu Tyr Arg Leu Leu Ser Arg Asn			

755	760	765	
Thr Tyr Leu Glu Trp Glu Asp Ser Val Leu Gly Arg His Ile Phe Trp			

770	775	780	
Arg Arg Leu Arg Lys Ala Leu Leu Asp Gly Lys Ser Trp Asn Pro Glu			

785	790	795	
Gly Thr Val Gly Thr Gly Cys Asn Trp Gln Glu Ala Thr Ser Ile			

<210> 19  
<211> 639  
<212> PRT  
<213> Homo sapiens

<400> 19

Met Pro Leu Leu Asn Leu Ser Leu Asp Leu Ser Leu Asn Pro Met Asn			
1	5	10	15

Phe Ile Gln Pro Gly Ala Phe Lys Glu Ile Arg Leu His Lys Leu Thr			
20	25	30	

Leu Arg Asn Asn Phe Asp Ser Leu Asn Val Met Lys Thr Cys Ile Gln			
35	40	45	

Gly Leu Ala Gly Leu Glu Val His Arg Leu Val Leu Gly Glu Phe Arg			
50	55	60	

Asn Glu Gly Asn Leu Glu Lys Phe Asp Lys Ser Ala Leu Glu Gly Leu			
65	70	75	80

Cys Asn Leu Thr Ile Glu Glu Phe Arg Leu Ala Tyr Leu Asp Tyr Tyr			
85	90	95	

Leu Asp Asp Ile Ile Asp Leu Phe Asn Cys Leu Thr Asn Val Ser Ser			
100	105	110	

Phe Ser Leu Val Ser Val Thr Ile Glu Arg Val Lys Asp Phe Ser Tyr			
115	120	125	

Asn Phe Gly Trp Gln His Leu Glu Leu Val Asn Cys Lys Phe Gly Gln			
130	135	140	

Phe Pro Thr Leu Lys Leu Lys Ser Leu Lys Arg Leu Thr Phe Thr Ser			
145	150	155	160

Asn Lys Gly Gly Asn Ala Phe Ser Glu Val Asp Leu Pro Ser Leu Glu			
165	170	175	

Phe Leu Asp Leu Ser Arg Asn Gly Leu Ser Phe Lys Gly Cys Cys Ser			
180	185	190	

Gln Ser Asp Phe Gly Thr Thr Ser Leu Lys Tyr Leu Asp Leu Ser Phe			
195	200	205	

Asn Gly Val Ile Thr Met Ser Ser Asn Phe Leu Gly Leu Glu Gln Leu  
210 215 220

Glu His Leu Asp Phe Gln His Ser Asn Leu Lys Gln Met ,Ser Glu Phe  
225 230 235 240

Ser Val Phe Leu Ser Leu Arg Asn Leu Ile Tyr Leu Asp Ile Ser His  
245 250 255

Thr His Thr Arg Val Ala Phe Asn Gly Ile Phe Asn Gly Leu Ser Ser  
260 265 270

Leu Glu Val Leu Lys Met Ala Gly Asn Ser Phe Gln Glu Asn Phe Leu  
275 280 285

Pro Asp Ile Phe Thr Glu Leu Arg Asn Leu Thr Phe Leu Asp Leu Ser  
290 295 300

Gln Cys Gln Leu Glu Gln Leu Ser Pro Thr Ala Phe Asn Ser Leu Ser  
305 310 315 320

Ser Leu Gln Val Leu Asn Met Ser His Asn Asn Phe Phe Ser Leu Asp  
325 330 335

Thr Phe Pro Tyr Lys Cys Leu Asn Ser Leu Gln Val Leu Asp Tyr Ser  
340 345 350

Leu Asn His Ile Met Thr Ser Lys Lys Gln Glu Leu Gln His Phe Pro  
355 360 365

Ser Ser Leu Ala Phe Leu Asn Leu Thr Gln Asn Asp Phe Ala Cys Thr  
370 375 380

Cys Glu His Gln Ser Phe Leu Gln Trp Ile Lys Asp Gln Arg Gln Leu  
385 390 395 400

Leu Val Glu Val Glu Arg Met Glu Cys Ala Thr Pro Ser Asp Lys Gln  
405 410 415

Gly Met Pro Val Leu Ser Leu Asn Ile Thr Cys Gln Met Asn Lys Thr  
420 425 430

Ile Ile Gly Val Ser Val Leu Ser Val Leu Val Val Ser Val Val Ala  
435 440 445

Val Leu Val Tyr Lys Phe Tyr Phe His Leu Met Leu Leu Ala Gly Cys  
450 455 460

Ile Lys Tyr Gly Arg Gly Glu Asn Ile Tyr Asp Ala Phe Val Ile Tyr  
465 470 475 480

Ser Ser Gln Asp Glu Asp Trp Val Arg Asn Glu Leu Val Lys Asn Leu  
485 490 495

Glu Glu Gly Val Pro Pro Phe Gln Leu Cys Leu His Tyr Arg Asp Phe  
500 505 510

Ile Pro Gly Val Ala Ile Ala Ala Asn Ile Ile His Glu Gly Phe His  
515 520 525

Lys Ser Arg Lys Val Ile Val Val Ser Gln His Phe Ile Gln Ser

530	535	540
Arg Trp Cys Ile Phe Glu Tyr Glu Ile Ala Gln Thr Trp Gln Phe Leu		
545	550	555
		560
Ser Ser Arg Ala Gly Ile Ile Phe Ile Val Leu Gln Lys Val Glu Lys		
565	570	575
Thr Leu Leu Arg Gln Gln Val Glu Leu Tyr Arg Leu Leu Ser Arg Asn		
580	585	590
Thr Tyr Leu Glu Trp Glu Asp Ser Val Leu Gly Arg His Ile Phe Trp		
595	600	605
Arg Arg Leu Arg Lys Ala Leu Leu Asp Gly Lys Ser Trp Asn Pro Glu		
610	615	620
Gly Thr Val Gly Thr Gly Cys Asn Trp Gln Glu Ala Thr Ser Ile		
625	630	635

<210> 20  
<211> 3866  
<212> DNA  
<213> murine

<400> 20		
ctgggtgcag aaaatgccag gatgatgcct ccctggctcc tggctaggac tctgatcatg	60	
gcactgttct tctcctgcct gacaccagga agcttgaatc cctgcataaga ggttagttcct	120	
aatattacct accaatgcat ggatcagaaa ctcagcaaag tccctgatga cattccttct	180	
tcaaccaaga acatagatct gagcttcaac cccttgaaga tcttaaaaag ctatagttcc	240	
tccaattttt cagaacttca gtggctggat ttatccaggt gtgaaattga aacaattgaa	300	
gacaaggcat ggcattggctt acaccaccc tcaaacttga tactgacagg aaaccctatc	360	
cagagttttt ccccaggaag tttcttgaa ctaaaaagtt tagagaatct ggtggctgtg	420	
gagacaaaaat tggcctctct agaaagcttc cctattggac agcttataac cttaaagaaa	480	
ctcaatgtgg ctcacaattt tatacattcc tctaagttac ctgcataattt ttccaatctg	540	
acgaacctag tacatgtgga tctttcttat aactatattc aaactattac tgtcaacgac	600	
ttacagtttc tacgtgaaaa tccacaagtc aatctcttt tagacatgtc tttgaaccca	660	
attgacttca ttcaagacca agccttcag ggaattaagc tccatgaact gactctaaga	720	
ggtaattttt atagctcaaataataatgaaa acttgccttc aaaacctggc tggtttacac	780	
gtccatcggt tgatcttggg agaatttaaa gatgaaagga atctggaaat ttttgaaccc	840	
tctatcatgg aaggactatg tgatgtgacc attgatgagt tcaggttaac atatacaaatt	900	
gatttttcag atgatattgt taagttccat tgcttggcga atgtttctgc aatgtctctg	960	
gcaggtgtat ctataaaaata tctagaagat gttcctaaac atttcaaattg gcaatcctta	1020	
tcaatcatta gatgtcaact taagcagttt ccaactctgg atctaccctt tcttaaaaagt	1080	

ttgactttaa ctatgaacaa agggctatac agtttaaaa aagtggccct accaagtctc 1140  
agctatctag atcttagtag aaatgcactg agcttagtg gttgctgttc ttattctgat 1200  
ttggaaacaa acagcctgag acacttagac ctcagcttca atggtgccat cattatgagt 1260  
gccaaattca tgggtctaga agagctgcag cacctggatt ttcagcactc tactttaaaa 1320  
agggtcacag aattctcagc gttcttatcc cttgaaaagc tactttacct tgacatctct 1380  
tatactaaca cccaaaattga ctgcgttgtt atatttcttg gcttgaccag tctcaacaca 1440  
ttaaaaatgg ctggcaattc tttcaaaagac aacaccctt caaatgtctt tgcaaacaca 1500  
acaaacttga cattcctgga tctttctaaa tgtcaattgg aacaaatatac ttggggggta 1560  
tttgacacccc tccatagact tcaattatta aatatgagtc acaacaatct attgttttg 1620  
gattcatccc attataacca gctgtattcc ctcagcactc ttgattgcag tttcaatcgc 1680  
atagagacat ctaaaggaat actgcaacat tttccaaaga gtctagcctt cttcaatctt 1740  
actaacaatt ctgttgcttg tatatgtgaa catcagaaat tcctgcagtg ggtcaaggaa 1800  
cagaagcagt tcttggtgaa tgttgaacaa atgacatgtg caacacctgt agagatgaat 1860  
acctccttag tggattttttaataattctt acctgttata tgtacaagac aatcatcagt 1920  
gtgtcagtgg tcagtgtgat tgtggatcc actgttagcat ttctgatata ccacttctat 1980  
tttcacctga tacttattgc tggctgtaaa aagtacagca gaggagaaag catctatgat 2040  
gcatttgcgttga tctactcgag tcagaatgag gactgggtga gaaatgagct ggtaaagaat 2100  
ttagaagaag gagtgccccg cttcacctc tgccttcaact acagagactt tattcctgg 2160  
gtagccattg ctgccaacat catccaggaa ggcttccaca agagccggaa ggttattgtg 2220  
gtagtgtcta gacactttat tcagagccgt tgggttatct ttgaatatga gattgctcaa 2280  
acatggcagt ttctgagcag ccgctctggc atcatcttca ttgtccttga gaagggtttag 2340  
aagtccctgc tgaggcagca ggtggaaattg tategccttc ttagcagaaa cacctacctg 2400  
gaatgggagg acaatccctc ggggaggcac atcttctgga gaagacttaa aaatgcccta 2460  
ttggatggaa aagcctcgaa tcctgagcaa acagcagagg aagaacaaga aacggcaact 2520  
tggacctgag gagaacaaaa ctctggggcc taaacccagt ctgtttgcaa ttaataatg 2580  
ctacagctca cctggggctc tgctatggac cgagagccca tggaacacat ggctgctaag 2640  
ctatagcatg gaccttaccg ggcagaagga agtagcactg acaccttcc ttccagggt 2700  
atgaattacc taactcgaaa aaagaaacat aatccagaat ctttacctt aatctgaagg 2760  
agaagaggct aaggcctagt gagaacagaa aggagaacca gtcttcactg ggcctttga 2820  
atacaagcca tgtcatgttc tgtgttcag ttgctttaga agagtattga tagttcaac 2880  
tgaactgaac ggtttcttac ttccctttt ttctactgaa tgcaatatta aatacgctt 2940  
tttgagaggt cttcattcca attcatctt ccattttatg tcattttctt ttctttttg 3000

tttttatcta	attctataag	aaatatgatt	gatacacgct	cacagatgc	ctggccaatc	3060
ctaagaatgc	tatatttatt	aaatacaatt	cctagtatac	tttactttt	ataaattcag	3120
ttatcgffff	tcatgccttg	actataaaact	aatatcataa	ataagattgt	tacaggtatg	3180
ctaagaaggc	ccatatttga	ctataatttt	ttaagaaaagt	atataaaata	tactttgtca	3240
tattgtcact	aatgtcatt	cttaagttat	tacctaagtt	atggatgtca	cagagtcagt	3300
gttaaaaata	atttgggtga	tagaaatatt	tttaatcagg	agggaaaagt	ggagaggggt	3360
gcaggaacag	aatcatgat	ttcatcattt	attttgatt	tttccggaag	ttcacatagc	3420
tgaatgacaa	gactacatat	gctgcaactg	atgttccttc	tcatcaagga	tactctctga	3480
acttggaaac	attttgggga	ggaagaaaagg	tctaacatcc	tttccttca	tcattctcat	3540
ttctggacat	gccttgtgag	atggatcaat	gttgggagta	cacatttctg	cttcacaccc	3600
atttcagtca	gcatgaacac	tgaatatata	atgtcatttc	acagtgtgt	tgtgttgtgt	3660
atgtacatat	atgaacctgt	acatgtgttt	aagtttaaag	agaaaatagt	gtacagagca	3720
ggtgtatatt	tgtgataggg	ctttaaatag	ttgagcta	tcagaaaaagt	atggaggttt	3780
cttggtaaac	caaaccaaaa	gtagaatcat	tacaagatct	aacaataaaa	atttgaaaaa	3840
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	3866

<210> 21  
<211> 2520  
<212> DNA  
<213> murine

<400> 21	atgatgcctc	cctggctcct	ggcttaggact	ctgatcatgg	cactgttctt	ctcctgcctg	60
	acaccaggaa	gcttgaatcc	ctgcata	gtagttccta	atattaccta	ccaatgc	120
	gatcagaaac	tcagcaa	ccctgatgac	attccttctt	caaccaagaa	catagatctg	180
	agcttcaacc	cttgaagat	ctttaaaaagc	tatagcttct	ccaattttc	agaacttcag	240
	tggctggatt	tatccaggt	tgaaattgaa	acaattgaag	acaaggcatg	gcatggctt	300
	caccac	cataactt	actgacagga	aaccctatcc	agagtttcc	cccaggaagt	360
	ttctctggac	taacaagttt	agagaatctg	gtggctgtgg	agacaaaatt	ggcctctcta	420
	gaaagcttcc	ctattggaca	gcttataacc	ttaaagaaac	tcaatgtggc	tcacaat	480
	atacattcct	gtaagttacc	tgcata	tccaaatctga	cgaacctagt	acatgtggat	540
	ctttcttata	actatattca	aactattact	gtcaacgact	tacagttct	acgtaaaat	600
	ccacaagtca	atctctttt	agacatatct	ttgaacccaa	ttgacttcat	tcaagaccaa	660
	gccttcagg	gaattaagct	ccatgaa	actctaagag	gtaattttaa	tagctcaa	720

ataataaaa cttgccttca aaacctggct ggtttacaca tccatcggtt gatcttggga 780  
gaatttaaag atgaaaggaa tctggaaatt tttgaaccct ctatcatgga aggactatgt 840  
gatgtgacca ttgatgagtt caggtaaca tatacaaatg attttcaga tgatattgtt 900  
aagttccatt gcttggcgaa tgtttctgca atgtctctgg caggtgtatc tataaaatat 960  
ctagaagatg ttcctaaaca tttcaaattgg caatccttat caatcattag atgtcaactt 1020  
aagcagttc caactctggta tctacccttt cttaaaaagtt tgactttaac tatgaacaaa 1080  
gggtctatca gttttaaaaa agtggcccta ccaagtctca gctatctaga tcttagtaga 1140  
aatgcactga gcttttagtgg ttgctgttct tattctgatt tgggaacaaa cagcctgaga 1200  
cacttagacc tcagcttcaa tggtgccatc attatgagtg ccaatttcatt gggtctagaa 1260  
gagctgcagc acctggattt tcagcactct actttaaaaa gggtcacaga attctcagcg 1320  
ttcttatccc ttgaaaagct actttacctt gacatcttctt atactaacac caaaattgac 1380  
ttcgatggta tatttcttgg cttgaccagt ctcaacacat taaaaatggc tggcaattct 1440  
ttcaaagaca acacccttcc aaatgtcttt gcaaacadcaa caaacttgac attcctggat 1500  
ctttctaaat gtcaatttgg acaaataatct tggggggat ttgacaccctt ccatagactt 1560  
caattattaa atatgagtca caacaatcta ttgttttgg attcatccca ttataaccag 1620  
ctgtattccc tcagcactct tgattgcagt ttcaatcgca tagagacatc taaaggaata 1680  
ctgcaacatt ttccaaagag tctagccttc ttcaatctt ctaacaatttgc tggcattgt 1740  
atatgtgaac atcagaaatt cctgcagtgg gtcaaggacc agaagcagtt ctttgtgaat 1800  
gttgaacaaa tgacatgtgc aacacctgta gagatgaata cttcccttagt gttggatttt 1860  
aataattcta cctgttataat gtacaagaca atcatcagtg tgtcagtggc cagtgtgatt 1920  
gtggtatcca ctgtatcattt tctgatatac cacttcttattt ttcacctgtt acttattgtt 1980  
ggctgtaaaa agtacagcag aggagaaagc atctatgtt catttgtat ctaactcgagt 2040  
cagaatgagg actgggttag aaatgagctg gtaaagaatt tagaagaagg agtgccccgc 2100  
ttcacctct gccttcacta cagagactttt attcctgggtg tagccattgc tgccaaatatc 2160  
atccaggaag gttccacaa gagccggaag gttattgtgg tagtgtctag acactttatt 2220  
cagagccgtt ggtgtatctt tgaatatgag attgctcaaa catggcagtt tctgagcagc 2280  
cactctggca tcatttcattt tgccttgag aaggttgaga agtccctgtt gaggcagcag 2340  
gtggaaattgt atgccttct tagcagaaac acctacctgg aatgggagga caatcctctg 2400  
gggaggcaca tcttctggag aagacttaaa aatgccctat tggatggaaa agcctcgaat 2460  
cctgagcaaa cagcagagga agaacaagaa acggcaactt ggacctgagg agaaccgcgg 2520

<212> DNA  
<213> murine

<400> 22  
ctgggtgcag aaaatgccag gatgatgcct ccctggctcc tggcttaggac tctgatcatg 60  
gcactgttct ttcctgcct gacaccagga agcttgaatc cctgcataaga ggttagttct 120  
aatattacct accaatgcac ggatcagaaa ctcagcaaag tccctgtatc cattccctct 180  
tcaaccaaga acatagatct gagcttcaac cccttgaaga tcttaaaaag ctatagctc 240  
tccaatttt cagaacttca gtggctggat ttatccagggt gtgaaattga aacaattgaa 300  
gacaaggcat ggcattggctt acaccaccc tc当地acttga tactgacagg aaaccctatc 360  
cagagttttt ccccaggaag tttctctgga ctaacaagtt tagagaatct ggtggctgtg 420  
gagacaaaaat tggcctctct agaaagcttc cctattggac agcttataac ct当地agaaa 480  
ctcaatgtgg ctcacaattt tatacattcc tctaagttac ctgcataattt ttccaatctg 540  
acgaacctag tacatgtgga tctttcttat aactatattc aaactattac tgtcaacgac 600  
ttacagtttc tacgtgaaaa tccacaagtc aatctcttt tagacatgtc tttgaaccca 660  
attgacttca ttcaagacca agccttcag ggaattaagc tccatgaact gactctaaga 720  
ggtaattttt atagctcaaa tataatgaaa acttgccttc aaaacctggc tggtttacac 780  
gtccatcggt tgatcttggg agaattttaa gatgaaagga atctggaaat ttttgaaccc 840  
tctatcatgg aaggactatg tgatgtgacc attgatgagt tcaggttaac atatacaaatt 900  
gattttcag atgatattgt taagttccat tgcttggcga atgtttctgc aatgtctctg 960  
gcaggtgtat ctataaaata tctagaagat gtcctaaac atttcaaattg gcaatcctta 1020  
tcaatcatta gatgtcaact taagcagttt ccaactctgg atctaccctt tctaaaaatt 1080  
ttgactttaa ctatgaacaa agggctatc agttttaaaa aagtggccct accaagtctc 1140  
agctatctag atcttagtag aatgcactg agcttttagtg gttgctgttc ttattctgat 1200  
ttgggaacaa acagcctgag acacttagac ctcagcttca atggtgcctt cattatgagt 1260  
gccaatttca tgggtctaga agagctgcag cacctggatt ttcagcactc tactttaaaa 1320  
agggtcacag aattctcagc gttcttatcc ctgaaaagc tactttacct tgacatctct 1380  
tatactaaca ccaaaattga ctgcgttgtt atatttcttg gcttgaccag tctcaacaca 1440  
ttaaaaatgg ctggcaattt tttcaaaagac aacacccttt caaatgtctt tgcaaacaca 1500  
acaaacttga cattcctgga tctttctaaa tgtcaattgg aacaaatatac ttggggggta 1560  
tttgacaccc tccatagact tcaatttata aatatgagtc acaacaatct attgttttg 1620  
gattcatccc attataacca gctgtattcc ctcagcactc ttgattgcag ttcaatctc 1680  
atagagacat ctaaaggaat actgcaacat tttccaaaga gtctagcctt ctcaatctt 1740

actaacaatt ctgttgcctg tatatgtgaa catcagaaat tcctgcagt ggtcaaggaa	1800
cagaagcagt tcttggtgaa tggtgaacaa atgacatgtg caacacctgt agagatgaat	1860
accccttag tggggat ttataattct acctgttata tgtacaagac aatcatcagt	1920
gtgtcagtgg tcagtgtgat tgggtatcc actgttagcat ttctgatata ccacttctat	1980
tttcacctga tacttattgc tggctgtaaa aagtacagca gaggagaaag catctatgat	2040
gcatttgta tctactcgag tcagaatgag gactgggtga gaaatgagct ggtaaagaat	2100
ttagaagaag gagtgcggccg ctttcaccc tcgccttact acagagactt tattcctgg	2160
gtagccattg ctgccaacat catccaggaa ggcttccaca agagccggaa ggttattgtg	2220
gtagtgtcta gacactttat tcagagccgt tgggtatct ttgaatatga gattgctaa	2280
acatggcagt ttctgagcag ccgctctggc atcatttca ttgtccttga gaagggtttag	2340
aagtccctgc tgaggcagca ggttggattt tattgccttc ttagcagaaa cacctacctg	2400
aatgggagg acaatccctt ggggaggcac atcttctggaa gaagacttaa aaatgcctta	2460
ttggatggaa aagcctcgaa tcctgagcaa acagcagagg aagaacaaga aacggcaact	2520
tggacctgag gagaacaaaaa ctctggggcc taaaccctgt ctgtttgcaaa ttaataatg	2580
ctacagctca cctggggctc tgctatggac cgagagccca tggAACACAT ggctgctaag	2640
ctatacgatg gaccttaccg ggcagaagga agtagcactg acaccttctt ttccagggtt	2700
atgaattacc taactcgaaa aaagaaacat aatccagaat cttaaccttt aatctgaagg	2760
agaagaggct aaggcctagt gagaacagaa aggagaacca gtcttactg ggcctttga	2820
atacaagcca tgcattgttc tgggtttcag ttgtttttaga agagtattga tagttcaac	2880
tgaactgaac ggttttttac ttccctttt ttctactgaa tgcaatatta aatacgctt	2940
tttgagaggt cttcattcca atttcattttt ccattttatg tcattttttt ttctttttt	3000
tttttatcta attctataag aaatatgatt gatacagct cacagatgc ctggccaatc	3060
ctaagaatgc tatattttt aaatacaatt cctagtatac ttttactttt ataaattcag	3120
ttatcgttt tcatgccttg actataaact aatatcataa ataagattgt tacaggtatg	3180
ctaagaaggc ccatatttga ctataatttt ttaagaaagt atataaaata tactttgtca	3240
tattgtcact gaatgtcatt cttaagttt taccttaagtt atggatgtca cagagtca	3300
gttaaaaata atttgggttga tagaaatatt tttaatcagg agggaaaagt ggagaggggt	3360
gcaggaacag aaatcatgat ttcatcattt attcttgatt ttccggaaag ttccacatgc	3420
tgaatgacaa gactacatgat gctgcaactg atgttccttc tcatcaagga tactctctga	3480
acttgagaac attttggggaa ggaagaaagg tctaacatcc ttcccttca tcattctcat	3540
ttctggacat gccttgcgtt atggatcaat gttggggatca cacatttctg ctccaccc	3600
atttcagtca gcatgaacac tgaatataata atgtcatttc acagtgtgtg tgggttgcgtt	3660

atgtacatat atgaacctgt acatgtgtt aagtttaaag agaaaatagt gtacagagca	3720
ggtgttatatt tgtgataggg ctttaaatag ttgagcta atcagaaaatgt atggaggttt	3780
cttggtaaac caaacaaaaaa gtagaatcat tacaagatct aacaataaaa attttgaaaa	3840
aaaaaaaaaaa aaaaaaaaaaaa aaaaaaa	3866

<210> 23  
<211> 835  
<212> PRT  
<213> murine

<400> 23

Met Met Pro Pro Trp Leu Leu Ala Arg Thr Leu Ile Met Ala Leu Phe			
1	5	10	15
10	15		

Phe Ser Cys Leu Thr Pro Gly Ser Leu Asn Pro Cys Ile Glu Val Val			
20	25	30	
30			

Pro Asn Ile Thr Tyr Gln Cys Met Asp Gln Lys Leu Ser Lys Val Pro			
35	40	45	
45			

Asp Asp Ile Pro Ser Ser Thr Lys Asn Ile Asp Leu Ser Phe Asn Pro			
50	55	60	
60			

Leu Lys Ile Leu Lys Ser Tyr Ser Phe Ser Asn Phe Ser Glu Leu Gln			
65	70	75	80
75	80		

Trp Leu Asp Leu Ser Arg Cys Glu Ile Glu Thr Ile Glu Asp Lys Ala			
85	90	95	
95			

Trp His Gly Leu His His Leu Ser Asn Leu Ile Leu Thr Gly Asn Pro			
100	105	110	
110			

Ile Gln Ser Phe Ser Pro Gly Ser Phe Ser Gly Leu Thr Ser Leu Glu			
115	120	125	
125			

Asn Leu Val Ala Val Glu Thr Lys Leu Ala Ser Leu Glu Ser Phe Pro			
130	135	140	
140			

Ile Gly Gln Leu Ile Thr Leu Lys Lys Leu Asn Val Ala His Asn Phe			
145	150	155	160
155	160		

Ile His Ser Cys Lys Leu Pro Ala Tyr Phe Ser Asn Leu Thr Asn Leu			
165	170	175	
175			

Val His Val Asp Leu Ser Tyr Asn Tyr Ile Gln Thr Ile Thr Val Asn			
180	185	190	
190			

Asp Leu Gln Phe Leu Arg Glu Asn Pro Gln Val Asn Leu Ser Leu Asp			
195	200	205	
205			

Met Ser Leu Asn Pro Ile Asp Phe Ile Gln Asp Gln Ala Phe Gln Gly			
210	215	220	
220			

Ile Lys Leu His Glu Leu Thr Leu Arg Gly Asn Phe Asn Ser Ser Asn			
225	230	235	240
235	240		

Ile Met Lys Thr Cys Leu Gln Asn Leu Ala Gly Leu His Val His Arg  
245 250 255

Leu Ile Leu Gly Glu Phe Lys Asp Glu Arg Asn Leu Glu Ile Phe Glu  
260 265 270

Pro Ser Ile Met Glu Gly Leu Cys Asp Val Thr Ile Asp Glu Phe Arg  
275 280 285

Leu Thr Tyr Thr Asn Asp Phe Ser Asp Asp Ile Val Lys Phe His Cys  
290 295 300

Leu Ala Asn Val Ser Ala Met Ser Leu Ala Gly Val Ser Ile Lys Tyr  
305 310 315 320

Leu Glu Asp Val Pro Lys His Phe Lys Trp Gln Ser Leu Ser Ile Ile  
325 330 335

Arg Cys Gln Leu Lys Gln Phe Pro Thr Leu Asp Leu Pro Phe Leu Lys  
340 345 350

Ser Leu Thr Leu Thr Met Asn Lys Gly Ser Ile Ser Phe Lys Lys Val  
355 360 365

Ala Leu Pro Ser Leu Ser Tyr Leu Asp Leu Ser Arg Asn Ala Leu Ser  
370 375 380

Phe Ser Gly Cys Cys Ser Tyr Ser Asp Leu Gly Thr Asn Ser Leu Arg  
385 390 395 400

His Leu Asp Leu Ser Phe Asn Gly Ala Ile Ile Met Ser Ala Asn Phe  
405 410 415

Met Gly Leu Glu Glu Leu Gln His Leu Asp Phe Gln His Ser Thr Leu  
420 425 430

Lys Arg Val Thr Glu Phe Ser Ala Phe Leu Ser Leu Glu Lys Leu Leu  
435 440 445

Tyr Leu Asp Ile Ser Tyr Thr Asn Thr Lys Ile Asp Phe Asp Gly Ile  
450 455 460

Phe Leu Gly Leu Thr Ser Leu Asn Thr Leu Lys Met Ala Gly Asn Ser  
465 470 475 480

Phe Lys Asp Asn Thr Leu Ser Asn Val Phe Ala Asn Thr Thr Asn Leu  
485 490 495

Thr Phe Leu Asp Leu Ser Lys Cys Gln Leu Glu Gln Ile Ser Trp Gly  
500 505 510

Val Phe Asp Thr Leu His Arg Leu Gln Leu Leu Asn Met Ser His Asn  
515 520 525

Asn Leu Leu Phe Leu Asp Ser Ser His Tyr Asn Gln Leu Tyr Ser Leu  
530 535 540

Ser Thr Leu Asp Cys Ser Phe Asn Arg Ile Glu Thr Ser Lys Gly Ile  
545 550 555 560

Leu Gln His Phe Pro Lys Ser Leu Ala Phe Phe Asn Leu Thr Asn Asn

	565	570	575
Ser Val Ala Cys Ile Cys Glu His Gln Lys Phe Leu Gln Trp Val Lys			
	580	585	590
Glu Gln Lys Gln Phe Leu Val Asn Val Glu Gln Met Thr Cys Ala Thr			
	595	600	605
Pro Val Glu Met Asn Thr Ser Leu Val Leu Asp Phe Asn Asn Ser Thr			
	610	615	620
Cys Tyr Met Tyr Lys Thr Ile Ile Ser Val Ser Val Val Ser Val Ile			
	625	630	635
Val Val Ser Thr Val Ala Phe Leu Ile Tyr His Phe Tyr Phe His Leu			
	645	650	655
Ile Leu Ile Ala Gly Cys Lys Lys Tyr Ser Arg Gly Glu Ser Ile Tyr			
	660	665	670
Asp Ala Phe Val Ile Tyr Ser Ser Gln Asn Glu Asp Trp Val Arg Asn			
	675	680	685
Glu Leu Val Lys Asn Leu Glu Glu Gly Val Pro Arg Phe His Leu Cys			
	690	695	700
Leu His Tyr Arg Asp Phe Ile Pro Gly Val Ala Ile Ala Ala Asn Ile			
	705	710	715
Ile Gln Glu Gly Phe His Lys Ser Arg Lys Val Ile Val Val Val Ser			
	725	730	735
Arg His Phe Ile Gln Ser Arg Trp Cys Ile Phe Glu Tyr Glu Ile Ala			
	740	745	750
Gln Thr Trp Gln Phe Leu Ser Ser Arg Ser Gly Ile Ile Phe Ile Val			
	755	760	765
Leu Glu Lys Val Glu Lys Ser Leu Leu Arg Gln Gln Val Glu Leu Tyr			
	770	775	780
Arg Leu Leu Ser Arg Asn Thr Tyr Leu Glu Trp Glu Asp Asn Pro Leu			
	785	790	795
Gly Arg His Ile Phe Trp Arg Arg Leu Lys Asn Ala Leu Leu Asp Gly			
	805	810	815
Lys Ala Ser Asn Pro Glu Gln Thr Ala Glu Glu Glu Gln Glu Thr Ala			
	820	825	830
Thr Trp Thr			
	835		

<210> 24  
<211> 835  
<212> PRT  
<213> murine

<400> 24

Met Met Pro Pro Trp Leu Leu Ala Arg Thr Leu Ile Met Ala Leu Phe  
1               5               10               15

Phe Ser Cys Leu Thr Pro Gly Ser Leu Asn Pro Cys Ile Glu Val Val  
20 25 30

Pro Asn Ile Thr Tyr Gln Cys Met Asp Gln Lys Leu Ser Lys Val Pro  
35 40 45

Asp Asp Ile Pro Ser Ser Thr Lys Asn Ile Asp Leu Ser Phe Asn Pro  
50 55 60

Leu Lys Ile Leu Lys Ser Tyr Ser Phe Ser Asn Phe Ser Glu Leu Gln  
65 70 75 80

Trp Leu Asp Leu Ser Arg Cys Glu Ile Glu Thr Ile Glu Asp Lys Ala  
85 90 95

Trp His Gly Leu His His Leu Ser Asn Leu Ile Leu Thr Gly Asn Pro  
100 105 110

Ile Gln Ser Phe Ser Pro Gly Ser Phe Ser Gly Leu Thr Ser Leu Glu  
115 120 125

Asn Leu Val Ala Val Glu Thr Lys Leu Ala Ser Leu Glu Ser Phe Pro  
130 135 140

Ile Gly Gln Leu Ile Thr Leu Lys Lys Leu Asn Val Ala His Asn Phe  
145 150 155 160

Ile His Ser Cys Lys Leu Pro Ala Tyr Phe Ser Asn Leu Thr Asn Leu  
165 170 175

Val His Val Asp Leu Ser Tyr Asn Tyr Ile Gln Thr Ile Thr Val Asn  
180 185 190

Asp Leu Gln Phe Leu Arg Glu Asn Pro Gln Val Asn Leu Ser Leu Asp  
195 200 205

Ile Ser Leu Asn Pro Ile Asp Phe Ile Gln Asp Gln Ala Phe Gln Gly  
210 215 220

Ile Lys Leu His Glu Leu Thr Leu Arg Gly Asn Phe Asn Ser Ser Asn  
225 230 235 240

Ile Met Lys Thr Cys Leu Gln Asn Leu Ala Gly Leu His Ile His Arg  
245 250 255

Leu Ile Leu Gly Glu Phe Lys Asp Glu Arg Asn Leu Glu Ile Phe Glu  
260 265 270

Pro Ser Ile Met Glu Gly Leu Cys Asp Val Thr Ile Asp Glu Phe Arg  
275 280 285

Leu Thr Tyr Thr Asn Asp Phe Ser Asp Asp Ile Val Lys Phe His Cys  
290 295 300

Leu Ala Asn Val Ser Ala Met Ser Leu Ala Gly Val Ser Ile Lys Tyr  
305 310 315 320

Leu Glu Asp Val Pro Lys His Phe Lys Trp Gln Ser Leu Ser Ile Ile  
325 330 335

Arg Cys Gln Leu Lys Gln Phe Pro Thr Leu Asp Leu Pro Phe Leu Lys

340	345	350
Ser Leu Thr Leu Thr Met Asn Lys Gly Ser Ile Ser Phe Lys Lys Val		
355	360	365
Ala Leu Pro Ser Leu Ser Tyr Leu Asp Leu Ser Arg Asn Ala Leu Ser		
370	375	380
Phe Ser Gly Cys Cys Ser Tyr Ser Asp Leu Gly Thr Asn Ser Leu Arg		
385	390	395
His Leu Asp Leu Ser Phe Asn Gly Ala Ile Ile Met Ser Ala Asn Phe		
405	410	415
Met Gly Leu Glu Glu Leu Gln His Leu Asp Phe Gln His Ser Thr Leu		
420	425	430
Lys Arg Val Thr Glu Phe Ser Ala Phe Leu Ser Leu Glu Lys Leu Leu		
435	440	445
Tyr Leu Asp Ile Ser Tyr Thr Asn Thr Lys Ile Asp Phe Asp Gly Ile		
450	455	460
Phe Leu Gly Leu Thr Ser Leu Asn Thr Leu Lys Met Ala Gly Asn Ser		
465	470	475
Phe Lys Asp Asn Thr Leu Ser Asn Val Phe Ala Asn Thr Thr Asn Leu		
485	490	495
Thr Phe Leu Asp Leu Ser Lys Cys Gln Leu Glu Gln Ile Ser Trp Gly		
500	505	510
Val Phe Asp Thr Leu His Arg Leu Gln Leu Leu Asn Met Ser His Asn		
515	520	525
Asn Leu Leu Phe Leu Asp Ser Ser His Tyr Asn Gln Leu Tyr Ser Leu		
530	535	540
Ser Thr Leu Asp Cys Ser Phe Asn Arg Ile Glu Thr Ser Lys Gly Ile		
545	550	555
Leu Gln His Phe Pro Lys Ser Leu Ala Phe Phe Asn Leu Thr Asn Asn		
565	570	575
Ser Val Ala Cys Ile Cys Glu His Gln Lys Phe Leu Gln Trp Val Lys		
580	585	590
Asp Gln Lys Gln Phe Leu Val Asn Val Glu Gln Met Thr Cys Ala Thr		
595	600	605
Pro Val Glu Met Asn Thr Ser Leu Val Leu Asp Phe Asn Asn Ser Thr		
610	615	620
Cys Tyr Met Tyr Lys Thr Ile Ile Ser Val Ser Val Val Ser Val Ile		
625	630	635
Val Val Ser Thr Val Ala Phe Leu Ile Tyr His Phe Tyr Phe His Leu		
645	650	655
Ile Leu Ile Ala Gly Cys Lys Tyr Ser Arg Gly Glu Ser Ile Tyr		
660	665	670
Asp Ala Phe Val Ile Tyr Ser Ser Gln Asn Glu Asp Trp Val Arg Asn		

675	680	685
Glu Leu Val Lys Asn Leu Glu Glu Gly Val Pro Arg Phe His Leu Cys		
690	695	700
Leu His Tyr Arg Asp Phe Ile Pro Gly Val Ala Ile Ala Ala Asn Ile		
705	710	715
Ile Gln Glu Gly Phe His Lys Ser Arg Lys Val Ile Val Val Val Ser		
725	730	735
Arg His Phe Ile Gln Ser Arg Trp Cys Ile Phe Glu Tyr Glu Ile Ala		
740	745	750
Gln Thr Trp Gln Phe Leu Ser Ser His Ser Gly Ile Ile Phe Ile Val		
755	760	765
Leu Glu Lys Val Glu Lys Ser Leu Leu Arg Gln Gln Val Glu Leu Tyr		
770	775	780
Arg Leu Leu Ser Arg Asn Thr Tyr Leu Glu Trp Glu Asp Asn Pro Leu		
785	790	795
Gly Arg His Ile Phe Trp Arg Arg Leu Lys Asn Ala Leu Leu Asp Gly		
805	810	815
Lys Ala Ser Asn Pro Glu Gln Thr Ala Glu Glu Glu Gln Glu Thr Ala		
820	825	830
Thr Trp Thr		
835		

<210> 25  
 <211> 3431  
 <212> DNA  
 <213> Homo sapiens

<400> 25	60
ggcttatagg gctcgagcgg ccgccccggc aggtatagaa ttcaagcgcc gctgaattct	60
agggttttca ggagcccgag cgagggcgcc gctttgcgt ccgggaggag ccaaccgtgg	120
cgcaggcgcc gcggggaggc gtcccagagt ctcaactctgc cgcccaggct ggactgcagt	180
gacacaatct cggctgactg caaccactgc ctccagggtt caagcgattc tcttcctca	240
gcctcccaag tagctggat tacagattga tgttcatgtt cctggacta ctacaagatt	300
cataactcctg atgctactga caacgtggct tctccacagt caccaaacca gggatgctat	360
actggacttc cctactctca tctgctccag cccccctgacc ttatagttgc ccagctttcc	420
tggcaattga ctttgcccat caatacacag gattttagcat ccaggaaaga tgtcggagcc	480
tcagatgtta attttcta at tgagaatgtt ggcgctgtcc gaacctggag acagaaaaac	540
aaaaagtccct ttctcctgat tcacaaaaaa ataaaaatact gactaccatc actgtgatga	600
gattcctata gtctcaggaa ctgaagtctt taaacaacca gggaccctct gcccctagaa	660
taagaacata ctagaagtcc cttctgctag gacaacgagg atcatggag accacctgga	720

ccttctccta ggagtgggtgc tcatggccgg tcctgtgttt ggaattcctt cctgctcctt	780
tgtatggccga atagcctttt atcgtttctg caacctcacc caggccccca aggtcctcaa	840
caccactgag aggctcctgc tgagcttcaa ctatatcagg acagtcactg cttcatcctt	900
cccccttctg gaacagctgc agctgctgga gctcgggagc cagtataccc ccttgactat	960
tgacaaggag gccttcagaa acctgccaa ccttagaatc ttggacctgg gaagtagtaa	1020
gatatacttc ttgcattccag atgctttca gggactgttc catctgtttg aacttagact	1080
gtatttctgt ggtctctctg atgctgtatt gaaagatggt tatttcagaa atttaaaggc	1140
ttaactcgc ttggatctat ccaaaaatca gattcgtagc ctttaccttc atccttcatt	1200
tgggaagttg aattccttaa agtccataga ttttcctcc aaccaaataat tccttgatg	1260
tgaacatgag ctcgagcccc tacaaggaa aacgctctcc ttttttagcc tcgcagctaa	1320
tagcttgtat agcagagtct cagtggactg gggaaaatgt atgaaccat tcagaaacat	1380
ggtgctggag atactagatg tttctggaaa tggctggaca gtggacatca cagggaaactt	1440
tagcaatgcc atcagcaaaa gccaggcctt ctctttgatt cttgcccacc acatcatggg	1500
tgcggggttt ggcttccata acatcaaaga tcctgaccag aacacatttgc ctggcctggc	1560
cagaagttca gtgagacacc tggatcttc acatgggttt gtcttctccc tgaactcacf	1620
agtcttgag acactcaagg atttgaaggt tctgaacctt gcctacaaca agataaataa	1680
gattgcagat gaagcatttt acggacttga caacctccaa gttctcaatt tgtcatataa	1740
ccttctgggg gaactttaca gttcgaattt ctatggacta cctaaggtag cctacattga	1800
tttgcaaaag aatcacatttca caataattca agaccaaaca ttcaaaattcc tggaaaaatt	1860
acagaccttgc atctcccgag acaatgtct tacaaccatt cattttatttca caagcataacc	1920
cgatatcttc ttgagtggca ataaactagt gactttgcca aagatcaacc ttacagcgaa	1980
cctcatccac ttatcagaaa acaggctaga aaatctagat attctctact ttcttctacg	2040
ggtacctcat ctccagattt tcattttaaa tcaaaatcgc ttctcctcct gtgtggaga	2100
tcaaaaccctt tcagagaatc ccagcttaga acagcttttc cttggagaaa atatgttgc	2160
acttgcctgg gaaactgagc tctgttggga tggggatggatggactttctc atcttcaagt	2220
tctgtatggatggactttcaacttccatccttccacca ggagtatttgc gcatctgac	2280
tgcattaagg ggactaagcc tcaactccaa caggctgaca gttcttctc acaatgattt	2340
acctgctaat tttagatcc tggacatatac caggaaccag ctccctagctc ctaatcctga	2400
tgtatggatggactttcaacttccatccttccacca ggagtatttgc gcatctgac	2460
acttagcact tttatcaattt ggcttaatca caccaatgtc actatagctg ggcctcctgc	2520
agacatataat tggatggactttcaacttccatccttccacca ggagtatttgc gcatctgac	2580
ggaagggtgt gatgaagagg aagtcttaaa gtcctaaag ttctccctt tcattgtatg	2640

cactgtcact ctgactctgt tcctcatgac catcctcaca gtcacaaaagt tccggggctt	2700
ctgtttatc tggataaga cagcccagag actgggttca aaggaccatc cccagggcac	2760
agaacctgat atgtacaaat atgatgccta ttgtgcttc agcagcaaag acttcacatg	2820
ggtcagaat gcttgctca aacacctgga cactcaatac agtgaccaaa acagattcaa	2880
cctgtgctt gaagaaagag actttgtccc aggagaaaac cgcatgtcca atatccagga	2940
tgcacatctgg aacagtagaa agatcgtttgc ttgtgagc agacacttcc ttagagatgg	3000
ctgggcctt gaaggcttca gttatgccc gggcaggtgc ttatctgacc ttaacagtgc	3060
tctcatcatg gtggtggttgc ggtccttgc ccagtaccag ttgatgaaac atcaatccat	3120
cagaggctt gtacagaaac agcagtattt gaggtggctt gaggatctcc aggatgttgg	3180
ctggttctt cataaaactct ctcaacagat actaaagaaa gaaaaagaaa agaagaaaaga	3240
caataacatt ccgttgcaaa ctgtagcaac catctcctaa tcaaaggagc aatttccaac	3300
ttatctcaag ccacaaataa ctcttcactt tgtatggca ccaagttatc atttgggt	3360
cctctctgga ggttttttt ttcttttgc tactatgaaa acaacataaa tctctcaatt	3420
ttcgtatcaa a	3431

&lt;210&gt; 26

&lt;211&gt; 858

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 26

Met	Gly	Asp	His	Leu	Asp	Leu	Leu	Leu	Gly	Val	Val	Leu	Met	Ala	Gly
1				5					10				15		

Pro	Val	Phe	Gly	Ile	Pro	Ser	Cys	Ser	Phe	Asp	Gly	Arg	Ile	Ala	Phe
		20					25					30			

Tyr	Arg	Phe	Cys	Asn	Leu	Thr	Gln	Val	Pro	Gln	Val	Leu	Asn	Thr	Thr
		35					40					45			

Glu	Arg	Leu	Ieu	Ieu	Ser	Phe	Asn	Tyr	Ile	Arg	Thr	Val	Thr	Ala	Ser
		50				55				60					

Ser	Phe	Pro	Phe	Leu	Glu	Gln	Leu	Gln	Leu	Leu	Glu	Leu	Gly	Ser	Gln
		65			70			75					80		

Tyr	Thr	Pro	Leu	Thr	Ile	Asp	Lys	Glu	Ala	Phe	Arg	Asn	Leu	Pro	Asn
					85			90				95			

Leu	Arg	Ile	Ieu	Asp	Leu	Gly	Ser	Ser	Lys	Ile	Tyr	Phe	Leu	His	Pro
					100			105					110		

Asp	Ala	Phe	Gln	Gly	Leu	Phe	His	Leu	Phe	Glu	Leu	Arg	Leu	Tyr	Phe
			115				120					125			

Cys	Gly	Leu	Ser	Asp	Ala	Val	Leu	Lys	Asp	Gly	Tyr	Phe	Arg	Asn	Leu
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

130                    135                    140  
 Lys Ala Leu Thr Arg Leu Asp Leu Ser Lys Asn Gln Ile Arg Ser Leu  
 145                    150                    155                    160  
 Tyr Leu His Pro Ser Phe Gly Lys Leu Asn Ser Leu Lys Ser Ile Asp  
 165                    170                    175  
 Phe Ser Ser Asn Gln Ile Phe Leu Val Cys Glu His Glu Leu Glu Pro  
 180                    185                    190  
 Leu Gln Gly Lys Thr Leu Ser Phe Phe Ser Leu Ala Ala Asn Ser Leu  
 195                    200                    205  
 Tyr Ser Arg Val Ser Val Asp Trp Gly Lys Cys Met Asn Pro Phe Arg  
 210                    215                    220  
 Asn Met Val Leu Glu Ile Leu Asp Val Ser Gly Asn Gly Trp Thr Val  
 225                    230                    235                    240  
 Asp Ile Thr Gly Asn Phe Ser Asn Ala Ile Ser Lys Ser Gln Ala Phe  
 245                    250                    255  
 Ser Leu Ile Leu Ala His His Ile Met Gly Ala Gly Phe Gly Phe His  
 260                    265                    270  
 Asn Ile Lys Asp Pro Asp Gln Asn Thr Phe Ala Gly Leu Ala Arg Ser  
 275                    280                    285  
 Ser Val Arg His Leu Asp Leu Ser His Gly Phe Val Phe Ser Leu Asn  
 290                    295                    300  
 Ser Arg Val Phe Glu Thr Leu Lys Asp Leu Lys Val Leu Asn Leu Ala  
 305                    310                    315                    320  
 Tyr Asn Lys Ile Asn Lys Ile Ala Asp Glu Ala Phe Tyr Gly Leu Asp  
 325                    330                    335  
 Asn Leu Gln Val Leu Asn Leu Ser Tyr Asn Leu Leu Gly Glu Leu Tyr  
 340                    345                    350  
 Ser Ser Asn Phe Tyr Gly Leu Pro Lys Val Ala Tyr Ile Asp Leu Gln  
 355                    360                    365  
 Lys Asn His Ile Ala Ile Ile Gln Asp Gln Thr Phe Lys Phe Leu Glu  
 370                    375                    380  
 Lys Leu Gln Thr Leu Asp Leu Arg Asp Asn Ala Leu Thr Thr Ile His  
 385                    390                    395                    400  
 Phe Ile Pro Ser Ile Pro Asp Ile Phe Leu Ser Gly Asn Lys Leu Val  
 405                    410                    415  
 Thr Leu Pro Lys Ile Asn Leu Thr Ala Asn Leu Ile His Leu Ser Glu  
 420                    425                    430  
 Asn Arg Leu Glu Asn Leu Asp Ile Leu Tyr Phe Leu Leu Arg Val Pro  
 435                    440                    445  
 His Leu Gln Ile Leu Ile Leu Asn Gln Asn Arg Phe Ser Ser Cys Ser  
 450                    455                    460  
 Gly Asp Gln Thr Pro Ser Glu Asn Pro Ser Leu Glu Gln Leu Phe Leu

465	470	475	480												
Gly	Glu	Asn	Met	Leu	Gln	Leu	Ala	Trp	Glu	Thr	Glu	Leu	Cys	Trp	Asp
485	490	495													
Val	Phe	Glu	Gly	Leu	Ser	His	Leu	Gln	Val	Leu	Tyr	Leu	Asn	His	Asn
500	505	510													
Tyr	Leu	Asn	Ser	Leu	Pro	Pro	Gly	Val	Phe	Ser	His	Leu	Thr	Ala	Leu
515	520	525													
Arg	Gly	Leu	Ser	Leu	Asn	Ser	Asn	Arg	Leu	Thr	Val	Leu	Ser	His	Asn
530	535	540													
Asp	Leu	Pro	Ala	Asn	Leu	Glu	Ile	Leu	Asp	Ile	Ser	Arg	Asn	Gln	Leu
545	550	555	560												
Leu	Ala	Pro	Asn	Pro	Asp	Val	Phe	Val	Ser	Leu	Ser	Val	Leu	Asp	Ile
565	570	575													
Thr	His	Asn	Lys	Phe	Ile	Cys	Glu	Cys	Glu	Leu	Ser	Thr	Phe	Ile	Asn
580	585	590													
Trp	Leu	Asn	His	Thr	Asn	Val	Thr	Ile	Ala	Gly	Pro	Pro	Ala	Asp	Ile
595	600	605													
Tyr	Cys	Val	Tyr	Pro	Asp	Ser	Phe	Ser	Gly	Val	Ser	Leu	Phe	Ser	Leu
610	615	620													
Ser	Thr	Glu	Gly	Cys	Asp	Glu	Glu	Glu	Val	Leu	Lys	Ser	Leu	Lys	Phe
625	630	635	640												
Ser	Leu	Phe	Ile	Val	Cys	Thr	Val	Thr	Leu	Thr	Phe	Leu	Met	Thr	
645	650	655													
Ile	Ieu	Thr	Val	Thr	Lys	Phe	Arg	Gly	Phe	Cys	Phe	Ile	Cys	Tyr	Lys
660	665	670													
Thr	Ala	Gln	Arg	Leu	Val	Phe	Lys	Asp	His	Pro	Gln	Gly	Thr	Glu	Pro
675	680	685													
Asp	Met	Tyr	Lys	Tyr	Asp	Ala	Tyr	Leu	Cys	Phe	Ser	Ser	Lys	Asp	Phe
690	695	700													
Thr	Trp	Val	Gln	Asn	Ala	Leu	Leu	Lys	His	Leu	Asp	Thr	Gln	Tyr	Ser
705	710	715	720												
Asp	Gln	Asn	Arg	Phe	Asn	Leu	Cys	Phe	Glu	Glu	Arg	Asp	Phe	Val	Pro
725	730	735													
Gly	Glu	Asn	Arg	Ile	Ala	Asn	Ile	Gln	Asp	Ala	Ile	Trp	Asn	Ser	Arg
740	745	750													
Lys	Ile	Val	Cys	Leu	Val	Ser	Arg	His	Phe	Leu	Arg	Asp	Gly	Trp	Cys
755	760	765													
Leu	Glu	Ala	Phe	Ser	Tyr	Ala	Gln	Gly	Arg	Cys	Leu	Ser	Asp	Leu	Asn
770	775	780													
Ser	Ala	Leu	Ile	Met	Val	Val	Gly	Ser	Leu	Ser	Gln	Tyr	Gln	Leu	
785	790	795	800												
Met	Lys	His	Gln	Ser	Ile	Arg	Gly	Phe	Val	Gln	Lys	Gln	Gln	Tyr	Leu

805	810	815
Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu His Lys Leu		
820	825	830

Ser Gln Gln Ile Leu Lys Lys Glu Lys Lys Lys Lys Asp Asn Asn		
835	840	845

Ile Pro Leu Gln Thr Val Ala Thr Ile Ser		
850	855	

<210> 27  
<211> 858  
<212> PRT  
<213> Homo sapiens

<400> 27

Met Gly Asp His Leu Asp Leu Leu Gly Val Val Leu Met Ala Gly		
1	5	10
		15

Pro Val Phe Gly Ile Pro Ser Cys Ser Phe Asp Gly Arg Ile Ala Phe		
20	25	30

Tyr Arg Phe Cys Asn Leu Thr Gln Val Pro Gln Val Leu Asn Thr Thr		
35	40	45

Glu Arg Leu Leu Leu Ser Phe Asn Tyr Ile Arg Thr Val Thr Ala Ser		
50	55	60

Ser Phe Pro Phe Leu Glu Gln Leu Gln Leu Leu Glu Leu Gly Ser Gln		
65	70	75
		80

Tyr Thr Pro Leu Thr Ile Asp Lys Glu Ala Phe Arg Asn Leu Pro Asn		
85	90	95

Leu Arg Ile Leu Asp Leu Gly Ser Ser Lys Ile Tyr Phe Leu His Pro		
100	105	110

Asp Ala Phe Gln Gly Leu Phe His Leu Phe Glu Leu Arg Leu Tyr Phe		
115	120	125

Cys Gly Leu Ser Asp Ala Val Leu Lys Asp Gly Tyr Phe Arg Asn Leu		
130	135	140

Lys Ala Leu Thr Arg Leu Asp Leu Ser Lys Asn Gln Ile Arg Ser Leu		
145	150	155
		160

Tyr Leu His Pro Ser Phe Gly Lys Leu Asn Ser Leu Lys Ser Ile Asp		
165	170	175

Phe Ser Ser Asn Gln Ile Phe Leu Val Cys Glu His Glu Leu Glu Pro		
180	185	190

Leu Gln Gly Lys Thr Leu Ser Phe Phe Ser Leu Ala Ala Asn Ser Leu		
195	200	205

Tyr Ser Arg Val Ser Val Asp Trp Gly Lys Cys Met Asn Pro Phe Arg		
210	215	220

Asn Met Val Leu Glu Ile Val Asp Val Ser Gly Asn Gly Trp Thr Val		
225	230	235
		240

Asp Ile Thr Gly Asn Phe Ser Asn Ala Ile Ser Lys Ser Gln Ala Phe  
245 250 255

Ser Leu Ile Leu Ala His His Ile Met Gly Ala Gly Phe Gly Phe His  
260 265 270

Asn Ile Lys Asp Pro Asp Gln Asn Thr Phe Ala Gly Leu Ala Arg Ser  
275 280 285

Ser Val Arg His Leu Asp Leu Ser His Gly Phe Val Phe Ser Leu Asn  
290 295 300

Ser Arg Val Phe Glu Thr Leu Lys Asp Leu Lys Val Leu Asn Leu Ala  
305 310 315 320

Tyr Asn Lys Ile Asn Lys Ile Ala Asp Glu Ala Phe Tyr Gly Leu Asp  
325 330 335

Asn Leu Gln Val Leu Asn Leu Ser Tyr Asn Leu Leu Gly Glu Leu Cys  
340 345 350

Ser Ser Asn Phe Tyr Gly Leu Pro Lys Val Ala Tyr Ile Asp Leu Gln  
355 360 365

Lys Asn His Ile Ala Ile Ile Gln Asp Gln Thr Phe Lys Phe Leu Glu  
370 375 380

Lys Leu Gln Thr Leu Asp Leu Arg Asp Asn Ala Leu Thr Thr Ile His  
385 390 395 400

Phe Ile Pro Ser Ile Pro Asp Ile Phe Leu Ser Gly Asn Lys Leu Val  
405 410 415

Thr Leu Pro Lys Ile Asn Leu Thr Ala Asn Leu Ile His Leu Ser Glu  
420 425 430

Asn Arg Leu Glu Asn Leu Asp Ile Leu Tyr Phe Leu Leu Arg Val Pro  
435 440 445

His Leu Gln Ile Leu Ile Leu Asn Gln Asn Arg Phe Ser Ser Cys Ser  
450 455 460

Gly Asp Gln Thr Pro Ser Glu Asn Pro Ser Leu Glu Gln Leu Phe Leu  
465 470 475 480

Gly Glu Asn Met Leu Gln Leu Ala Trp Glu Thr Glu Leu Cys Trp Asp  
485 490 495

Val Phe Glu Gly Leu Ser His Leu Gln Val Leu Tyr Leu Asn His Asn  
500 505 510

Tyr Leu Asn Ser Leu Pro Pro Gly Val Phe Ser His Leu Thr Ala Leu  
515 520 525

Arg Gly Leu Ser Leu Asn Ser Asn Arg Leu Thr Val Leu Ser His Asn  
530 535 540

Asp Leu Pro Ala Asn Leu Glu Ile Leu Asp Ile Ser Arg Asn Gln Leu  
545 550 555 560

Leu Ala Pro Asn Pro Asp Val Phe Val Ser Leu Ser Val Leu Asp Ile

	565	570	575
Thr His Asn Lys Phe Ile Cys Glu Cys Glu Leu Ser Thr Phe Ile Asn			
	580	585	590
Trp Leu Asn His Thr Asn Val Thr Ile Ala Gly Pro Pro Ala Asp Ile			
	595	600	605
Tyr Cys Val Tyr Pro Asp Ser Phe Ser Gly Val Ser Leu Phe Ser Leu			
	610	615	620
Ser Thr Glu Gly Cys Asp Glu Glu Glu Val Leu Lys Ser Leu Lys Phe			
	625	630	635
Ser Leu Phe Ile Val Cys Thr Val Thr Leu Thr Leu Phe Leu Met Thr			
	645	650	655
Ile Leu Thr Val Thr Lys Phe Arg Gly Phe Cys Phe Ile Cys Tyr Lys			
	660	665	670
Thr Ala Gln Arg Leu Val Phe Lys Asp His Pro Gln Gly Thr Glu Pro			
	675	680	685
Asp Met Tyr Lys Tyr Asp Ala Tyr Leu Cys Phe Ser Ser Lys Asp Phe			
	690	695	700
Thr Trp Val Gln Asn Ala Leu Leu Lys His Leu Asp Thr Gln Tyr Ser			
	705	710	715
			720
Asp Gln Asn Arg Phe Asn Leu Cys Phe Glu Glu Arg Asp Phe Val Pro			
	725	730	735
Gly Glu Asn Arg Ile Ala Asn Ile Gln Asp Ala Ile Trp Asn Ser Arg			
	740	745	750
Lys Ile Val Cys Leu Val Ser Arg His Phe Leu Arg Asp Gly Trp Cys			
	755	760	765
Leu Glu Ala Phe Ser Tyr Ala Gln Gly Arg Cys Leu Ser Asp Leu Asn			
	770	775	780
Ser Ala Leu Ile Met Val Val Val Gly Ser Leu Ser Gln Tyr Gln Leu			
	785	790	795
			800
Met Lys His Gln Ser Ile Arg Gly Phe Val Gln Lys Gln Gln Tyr Leu			
	805	810	815
Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu His Lys Leu			
	820	825	830
Ser Gln Gln Ile Leu Lys Lys Glu Lys Lys Lys Lys Asp Asn Asn			
	835	840	845
Ile Pro Leu Gln Thr Val Ala Thr Ile Ser			
	850	855	

<210> 28  
<211> 365  
<212> PRT  
<213> Homo sapiens

<400> 28

Cys Trp Asp Val Phe Glu Gly Leu Ser His Leu Gln Val Leu Tyr Leu  
1 5 10 15

Asn His Asn Tyr Leu Asn Ser Leu Pro Pro Gly Val Phe Ser His Leu  
20 25 30

Thr Ala Leu Arg Gly Leu Ser Leu Asn Ser Asn Arg Leu Thr Val Leu  
35 40 45

Ser His Asn Asp Leu Pro Ala Asn Leu Glu Ile Leu Asp Ile Ser Arg  
50 55 60

Asn Gln Leu Leu Ala Pro Asn Pro Asp Val Phe Val Ser Leu Ser Val  
65 70 75 80

Leu Asp Ile Thr His Asn Lys Phe Ile Cys Glu Cys Glu Leu Ser Thr  
85 90 95

Phe Ile Asn Trp Leu Asn His Thr Asn Val Thr Ile Ala Gly Pro Pro  
100 105 110

Ala Asp Ile Tyr Cys Val Tyr Pro Asp Ser Phe Ser Gly Val Ser Leu  
115 120 125

Phe Ser Leu Ser Thr Glu Gly Cys Asp Glu Glu Glu Val Leu Lys Ser  
130 135 140

Leu Lys Phe Ser Leu Phe Ile Val Cys Thr Val Thr Leu Thr Leu Phe  
145 150 155 160

Leu Met Thr Ile Leu Thr Val Thr Lys Phe Arg Gly Phe Cys Phe Ile  
165 170 175

Cys Tyr Lys Thr Ala Gln Arg Leu Val Phe Lys Asp His Pro Gln Gly  
180 185 190

Thr Glu Pro Asp Met Tyr Lys Tyr Asp Ala Tyr Leu Cys Phe Ser Ser  
195 200 205

Lys Asp Phe Thr Trp Val Gln Asn Ala Leu Leu Lys His Leu Asp Thr  
210 215 220

Gln Tyr Ser Asp Gln Asn Arg Phe Asn Leu Cys Phe Glu Glu Arg Asp  
225 230 235 240

Phe Val Pro Gly Glu Asn Arg Ile Ala Asn Ile Gln Asp Ala Ile Trp  
245 250 255

Asn Ser Arg Lys Ile Val Cys Leu Val Ser Arg His Phe Leu Arg Asp  
260 265 270

Gly Trp Cys Leu Glu Ala Phe Ser Tyr Ala Gln Gly Arg Cys Leu Ser  
275 280 285

Asp Leu Asn Ser Ala Leu Ile Met Val Val Gly Ser Leu Ser Gln  
290 295 300

Tyr Gln Leu Met Lys His Gln Ser Ile Arg Gly Phe Val Gln Lys Gln  
305 310 315 320

Gln Tyr Leu Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu

325	330	335
His Lys Leu Ser Gln Gln Ile Leu Lys Lys Glu Lys Glu Lys Lys Lys		
340	345	350

Asp Asn Asn Ile Pro Leu Gln Thr Val Ala Thr Ile Ser		
355	360	365

<210> 29  
<211> 4286  
<212> DNA  
<213> murine

<400> 29 ttgaaatctc acagcccggt tggttgcagt gaccacttc gttgaacata ttcttcctaa tccttagtact ttcaatttgc tctattccct ggtgtctatg catttaaatac gactatgggg ccattcttcc ttgaaccacc acagaagaca ttagctctct gggatccttg ttaattttt ctcctcttac atagcaccta cgcttggAAC atatgccaga cacatctgtg agacacccc tgccgctgca gctcatggat ggatgctgag ttccccacg caccacactt cagcaggtgg gtgtatttct gttcacatt atactccac acggccatgc atgtcaggca tggagcaggc tcataaccca cttaaattaag gtgatcatat cagatcctt atcaagatgc atagagtgc cagtgcctgt actatgatct cggatcttg ggagatggc tagatagagt ctggacaga atacagcaga gaaaccgata tgTTTATTGT ccgatcatca gctaagcttc tggagactag gaatggggct cttggatga acagaagtaa aaatgcctcg tcttatgac tttcaacttc cctcagcagg tctggatgg gtgaacaaac actgcctgCG tgggtgataa atgcctt tttgctgctt gttgctgct tttatggttc tgggagggaa cctagaacct agcacatgct agacaagtcc tctagactg agctatctcc ccagcttggA tgaaatatct gtaaagtact ggtgcccgTG tggaaaatAT gcaccattaa gtgttcaaga agaaaagact gggcatttct gttccaccaa gacaagaaga atctgccAGC agaatgtttG cgcagtcat tgagcaaagg ggtccaaggG acagtaccct ccagtgctgg ggaccatgt gccgagcctc aggctgtgat gtgggttgtt. ttttaattct ctctttccc ataggatcat ggcatgtcaa cttgacttgc tcataggtgt gatcttcatg gccagccccG tggggtaat atctccctgt tcttcagacg gcaggatagc cttttccGA ggctgtAAAC tcacccagat tccctggatC ctcaatacta ccactgagag gtcctgctc agcttcaact atatcagtat ggtgggtGCC acatcatttc cactcctggA gCGGCTCCAG ttgctggAGC tggggaccca gtagctaaC ttgaccattG gtccaggGGC tttcagaaAC ctgccccatC ttaggatctt ggacttggGC caaagccaga tcgaagtctt gaatcgagat gccttcaag gtctggggCA tctcttggAA cttcggctgt tttcctgtgg actctccAGt gctgtgttAA gtgacgggttA cttcagaaat ctatattcat	60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440
--	---

tagctcgctt agacctatct ggcaaccaga ttcacagcct ccgcctccat tcttcattcc	1500
gggaactgaa ttccctaaggc gacgttaatt ttgctttcaa ccaaataattc actatatgtg	1560
aagatgaact cgagcctctg cagggcaaaa cactgtcttt ctggccctc aaattaacta	1620
agctgttcag cagagtctct gtgggctggg agacatgcag gaacccttc agaggcgtga	1680
ggctagaaac tctagatctt tctgaaaatg gctggacggt ggacatcaca aggaacttca	1740
gcaacatcat ccagggaaagc cagatttctt ctggattct taaacaccac atcatgggtc	1800
ctggcttgg ctccagaac atcagagatc ctgaccagag cacatttgcc agcctggcca	1860
gaagttcggt gctgcaactg gacctttcgc acggctttat ctgccttg aatcctcgac	1920
tgtttggac actgaaggat ttgaagatgc tgaacctgc cttcaacaag ataaacaaga	1980
ttggagagaa tgccctttat gggcttgaca gcctccaggt tctcaatcta tcctataatc	2040
ttttggggga actctataat tccaaacttct atgggcttcc tagagtagcc tacgttgacc	2100
ttcaaaaggaa ccacattggg atcatcaag accaaacatt cagattatta aaaacgttac	2160
aaaccttaga tctccgtgac aatgctctt aggcattgg ttttattcca agcatacaga	2220
tggctctctt gggaggcaat aagctggtcc atttgccaca catccacttt actgccaact	2280
tccttagagtt atctgaaaac aggctagaaa acctgtccga cctctacttc ctccgtcgag	2340
tccccagct ccagtttctc atcttgaatc agaatcgctt ttcgtcatgc aaggcagccc	2400
acactccctc ggagaaccca agcttagaac agctttcct tacagagaat atgctgcagc	2460
tggcctggga gaccggcctc tggtggatg ttttcaagg ccttccccgc ctccagattc	2520
tttacctgag taataactac cttaattcc ttccacctgg gatatttaac gacctggttg	2580
cattacggat gcttagtctt agtgtaaca agctgaccgt gctctctccg ggcagttac	2640
ctgctaattt agagattctc gacatatcta gaaatcagct tttgtgtctt gaccctgctt	2700
tgtttcttc gttcgtgtt ttggacataa ctcataacga gttcgtctgc aactgtgaac	2760
ttagcacttt tatctctgg ctcaacccaa ccaacgtcac cctgttcggc tctcctgcag	2820
acgtgtattt catgtaccct aactcaatgc tagggggctc cctctacaac atatccaccg	2880
aagactgcga tgaagaggaa gccatgcggt ccctaaagtt ttccctttc atccgtgca	2940
cggtaacttt gactctattt ctcgtcatca cccttgttagt cataaaagttc cggggatct	3000
gtttcctgtg ctataagacc atccagaagc tgggtgtcaa ggacaaggc tggagttgg	3060
aacctgggtc atatagatat gatgcctact tctgcttcag cagcaaagac tttgaatggg	3120
cacagaatgc tttgctcaaa cacctggatg ctcactacag ttcccgaac aggctcaggc	3180
tatgctttga agaaagagac ttcatccgg gggaaaacca tatctccaaatccaggcgg	3240
ctgtctgggg cagcaggaag acggtgtgtc tagtgagcag acacttcctg aaggatggtt	3300
ggtgccctgga ggccttcagg tatgcccaga gccggagtct gtctgacccctc aagagcattc	3360

tcatecgtggt ggtggtgtggg	tcgctgtccc agtatcagct	gatgagacat gagaccatca	3420
gagggtttct gcaaaaagcaa	cagtacttga ggtggcctga	agacctccag gatgttggt	3480
ggtttctcgta taaactctcc	ggatgcattc taaaggaaga	aaaaggaaaag aaaagaagca	3540
gttccatcca gttgcgaacc	atagcaacca tttcctagca	ggagcgcctc ctagcagaag	3600
tgcaagcatc gtagataact	ctccacgctt tatccgcaca	gccgctgggg gtccttcct	3660
ggagtcattt ttctgacaat	gaaaacaaca ccaatctctt	gattttcat gtcaacaggg	3720
agctttgtct tcactgtttt	ccaaatggaa agtaagaggt	ccagaaagct gcctctaagg	3780
gctctcacct gccattgatg	tcctttcagg cccaatgaca	tggttccct ccatcttatt	3840
gcgtactgtc tgctacccag	gtggcaagag caccttggga	gaagttacag gcagttcat	3900
gctttctgtg ctgttcagtt	caaaagcagg tgccttgaga	atcctgaatt caagcactct	3960
gtagaacatg gacagacaag	atgggtcctt ctctggccat	aggcatgagg gccagttgct	4020
gaggactgct ctcactacac	ctaagtgcac aagtgataag	aagttggaca gatagacaga	4080
tagcagcagt cccattgctg	tagccagaat gcacttattt	cctgttctga ccctgcaggc	4140
ccagttttg gggaccacag	ccatgttctg caceggacct	ctcaacctgg cattcatgcc	4200
ctttcacgac tttagcaccgg	cctgcccttc tttttcccc	acaactatac aagagctgtt	4260
gcaaccactg aaaaaaaaaa	aaaaaaa		4286

<210> 30  
<211> 859  
<212> PRT  
<213> murine

<400> 30

Met Ala Cys Gln Leu Asp Leu Leu Ile Gly Val Ile Phe Met Ala Ser  
1 5 10 15

Pro Val Leu Val Ile Ser Pro Cys Ser Ser Asp Gly Arg Ile Ala Phe  
20 25 30

Phe Arg Gly Cys Asn Leu Thr Gln Ile Pro Trp Ile Leu Asn Thr Thr  
35 40 45

Thr Glu Arg Leu Leu Ser Phe Asn Tyr Ile Ser Met Val Val Ala  
50 55 60

Thr Ser Phe Pro Leu Leu Glu Arg Leu Gln Leu Leu Glu Leu Gly Thr  
65 70 75 80

Gln Tyr Ala Asn Leu Thr Ile Gly Pro Gly Ala Phe Arg Asn Leu Pro  
85 90 95

Asn Leu Arg Ile Leu Asp Leu Gly Gln Ser Gln Ile Glu Val Leu Asn  
100 105 110

Arg Asp Ala Phe Gln Gly Leu Pro His Leu Leu Glu Leu Arg Leu Phe  
115 120 125

Ser Cys Gly Leu Ser Ser Ala Val Leu Ser Asp Gly Tyr Phe Arg Asn  
130 135 140

Leu Tyr Ser Leu Ala Arg Leu Asp Leu Ser Gly Asn Gln Ile His Ser  
145 150 155 160

Leu Arg Leu His Ser Ser Phe Arg Glu Leu Asn Ser Leu Ser Asp Val  
165 170 175

Asn Phe Ala Phe Asn Gln Ile Phe Thr Ile Cys Glu Asp Glu Leu Glu  
180 185 190

Pro Leu Gln Gly Lys Thr Leu Ser Phe Phe Gly Leu Lys Leu Thr Lys  
195 200 205

Leu Phe Ser Arg Val Ser Val Gly Trp Glu Thr Cys Arg Asn Pro Phe  
210 215 220

Arg Gly Val Arg Leu Glu Thr Leu Asp Leu Ser Glu Asn Gly Trp Thr  
225 230 235 240

Val Asp Ile Thr Arg Asn Phe Ser Asn Ile Ile Gln Gly Ser Gln Ile  
245 250 255

Ser Ser Leu Ile Leu Lys His His Ile Met Gly Pro Gly Phe Gly Phe  
260 265 270

Gln Asn Ile Arg Asp Pro Asp Gln Ser Thr Phe Ala Ser Leu Ala Arg  
275 280 285

Ser Ser Val Leu Gln Leu Asp Leu Ser His Gly Phe Ile Phe Ser Leu  
290 295 300

Asn Pro Arg Leu Phe Gly Thr Leu Lys Asp Leu Lys Met Leu Asn Leu  
305 310 315 320

Ala Phe Asn Lys Ile Asn Lys Ile Gly Glu Asn Ala Phe Tyr Gly Leu  
325 330 335

Asp Ser Leu Gln Val Leu Asn Leu Ser Tyr Asn Leu Leu Gly Glu Leu  
340 345 350

Tyr Asn Ser Asn Phe Tyr Gly Leu Pro Arg Val Ala Tyr Val Asp Leu  
355 360 365

Gln Arg Asn His Ile Gly Ile Ile Gln Asp Gln Thr Phe Arg Leu Leu  
370 375 380

Lys Thr Leu Gln Thr Leu Asp Leu Arg Asp Asn Ala Leu Lys Ala Ile  
385 390 395 400

Gly Phe Ile Pro Ser Ile Gln Met Val Leu Leu Gly Gly Asn Lys Leu  
405 410 415

Val His Leu Pro His Ile His Phe Thr Ala Asn Phe Leu Glu Leu Ser  
420 425 430

Glu Asn Arg Leu Glu Asn Leu Ser Asp Leu Tyr Phe Leu Leu Arg Val

435                    440                    445  
Pro Gln Leu Gln Phe Leu Ile Leu Asn Gln Asn Arg Leu Ser Ser Cys  
450                    455                    460

Lys Ala Ala His Thr Pro Ser Glu Asn Pro Ser Leu Glu Gln Leu Phe  
465                    470                    475                    480

Leu Thr Glu Asn Met Leu Gln Leu Ala Trp Glu Thr Gly Leu Cys Trp  
485                    490                    495

Asp Val Phe Gln Gly Leu Ser Arg Leu Gln Ile Leu Tyr Leu Ser Asn  
500                    505                    510

Asn Tyr Leu Asn Phe Leu Pro Pro Gly Ile Phe Asn Asp Leu Val Ala  
515                    520                    525

Leu Arg Met Leu Ser Leu Ser Ala Asn Lys Leu Thr Val Leu Ser Pro  
530                    535                    540

Gly Ser Leu Pro Ala Asn Leu Glu Ile Leu Asp Ile Ser Arg Asn Gln  
545                    550                    555                    560

Leu Leu Cys Pro Asp Pro Ala Leu Phe Ser Ser Leu Arg Val Leu Asp  
565                    570                    575

Ile Thr His Asn Glu Phe Val Cys Asn Cys Glu Leu Ser Thr Phe Ile  
580                    585                    590

Ser Trp Leu Asn Gln Thr Asn Val Thr Leu Phe Gly Ser Pro Ala Asp  
595                    600                    605

Val Tyr Cys Met Tyr Pro Asn Ser Leu Leu Gly Gly Ser Leu Tyr Asn  
610                    615                    620

Ile Ser Thr Glu Asp Cys Asp Glu Glu Ala Met Arg Ser Leu Lys  
625                    630                    635                    640

Phe Ser Leu Phe Ile Leu Cys Thr Val Thr Leu Thr Leu Phe Leu Val  
645                    650                    655

Ile Thr Leu Val Val Ile Lys Phe Arg Gly Ile Cys Phe Leu Cys Tyr  
660                    665                    670

Lys Thr Ile Gln Lys Leu Val Phe Lys Asp Lys Val Trp Ser Leu Glu  
675                    680                    685

Pro Gly Ala Tyr Arg Tyr Asp Ala Tyr Phe Cys Phe Ser Ser Lys Asp  
690                    695                    700

Phe Glu Trp Ala Gln Asn Ala Leu Leu Lys His Leu Asp Ala His Tyr  
705                    710                    715                    720

Ser Ser Arg Asn Arg Leu Arg Leu Cys Phe Glu Glu Arg Asp Phe Ile  
725                    730                    735

Pro Gly Glu Asn His Ile Ser Asn Ile Gln Ala Ala Val Trp Gly Ser  
740                    745                    750

Arg Lys Thr Val Cys Leu Val Ser Arg His Phe Leu Lys Asp Gly Trp  
755                    760                    765

Cys Leu Glu Ala Phe Arg Tyr Ala Gln Ser Arg Ser Leu Ser Asp Leu

770                    775                    780  
 Lys Ser Ile Leu Ile Val Val Val Val Gly Ser Leu Ser Gln Tyr Gln  
 785                    790                    795                    800

Leu Met Arg His Glu Thr Ile Arg Gly Phe Leu Gln Lys Gln Gln Tyr  
 805                    810                    815

Leu Arg Trp Pro Glu Asp Leu Gln Asp Val Gly Trp Phe Leu Asp Lys  
 820                    825                    830

Leu Ser Gly Cys Ile Leu Lys Glu Glu Lys Gly Lys Lys Arg Ser Ser  
 835                    840                    845

Ser Ile Gln Leu Arg Thr Ile Ala Thr Ile Ser  
 850                    855

<210> 31  
<211> 3373  
<212> DNA  
<213> Homo sapiens

<400> 31		
agctggctag cgtttaaacg ggccctctag actcgagcgg ccgcgaattc actagtgatt		60
cacctctcat gctctgtct cttcaaccag acctctacat tccattttg aagaagacta		120
aaaatggtgt ttccaatgtg gacactgaag agacaaattc ttatcccttt taacataatc		180
ctaatttcca aactccttgg ggctagatgg tttcctaaaa ctctgccctg tgatgtcact		240
ctggatgttc caaagaacca tgtgatcgtg gactgcacag acaagcattt gacagaaatt		300
cctggaggta ttcccacgaa caccacaac ctcaccctca ccattaacca cataccagac		360
atctccccag cgtcctttca cagactggac catctggtag agatcgattt cagatgcaac		420
tgtgtaccta ttccactggg gtcaaaaaac aacatgtgca tcaagaggct gcagattaa		480
cccagaagct ttagtggact cacttattta aaatcccttt acctggatgg aaaccagcta		540
ctagagatac cgcagggcct cccgcctagc ttacagcttc tcagccttga ggccaaacaac		600
atcttttcca tcagaaaaaga gaatctaaca gaactggcca acatagaaat actctacctg		660
ggccaaaaact gttattatcg aaatccttgt tatgtttcat attcaataga gaaagatgcc		720
ttcctaaact tgacaaaagtt aaaagtgctc tccctgaaag ataacaatgt cacagccgtc		780
cctactgttt tgccatctac tttAACAGAA ctatatctct acaacaacat gattgcaaaa		840
atccaagaag atgattttaa taacctaac acattacaaa ttcttgacct aagtggaaat		900
tgcctcggtt gttataatgc cccatttctc tggcgccgt gtaaaaataa ttctccctta		960
cagatccctg taaatgcttt tgatgcgtc acagaattaa aagtttacg tctacacagt		1020
aactctcttc agcatgtgcc cccaaagatgg tttAAGAACCA tcaacaaact ccaggaactg		1080
gatctgtccc aaaacttctt ggccaaagaa attggggatg ctaaatttctc gcattttctc		1140
cccaagcctca tccaaattgga tctgtcttc aattttgaac ttcaggtcta tcgtgcattt		1200

atgaatctat cacaaggcatt ttcttcactg aaaaggcctga aaattctgcg gatcagagga 1260  
tatgtctta aagagttgaa aagctttaac ctctcgccat tacataatct tcaaaatctt 1320  
gaagttcttg atcttggcac taactttata aaaattgcta acctcagcat gtttaaacaa 1380  
tttaaaagac tgaaaagtcat agatcttca gtgaataaaa tatcacccttc aggagattca 1440  
agtgaagttg gcttctgctc aaatgccaga acttctgttag aaagttatga acccccaggc 1500  
cttggaaacaat tacatttattt cagatatgtat aagtatgcaa ggagttgcag attcaaaaac 1560  
aaagaggcctt ct当地atgtc tgttaatgaa agctgctaca agtatggca gaccttggat 1620  
cttaagtaaaa atagtatatt ttttgtcaag tcctctgatt ttcagcatct ttctttcctc 1680  
aaatgcctga atctgtcagg aaatctcatt agccaaactc ttaatggcag tgaattccaa 1740  
ccttttagcag agctgagata tttggacttc tccaacaacc ggcttgattt actccattca 1800  
acagcatttg aagagcttca caaactggaa gttctggata taagcagtaa tagccattat 1860  
tttcaatcag aaggaattac tcataatgcta aactttacca agaacctaaa ggttctgcag 1920  
aaactgatga tgaacgacaa tgacatctt tcctccacca gcaggaccat ggagagtgag 1980  
tctcttagaa ctctggaaatt cagagggaaat cacttagatg ttttatggag agaagggtgat 2040  
aacagataact tacaatttattt caagaatctg ctaaaatttag aggaatttaga catctctaaa 2100  
aattccctaa gtttcttgcc ttctggagtt tttgatggta tgcctccaaa tctaaagaat 2160  
ctctctttgg cccaaaatgg gctcaaactt ttccagttggc agaaactcca gtgtctaaag 2220  
aacctggaaa ctttggacct cagccacaac caactgacca ctgtccctga gagattatcc 2280  
aactgttcca gaaggcctcaa gaatctgatt cttaagaata atcaaatcag gagtctgacg 2340  
aagtattttc tacaagatgc cttccagttg cgatatctgg atctcagctc aaataaaaatc 2400  
cagatgatcc aaaagaccag cttcccagaa aatgtcctca acaatctgaa gatgttgctt 2460  
ttgcataatcata atcggtttct gtgcacctgt gatgctgtgt ggtttgcctg gtgggttaac 2520  
catacggagg tgactattcc ttacctggcc acagatgtga cttgtgtggg gccaggagca 2580  
cacaaggggcc aaagtgtgat cttccctggat ctgtacacccgtgagtttgc tctgactaac 2640  
ctgattctgt tctcactttc catatctgta tctcttttc tcatggtgat gatgacagca 2700  
agtcacccctt atttctggga tgtgtggat atttaccatt tctgtaaaggc caagataaaag 2760  
gggtatcagc gtctaatatc accagactgt tgctatgtat cttttattgt gtatgacact 2820  
aaagacccag ctgtgaccga gtgggttttgc gctgagctgg tggccaaact ggaagacccca 2880  
agagagaaaac attttaatattt atgtctcgag gaaagggact ggtaaccagg gcagccagtt 2940  
ctggaaaaacc tttccccagag catacagctt agcaaaaaga cagtgtttgt gatgacagac 3000  
aaqtatqcaa agactgaaaa tttaagata gcattttact tgcctccatca gaggctcatg 3060

gataaaaaaag ttgatgtat tatcttata ttttttggaa agcctttca gaagtccaa	3120
tccctccagg tcggaaaag gctctgtgg agttctgtcc ttgagtgccc aacaaacccg	3180
caagctcacc catacttctg gcagtgtcta aagaacgccc tggccacaga caatcatgtg	3240
gcctatagtc aggtgttcaa ggaaacggtc tagaatcgaa ttccccggc cgccactgtg	3300
ctggatatct gcagaattcc accacactgg actagtggat ccgagctcgg taccaagctt	3360
aagtttaaac cgc	3373

<210> 32  
<211> 3416  
<212> DNA  
<213> Homo sapiens

<400> 32	
tccagatata ggatcaactcc atgccatcaa gaaagttat gctattggc ccatctcaag	60
ctgatcttgg cacctctcat gctctgtct cttaaccag acctctacat tccatcttgg	120
aagaagacta aaaatggtgt ttccaatgtg gacactgaag agacaaattc ttatcctttt	180
taacataatc ctaatccca aactccttgg ggcttagatgg tttcctaaaa ctctgccttg	240
tgtatgtact ctggatgttc caaagaacca tgtatcgatg gactgcacag acaagcattt	300
gacagaaaatt ctggaggta ttcccacgaa caccacgaac ctcaccctca ccattaacca	360
cataccagac atctccccag cgtccttca cagactggac catctggtag agatcgattt	420
cagatgcaac tgtatgttca ttccacttgg gtcaaaaaac aacatgtca tcaagaggct	480
gcagattaaa cccagaagct ttagtggact cacttattta aaatccctt acctggatgg	540
aaaccagcta ctagagatac cgcagggcct cccgcctagc ttacagcttc tcagccttga	600
ggccaacaac atcttttccca tcagaaaaaa gaatctaaca gaactggcca acatagaaat	660
actctacctg ggccaaaact gttattatcg aaatccttgc tatgtttcat attcaataga	720
gaaagatgcc ttccctaaact tgacaaagtt aaaagtgtc tccctgaaag ataacaatgt	780
cacagccgtc cctactgttt tgccatctac tttaacagaa ctatatctt acaacaacat	840
gattgcaaaa atccaagaag atgattttaa taacctcaac caattacaaa ttcttgaccc	900
aagtggaaat tgccctcggt gttataatgc cccatttcct tgcgcgcgt gtaaaaataa	960
ttctccctca cagatccctg taaatgttt tgatgcgcgt acagaattaa aagttttacg	1020
tctacacagt aactctcttc agcatgtgcc cccaaagatgg tttaagaaca tcaacaaact	1080
ccaggaactg gatctgtccc aaaacttctt ggccaaagaa attggggatg ctaaatttct	1140
gcattttctc cccagcctca tccaaatggaa tctgtcttc aattttgaac ttcaggtcta	1200
tcgtgcacatct atgaatctat cacaagcatt ttcttcactg aaaaggctga aaattctgcg	1260

gatcagagga tatgtcttta aagagttgaa aagctttaac ctctcgccat tacataatct  
tcaaatctt gaagttcttg atcttggcac taacttata aaaattgcta acctcagcat  
gtttaaacaa tttaaaagac tgaaaagtcat agatcttca gtgaataaaa tattcaccc  
aggagattca agtgaagttg gcttctgctc aaatgccaga acttctgttag aagtttatga  
accccaggtc ctggaacaat tacattatatt cagatatgat aagtatgaa ggagttgcag  
attcaaaaac aaagaggcctt ctttcattgtc tgttaatgaa agctgctaca agtatggca  
gacccttggat ctaagtaaaa atagttatatt ttttgcataag tcctctgtt ttcagcatct  
ttcttccttc aaatgcctga atctgtcagg aaatctcatt agccaaactc ttaatggcag  
tgaattccaa ccttttagcag agttgagata tttggacttc tccaacaacc ggcttgattt  
actccattca acagcatttg aagagcttca caaactggaa gttctggata taagcagtaa  
tagccattat tttcaatcag aaggaattac tcataatgcta aactttacca agaacctaaa  
ggttctgcag aaactgatga tgaacgacaa tgacatctct tcctccacca gcaggaccat  
ggagagttag tctcttagaa ctctggaaatt cagagaaat cacttagatg tttatggag  
agaaggtgat aacagataact tacaattatt caagaatctg ctaaaattag aggaattaga  
catctctaaa aattccctaa gtttcttgcctt ttctggagtt tttgatggta tgcctccaaa  
tctaaagaat ctctcttgg cccaaaatgg gctcaaattct ttcagttgga agaaactcca  
gtgtctaaag aacctggaaa ctttggacct cagccacaac caactgacca ctgtccctga  
gagattatcc aactgttcca gaagccacaa gaatctgatt cttaagaata atcaaattcag  
gagtcgcacg aagtattttc tacaagatgc cttccagttg cgatatctgg atctcagctc  
aaataaaatc cagatgatcc aaaagaccag cttcccgagaa aatgtcctca acaatctgaa  
gatgttgcattt ttgcataatcgatcttctt gtcacactgt gatgctgtgt ggtttgtctg  
gtgggttaac catacgagg tgactattcc ttacctggcc acagatgtga cttgtgtgg  
gccaggagca cacaaggggcc aaagtgtgat ctccctggat ctgtacacact gtgagttaga  
tctgactaac ctgattctgt tctcaatttc catatctgta tctcttttc tcatggat  
gatgacagca agtcacacttctt atttctggta tttgtgttat atttaccatt tctgtaaaggc  
caagataaaag gggtatcagc gtctaatatc accagactgt tgctatgatg cttttattgt  
gtatgacact aaagacccag ctgtgaccga gtgggtttt gctgagctgg tggccaaact  
ggaagacccca agagagaaac attttatattt atgtctcgag gaaaggact ggttaccagg  
gcagccagtt ctggaaaacc tttcccgag catacagctt agcaaaaaga cagtgtttgt  
gatgacagac aagtatgcaa agactgaaaa tttaagata gcattttact tgcctccatca  
gaggctcatg gatgaaaaag ttgtatgtat tatcttgcata tttcttgcata agccctttca  
gaagtccaaag ttccctccagc tccggaaaaag gctctgtggg agttctgtcc ttgagttggcc  
3180

aacaaacccg caagctcacc cataacttctg gcagtgtcta aagaacgccc tggcacaga	3240
caatcatgtg gcctatagtc aggtgttcaa ggaaacggtc tagcccttct ttgcaaaaaca	3300
caactgccta gtttaccaag gagaggctg gctgtttaaa ttgttttcat atatatcaca	3360
ccaaaagcgt gtttgaaat tcttcaagaa atgagattgc ccataattca ggggag	3416

<210> 33  
<211> 3418  
<212> DNA  
<213> Homo spaiens

<400> 33	
actccagata taggatcaact ccatgccatc aagaaagttg atgctattgg gccccatctca	60
agctgatctt ggcacctctc atgctctgct ctcttcaacc agacctctac attccatttt	120
ggaagaagac taaaaatggt gttccaatg tggacactga agagacaaat tcttacccctt	180
tttaacataa tccttaatttc caaactccctt gggcttagat ggtttcccaa aactctgccc	240
tgtgatgtca ctctggatgt tccaaagaac catgtgatcg tggactgcac agacaagcat	300
ttgacagaaa ttccctggagg tattccacg aacaccacga acctcacccct caccattaac	360
cacataccag acatctcccc agcgtccctt cacagactgg accatctggt agagatcgat	420
ttcagatgca actgtgtacc tattccactg gggtaaaaaa acaacatgtg catcaagagg	480
ctgcagatta aacccagaag cttagtgga ctcacttatt taaaatccctt ttacctggat	540
ggaaaccagg tactagagat accgcagggc ctccggctta gcttacagct tctcagccctt	600
gaggccaaca acatcttttc catcagaaaa gagaatctaa cagaactggc caacatagaa	660
atactctacc tggccaaaaa ctgttattat cgaaatccctt gttatgttc atattcaata	720
gagaaagatg cttccctaaa cttgacaaag taaaatgtgc tctccctgaa agataacaat	780
gtcacagccg tccctactgt tttgccatct actttaacag aactatatct ctacaacaac	840
atgattgcaa aaatccaaga agatgatttt aataacctca accaattaca aattcttgac	900
ctaagtggaa attgcctcg ttgttataat gccccatttc ttgtgcgc tgacagaatt aaaagtttta	960
aattctcccc tacagatccc tgtaaatgtc ttgtatgcgc tgacagaatt aaaagtttta	1020
cgtctacaca gtaactctct tcagcatgtg ccccaagat ggtttaagaa catcaacaaa	1080
ctccaggaac tggatctgtc cccaaacttc ttggccaaag aaattgggga tgctaaattt	1140
ctgcattttc tccccagcct catccaattt gatctgttct tcaattttga acttcaggc	1200
tatcgatgtcat ctatgaatct atcacaagca ttttcttcac tgaaaagctt gaaaattctg	1260
cggatcagag gatatgtctt taaagagttg aaaagcttta acctctgcattacataat	1320
cttcaaaatc ttgaagttct tgatcttggc actaacttttta taaaattgc taacctcagc	1380

atgttaaac aattttaaag actgaaaatgc atagatctt cagtgaataa aatatcacct 1440  
 tcaggagatt caagtgaagt tggcttcgc tcaaattgcga gaacttctgt agaaagttat 1500  
 gaaccccagg tccttggaca attacattat ttcatatgc ataagtatgc aaggagttgc 1560  
 agattcaaaa acaaagaggc ttcttcatg tctgttaatg aaagctgcta caagtatggg 1620  
 cagaccttgg atctaagtaa aaatagtata tttttgtca agtcctctga ttttcagcat 1680  
 ctttttcc tcaaattgcct gaatctgtca gggaaatctca ttagccaaac tcttaatggc 1740  
 agtgaattcc aaccttttagc agagctgaga tatttggact tctccaacaa ccggcttgat 1800  
 ttactccatt caacagcatt tgaagagctt cacaaactgg aagttctgga tataaggcagt 1860  
 aatagccatt atttcaatc agaaggaatt actcatatgc taaactttac caagaaccta 1920  
 aaggttctgc agaaaactgat gatgaacgc aatgacatct cttcctccac cagcaggacc 1980  
 atggagagtg agtctcttag aactctggaa ttcatagggaa atcacttaga tgtttatgg 2040  
 agagaaggcgataaacagata cttacaatta ttcaagaatc tgctaaaatt agaggaatta 2100  
 gacatctcta aaaattcccct aagtttcttg ctttctggag ttttgatgg tatgcctcca 2160  
 aatctaaaga atctctcttt ggccaaaaat gggctcaa at cttcagtttgc 2220  
 cagtgtctaa agaacctgga aactttggac ctcagccaca accaactgac cactgtccct 2280  
 gagagattat ccaactgttc cagaagcctc aagaatctga ttcttaagaa taatcaaatc 2340  
 aggagtctga cgaagtattt tctacaagat gccttccagt tgcatatctt ggttctcagc 2400  
 tcaaataaaa tccagatgat cccaaaagacc agcttcccag aaaatgtccct caacaatctg 2460  
 aagatgttgc ttttgcata taatcggtt ctgtgcaccc gtgtatgtgt gtggtttgc 2520  
 tggtgggtta accatacgga ggtgactatt ctttacctgg ccacagatgt gacttgtgt 2580  
 gggccaggag cacacaaggg cccaaatgtg atctccctgg atctgtacac ctgtgagtt 2640  
 gatctgacta acctgattct gttctcaattt tccatatctg tatctctttt tctcatggtg 2700  
 atgatgacag caagtcaccc ctatttctgg gatgtgtggt atatccatca tttctgttaag 2760  
 gccaagataa aggggtatca gcgtctaata tcaccagact gttgtatga tgcttttatt 2820  
 gtgtatgaca ctaaagaccc agctgtgacc gagtgggtt tggctgagct ggtggccaaa 2880  
 ctggaagacc caagagagaa acattttaat ttatgtctcg aggaaaggga ctggttacca 2940  
 gggcagccag ttctggaaaaa ctttccctgg agcatacagc ttagcaaaaaa gacagtgttt 3000  
 gtgtatgacag acaagtatgc aaagactgaa aattttaaga tagcattttt cttgtccccat 3060  
 cagaggctca tggatgaaaaa agttgtatgtt attatcttgc tattttcttgc gaageccctt 3120  
 cagaagtccca agttccctccca gctccggaaa aggctctgtg ggagttctgt ctttgcgtgg 3180  
 ccaacaaacc cgcaagctca cccatacttc tggcagtgtc taaagaacgc cctggccaca 3240  
 gacaatcatg tggcctatag tcaggtgttc aaggaaacgg tctagccctt ctttgcaaaaa 3300

cacaactgcc tagtttacca aggagaggcc tggctgtta aattgtttc atatatatca 3360  
cacaaaaagc gtgtttgaa attcttcaag aaatgagatt gccccatattt caggggag 3418

<210> 34  
<211> 1049  
<212> PRT  
<213> Homo sapiens

<400> 34

Met Val Phe Pro Met Trp Thr Leu Lys Arg Gln Ile Leu Ile Leu Phe  
1 5 10 15

Asn Ile Ile Leu Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro Lys  
20 25 30

Thr Leu Pro Cys Asp Val Thr Leu Asp Val Pro Lys Asn His Val Ile  
35 40 45

Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Gly Gly Ile Pro  
50 55 60

Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Asp Ile  
65 70 75 80

Ser Pro Ala Ser Phe His Arg Leu Asp His Leu Val Glu Ile Asp Phe  
85 90 95

Arg Cys Asn Cys Val Pro Ile Pro Leu Gly Ser Lys Asn Asn Met Cys  
100 105 110

Ile Lys Arg Leu Gln Ile Lys Pro Arg Ser Phe Ser Gly Leu Thr Tyr  
115 120 125

Leu Lys Ser Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
130 135 140

Gly Leu Pro Pro Ser Leu Gln Leu Leu Ser Leu Glu Ala Asn Asn Ile  
145 150 155 160

Phe Ser Ile Arg Lys Glu Asn Leu Thr Glu Leu Ala Asn Ile Glu Ile  
165 170 175

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Tyr Val Ser  
180 185 190

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Asn Leu Thr Lys Leu Lys Val  
195 200 205

Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Val Leu Pro  
210 215 220

Ser Thr Leu Thr Glu Leu Tyr Leu Tyr Asn Asn Met Ile Ala Lys Ile  
225 230 235 240

Gln Glu Asp Asp Phe Asn Asn Leu Asn Gln Leu Gln Ile Leu Asp Leu  
245 250 255

Ser Gly Asn Cys Pro Arg Cys Tyr Asn Ala Pro Phe Pro Cys Ala Pro

	260	265	270
Cys Lys Asn Asn Ser Pro Leu Gln Ile Pro Val Asn Ala Phe Asp Ala			
275	280	285	
Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His			
290	295	300	
Val Pro Pro Arg Trp Phe Lys Asn Ile Asn Lys Leu Gln Glu Leu Asp			
305	310	315	320
Leu Ser Gln Asn Phe Leu Ala Lys Glu Ile Gly Asp Ala Lys Phe Leu			
325	330	335	
His Phe Leu Pro Ser Leu Ile Gln Leu Asp Leu Ser Phe Asn Phe Glu			
340	345	350	
Leu Gln Val Tyr Arg Ala Ser Met Asn Leu Ser Gln Ala Phe Ser Ser			
355	360	365	
Leu Lys Ser Leu Lys Ile Leu Arg Ile Arg Gly Tyr Val Phe Lys Glu			
370	375	380	
Leu Lys Ser Phe Asn Leu Ser Pro Leu His Asn Leu Gln Asn Leu Glu			
385	390	395	400
Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asn Leu Ser Met			
405	410	415	
Phe Lys Gln Phe Lys Arg Leu Lys Val Ile Asp Leu Ser Val Asn Lys			
420	425	430	
Ile Ser Pro Ser Gly Asp Ser Ser Glu Val Gly Phe Cys Ser Asn Ala			
435	440	445	
Arg Thr Ser Val Glu Ser Tyr Glu Pro Gln Val Leu Glu Gln Leu His			
450	455	460	
Tyr Phe Arg Tyr Asp Lys Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys			
465	470	475	480
Glu Ala Ser Phe Met Ser Val Asn Glu Ser Cys Tyr Lys Tyr Gly Gln			
485	490	495	
Thr Leu Asp Leu Ser Lys Asn Ser Ile Phe Phe Val Lys Ser Ser Asp			
500	505	510	
Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn Leu			
515	520	525	
Ile Ser Gln Thr Leu Asn Gly Ser Glu Phe Gln Pro Leu Ala Glu Leu			
530	535	540	
Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu His Ser Thr			
545	550	555	560
Ala Phe Glu Glu Leu His Lys Leu Glu Val Leu Asp Ile Ser Ser Asn			
565	570	575	
Ser His Tyr Phe Gln Ser Glu Gly Ile Thr His Met Leu Asn Phe Thr			
580	585	590	
Lys Asn Leu Lys Val Leu Gln Lys Leu Met Met Asn Asp Asn Asp Ile			

595	600	605
Ser Ser Ser Thr Ser Arg Thr Met Glu Ser Glu Ser Leu Arg Thr Leu		
610	615	620
Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Glu Gly Asp Asn		
625	630	635
Arg Tyr Leu Gln Leu Phe Lys Asn Leu Leu Lys Leu Glu Glu Leu Asp		
645	650	655
Ile Ser Lys Asn Ser Leu Ser Phe Leu Pro Ser Gly Val Phe Asp Gly		
660	665	670
Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu Lys		
675	680	685
Ser Phe Ser Trp Lys Lys Leu Gln Cys Leu Lys Asn Leu Glu Thr Leu		
690	695	700
Asp Leu Ser His Asn Gln Leu Thr Thr Val Pro Glu Arg Leu Ser Asn		
705	710	715
Cys Ser Arg Ser Leu Lys Asn Leu Ile Leu Lys Asn Asn Gln Ile Arg		
725	730	735
Ser Leu Thr Lys Tyr Phe Leu Gln Asp Ala Phe Gln Leu Arg Tyr Leu		
740	745	750
Asp Leu Ser Ser Asn Lys Ile Gln Met Ile Gln Lys Thr Ser Phe Pro		
755	760	765
Glu Asn Val Leu Asn Asn Leu Lys Met Leu Leu Leu His His Asn Arg		
770	775	780
Phe Leu Cys Thr Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn His		
785	790	795
Thr Glu Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val Gly		
805	810	815
Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr Thr		
820	825	830
Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Leu Ser Ile Ser		
835	840	845
Val Ser Leu Phe Leu Met Val Met Met Thr Ala Ser His Leu Tyr Phe		
850	855	860
Trp Asp Val Trp Tyr Ile Tyr His Phe Cys Lys Ala Lys Ile Lys Gly		
865	870	875
Tyr Gln Arg Leu Ile Ser Pro Asp Cys Cys Tyr Asp Ala Phe Ile Val		
885	890	895
Tyr Asp Thr Lys Asp Pro Ala Val Thr Glu Trp Val Leu Ala Glu Leu		
900	905	910
Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys Leu		
915	920	925
Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu Ser		

930	935	940
Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Asp Lys		
945	950	955
Tyr Ala Lys Thr Glu Asn Phe Lys Ile Ala Phe Tyr Leu Ser His Gln		
965	970	975
Arg Leu Met Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu Glu		
980	985	990
Lys Pro Phe Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu Cys		
995	1000	1005
Gly Ser Ser Val Leu Glu Trp Pro Thr Asn Pro Gln Ala His Pro		
1010	1015	1020
Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Ala Thr Asp Asn His		
1025	1030	1035
Val Ala Tyr Ser Gln Val Phe Lys Glu Thr Val		
1040	1045	

<210> 35  
<211> 1049  
<212> PRT  
<213> Homo sapiens

<400> 35

Met Val Phe Pro Met Trp Thr Leu Lys Arg Gln Ile Leu Ile Leu Phe		
1	5	10
		15
Asn Ile Ile Leu Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro Lys		
20	25	30
Thr Leu Pro Cys Asp Val Thr Leu Asp Val Pro Lys Asn His Val Ile		
35	40	45
Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Gly Gly Ile Pro		
50	55	60
Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Asp Ile		
65	70	75
		80
Ser Pro Ala Ser Phe His Arg Leu Asp His Leu Val Glu Ile Asp Phe		
85	90	95
Arg Cys Asn Cys Val Pro Ile Pro Leu Gly Ser Lys Asn Asn Met Cys		
100	105	110
Ile Lys Arg Leu Gln Ile Lys Pro Arg Ser Phe Ser Gly Leu Thr Tyr		
115	120	125
Leu Lys Ser Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln		
130	135	140
Gly Leu Pro Pro Ser Leu Gln Leu Leu Ser Leu Glu Ala Asn Asn Ile		
145	150	155
Phe Ser Ile Arg Lys Glu Asn Leu Thr Glu Leu Ala Asn Ile Glu Ile		
165	170	175

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Tyr Val Ser  
180 185 190

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Asn Leu Thr Lys Leu Lys Val  
195 200 205

Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Val Leu Pro  
210 215 220

Ser Thr Leu Thr Glu Leu Tyr Leu Tyr Asn Asn Met Ile Ala Lys Ile  
225 230 235 240

Gln Glu Asp Asp Phe Asn Asn Leu Asn Gln Leu Gln Ile Leu Asp Leu  
245 250 255

Ser Gly Asn Cys Pro Arg Cys Tyr Asn Ala Pro Phe Pro Cys Ala Pro  
260 265 270

Cys Lys Asn Asn Ser Pro Leu Gln Ile Pro Val Asn Ala Phe Asp Ala  
275 280 285

Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
290 295 300

Val Pro Pro Arg Trp Phe Lys Asn Ile Asn Lys Leu Gln Glu Leu Asp  
305 310 315 320

Leu Ser Gln Asn Phe Leu Ala Lys Glu Ile Gly Asp Ala Lys Phe Leu  
325 330 335

His Phe Leu Pro Ser Leu Ile Gln Leu Asp Leu Ser Phe Asn Phe Glu  
340 345 350

Leu Gln Val Tyr Arg Ala Ser Met Asn Leu Ser Gln Ala Phe Ser Ser  
355 360 365

Leu Lys Ser Leu Lys Ile Leu Arg Ile Arg Gly Tyr Val Phe Lys Glu  
370 375 380

Leu Lys Ser Phe Asn Leu Ser Pro Leu His Asn Leu Gln Asn Leu Glu  
385 390 395 400

Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asn Leu Ser Met  
405 410 415

Phe Lys Gln Phe Lys Arg Leu Lys Val Ile Asp Leu Ser Val Asn Lys  
420 425 430

Ile Ser Pro Ser Gly Asp Ser Ser Glu Val Gly Phe Cys Ser Asn Ala  
435 440 445

Arg Thr Ser Val Glu Ser Tyr Glu Pro Gln Val Leu Glu Gln Leu His  
450 455 460

Tyr Phe Arg Tyr Asp Lys Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
465 470 475 480

Glu Ala Ser Phe Met Ser Val Asn Glu Ser Cys Tyr Lys Tyr Gly Gln  
485 490 495

Thr Leu Asp Leu Ser Lys Asn Ser Ile Phe Phe Val Lys Ser Ser Asp

	500	505	510												
Phe	Gln	His	Leu	Ser	Phe	Leu	Lys	Cys	Leu	Asn	Leu	Ser	Gly	Asn	Leu
			515				520				525				
Ile	Ser	Gln	Thr	Leu	Asn	Gly	Ser	Glu	Phe	Gln	Pro	Leu	Ala	Glu	Leu
			530				535				540				
Arg	Tyr	Leu	Asp	Phe	Ser	Asn	Asn	Arg	Leu	Asp	Leu	Leu	His	Ser	Thr
			545				550				555			560	
Ala	Phe	Glu	Glu	Leu	His	Lys	Leu	Glu	Val	Leu	Asp	Ile	Ser	Ser	Asn
			565				570				575				
Ser	His	Tyr	Phe	Gln	Ser	Glu	Gly	Ile	Thr	His	Met	Leu	Asn	Phe	Thr
			580				585				590				
Lys	Asn	Leu	Lys	Val	Leu	Gln	Lys	Leu	Met	Met	Asn	Asp	Asn	Asp	Ile
			595				600				605				
Ser	Ser	Ser	Thr	Ser	Arg	Thr	Met	Glu	Ser	Glu	Ser	Leu	Arg	Thr	Leu
			610				615				620				
Glu	Phe	Arg	Gly	Asn	His	Leu	Asp	Val	Leu	Trp	Arg	Glu	Gly	Asp	Asn
			625				630				635			640	
Arg	Tyr	Leu	Gln	Leu	Phe	Lys	Asn	Leu	Leu	Lys	Leu	Glu	Glu	Leu	Asp
			645				650				655				
Ile	Ser	Lys	Asn	Ser	Leu	Ser	Phe	Leu	Pro	Ser	Gly	Val	Phe	Asp	Gly
			660				665				670				
Met	Pro	Pro	Asn	Leu	Lys	Asn	Leu	Ser	Leu	Ala	Lys	Asn	Gly	Leu	Lys
			675				680				685				
Ser	Phe	Ser	Trp	Lys	Lys	Leu	Gln	Cys	Leu	Lys	Asn	Leu	Glu	Thr	Leu
			690				695				700				
Asp	Leu	Ser	His	Asn	Gln	Leu	Thr	Thr	Val	Pro	Glu	Arg	Leu	Ser	Asn
			705				710				715			720	
Cys	Ser	Arg	Ser	His	Lys	Asn	Leu	Ile	Leu	Lys	Asn	Asn	Gln	Ile	Arg
			725				730				735				
Ser	Pro	Thr	Lys	Tyr	Phe	Leu	Gln	Asp	Ala	Phe	Gln	Leu	Arg	Tyr	Leu
			740				745				750				
Asp	Leu	Ser	Ser	Asn	Lys	Ile	Gln	Met	Ile	Gln	Lys	Thr	Ser	Phe	Pro
			755				760				765				
Glu	Asn	Val	Leu	Asn	Asn	Leu	Lys	Met	Leu	Leu	Leu	His	His	Asn	Arg
			770				775				780				
Phe	Leu	Cys	Thr	Cys	Asp	Ala	Val	Trp	Phe	Val	Trp	Trp	Val	Asn	His
			785				790				795			800	
Thr	Glu	Val	Thr	Ile	Pro	Tyr	Leu	Ala	Thr	Asp	Val	Thr	Cys	Val	Gly
			805				810				815				
Pro	Gly	Ala	His	Lys	Gly	Gln	Ser	Val	Ile	Ser	Leu	Asp	Leu	Tyr	Thr
			820				825				830				
Cys	Glu	Leu	Asp	Leu	Thr	Asn	Leu	Ile	Leu	Phe	Ser	Leu	Ser	Ile	Ser

835	840	845
Val Ser Leu Phe Leu Met Val Met Met Thr Ala Ser His Leu Tyr Phe		
850	855	860
Trp Asp Val Trp Tyr Ile Tyr His Phe Cys Lys Ala Lys Ile Lys Gly		
865	870	875
Tyr Gln Arg Leu Ile Ser Pro Asp Cys Cys Tyr Asp Ala Phe Ile Val		
885	890	895
Tyr Asp Thr Lys Asp Pro Ala Val Thr Glu Trp Val Leu Ala Glu Leu		
900	905	910
Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys Leu		
915	920	925
Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu Ser		
930	935	940
Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Asp Lys		
945	950	955
Tyr Ala Lys Thr Glu Asn Phe Lys Ile Ala Phe Tyr Leu Ser His Gln		
965	970	975
Arg Leu Met Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu Glu		
980	985	990
Lys Pro Phe Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu Cys		
995	1000	1005
Gly Ser Ser Val Leu Glu Trp Pro Thr Asn Pro Gln Ala His Pro		
1010	1015	1020
Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Ala Thr Asp Asn His		
1025	1030	1035
Val Ala Tyr Ser Gln Val Phe Lys Glu Thr Val		
1040	1045	

<210> 36  
<211> 1049  
<212> PRT  
<213> Homo spaiens

<400> 36

Met Val Phe Pro Met Trp Thr Leu Lys Arg Gln Ile Leu Ile Leu Phe		
1	5	10
		15
Asn Ile Ile Leu Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro Lys		
20	25	30
Thr Leu Pro Cys Asp Val Thr Leu Asp Val Pro Lys Asn His Val Ile		
35	40	45
Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Gly Gly Ile Pro		
50	55	60
Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Asp Ile		
65	70	75
		80

Ser Pro Ala Ser Phe His Arg Leu Asp His Leu Val Glu Ile Asp Phe  
85 90 95

Arg Cys Asn Cys Val Pro Ile Pro Leu Gly Ser Lys Asn Asn Met Cys  
100 105 110

Ile Lys Arg Leu Gln Ile Lys Pro Arg Ser Phe Ser Gly Leu Thr Tyr  
115 120 125

Leu Lys Ser Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
130 135 140

Gly Leu Pro Pro Ser Leu Gln Leu Leu Ser Leu Glu Ala Asn Asn Ile  
145 150 155 160

Phe Ser Ile Arg Lys Glu Asn Leu Thr Glu Leu Ala Asn Ile Glu Ile  
165 170 175

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Tyr Val Ser  
180 185 190

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Asn Leu Thr Lys Leu Lys Val  
195 200 205

Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Val Leu Pro  
210 215 220

Ser Thr Leu Thr Glu Leu Tyr Leu Tyr Asn Asn Met Ile Ala Lys Ile  
225 230 235 240

Gln Glu Asp Asp Phe Asn Asn Leu Asn Gln Leu Gln Ile Leu Asp Leu  
245 250 255

Ser Gly Asn Cys Pro Arg Cys Tyr Asn Ala Pro Phe Pro Cys Ala Pro  
260 265 270

Cys Lys Asn Asn Ser Pro Leu Gln Ile Pro Val Asn Ala Phe Asp Ala  
275 280 285

Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
290 295 300

Val Pro Pro Arg Trp Phe Lys Asn Ile Asn Lys Leu Gln Glu Leu Asp  
305 310 315 320

Leu Ser Gln Asn Phe Leu Ala Lys Glu Ile Gly Asp Ala Lys Phe Leu  
325 330 335

His Phe Leu Pro Ser Leu Ile Gln Leu Asp Leu Ser Phe Asn Phe Glu  
340 345 350

Leu Gln Val Tyr Arg Ala Ser Met Asn Leu Ser Gln Ala Phe Ser Ser  
355 360 365

Leu Lys Ser Leu Lys Ile Leu Arg Ile Arg Gly Tyr Val Phe Lys Glu  
370 375 380

Leu Lys Ser Phe Asn Leu Ser Pro Leu His Asn Leu Gln Asn Leu Glu  
385 390 395 400

Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asn Leu Ser Met

Phe Lys Gln Phe Lys Arg Leu Lys Val Ile Asp Leu Ser Val Asn Lys	405	410	415
420		425	430
Ile Ser Pro Ser Gly Asp Ser Ser Glu Val Gly Phe Cys Ser Asn Ala			
435		440	445
Arg Thr Ser Val Glu Ser Tyr Glu Pro Gln Val Leu Glu Gln Leu His			
450		455	460
Tyr Phe Arg Tyr Asp Lys Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys			
465		470	475
480			
Glu Ala Ser Phe Met Ser Val Asn Glu Ser Cys Tyr Lys Tyr Gly Gln			
485		490	495
Thr Leu Asp Leu Ser Lys Asn Ser Ile Phe Phe Val Lys Ser Ser Asp			
500		505	510
Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn Leu			
515		520	525
Ile Ser Gln Thr Leu Asn Gly Ser Glu Phe Gln Pro Leu Ala Glu Leu			
530		535	540
Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu His Ser Thr			
545		550	555
560			
Ala Phe Glu Glu Leu His Lys Leu Glu Val Leu Asp Ile Ser Ser Asn			
565		570	575
Ser His Tyr Phe Gln Ser Glu Gly Ile Thr His Met Leu Asn Phe Thr			
580		585	590
Lys Asn Leu Lys Val Leu Gln Lys Leu Met Met Asn Asp Asn Asp Ile			
595		600	605
Ser Ser Ser Thr Ser Arg Thr Met Glu Ser Glu Ser Leu Arg Thr Leu			
610		615	620
Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Glu Gly Asp Asn			
625		630	635
640			
Arg Tyr Leu Gln Leu Phe Lys Asn Leu Leu Lys Leu Glu Glu Leu Asp			
645		650	655
Ile Ser Lys Asn Ser Leu Ser Phe Leu Pro Ser Gly Val Phe Asp Gly			
660		665	670
Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu Lys			
675		680	685
Ser Phe Ser Trp Lys Lys Leu Gln Cys Leu Lys Asn Leu Glu Thr Leu			
690		695	700
Asp Leu Ser His Asn Gln Leu Thr Thr Val Pro Glu Arg Leu Ser Asn			
705		710	715
720			
Cys Ser Arg Ser Leu Lys Asn Leu Ile Leu Lys Asn Asn Gln Ile Arg			
725		730	735
Ser Leu Thr Lys Tyr Phe Leu Gln Asp Ala Phe Gln Leu Arg Tyr Leu			

	740	745	750												
Asp	Leu	Ser	Ser	Asn	Lys	Ile	Gln	Met	Ile	Gln	Lys	Thr	Ser	Phe	Pro
								755	760						765
Glu	Asn	Val	Leu	Asn	Asn	Leu	Lys	Met	Leu	Leu	Leu	His	His	Asn	Arg
								770	775						780
Phe	Leu	Cys	Thr	Cys	Asp	Ala	Val	Trp	Phe	Val	Trp	Trp	Val	Asn	His
								785	790						800
Thr	Glu	Val	Thr	Ile	Pro	Tyr	Leu	Ala	Thr	Asp	Val	Thr	Cys	Val	Gly
								805		810					815
Pro	Gly	Ala	His	Lys	Gly	Gln	Ser	Val	Ile	Ser	Leu	Asp	Leu	Tyr	Thr
								820		825					830
Cys	Glu	Leu	Asp	Leu	Thr	Asn	Leu	Ile	Leu	Phe	Ser	Leu	Ser	Ile	Ser
								835		840					845
Val	Ser	Leu	Phe	Leu	Met	Val	Met	Met	Thr	Ala	Ser	His	Leu	Tyr	Phe
								850		855					860
Trp	Asp	Val	Trp	Tyr	Ile	Tyr	His	Phe	Cys	Lys	Ala	Lys	Ile	Lys	Gly
								865	870			875			880
Tyr	Gln	Arg	Leu	Ile	Ser	Pro	Asp	Cys	Cys	Tyr	Asp	Ala	Phe	Ile	Val
								885		890					895
Tyr	Asp	Thr	Lys	Asp	Pro	Ala	Val	Thr	Glu	Trp	Val	Leu	Ala	Glu	Leu
								900		905					910
Val	Ala	Lys	Leu	Glu	Asp	Pro	Arg	Glu	Lys	His	Phe	Asn	Leu	Cys	Leu
								915		920					925
Glu	Glu	Arg	Asp	Trp	Leu	Pro	Gly	Gln	Pro	Val	Leu	Glu	Asn	Leu	Ser
								930	935			940			
Gln	Ser	Ile	Gln	Leu	Ser	Lys	Lys	Thr	Val	Phe	Val	Met	Thr	Asp	Lys
								945	950			955			960
Tyr	Ala	Lys	Thr	Glu	Asn	Phe	Lys	Ile	Ala	Phe	Tyr	Leu	Ser	His	Gln
								965		970					975
Arg	Leu	Met	Asp	Glu	Lys	Val	Asp	Val	Ile	Ile	Leu	Ile	Phe	Leu	Glu
								980		985					990
Lys	Pro	Phe	Gln	Lys	Ser	Lys	Phe	Leu	Gln	Leu	Arg	Lys	Arg	Leu	Cys
								995		1000					1005
Gly	Ser	Ser	Val	Leu	Glu	Trp	Pro	Thr	Asn	Pro	Gln	Ala	His	Pro	
								1010		1015					1020
Tyr	Phe	Trp	Gln	Cys	Leu	Lys	Asn	Ala	Leu	Ala	Thr	Asp	Asn	His	
								1025		1030					1035
Val	Ala	Tyr	Ser	Gln	Val	Phe	Lys	Glu	Thr	Val					
								1040		1045					

<210> 37  
<211> 1049  
<212> PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 37

Met Val Phe Pro Met Trp Thr Leu Lys Arg Gln Ile Leu Ile Leu Phe  
1 5 10 15

Asn Ile Ile Leu Ile Ser Lys Leu Leu Gly Ala Arg Trp Phe Pro Lys  
20 25 30

Thr Leu Pro Cys Asp Val Thr Leu Asp Val Pro Lys Asn His Val Ile  
35 40 45

Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Gly Gly Ile Pro  
50 55 60

Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Asp Ile  
65 70 75 80

Ser Pro Ala Ser Phe His Arg Leu Asp His Leu Val Glu Ile Asp Phe  
85 90 95

Arg Cys Asn Cys Val Pro Ile Pro Leu Gly Ser Lys Asn Asn Met Cys  
100 105 110

Ile Lys Arg Leu Gln Ile Lys Pro Arg Ser Phe Ser Gly Leu Thr Tyr  
115 120 125

Leu Lys Ser Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
130 135 140

Gly Leu Pro Pro Ser Leu Gln Leu Leu Ser Leu Glu Ala Asn Asn Ile  
145 150 155 160

Phe Ser Ile Arg Lys Glu Asn Leu Thr Glu Leu Ala Asn Ile Glu Ile  
165 170 175

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Tyr Val Ser  
180 185 190

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Asn Leu Thr Lys Leu Lys Val  
195 200 205

Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Val Leu Pro  
210 215 220

Ser Thr Leu Thr Glu Leu Tyr Leu Tyr Asn Asn Met Ile Ala Lys Ile  
225 230 235 240

Gln Glu Asp Asp Phe Asn Asn Leu Asn Gln Leu Gln Ile Leu Asp Leu  
245 250 255

Ser Gly Asn Cys Pro Arg Cys Tyr Asn Ala Pro Phe Pro Cys Ala Pro  
260 265 270

Cys Lys Asn Asn Ser Pro Leu Gln Ile Pro Val Asn Ala Phe Asp Ala  
275 280 285

Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
290 295 300

Val Pro Pro Arg Trp Phe Lys Asn Ile Asn Lys Leu Gln Glu Leu Asp  
305 310 315 320

Leu Ser Gln Asn Phe Leu Ala Lys Glu Ile Gly Asp Ala Lys Phe Leu  
325 330 335

His Phe Leu Pro Ser Leu Ile Gln Leu Asp Leu Ser Phe Asn Phe Glu  
340 345 350

Leu Gln Val Tyr Arg Ala Ser Met Asn Leu Ser Gln Ala Phe Ser Ser  
355 360 365

Leu Lys Ser Leu Lys Ile Leu Arg Ile Arg Gly Tyr Val Phe Lys Glu  
370 375 380

Leu Lys Ser Phe Asn Leu Ser Pro Leu His Asn Leu Gln Asn Leu Glu  
385 390 395 400

Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asn Leu Ser Met  
405 410 415

Phe Lys Gln Phe Lys Arg Leu Lys Val Ile Asp Leu Ser Val Asn Lys  
420 425 430

Ile Ser Pro Ser Gly Asp Ser Ser Glu Val Gly Phe Cys Ser Asn Ala  
435 440 445

Arg Thr Ser Val Glu Ser Tyr Glu Pro Gln Val Leu Glu Gln Leu His  
450 455 460

Tyr Phe Arg Tyr Asp Lys Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
465 470 475 480

Glu Ala Ser Phe Met Ser Val Asn Glu Ser Cys Tyr Lys Tyr Gly Gln  
485 490 495

Thr Leu Asp Leu Ser Lys Asn Ser Ile Phe Phe Val Lys Ser Ser Asp  
500 505 510

Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn Leu  
515 520 525

Ile Ser Gln Thr Leu Asn Gly Ser Glu Phe Gln Pro Leu Ala Glu Leu  
530 535 540

Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu His Ser Thr  
545 550 555 560

Ala Phe Glu Leu His Lys Leu Glu Val Leu Asp Ile Ser Ser Asn  
565 570 575

Ser His Tyr Phe Gln Ser Glu Gly Ile Thr His Met Leu Asn Phe Thr  
580 585 590

Lys Asn Leu Lys Val Leu Gln Lys Leu Met Met Asn Asp Asn Asp Ile  
595 600 605

Ser Ser Ser Thr Ser Arg Thr Met Glu Ser Glu Ser Leu Arg Thr Leu  
610 615 620

Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Glu Gly Asp Asn  
625 630 635 640

Arg Tyr Leu Gln Leu Phe Lys Asn Leu Leu Lys Leu Glu Leu Asp

	645	650	655
Ile Ser Lys Asn Ser Leu Ser Phe Leu Pro Ser Gly Val Phe Asp Gly			
660	665	670	
Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu Lys			
675	680	685	
Ser Phe Ser Trp Lys Lys Leu Gln Cys Leu Lys Asn Leu Glu Thr Leu			
690	695	700	
Asp Leu Ser His Asn Gln Leu Thr Thr Val Pro Glu Arg Leu Ser Asn			
705	710	715	720
Cys Ser Arg Ser Leu Lys Asn Leu Ile Leu Lys Asn Asn Gln Ile Arg			
725	730	735	
Ser Leu Thr Lys Tyr Phe Leu Gln Asp Ala Phe Gln Leu Arg Tyr Leu			
740	745	750	
Asp Leu Ser Ser Asn Lys Ile Gln Met Ile Gln Lys Thr Ser Phe Pro			
755	760	765	
Glu Asn Val Leu Asn Asn Leu Lys Met Leu Leu Leu His His Asn Arg			
770	775	780	
Phe Leu Cys Thr Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn His			
785	790	795	800
Thr Glu Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val Gly			
805	810	815	
Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr Thr			
820	825	830	
Cys Glu Ile Asp Leu Thr Asn Leu Ile Leu Phe Ser Leu Ser Ile Ser			
835	840	845	
Val Ser Leu Phe Leu Met Val Met Met Thr Ala Ser His Leu Tyr Phe			
850	855	860	
Trp Asp Val Trp Tyr Ile Tyr His Phe Cys Lys Ala Lys Ile Lys Gly			
865	870	875	880
Tyr Gln Arg Leu Ile Ser Pro Asp Cys Cys Tyr Asp Ala Phe Ile Val			
885	890	895	
Tyr Asp Thr Lys Asp Pro Ala Val Thr Glu Trp Val Leu Ala Glu Leu			
900	905	910	
Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys Leu			
915	920	925	
Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu Ser			
930	935	940	
Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Asp Lys			
945	950	955	960
Tyr Ala Lys Thr Glu Asn Phe Lys Ile Ala Phe Tyr Leu Ser His Gln			
965	970	975	
Arg Leu Met Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu Glu			

980	985	990
Lys Pro Phe Gln Lys Ser Lys Phe	Leu Gln Leu Arg Lys	Arg Leu Cys
995	1000	1005
Gly Ser Ser Val Leu Glu Trp Pro Thr Asn Pro Gln Ala His Pro		
1010	1015	1020
Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Ala Thr Asp Asn His		
1025	1030	1035
Val Ala Tyr Ser Gln Val Phe Lys Glu Thr Val		
1040	1045	

<210> 38  
<211> 3243  
<212> DNA  
<213> murine

<400> 38	60
attctcctcc accagacctc ttgattccat tttgaaaagaa aactgaaaat ggtgtttcg	120
atgtggacac ggaagagaca aattttgatc tttttaata tgctcttagt ttcttagatc	180
tttgggttcc gatgggttcc taaaactcta ctttgtgaag taaaagtaaa tatcccagag	240
gcccatgtga tcgtggactg cacagacaag catttgacag aaatccctga gggcattccc	300
actaacacca ccaatcttac cttaccatc aaccacatac caagcatctc tccagattcc	360
ttccgtaggc tgaaccatct ggaagaaaatc gatattaatg gcaattgtgt acctgttcta	420
ctggggtcca aagccaatgt gtgtaccaag aggctgcaga tttagacctgg aagcttttagt	480
ggactctctg actaaaagc cctttacctg gatggaaacc aacttctgga gataccacag	540
gatctgccat ccagcttaca tcttctgagc cttgaggcta acaacatctt ctccatcacg	600
aaggagaatc taacagaact ggtcaacatt gaaacactct acctgggtca aaactgttat	660
tatcgaaaatc ttgcataatgt ttcctattct attgaaaaag atgcttcct agttatgaga	720
aatttgaagg ttctctcaact aaaagataac aatgtcacag ctgtccccac cactttgcca	780
cctaatttac tagagctcta tctttataac aatatcatta agaaaatcca agaaaatgat	840
ttaataacc tcaatgagtt gcaagtctt gacctaagt gaaattgcc tcgatgttat	900
aatgtcccat atccgtgtac accgtgtcaa aataattccc cttacagat ccatgacaat	960
gtttcaatt cattgacaga attaaaagtt ttacgtttac acagtaatc tcttcagcat	1020
ttggattttt cttaattta tgagctgcag gtctaccatg catctataac tttaccacat	1080
tcactctctt cattggaaaa cttgaaaatt ctgcgtgtca aggggtatgt cttaaaagag	1140
ctgaaaaact ccagtcttc tgtattgcac aagttccca ggctggaagt tcttgacctt	1200
	1260

ggcactaact tcataaaaat tgctgaccc tc acatattca aacatttga aaaccca ctcatagacc ttcagtcaa taagatatct cttcagaag agtcaagaga agttgg 1320
1380
tgtcctaatg ctcaaaacttc tgttagaccgt catgggcccc aggtccttga ggccttacac tatccgat acgatgaata tgcacggagc tgcaggttca aaaacaaaga gccaccc 1440
1500
ttctgcctt tgaatgcaga ctgccacata tatggcaga ccttagactt aagttagaaat aacatatttt ttattaaacc ttctgatttt cagcatctt cattcctcaa atgcctcaac 1560
1620
ttatcaggaa acaccattgg ccaaactctt aatggcagtg aactctggcc gttgagagag ttgcgtact tagacttctc caacaaccgg cttagattac tctactcaac agcctt 1680
1740
gagctccaga gtcttgaagt tctggatcta agtagtaaca gccactattt tcaagcagaa ggaattactc acatgctaaa ctttaccaag aaattacggc ttctggacaa actcatgatg 1800
1860
aatgataatg acatctctac ttccggccagc aggaccatgg aaagtgactc tcttcgaatt ctggagttca gaggcaacca ttttagatgtt ctatggagag ccggtgataa cagatactt 1920
1980
gacttcttca agaatttgtt caattttagag gtatttagata tctccagaaaa ttccctgaat tccttcctc ctgagggttt tgagggtatg ccggccaaatc taaaagatct ctccctggcc 2040
2100
aaaaatgggc tcaaattttt cttttggac agactccagt tactgaagca tttggaaatt ttggacctca gccataacca gctgacaaaa gtacctgaga gattggccaa ctgttccaaa 2160
2220
agtctcacaa cactgattct taagcataat caaatcaggc aattgacaaa atattttcta gaagatgctt tgcaattgct ctatctagac atcagttcaa ataaaatcca ggtcattcag 2280
2340
aagactagct tcccagaaaa tgtcctcaac aatctggaga ttttggtttt acatcacaat cgctttcttt gcaactgtga tgctgtgtgg tttgtctggt gggtaacca tacagatgtt 2400
2460
actattccat acctggccac tgatgtgact tgtgttaggtc caggagcaca caaaggtcaa agtgtcatat cccttgatct gtatacgtgt gagttagatc tcacaaacct gattctgttc 2520
2580
tcagtttcca tatcatcagt ccttttctt atggtagtta tgacaacaag tcacctttt ttctggata tgtggtacat ttattttt tggaaagcaa agataaaggg gtatcagcat 2640
2700
ctgcaatcca tggagtctt ttagatgct tttattgtgt atgacactaa aaactcagct gtgacagaat gggtttgca ggagctggtg gcaaaattgg aagatccaag agaaaaacac 2760
2820
ttcaatttgt gtctagaaga aagagactgg ctaccaggac agccagttct agaaaacctt tcccagagca tacagctcag caaaaagaca gtgtttgtga tgacacagaa atatgctaag 2880
2940
actgagagtt ttaagatggc attttatgg tctcatcaga ggctccttga tgaaaaagt gatgtgatta tcttgatatt cttggaaaag cctcttcaga agtctaagtt tcttcagctc 3000
3060
aggaagagac tctgcaggag ctctgtcctt gagtggcctg caaatccaca ggctcaccca tacttctggc agtgcctgaa aaatgcctg accacagaca atcatgtggc ttatagtcaa 3120
3180

atgttcaagg aaacagtcta gctctctgaa gaatgtcacc acctaggaca tgccttgaat	3240
cga	3243
<210> 39	
<211> 3747	
<212> DNA	
<213> murine	
<400> 39	
gagctcaaag gctctgcgag ttcgggttt ctgttgccct ctctctgtct cagaggactc	60
catctataga accactctat gccttcaaga aagatgtcct tggctccctt ctcaggatga	120
tcctggccta tctctgactc ttttctccctc caccagacct cttgattcca ttttgaaaaga	180
aaactgaaaa tgggttttc gatgtggaca cggaagagac aaattttgat ctttttaaat	240
atgctcttag tttctagagt ctttgggttt cgtgggttc ctaaaaactct accttgtgaa	300
gttaaagtaa atatcccaga ggcggatgtg atcggtggact gcacagacaa gcatttgaca	360
gaaatccctg agggcattcc cactaacacc accaatctt cccttaccat caaccacata	420
ccaagcatct ctccagattc cttccgttagg ctgaaccatc tggaagaaat cgatttaaga	480
tgcaattgtg tacctgttct actggggtcc aaagccaatg tgtgtaccaa gaggctgcag	540
attagacctg gaagctttag tggactctct gactttaaag ccctttaccc ggtatggaaac	600
caacttctgg agataccaca ggtatctgcca tccagcttac atcttctgag ccttgaggct	660
aacaacatct tctccatcac gaaggagaat ctaacagaac tggtcaacat tgaaacactc	720
tacctgggtc aaaactgtta ttatcgaaat ctttgcaatg tttccttattc tattaaaaaa	780
gatgctttcc tagttatgag aaatttgaag gttctctcac taaaagataa caatgtcaca	840
gctgtccccca ccactttgcc acctaattta ctagagctct atctttataa caatatcatt	900
aagaaaatcc aagaaaatga ttttaataac ctaaatgagt tgcaagttct tgacttaagt	960
ggaaattgcc ctcgatgtta taatgtccccca tatccgtgtta caccgtgtga aaataattcc	1020
cccttacaga tccatgacaa tgctttcaat tcattgacag aattaaaaagt tttacgttta	1080
cacagtaatt ctcttcagca tgtgccccca acatggttta aaaacatgag aaacctccag	1140
gaactagacc tctccaaaaa ctacttggcc agagaaaattg aggaggccaa atttttgcatt	1200
tttcttccca accttggatgttga gttggatttt tctttcaatt atgagctgca ggtctaccat	1260
gcatactataa ctttaccaca ttcaactctct tcattggaaa acttgaaaat tctgcgtgtc	1320
aaggggtatg tctttaaaga gctgaaaaac tccagttttt ctgtattgca caagcttccc	1380
aggctgaaag ttcttgaccc tggcactaac ttcataaaaa ttgctgaccc caacatattc	1440
aaacattttg aaaacctcaa actcatagac ctttcagtga ataagatatc tccttcagaa	1500

gagtcaagag aagttggctt ttgtcctaat gctcaaactt ctgttagaccg tcatgggcc	1560
caggtccttg aggccttaca ctatttcga tacgatgaat atgcacggag ctgcagggtc	1620
aaaaacaaag agccacccctc tttcttgccc ttgaatgcag actgccacat atatggcag	1680
accttagact taagtagaaa taacatattt tttattaaac cttctgattt tcagcatctt	1740
tcattcctca aatgcctcaa cttatcagga aacaccattt gccaaactct taatggcagt	1800
gaactctggc cggtgagaga gttcggtac ttagacttct ccaacaaccg gtttggat	1860
ctctactcaa cagccttga agagctccag agtcttgaag ttctggatct aagtagtaac	1920
agccactatt ttcaaggcaga aggaattact cacatgctaa actttaccaa gaaattacgg	1980
cttctggaca aactcatgat gaatgataat gacatctcta cttcgccag caggaccatg	2040
gaaagtgact ctcttcgaat tctggagttc agaggcaacc atttagatgt tctatggaga	2100
gccggtgata acagataactt ggacttcttc aagaatttgt tcaatttgc ggtattagat	2160
atctccagaa attccctgaa ttccctgcct cctgagggtt ttgagggtat gccgccaat	2220
ctaaagaatc tctccttggc caaaaatggg ctcaaatttt tcttttggg cagactccag	2280
ttactgaagc atttggaaat tttggacctc agccataacc agctgacaaa agtacctgag	2340
agattggcca actgttccaa aagtctcaca acactgattt ttaagcataa tcaaattcagg	2400
caattgacaa aatattttct agaagatgct ttgcaattgc gctatctaga catcagttca	2460
aataaaatcc aggtcattca gaagactagc ttcccagaaa atgtcctcaa caatctggag	2520
atgttggttt tacatcacaa tcgctttctt tgcaactgtg atgctgtgtg gtttgtctgg	2580
tgggttaacc atacagatgt tactattcca tacctggcca ctgatgtgac ttgtgttaggt	2640
ccaggagcac acaaaggtaa aagtgtcata tcccttgatc tgtatacgtg tgagtttagat	2700
ctcacaacc tgattctgtt ctcagttcc atatcatcag tcctcttct tatggtagtt	2760
atgacaacaa gtcacccctt tttctggat atgtggtaca tttattttt ttggaaagca	2820
aagataaagg ggtatcagca tctgcaatcc atggagtctt gttatgtgc ttttattgtg	2880
tatgacacta aaaactcagc tgtgacagaa tgggtttgc aggagctggt ggcaaaattt	2940
gaagatccaa gagaaaaaca cttcaatttg tgtctagaag aaagagactg gctaccagga	3000
cagccagttc tagaaaacct ttcccagagc atacagctca gcaaaaagac agtgtttgtg	3060
atgacacaga aatatgtcaa gactgagagt tttaagatgg catttttattt gtctcatcag	3120
aggctctgg atgaaaaagt ggatgtgatt atcttgatat tcttggaaaa gcctcttcag	3180
aagtctaagt ttcttcagct caggaagaga ctctgcagga gctctgtcct tgagtggcct	3240
gcaaatccac aggctcaccc atacttctgg cagtgccctga aaaatgcctt gaccacagac	3300
aatcatgtgg cttatagtca aatgttcaag gaaacagtct agtctctga agaatgtcac	3360
cacctaggac atgccttggtt acctgaagtt ttccataaagg ttccataaaa tgaaggcttg	3420

aatttttcct aacagttgtc atggctcaga ttgggtggaa atcatcaata tatggctaag	3480
aaattaagaa ggggagactg atagaagata atttctttct tcatgtgcc a tgctcagtt	3540
aatatttccc ctagctcaaa tctgaaaaac tgtgcctagg agacaacaca aggctttgat	3600
ttatctgcat acaattgata agagcccacac atctgccctg aagaagtact agtagttta	3660
gtagtagggt aaaaattaca caagctttct ctctctctga tactgaactg taccagagtt	3720
caatgaaata aaagccccaga gaacttc	3747

<210> 40  
<211> 3449  
<212> DNA  
<213> murine

<400> 40  
gcgagtctcg gtttctgtt gccttctc tgcgttcagag gactccatct atagaaccac 60  
tctatgcctt caagaaaat gtccttggtt cccttctcag gatgtatcctg gcctatctct 120  
gactctcttc tcctccacca gacctcttga ttccatTTTaaagaaaaact gaaaatggtg 180  
tttgcgtgt ggacacggaa gagacaaaatt ttgatctttt taaatatgct ctttagttct 240  
agagtctttg ggttcgtat gtttcctaaa actctacctt gtgaagttaa agtaaatatc 300  
ccagaggccc atgtgatcgt ggactgcaca gacaagcatt tgacagaaaat ccctgagggc 360  
atccccacta acaccaccaa tcttaccctt accatcaacc acataccaag catctctcca 420  
gattccttcc gtaggctgaa ccatctggaa gaaatcgatt taagatgcaa ttgtgtacct 480  
gttctactgg ggtccaaagc caatgtgtgt accaagaggc tgcagattag acctgaaagc 540  
tttagtggac tctctgactt aaaagccctt tacctggatg gaaaccaact tctggagata 600  
ccacaggatc tgccatccag cttacatctt ctgagccttg aggctaacaa catctctcc 660  
atcacgaagg agaatctaac agaactggtc aacattgaaa cactctacct gggtaaaaac 720  
tgttattatc gaaatccttg caatgtttcc tattctattt gaaaagatgc ttccctagtt 780  
atgagaaaatt tgaaggttct ctcactaaaa gataacaatg tcacagctgt ccccaccact 840  
ttgccaccta atttactaga gctctatctt tataacaata tcattaagaa aatccaagaa 900  
aatgatttta ataacctcaa tgagttgcaa gttcttgacc taagtggaaa ttgcctcga 960  
tgttataatg tccccatccatcc gtgtacacccg tgtggaaaata attccccctt acagatccat 1020  
gacaatgctt tcaattcatt gacagaattt aaagttttac gtttacacag taattctctt 1080  
cagcatgtgc ccccaacatg gttaaaaac atgagaaaacc tccaggaact agacctctcc 1140  
caaaaactact tggccagaga aattgaggag gccaaatTTTtgcattttct tcccaacctt 1200  
gttgagttgg attttttttt caattatgag ctgcaggatc accatgcac tataacttta 1260

ccacattcac tcttccatt ggaaaacttg aaaattctgc gtgtcaaggg gtatgtcttt 1320  
 aaagagctga aaaactccag tcttcgtta ttgcacaagc ttcccaggct ggaagttctt 1380  
 gaccttggca ctaacttcat aaaaattgct gacctaaca tattcaaaca ttttggaaac 1440  
 ctcaaactca tagacctttc agtgaataag atatctcatt cagaagagtc aagagaagtt 1500  
 ggctttgtc ctaatgctca aacttctgtta gaccgtcatg ggccccaggc ccttgaggcc 1560  
 ttacactatt tccgatacga tgaatatgca cggagctgca ggttcaaaaa caaagagcca 1620  
 cttctttct tgcctttgaa tgcagactgc cacatatacg ggcagacctt agacttaagt 1680  
 agaaataaca tatttttat taaaccttct gatttcagc atcttcatt cctcaaatgc 1740  
 ctcaacttat cagggaaacac cattggccaa actcttaatg gcagtgaact ctggccgttg 1800  
 agagagttgc ggtacttaga cttctccaac aaccggcttg atttactcta ctcaacagcc 1860  
 tttgaagagc tccagagtct tgaagttctg gatctaagta gtaacagcca ctattttcaa 1920  
 gcagaaggaa ttactcacaat gctaaacttt accaagaaat tacggcttct ggacaaactc 1980  
 atgatgaatg ataatgacat ctctacttgc gccagcagga ccatggaaag tgactcttt 2040  
 cgaattctgg agttcagagg caaccattta gatgttctat ggagagccgg tgataacaga 2100  
 tacttggact tcttcaagaa tttgttcaat ttagaggtat tagatatctc cagaaattcc 2160  
 ctgaattcct tgcctcctga ggttttgag ggtatgccgc caaatctaaa gaatctctcc 2220  
 ttggccaaaa atgggcctcaa atctttctt tggcacagac tccagttact gaagcatttg 2280  
 gaaattttgg acctcagcca taaccagctg acaaaaagtac ctgagagatt ggccaactgt 2340  
 tccaaaagtc tcacaacact gattcttaag cataatcaa tcaggcaatt gacaaaatat 2400  
 tttctagaag atgctttgca attgcgtat cttagacatca gttcaaaataa aatccaggc 2460  
 attcagaaga cttagttccc agaaaatgtc ctcaacaatc tggagatgtt ggttttacat 2520  
 cacaatcgct ttcttgcaa ctgtgatgct gtgtggtttgc tctgggtgggt taaccataca 2580  
 gatgttacta ttccataacct ggccactgat gtgacttgtg taggtccagg agcacacaaaa 2640  
 ggtcaaagtg tcatatccct tgatctgtat acgtgtgagt tagatctcac aaacctgatt 2700  
 ctgttctcag tttccatatac atcagtcctc tttcttatgg tagttatgac aacaagtcac 2760  
 ctcttttct gggatatgtg gtacatttat tattttggaa aagcaaagat aaaggggtat 2820  
 cagcatctgc aatccatggaa gtcttggat gatgcttttgc ttgtgtatgaa cactaaaaac 2880  
 tcagctgtga cagaatgggt tttgcaggag ctggtggccaa aattggaaaga tccaaagagaa 2940  
 aaacacttca atttgtgtct agaagaaaaga gactggctac caggacagcc agttctagaa 3000  
 aacctttccc agagcataca gctcagcaaa aagacagtgt ttgtgtatgac acagaaatat 3060  
 gctaagactg agagttttaa gatggcattt tatttgcattc atcagaggct cctggatgaa 3120  
 aaagtggatg tgattatctt gatattcttgc gaaaagcctc ttcagaagtc taagtttctt 3180

cagctcagga agagactctg caggagctct gtccttgagt ggcctgcaaa tccacaggct	3240
caccatact tctggcagtg cctgaaaaat gccctgacca cagacaatca tgtggcttat	3300
agtcaaatgt tcaaggaaac agtctagctc tctgaagaat gtcaccacct aggacatgcc	3360
ttggcacctg aagtttcat aaaggttcc ataaatgaag gtctgaattt ttcctaacag	3420
ttgtcatggc tcagatttgtt gggaaatca	3449

<210> 41  
<211> 1050  
<212> PRT  
<213> murine  
  
<400> 41

Met Val Phe Ser Met Trp Thr Arg Lys Arg Gln Ile Leu Ile Phe Leu			
1	5	10	15
10	15		

Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys			
20	25	30	
30			

Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile			
35	40	45	
45			

Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro			
50	55	60	
60			

Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Ser Ile			
65	70	75	80
75	80		

Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu			
85	90	95	
95			

Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys			
100	105	110	
110			

Thr Lys Arg Leu Gln Ile Arg Pro Gly Ser Phe Ser Gly Leu Ser Asp			
115	120	125	
125			

Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln			
130	135	140	
140			

Asp Leu Pro Ser Ser Leu His Leu Leu Ser Leu Glu Ala Asn Asn Ile			
145	150	155	160
155	160		

Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr			
165	170	175	
175			

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Asn Val Ser			
180	185	190	
190			

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val			
195	200	205	
205			

Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro			
210	215	220	
220			

Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile	
---	--

225                    230                    235                    240  
 Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp Leu  
 245                    250                    255  
  
 Ser Gly Asn Cys Pro Arg Cys Tyr Asn Val Pro Tyr Pro Cys Thr Pro  
 260                    265                    270  
  
 Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn Ser  
 275                    280                    285  
  
 Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
 290                    295                    300  
  
 Val Pro Pro Thr Trp Phe Lys Asn Met Arg Asn Leu Gln Glu Leu Asp  
 305                    310                    315                    320  
  
 Leu Ser Gln Asn Tyr Leu Ala Arg Glu Ile Glu Glu Ala Lys Phe Leu  
 325                    330                    335  
  
 His Phe Leu Pro Asn Leu Val Glu Leu Asp Phe Ser Phe Asn Tyr Glu  
 340                    345                    350  
  
 Leu Gln Val Tyr His Ala Ser Ile Thr Leu Pro His Ser Leu Ser Ser  
 355                    360                    365  
  
 Leu Glu Asn Leu Lys Ile Leu Arg Val Lys Gly Tyr Val Phe Lys Glu  
 370                    375                    380  
  
 Leu Lys Asn Ser Ser Leu Ser Val Leu His Lys Leu Pro Arg Leu Glu  
 385                    390                    395                    400  
  
 Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asp Leu Asn Ile  
 405                    410                    415  
  
 Phe Lys His Phe Glu Asn Leu Lys Leu Ile Asp Leu Ser Val Asn Lys  
 420                    425                    430  
  
 Ile Ser Pro Ser Glu Glu Ser Arg Glu Val Gly Phe Cys Pro Asn Ala  
 435                    440                    445  
  
 Gln Thr Ser Val Asp Arg His Gly Pro Gln Val Leu Glu Ala Leu His  
 450                    455                    460  
  
 Tyr Phe Arg Tyr Asp Glu Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
 465                    470                    475                    480  
  
 Glu Pro Pro Ser Phe Leu Pro Leu Asn Ala Asp Cys His Ile Tyr Gly  
 485                    490                    495  
  
 Gln Thr Leu Asp Leu Ser Arg Asn Asn Ile Phe Phe Ile Lys Pro Ser  
 500                    505                    510  
  
 Asp Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn  
 515                    520                    525  
  
 Thr Ile Gly Gln Thr Leu Asn Gly Ser Glu Leu Trp Pro Leu Arg Glu  
 530                    535                    540  
  
 Leu Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu Tyr Ser  
 545                    550                    555                    560  
  
 Thr Ala Phe Glu Glu Leu Gln Ser Leu Glu Val Leu Asp Leu Ser Ser

565                    570                    575  
Asn Ser His Tyr Phe Gln Ala Glu Gly Ile Thr His Met Leu Asn Phe  
580                    585                    590

Thr Lys Lys Leu Arg Leu Leu Asp Lys Leu Met Met Asn Asp Asn Asp  
595                    600                    605

Ile Ser Thr Ser Ala Ser Arg Thr Met Glu Ser Asp Ser Leu Arg Ile  
610                    615                    620

Leu Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Ala Gly Asp  
625                    630                    635                    640

Asn Arg Tyr Leu Asp Phe Phe Lys Asn Leu Phe Asn Leu Glu Val Leu  
645                    650                    655

Asp Ile Ser Arg Asn Ser Leu Asn Ser Leu Pro Pro Glu Val Phe Glu  
660                    665                    670

Gly Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu  
675                    680                    685

Lys Ser Phe Phe Trp Asp Arg Leu Gln Leu Leu Lys His Leu Glu Ile  
690                    695                    700

Leu Asp Leu Ser His Asn Gln Leu Thr Lys Val Pro Glu Arg Leu Ala  
705                    710                    715                    720

Asn Cys Ser Lys Ser Leu Thr Thr Leu Ile Leu Lys His Asn Gln Ile  
725                    730                    735

Arg Gln Leu Thr Lys Tyr Phe Leu Glu Asp Ala Leu Gln Leu Arg Tyr  
740                    745                    750

Leu Asp Ile Ser Ser Asn Lys Ile Gln Val Ile Gln Lys Thr Ser Phe  
755                    760                    765

Pro Glu Asn Val Leu Asn Asn Leu Glu Met Leu Val Leu His His Asn  
770                    775                    780

Arg Phe Leu Cys Asn Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn  
785                    790                    795                    800

His Thr Asp Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val  
805                    810                    815

Gly Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr  
820                    825                    830

Thr Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Val Ser Ile  
835                    840                    845

Ser Ser Val Leu Phe Leu Met Val Val Met Thr Thr Ser His Leu Phe  
850                    855                    860

Phe Trp Asp Met Trp Tyr Ile Tyr Tyr Phe Trp Lys Ala Lys Ile Lys  
865                    870                    875                    880

Gly Tyr Gln His Leu Gln Ser Met Glu Ser Cys Tyr Asp Ala Phe Ile  
885                    890                    895

Val Tyr Asp Thr Lys Asn Ser Ala Val Thr Glu Trp Val Leu Gln Glu

900                    905                    910  
Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys  
915                    920                    925

Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu  
930                    935                    940

Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln  
945                    950                    955                    960

Lys Tyr Ala Lys Thr Glu Ser Phe Lys Met Ala Phe Tyr Leu Ser His  
965                    970                    975

Gln Arg Leu Leu Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu  
980                    985                    990

Glu Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu  
995                    1000                    1005

Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His  
1010                    1015                    1020

Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn  
1025                    1030                    1035

His Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val  
1040                    1045                    1050

&lt;210&gt; 42

&lt;211&gt; 1050

&lt;212&gt; PRT

&lt;213&gt; murine

&lt;400&gt; 42

Met Val Phe Ser Met Trp Thr Arg Lys Arg Gln Ile Leu Ile Phe Leu  
1                    5                    10                    15

Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys  
20                    25                    30

Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile  
35                    40                    45

Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro  
50                    55                    60

Thr Asn Thr Thr Asn Leu Thr Ile Asn His Ile Pro Ser Ile  
65                    70                    75                    80

Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu  
85                    90                    95

Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys  
100                    105                    110

Thr Lys Arg Leu Gln Ile Arg Pro Gly Ser Phe Ser Gly Leu Ser Asp  
115                    120                    125

Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
130                    135                    140

Asp Leu Pro Ser Ser Leu His Leu Leu Ser Leu Glu Ala Asn Asn Ile  
 145 150 155 160  
 Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr  
 165 170 175  
 Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Asn Val Ser  
 180 185 190  
 Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val  
 195 200 205  
 Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro  
 210 215 220  
 Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile  
 225 230 235 240  
 Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp Leu  
 245 250 255  
 Ser Gly Asn Cys Pro Arg Cys Tyr Asn Val Pro Tyr Pro Cys Thr Pro  
 260 265 270  
 Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn Ser  
 275 280 285  
 Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
 290 295 300  
 Val Pro Pro Thr Trp Phe Lys Asn Met Arg Asn Leu Gln Glu Leu Asp  
 305 310 315 320  
 Leu Ser Gln Asn Tyr Leu Ala Arg Glu Ile Glu Glu Ala Lys Phe Leu  
 325 330 335  
 His Phe Leu Pro Asn Leu Val Glu Leu Asp Phe Ser Phe Asn Tyr Glu  
 340 345 350  
 Leu Gln Val Tyr His Ala Ser Ile Thr Leu Pro His Ser Leu Ser Ser  
 355 360 365  
 Leu Glu Asn Leu Lys Ile Leu Arg Val Lys Gly Tyr Val Phe Lys Glu  
 370 375 380  
 Leu Lys Asn Ser Ser Leu Ser Val Leu His Lys Leu Pro Arg Leu Glu  
 385 390 395 400  
 Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asp Leu Asn Ile  
 405 410 415  
 Phe Lys His Phe Glu Asn Leu Lys Leu Ile Asp Leu Ser Val Asn Lys  
 420 425 430  
 Ile Ser Pro Ser Glu Glu Ser Arg Glu Val Gly Phe Cys Pro Asn Ala  
 435 440 445  
 Gln Thr Ser Val Asp Arg His Gly Pro Gln Val Leu Glu Ala Leu His  
 450 455 460  
 Tyr Phe Arg Tyr Asp Glu Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys

465	470	475	480
Glu Pro Pro Ser Phe Leu Pro Leu Asn Ala Asp Cys His Ile Tyr Gly			
485		490	495
Gln Thr Leu Asp Leu Ser Arg Asn Asn Ile Phe Phe Ile Lys Pro Ser			
500	505		510
Asp Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn			
515	520	525	
Thr Ile Gly Gln Thr Leu Asn Gly Ser Glu Leu Trp Pro Leu Arg Glu			
530	535	540	
Leu Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu Tyr Ser			
545	550	555	560
Thr Ala Phe Glu Glu Leu Gln Ser Leu Glu Val Leu Asp Leu Ser Ser			
565	570	575	
Asn Ser His Tyr Phe Gln Ala Glu Gly Ile Thr His Met Leu Asn Phe			
580	585	590	
Thr Lys Lys Leu Arg Leu Leu Asp Lys Leu Met Met Asn Asp Asn Asp			
595	600	605	
Ile Ser Thr Ser Ala Ser Arg Thr Met Glu Ser Asp Ser Leu Arg Ile			
610	615	620	
Leu Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Ala Gly Asp			
625	630	635	640
Asn Arg Tyr Leu Asp Phe Phe Lys Asn Leu Phe Asn Leu Glu Val Leu			
645	650	655	
Asp Ile Ser Arg Asn Ser Leu Asn Ser Leu Pro Pro Glu Val Phe Glu			
660	665	670	
Gly Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu			
675	680	685	
Lys Ser Phe Phe Trp Asp Arg Leu Gln Leu Leu Lys His Leu Glu Ile			
690	695	700	
Leu Asp Leu Ser His Asn Gln Leu Thr Lys Val Pro Glu Arg Leu Ala			
705	710	715	720
Asn Cys Ser Lys Ser Leu Thr Thr Leu Ile Leu Lys His Asn Gln Ile			
725	730	735	
Arg Gln Leu Thr Lys Tyr Phe Leu Glu Asp Ala Leu Gln Leu Arg Tyr			
740	745	750	
Leu Asp Ile Ser Ser Asn Lys Ile Gln Val Ile Gln Lys Thr Ser Phe			
755	760	765	
Pro Glu Asn Val Leu Asn Asn Leu Glu Met Leu Val Leu His His Asn			
770	775	780	
Arg Phe Leu Cys Asn Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn			
785	790	795	800
His Thr Asp Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val			

	805	810	815
Gly Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr			
	820	825	830
Thr Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Val Ser Ile			
	835	840	845
Ser Ser Val Leu Phe Leu Met Val Val Met Thr Thr Ser His Leu Phe			
	850	855	860
Phe Trp Asp Met Trp Tyr Ile Tyr Tyr Phe Trp Lys Ala Lys Ile Lys			
	865	870	875
			880
Gly Tyr Gln His Leu Gln Ser Met Glu Ser Cys Tyr Asp Ala Phe Ile			
	885	890	895
Val Tyr Asp Thr Lys Asn Ser Ala Val Thr Glu Trp Val Leu Gln Glu			
	900	905	910
Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys			
	915	920	925
Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu			
	930	935	940
Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln			
	945	950	955
			960
Lys Tyr Ala Lys Thr Glu Ser Phe Lys Met Ala Phe Tyr Leu Ser His			
	965	970	975
Gln Arg Leu Leu Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu			
	980	985	990
Glu Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu			
	995	1000	1005
Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His			
	1010	1015	1020
Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn			
	1025	1030	1035
His Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val			
	1040	1045	1050
<210> 43			
<211> 1050			
<212> PRT			
<213> murine			
<400> 43			
Met Val Phe Ser Met Trp Thr Arg Lys Arg Gln Ile Leu Ile Phe Leu			
	1	5	10
			15
Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys			
	20	25	30
Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile			
	35	40	45

Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro  
 50 55 60

Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Ser Ile  
 65 70 75 80

Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu  
 85 90 95

Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys  
 100 105 110

Thr Lys Arg Leu Gln Ile Arg Pro Gly Ser Phe Ser Gly Leu Ser Asp  
 115 120 125

Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln  
 130 135 140

Asp Leu Pro Ser Ser Leu His Leu Leu Ser Leu Glu Ala Asn Asn Ile  
 145 150 155 160

Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr  
 165 170 175

Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Asn Val Ser  
 180 185 190

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val  
 195 200 205

Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro  
 210 215 220

Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile  
 225 230 235 240

Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp Leu  
 245 250 255

Ser Gly Asn Cys Pro Arg Cys Tyr Asn Val Pro Tyr Pro Cys Thr Pro  
 260 265 270

Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn Ser  
 275 280 285

Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
 290 295 300

Val Pro Pro Thr Trp Phe Lys Asn Met Arg Asn Leu Gln Glu Leu Asp  
 305 310 315 320

Leu Ser Gln Asn Tyr Leu Ala Arg Glu Ile Glu Glu Ala Lys Phe Leu  
 325 330 335

His Phe Leu Pro Asn Leu Val Glu Leu Asp Phe Ser Phe Asn Tyr Glu  
 340 345 350

Leu Gln Val Tyr His Ala Ser Ile Thr Leu Pro His Ser Leu Ser Ser  
 355 360 365

Leu Glu Asn Leu Lys Ile Leu Arg Val Lys Gly Tyr Val Phe Lys Glu

370                   375                   380  
Leu Lys Asn Ser Ser Leu Ser Val Leu His Lys Leu Pro Arg Leu Glu  
385                   390                   395                   400

Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asp Leu Asn Ile  
405                   410                   415

Phe Lys His Phe Glu Asn Leu Lys Leu Ile Asp Leu Ser Val Asn Lys  
420                   425                   430

Ile Ser Pro Ser Glu Glu Ser Arg Glu Val Gly Phe Cys Pro Asn Ala  
435                   440                   445

Gln Thr Ser Val Asp Arg His Gly Pro Gln Val Leu Glu Ala Leu His  
450                   455                   460

Tyr Phe Arg Tyr Asp Glu Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
465                   470                   475                   480

Glu Pro Pro Ser Phe Leu Pro Leu Asn Ala Asp Cys His Ile Tyr Gly  
485                   490                   495

Gln Thr Leu Asp Leu Ser Arg Asn Asn Ile Phe Phe Ile Lys Pro Ser  
500                   505                   510

Asp Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn  
515                   520                   525

Thr Ile Gly Gln Thr Leu Asn Gly Ser Glu Leu Trp Pro Leu Arg Glu  
530                   535                   540

Leu Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu Tyr Ser  
545                   550                   555                   560

Thr Ala Phe Glu Glu Leu Gln Ser Leu Glu Val Leu Asp Leu Ser Ser  
565                   570                   575

Asn Ser His Tyr Phe Gln Ala Glu Gly Ile Thr His Met Leu Asn Phe  
580                   585                   590

Thr Lys Lys Leu Arg Leu Leu Asp Lys Leu Met Met Asn Asp Asn Asp  
595                   600                   605

Ile Ser Thr Ser Ala Ser Arg Thr Met Glu Ser Asp Ser Leu Arg Ile  
610                   615                   620

Leu Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Ala Gly Asp  
625                   630                   635                   640

Asn Arg Tyr Leu Asp Phe Phe Lys Asn Leu Phe Asn Leu Glu Val Leu  
645                   650                   655

Asp Ile Ser Arg Asn Ser Leu Asn Ser Leu Pro Pro Glu Val Phe Glu  
660                   665                   670

Gly Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu  
675                   680                   685

Lys Ser Phe Phe Trp Asp Arg Leu Gln Leu Leu Lys His Leu Glu Ile  
690                   695                   700

Leu Asp Leu Ser His Asn Gln Leu Thr Lys Val Pro Glu Arg Leu Ala

705	710	715	720
Asn Cys Ser Lys Ser Leu Thr Thr Leu Ile Leu Lys His Asn Gln Ile			
725	730	735	
Arg Gln Leu Thr Lys Tyr Phe Leu Glu Asp Ala Leu Gln Leu Arg Tyr			
740	745	750	
Leu Asp Ile Ser Ser Asn Lys Ile Gln Val Ile Gln Lys Thr Ser Phe			
755	760	765	
Pro Glu Asn Val Leu Asn Asn Leu Glu Met Leu Val Leu His His Asn			
770	775	780	
Arg Phe Leu Cys Asn Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn			
785	790	795	800
His Thr Asp Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val			
805	810	815	
Gly Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr			
820	825	830	
Thr Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Val Ser Ile			
835	840	845	
Ser Ser Val Leu Phe Leu Met Val Val Met Thr Thr Ser His Leu Phe			
850	855	860	
Phe Trp Asp Met Trp Tyr Tyr Phe Trp Lys Ala Lys Ile Lys			
865	870	875	880
Gly Tyr Gln His Leu Gln Ser Met Glu Ser Cys Tyr Asp Ala Phe Ile			
885	890	895	
Val Tyr Asp Thr Lys Asn Ser Ala Val Thr Glu Trp Val Leu Gln Glu			
900	905	910	
Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys			
915	920	925	
Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu			
930	935	940	
Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln			
945	950	955	960
Lys Tyr Ala Lys Thr Glu Ser Phe Lys Met Ala Phe Tyr Leu Ser His			
965	970	975	
Gln Arg Leu Leu Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu			
980	985	990	
Glu Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu			
995	1000	1005	
Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His			
1010	1015	1020	
Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn			
1025	1030	1035	
His Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val			

1040 <210> 44 <211> 1050 <212> PRT <213> murine	1045	1050
 <400> 44		
Met Val Phe Ser Met Trp Thr Arg Lys Arg Gln Ile Leu Ile Phe Leu		
1	5	10      ~15
Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys		
20	25	30
Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile		
35	40	45
Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro		
50	55	60
Thr Asn Thr Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Ser Ile		
65	70	75      80
Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu		
85	90	95
Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys		
100	105	110
Thr Lys Arg Leu Gln Ile Arg Pro Gly Ser Phe Ser Gly Leu Ser Asp		
115	120	125
Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln		
130	135	140
Asp Leu Pro Ser Ser Leu His Leu Leu Ser Leu Glu Ala Asn Asn Ile		
145	150	155      160
Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr		
165	170	175
Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Asn Val Ser		
180	185	190
Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val		
195	200	205
Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro		
210	215	220
Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile		
225	230	235      240
Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp Leu		
245	250	255
Ser Gly Asn Cys Pro Arg Cys Tyr Asn Val Pro Tyr Pro Cys Thr Pro		
260	265	270
Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn Ser		
275	280	285

Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
290 295 300

Val Pro Pro Thr Trp Phe Lys Asn Met Arg Asn Leu Gln Glu Leu Asp  
305 310 315 320

Leu Ser Gln Asn Tyr Leu Ala Arg Glu Ile Glu Glu Ala Lys Phe Leu  
325 330 335

His Phe Leu Pro Asn Leu Val Glu Leu Asp Phe Ser Phe Asn Tyr Glu  
340 345 350

Leu Gln Val Tyr His Ala Ser Ile Thr Leu Pro His Ser Leu Ser Ser  
355 360 365

Leu Glu Asn Leu Lys Ile Leu Arg Val Lys Gly Tyr Val Phe Lys Glu  
370 375 380

Leu Lys Asn Ser Ser Leu Ser Val Leu His Lys Leu Pro Arg Leu Glu  
385 390 395 400

Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asp Leu Asn Ile  
405 410 415

Phe Lys His Phe Glu Asn Leu Lys Leu Ile Asp Leu Ser Val Asn Lys  
420 425 430

Ile Ser Pro Ser Glu Glu Ser Arg Glu Val Gly Phe Cys Pro Asn Ala  
435 440 445

Gln Thr Ser Val Asp Arg His Gly Pro Gln Val Leu Glu Ala Leu His  
450 455 460

Tyr Phe Arg Tyr Asp Glu Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
465 470 475 480

Glu Pro Pro Ser Phe Leu Pro Leu Asn Ala Asp Cys His Ile Tyr Gly  
485 490 495

Gln Thr Leu Asp Leu Ser Arg Asn Asn Ile Phe Phe Ile Lys Pro Ser  
500 505 510

Asp Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn  
515 520 525

Thr Ile Gly Gln Thr Leu Asn Gly Ser Glu Leu Trp Pro Leu Arg Glu  
530 535 540

Leu Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu Tyr Ser  
545 550 555 560

Thr Ala Phe Glu Glu Leu Gln Ser Leu Glu Val Leu Asp Leu Ser Ser  
565 570 575

Asn Ser His Tyr Phe Gln Ala Glu Gly Ile Thr His Met Leu Asn Phe  
580 585 590

Thr Lys Lys Leu Arg Leu Leu Asp Lys Leu Met Met Asn Asp Asn Asp  
595 600 605

Ile Ser Thr Ser Ala Ser Arg Thr Met Glu Ser Asp Ser Leu Arg Ile

610	615	620
Leu Glu Phe Arg Gly Asn His Leu Asp Val	Leu Trp Arg Ala Gly Asp	
625	630	635
Asn Arg Tyr Leu Asp Phe Phe Lys Asn Leu Phe Asn Leu Glu Val Leu		
645	650	655
Asp Ile Ser Arg Asn Ser Leu Asn Ser Leu Pro Pro Glu Val Phe Glu		
660	665	670
Gly Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu		
675	680	685
Lys Ser Phe Phe Trp Asp Arg Leu Gln Leu Leu Lys His Leu Glu Ile		
690	695	700
Leu Asp Leu Ser His Asn Gln Leu Thr Lys Val Pro Glu Arg Leu Ala		
705	710	715
Asn Cys Ser Lys Ser Leu Thr Thr Leu Ile Leu Lys His Asn Gln Ile		
725	730	735
Arg Gln Leu Thr Lys Tyr Phe Leu Glu Asp Ala Leu Gln Leu Arg Tyr		
740	745	750
Leu Asp Ile Ser Ser Asn Lys Ile Gln Val Ile Gln Lys Thr Ser Phe		
755	760	765
Pro Glu Asn Val Leu Asn Asn Leu Glu Met Leu Val Leu His His Asn		
770	775	780
Arg Phe Leu Cys Asn Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn		
785	790	795
His Thr Asp Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val		
805	810	815
Gly Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr		
820	825	830
Thr Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Val Ser Ile		
835	840	845
Ser Ser Val Leu Phe Leu Met Val Val Met Thr Thr Ser His Leu Phe		
850	855	860
Phe Trp Asp Met Trp Tyr Ile Tyr Tyr Phe Trp Lys Ala Lys Ile Lys		
865	870	875
Gly Tyr Gln His Leu Gln Ser Met Glu Ser Cys Tyr Asp Ala Phe Ile		
885	890	895
Val Tyr Asp Thr Lys Asn Ser Ala Val Thr Glu Trp Val Leu Gln Glu		
900	905	910
Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys		
915	920	925
Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu		
930	935	940
Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln		

945	950	955	960
Lys Tyr Ala Lys Thr Glu Ser Phe Lys Met Ala Phe Tyr Leu Ser His			
965	970	975	
Gln Arg Leu Leu Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu			
980	985	990	
Glu Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu			
995	1000	1005	
Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His			
1010	1015	1020	
Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn			
1025	1030	1035	
His Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val			
1040	1045	1050	
<210> 45			
<211> 1050			
<212> PRT			
<213> murine			
<400> 45			
Met Val Phe Ser Met Trp Thr Arg Lys Arg Gln Ile Leu Ile Phe Leu			
1	5	10	15
Asn Met Leu Leu Val Ser Arg Val Phe Gly Phe Arg Trp Phe Pro Lys			
20	25	30	
Thr Leu Pro Cys Glu Val Lys Val Asn Ile Pro Glu Ala His Val Ile			
35	40	45	
Val Asp Cys Thr Asp Lys His Leu Thr Glu Ile Pro Glu Gly Ile Pro			
50	55	60	
Thr Asn Thr Asn Leu Thr Leu Thr Ile Asn His Ile Pro Ser Ile			
65	70	75	80
Ser Pro Asp Ser Phe Arg Arg Leu Asn His Leu Glu Glu Ile Asp Leu			
85	90	95	
Arg Cys Asn Cys Val Pro Val Leu Leu Gly Ser Lys Ala Asn Val Cys			
100	105	110	
Thr Lys Arg Leu Gln Ile Arg Pro Gly Ser Phe Ser Gly Leu Ser Asp			
115	120	125	
Leu Lys Ala Leu Tyr Leu Asp Gly Asn Gln Leu Leu Glu Ile Pro Gln			
130	135	140	
Asp Leu Pro Ser Ser Leu His Leu Leu Ser Leu Glu Ala Asn Asn Ile			
145	150	155	160
Phe Ser Ile Thr Lys Glu Asn Leu Thr Glu Leu Val Asn Ile Glu Thr			
165	170	175	
Leu Tyr Leu Gly Gln Asn Cys Tyr Tyr Arg Asn Pro Cys Asn Val Ser			
180	185	190	

Tyr Ser Ile Glu Lys Asp Ala Phe Leu Val Met Arg Asn Leu Lys Val  
195 200 205

Leu Ser Leu Lys Asp Asn Asn Val Thr Ala Val Pro Thr Thr Leu Pro  
210 215 220

Pro Asn Leu Leu Glu Leu Tyr Leu Tyr Asn Asn Ile Ile Lys Lys Ile  
225 230 235 240

Gln Glu Asn Asp Phe Asn Asn Leu Asn Glu Leu Gln Val Leu Asp Leu  
245 250 255

Ser Gly Asn Cys Pro Arg Cys Tyr Asn Val Pro Tyr Pro Cys Thr Pro  
260 265 270

Cys Glu Asn Asn Ser Pro Leu Gln Ile His Asp Asn Ala Phe Asn Ser  
275 280 285

Leu Thr Glu Leu Lys Val Leu Arg Leu His Ser Asn Ser Leu Gln His  
290 295 300

Val Pro Pro Thr Trp Phe Lys Asn Met Arg Asn Leu Gln Glu Leu Asp  
305 310 315 320

Leu Ser Gln Asn Tyr Leu Ala Arg Glu Ile Glu Glu Ala Lys Phe Leu  
325 330 335

His Phe Leu Pro Asn Leu Val Glu Leu Asp Phe Ser Phe Asn Tyr Glu  
340 345 350

Leu Gln Val Tyr His Ala Ser Ile Thr Leu Pro His Ser Leu Ser Ser  
355 360 365

Leu Glu Asn Leu Lys Ile Leu Arg Val Lys Gly Tyr Val Phe Lys Glu  
370 375 380

Leu Lys Asn Ser Ser Leu Ser Val Leu His Lys Leu Pro Arg Leu Glu  
385 390 395 400

Val Leu Asp Leu Gly Thr Asn Phe Ile Lys Ile Ala Asp Leu Asn Ile  
405 410 415

Phe Lys His Phe Glu Asn Leu Lys Leu Ile Asp Leu Ser Val Asn Lys  
420 425 430

Ile Ser Pro Ser Glu Glu Ser Arg Glu Val Gly Phe Cys Pro Asn Ala  
435 440 445

Gln Thr Ser Val Asp Arg His Gly Pro Gln Val Leu Glu Ala Leu His  
450 455 460

Tyr Phe Arg Tyr Asp Glu Tyr Ala Arg Ser Cys Arg Phe Lys Asn Lys  
465 470 475 480

Glu Pro Pro Ser Phe Leu Pro Leu Asn Ala Asp Cys His Ile Tyr Gly  
485 490 495

Gln Thr Leu Asp Leu Ser Arg Asn Asn Ile Phe Phe Ile Lys Pro Ser  
500 505 510

Asp Phe Gln His Leu Ser Phe Leu Lys Cys Leu Asn Leu Ser Gly Asn

515	520	525
Thr Ile Gly Gln Thr Leu Asn Gly Ser Glu Leu Trp Pro Leu Arg Glu		
530	535	540
Leu Arg Tyr Leu Asp Phe Ser Asn Asn Arg Leu Asp Leu Leu Tyr Ser		
545	550	555
560		
Thr Ala Phe Glu Glu Leu Gln Ser Leu Glu Val Leu Asp Leu Ser Ser		
565	570	575
Asn Ser His Tyr Phe Gln Ala Glu Gly Ile Thr His Met Leu Asn Phe		
580	585	590
Thr Lys Lys Leu Arg Leu Leu Asp Lys Leu Met Met Asn Asp Asn Asp		
595	600	605
Ile Ser Thr Ser Ala Ser Arg Thr Met Glu Ser Asp Ser Leu Arg Ile		
610	615	620
Leu Glu Phe Arg Gly Asn His Leu Asp Val Leu Trp Arg Ala Gly Asp		
625	630	635
640		
Asn Arg Tyr Leu Asp Phe Phe Lys Asn Leu Phe Asn Leu Glu Val Leu		
645	650	655
Asp Ile Ser Arg Asn Ser Leu Asn Ser Leu Pro Pro Glu Val Phe Glu		
660	665	670
Gly Met Pro Pro Asn Leu Lys Asn Leu Ser Leu Ala Lys Asn Gly Leu		
675	680	685
Lys Ser Phe Phe Trp Asp Arg Leu Gln Leu Leu Lys His Leu Glu Ile		
690	695	700
Leu Asp Leu Ser His Asn Gln Leu Thr Lys Val Pro Glu Arg Leu Ala		
705	710	720
Asn Cys Ser Lys Ser Leu Thr Thr Leu Ile Leu Lys His Asn Gln Ile		
725	730	735
Arg Gln Leu Thr Lys Tyr Phe Leu Glu Asp Ala Leu Gln Leu Arg Tyr		
740	745	750
Leu Asp Ile Ser Ser Asn Lys Ile Gln Val Ile Gln Lys Thr Ser Phe		
755	760	765
Pro Glu Asn Val Leu Asn Asn Leu Glu Met Leu Val Leu His His Asn		
770	775	780
Arg Phe Leu Cys Asn Cys Asp Ala Val Trp Phe Val Trp Trp Val Asn		
785	790	800
His Thr Asp Val Thr Ile Pro Tyr Leu Ala Thr Asp Val Thr Cys Val		
805	810	815
Gly Pro Gly Ala His Lys Gly Gln Ser Val Ile Ser Leu Asp Leu Tyr		
820	825	830
Thr Cys Glu Leu Asp Leu Thr Asn Leu Ile Leu Phe Ser Val Ser Ile		
835	840	845
Ser Ser Val Leu Phe Leu Met Val Val Met Thr Thr Ser His Leu Phe		

850                    855                    860  
 Phe Trp Asp Met Trp Tyr Ile Tyr Tyr Phe Trp Lys Ala Lys Ile Lys  
 865                    870                    875                    880  
  
 Gly Tyr Gln His Leu Gln Ser Met Glu Ser Cys Tyr Asp Ala Phe Ile  
 885                    890                    895  
  
 Val Tyr Asp Thr Lys Asn Ser Ala Val Thr Glu Trp Val Leu Gln Glu  
 900                    905                    910  
  
 Leu Val Ala Lys Leu Glu Asp Pro Arg Glu Lys His Phe Asn Leu Cys  
 915                    920                    925  
  
 Leu Glu Glu Arg Asp Trp Leu Pro Gly Gln Pro Val Leu Glu Asn Leu  
 930                    935                    940  
  
 Ser Gln Ser Ile Gln Leu Ser Lys Lys Thr Val Phe Val Met Thr Gln  
 945                    950                    955                    960  
  
 Lys Tyr Ala Lys Thr Glu Ser Phe Lys Met Ala Phe Tyr Leu Ser His  
 965                    970                    975  
  
 Gln Arg Leu Leu Asp Glu Lys Val Asp Val Ile Ile Leu Ile Phe Leu  
 980                    985                    990  
  
 Glu Lys Pro Leu Gln Lys Ser Lys Phe Leu Gln Leu Arg Lys Arg Leu  
 995                    1000                    1005  
  
 Cys Arg Ser Ser Val Leu Glu Trp Pro Ala Asn Pro Gln Ala His  
 1010                    1015                    1020  
  
 Pro Tyr Phe Trp Gln Cys Leu Lys Asn Ala Leu Thr Thr Asp Asn  
 1025                    1030                    1035  
  
 His Val Ala Tyr Ser Gln Met Phe Lys Glu Thr Val  
 1040                    1045                    1050

<210> 46  
 <211> 3311  
 <212> DNA  
 <213> Homo sapiens

<400> 46  
 ttctgcgctg ctgcaagtta cggaatgaaa aattagaaca acagaaacat ggaaaacatg        60  
 ttccttcagt cgtcaatgct gacctgcatt ttcctgctaa tatctggttc ctgtgagttt        120  
 tgccgccgaag aaaatttttc tagaagctat ctttgtatg agaaaaagca aaatgactca        180  
 gttattgcag agtgcagcaa tcgtcgacta caggaagttc cccaaacggt gggcaaataat        240  
 gtgacagaac tagacctgtc tgataatttc atcacacaca taacgaatga atcattcaa        300  
 gggctgcaaa atctcaactaa aataaatcta aaccacaacc ccaatgtaca gcaccagaac        360  
 gggaaatcccg gtataacaatc aaatggctt aatatcacag acggggcatt cctcaaccta        420  
 aaaaacctaa gggagttact gcttgaagac aaccagttac cccaaatacc ctctggttt        480  
 ccagagtctt tgacagaact tagtctaatt caaaaacaata tataacaacat aactaaagag        540

ggcatttcaa gacttataaa cttgaaaaat ctctatttg cctggaaactg ctatTTAAC	600
aaagttgcg agaaaactaa catagaagat ggagtattt aaacgctgac aaattggag	660
ttgctatcac tatctttcaa ttctctttca cacgtgccac ccaaactgcc aagctcccta	720
cgcAAacttt ttctgagcaa cacccagatc aaatacatta gtgaagaaga tttcaaggga	780
ttgataaatt taacattact agatTTAAGC gggAACTGTC cgaggtgctt caatGCCCA	840
tttccatgcg tgccTTGTGA tggtgggtct tcaattaata tagatcgTTT tgctttcaa	900
aacttgacCC aacttcgata cctAAACCTC tctAGCactt ccctcaggaa gattaATGCT	960
gcctggTTTA aaaatATGCC tcATCTGAAG gtGCTGGATC ttGAATTCAA CTATTTAGTG	1020
ggagAAAATAG CCTCTGGGGC ATTTTAACG ATGCTGCCCG GCTTAGAAAT ACTTGACTTG	1080
tcttttaact atataaAGGG gagttatCCA cagcatatta atatttCCAG AAACttCTCT	1140
aaactttgt ctctacgggc attgcatttA agaggTTATG tGTTCCAGGA ACTCAGAGAA	1200
gatgatttcc agccccTGTGCAGCTTCA AACTTATCGA CTATCAACTT GGGTATTAAAT	1260
tttattaAGC AAATCGATT CAAACTTTTC CAAAATTTCT CCAATCTGGA ATTATTTAC	1320
ttgtcagAAA acagaatATC accgttggta AAAGATAACCC GGCAGAGTT TGCAAATAGT	1380
tcctcttttC AACGTCAATC CGGAAACGA CGCTCAACAG ATTTGAGTT TGACCCACAT	1440
tcgAACTTTT ATCATTTCAC CGTCCTTTA ATAAAGCCAC AATGTGCTGC TTATGGAAAA	1500
gccttagatt taAGCCTCAA CAGTATTTTC TTCATTGGGC CAAACCAATT TGAATTCCTT	1560
cctgacATTG CCTGTAAACTA TCTGTCTGCA AATAGCAATG CTCAAGTGT AAGTGGAACT	1620
gaATTTCAg CCATTCCCTCA TGTCAAATAT TTGGATTGAA CAAACAATAG ACTAGACTTT	1680
gataATGCTA GTGCTCTTAC TGAATTGTCC GACTTGGAAAG TTCTAGATCT CAGCTATAAT	1740
TCACACTATT TCAGAAATGC AGGCGTAACA CATCATCTAG AATTATTCA AAATTTCACA	1800
AATCTAAAAG TTtTAACCTT GAGCCACAAc AACATTATA CTtTAACAGA TAAGTATAAC	1860
CTGGAAAGCA AGTCCCTGGT AGAATTAGTT TTCAGTGGCA ATCGCCTGAA CATTtTGtGG	1920
AATGATGATG ACAACAGGTA TATCTCCATT TTCAAAGGTC TCAAGAATCT GACACGTCTG	1980
GATTtATCCC TTAATAGGCT GAAGCACATC CCAAATGAAG CATTCCtAA TTTGCCAGCG	2040
AGTCTCACTG AACTACATAT AAATGATAAT ATGTTAAAGT TTtTAACTG GACATTACTC	2100
CAGCAGTTCC CTCGTCTCGA GTTGCTTGAC TTACGTGGAA ACATAACTACT CTtTTAACT	2160
GATAGCCTAT CTGACTTTAC ATCTCCCTT CGGACACTGC TGCTGAGTCA TAACAGGATT	2220
TCCACCTAC CCTCTGGCTT TCTTCTGAA GTCACTGAGTC TGAAGCACCT CGATTTAAGT	2280
TCCAATCTGC TAAAAACAAAT CAACAAATCC GCACtTGAAA CTAAGACCAC CACCAAATTA	2340
TCTATGTTGG AACTACACGG AAACCCCTT GAATGCACCT GTGACATTGG AGATTTCCGA	2400
AGATGGATGG ATGAACATCT GAATGTCAAAT ATTCCAGAC TGGTAGATGT CATTGTGCC	2460

agtccctgggg atcaaagagg gaagagtatt gtgagtctgg agctgacaac ttgtgtttca	2520
gatgtcactg cagtgatatt attttcttc acgttctta tcaccaccat ggttatgttgc	2580
gctgccctgg ctcaccattt gtttactgg gatgttttgttataataa tgtgtgttta	2640
gctaaggtaa aaggctacag gtctcttcc acatccccaaa ctttctatga tgcttacatt	2700
tcttatgaca ccaaagatgc ctctgttact gactgggtga taaatgagct gcgcattaccac	2760
cttgaagaga gccgagacaa aaacgttctc ctttgtcttag aggagaggga ttgggaccgg	2820
ggattggcca tcatcgacaa cctcatgcag agcatcaacc aaagcaagaa aacagtattt	2880
gttttaacca aaaaatatgc aaaaagctgg aactttaaaaa cagctttta cttggctttg	2940
cagaggctaa tggatgagaa catggatgtg attatattta tcctgcttgg gccagtgtta	3000
cagcattctc agtatttgag gctacggcag cggtatctgtt agagctccat cctccagtgg	3060
cctgacaacc cgaaggcaga aggcttggg tggcaaaactc tgagaaatgt ggtcttgact	3120
gaaaatgatt cacggtataa caatatgtat gtcgattcca ttaagcaata ctaactgacg	3180
ttaagtcatg atttcgcgcc ataataaaga tgcaaaggaa tgacatttct gtatttagtta	3240
tctattgcta tgtaacaaat tatccaaaaa cttagtgggtt taaaacaaca catttgctgg	3300
cccacagttt t	3311

<210> 47  
 <211> 3367  
 <212> DNA  
 <213> Homo spaiens

<400> 47	
ctcctgcata gagggtacca ttctgcgctg ctgcaagtta cgaaatgaaa aattagaaca	60
acagaaaacgt ggttctcttg acacttcagt gtttagggac atcagcaaga .cccatcccag	120
gagaccttga aggaagcctt tgaaaggag aatgaaggag tcattttgc aaaatagctc	180
ctgcagcctg ggaaaggaga ctaaaaagga aaacatgttc cttcagtcgt caatgctgac	240
ctgcattttc ctgctaataat ctggttcttg tgagttatgc gccgaagaaa attttctag	300
aagctatcct tgtgatgaga aaaagcaaaa tgactcagtt attgcagagt gcagcaatcg	360
tcgactacag gaagttcccc aaacgggtggg caaatatgtg acagaactag acctgtctga	420
taatttcatc acacacataa cgaatgaatc atttcaaggg ctgcaaaatc tcactaaaat	480
aaatctaaac cacaacccca atgtacagca ccagaacgga aatcccgta tacaatcaaa	540
tggcttgaat atcacagacg gggcattcct caacctaaaaa aacctaaggg agttactgct	600
tgaagacaac cagttacccc aaataccctc tggttgcca gagtctttga cagaacttag	660
tctaattcaa aacaatataat acaacataac taaagaggc atttcaagac ttataaaactt	720

aaaaaatctc tatttggcct ggaactgcta ttttaacaaa gtttgcgaga aaactaaatc 780  
agaagatgga gtatggaaa cgctgacaaa tttggagttg ctatcactat ctttcaattc 840  
tctttcacac gtgtcaccca aactgccaaag ctccctacgc aaacttttc tgagcaacac 900  
ccagatcaaa tacattagtg aagaagattt caagggattt ataaatttaa cattactaga 960  
tttaagcggg aactgtccga ggtgcttcaa tgccccattt ccatgcgtgc cttgtatgg 1020  
tggtgcttca attaatatac atcggtttgc tttcaaaac ttgacccaaac ttgcataacct 1080  
aaacctctct agcacttccc tcaggaagat taatgctgcc tggtttaaaa atatgcctca 1140  
tctgaagggtg ctggatcttgc aattcaacta ttttagtgggaa gaaatagcct ctggggcatt 1200  
tttaacgatg ctgccccgct tagaaatact tgacttgtct ttttaactata taaaggggag 1260  
ttatccacag catattaata tttccagaaaa cttctctaaa cctttgtctc tacgggcatt 1320  
gcatttaaga ggttatgtgt tccaggaact cagagaagat gatttccagc ccctgatgca 1380  
gcttccaaac ttatcgacta tcaacttggg tattaatttt attaagcaaa tcgatttcaa 1440  
actttccaa aatttctcca atctggaaat tatttacttg tcagaaaaca gaatatcacc 1500  
gttggtaaaa gatacccgcc agagttatgc aaatagttcc tctttcaac gtcatatccg 1560  
gaaacgacgc tcaacagatt ttgagttga cccacattcg aacttttatac atttcacccg 1620  
tcctttaata aagccacaat gtgctgctta tggaaaagcc ttagatttaa gcctcaacag 1680  
tattttcttc attgggccaa accaatttga aaatcttcct gacattgcct gtttaaatct 1740  
gtctgcaaata agcaatgctc aagtgttaag tggaaactgaa ttttcagcca ttccctatgt 1800  
caaataatttgc gatttgacaa acaatagact agactttgat aatgcttagtgc ctcttactga 1860  
attgtccgac ttggaagttc tagatctcag ctataattca cactatttca gaatagcagg 1920  
cgtaacacat catctagaat ttattcaaaa ttccacaaat ctaaaagttaa taaacttgag 1980  
ccacaacaac atttataactt taacagataa gtataacctg gaaagcaagt ccctggtaga 2040  
attagtttc agtggcaatc gccttgacat tttgtggaaat gatgatgaca acaggtatata 2100  
ctccattttc aaaggtctca agaatctgac acgtctggat ttatccctta ataggctgaa 2160  
gcacatccca aatgaagcat tccttaattt gccagcgagt ctcactgaac tacatataaa 2220  
tgataatatg ttaaaagtttt ttaactggac attactccag cagtttcctc gtctcgagtt 2280  
gcttgactta cgtggaaaca aactactctt tttaactgat agcctatctg actttacatc 2340  
ttcccttcgg acactgctgc tgagtcttacaa caggatttcc cacctaccct ctggctttct 2400  
ttctgaagtc agtagtctga agcacctcga tttaagttcc aatctgctaa aaacaatcaa 2460  
caaatccgca cttgaaacta agaccaccac caaattatct atgttggaaac tacacggaaa 2520  
cccccttgaa tgcacctgtg acattggaga ttccgaaga tggatggatg aacatctgaa 2580  
tgtcaaaattt cccagactgg tagatgtcat ttgtgccagt cctggggatc aaagagggaa 2640

gagtattgtg agtctggagc taacaacttg tggttcagat gtcactgcag tgatattatt	2700
tttcttcacg ttctttatca ccaccatggt tatgttggct gccctggctc accatttgg	2760
ttactggat gtttggttta tatataatgt gtgttagct aagataaaag gctacaggc	2820
tctttccaca tcccaaactt tctatgatgc ttacatttct tatgacacca aagatgcctc	2880
tgttactgac tgggtgataa atgagctgcg ctaccacctt gaagagagcc gagacaaaaa	2940
cgttctcctt tgtcttagagg agagggattt ggacccggga ttggccatca tcgacaacct	3000
catgcagagc atcaacccaaa gcaagaaaac agtatttgtt ttaacccaaa aatatgc当地	3060
aagctggaac tttaaaacag ctttttactt ggcttgcag aggctaattgg atgagaacat	3120
ggatgtgatt atatttatcc tgctggagcc agtgttacag cattctcagt atttgggct	3180
acggcagcgg atctgtttaaga gctccatcct ccagtggcct gacaacccga aggccagaagg	3240
cttgggggg ccaaactctga gaaatgtggt cttgactgaa aatgattcac ggtataacaa	3300
tatgtatgtc gattccatta agcaatacta actgacgtta agtcatgatt tcgcgccata	3360
ataaaaga	3367

<210> 48  
<211> 4211  
<212> DNA  
<213> Homo spaiens

<400> 48	
ctcctgcata gagggtacca ttctgcgtc ctgcaagtta cggaatgaaa aattagaaca	60
acagaaaacat gaaaaacatg ttcttcagt cgtcaatgct gacctgcatt ttccctgctaa	120
tatctggttc ctgtgagttt tgccggaaag aaaatttttc tagaagctat ctttgtatg	180
agaaaaagca aaatgactca gttattgcag agtgcagcaa tcgtcgacta caggaagttc	240
cccaaacggt gggcaaatat gtgacagaac tagacctgtc tgataatttc atcacacaca	300
taacgaatga atcatttcaa gggctgcaaa atctcactaa aataaatcta aaccacaacc	360
ccaatgtaca gcaccagaac gaaaaatcccgt tatacataatc aaatggctt aatatcacag	420
acggggcatt cctcaaccta aaaaacctaa gggagttact gcttgaagac aaccagttac	480
cccaaatacc ctctggtttccagacttcc ttgacagaact tagtctaatt caaaacaata	540
tatacaacat aactaaagag ggcatttcaa gacttataaa cttgaaaaat ctctatttgg	600
cctggaactg ctatTTAAC aaagtttgcg agaaaaactaa catagaagat ggagtatttgc	660
aaacgctgac aaatttggag ttgctatcac tatctttcaa ttctcttca cacgtgccac	720
ccaaactgcc aagctcccta cgcaaaacttt ttctgagcaa cacccagatc aaatacatta	780
gtgaagaaga tttcaaggga ttgataaatt taacattact agatitaagc ggaaactgtc	840

cgaggtgctt caatgcggcc tttccatgcg tgccttgtga tggtggtgct tcaattaata 900  
 tagatogttt tgctttcaa aacttgaccc aacttcgata cctaaacctc tctagactt 960  
 ccctcaggaa gattaatgct gcctggttta aaaatatgcc tcatctgaag gtgctggatc 1020  
 ttgaattcaa ctattnatgt ggagaaaatag cctctggggc attttaacg atgctgcccc 1080  
 gcttagaaat acttgacttg tcttttaact atataaaggg gagttatcca cagcatatta 1140  
 atatccag aaacttctct aaactttgt ctctacgggc attgcattt aagagttatg 1200  
 tggccagga actcagagaa gatgattcc agcccctgat gcagcttcca aacttatcg 1260  
 ctatcaactt ggttattaaat ttattnaagc aaatcgattt caaacttttc caaaatttct 1320  
 ccaatctgga aattattnac ttgtcagaaa acagaatatac accgttggta aaagataccc 1380  
 ggcagagtta tgcaaatagt tcctctttc aacgtcatat ccggaaacga cgctcaacag 1440  
 atttttagtt tgaccacat tcgaactttt atcatttcac ccgtccttta ataaagccac 1500  
 aatgtgctgc ttatggaaaa gccttagatt taagcctcaa cagtatttc ttcatgggc 1560  
 caaaccaatt tgaaaatctt cctgacattt cctgtttaaa tctgtctgca aatagcaatg 1620  
 ctcaagtgtt aagtggaaact gaattttcag ccattcctca tgtcaaataat ttggatttga 1680  
 caaacaatag actagacttt gataatgcta gtgctttac tgaattgtcc gacttggaaag 1740  
 ttcttagatct cagctataat tcacactatt tcagaatagc aggcgtaaca catcatctag 1800  
 aatttattca aaatttcaca aatctaaaag ttttaactt gagccacaac aacattata 1860  
 cttaacaga taagtataac ctggaaagca agtccctggt agaatttagtt ttcatggca 1920  
 atcgccctga cattttgtgg aatgatgatg acaacaggta tatctccatt ttcaaaggtc 1980  
 tcaagaatct gacacgtctg gatttatccc ttaataggct gaagcacatc ccaaatacg 2040  
 cattccttaa ttgccagcg agtctcactg aactacatataaatgataat atgttaaagt 2100  
 ttttaactg gacattactc cagcagttt ctcgtctcga gttgcttgac ttacgtggaa 2160  
 acaaactact cttttaact gatagccat ctgactttac atcttccctt cggacactgc 2220  
 tgctgagtca taacaggatt tcccacccat cctctggctt tctttctgaa gtcagtagtc 2280  
 tgaagcacct cgattnaagt tccaaatctgc taaaaacaat caacaaatcc gcacttgaaa 2340  
 ctaagaccac caccaaatta totatgttgg aactacacgg aaacccttt gaatgcaccc 2400  
 gtgacattgg agattnccga agatggatgg atgaacatct gaatgtcaaa attccagac 2460  
 tggtagatgt catttgccttgc agtcctgggg atcaaagagg gaagagtatt gtgagtcgtt 2520  
 agctaacaac ttgtgtttca gatgtcactg cagtgatatt attttcttc acgttcttta 2580  
 tcaccaccat gttatgttg gtcgtccctgg ctcaccattt gtttactgg gatgtttgg 2640  
 ttatataaa tgggtttca gctaaaggtaa aaggctacag gtctctttcc acatccaaa 2700  
 ctttctatga tgcttacatt tcttatgaca ccaaagatgc ctctgttact gactgggtga 2760

taaatgagct ggcgttaccac cttgaagaga gccgagacaa aaacgttctc ctttgtctag	2820
aggagaggga ttggatccg ggattggcca tcatcgacaa cctcatgcag agcatcaacc	2880
aaagcaagaa aacagtattt gtttaacca aaaaatatgc aaaaagctgg aactttaaaa	2940
cagctttta cttggctttg cagaggctaa tggatgagaa catggatgtg attatattta	3000
tcctgctgga gccagtgtta cagcattctc agtatttgag gctacggcag cggatctgta	3060
agagctccat cctccagtgg cctgacaacc cgaaggcaga aggcttgtt tggcaaactc	3120
tgagaaatgt ggtcttgact gaaaatgatt cacggtataa caatatgtat gtcgattcca	3180
ttaagcaata ctaactgacg ttaagtcatg atttcgcgcc ataataaaga tgcaaaggaa	3240
tgacatttct gtatttagtta tctattgcta tgtaacaaat tatccaaaaa cttagtggtt	3300
taaaacaaca catttgcgtt cccacagttt ttgagggtca ggagtccagg cccagcataa	3360
ctgggtcctc tgctcagggt gtctcagagg ctgcaatgta ggtgttccacc agagacatag	3420
gcatcactgg ggtcacactc atgtgggtgt tttctggatt caattcctcc tggcttattg	3480
gccaaggct atactcatgt aagccatgctg agcctctccc acaaggcagc ttgcttcattc	3540
agagctagca aaaaagagag gttgctagca agatgaagtc acaatctttt gtaatcgaat	3600
caaaaaaagtg atatctcatc actttggcca tattctattt gttagaagta aaccacaggt	3660
cccacccagct ccatgggagt gaccacctca gtccaggaa aacagctgaa gaccaagatg	3720
gtgagctctg attgcttcag ttggcatca actattttcc cttgactgct gtcctggat	3780
ggcctgctat cttgatgata gattgtgaat atcaggaggc agggatcaact gtggaccatc	3840
ttagcagttg acctaacaca tcttctttc aatatctaag aacttttgcactgtgacta	3900
atggtcctaa tattaagctg ttgttatata ttatcatata tctatggcta catggttata	3960
ttatgctgtg gttgcgttcg gttttatata cagttgttt tacaaatatt tgctgtaaaca	4020
tttgacttct aaggtttaga tgccattaa gaactgagat ggatagctt taaagcatct	4080
tttacttctt accatttttt aaaagtatgc agctaaattc gaagctttg gtctatattg	4140
ttaattgcca ttgctgtaaa tcttaaaatg aatgaataaa aatgtttcat tttacaaaaaa	4200
aaaaaaaaaa a	4211

<210> 49  
<211> 3468  
<212> DNA  
<213> Homo sapiens

<400> 49  
ctcctgcata gagggtacca ttctgcgtc ctgcaagtta cggaatgaaa aattagaaca      60  
acagaaaacat gtttctttt acacttcagt gtttagggAAC atcagcaaga cccatcccag      120

gagacccttga aggaagcctt tgaaaggag aatgaaggag tcatctttgc aaaatagctc 180  
ctgcaggctg ggaaaggaga ctaaaaagga aaacatgttc ctgcagtcgt caatgtgac 240  
ctgcatttc ctgctaataat ctggttcctg tgagttatgc gccgaagaaa attttctag 300  
aagctatcct tgttatgaga aaaagcaaaa tgactcagtt attgcagagt gcagcaatcg 360  
tcgactacag gaagttcccc aaacgggtggg caaatatgtg acagaactag acctgtctga 420  
taatttcatc acacacataa cgaatgaatc atttcaaggg ctgaaaaatc tcactaaaat 480  
aaatctaaac cacaacccca atgtacagca ccagaacgga aatcccggtt tacaatcaaa 540  
tggcttgaat atcacagacg gggcattcct caacctaaaa aacctaaggg agttactgct 600  
tgaagacaac cagttacccc aaataccctc tggtttgcca gagtcittga cagaacttag 660  
tctaattcaa aacaatataat acaacataaac taaagagggc atttcaagac ttataaaactt 720  
aaaaaatctc tatttggcct ggaactgcta ttttaacaaa gtttgcgaga aaactaacat 780  
agaagatgga gtatTTgaaa cgctgacaaa tttggagttt ctatcactat ctttcaattc 840  
tcttcacac gtgccacccca aactgccaag ctccctacgc aaacttttc tgagcaacac 900  
ccagatcaaa tacatttagt aagaagattt caagggattt gataatTTaa cattactaga 960  
tttaagcggg aactgtccga ggtgcttcaa tgccccattt ccatgcgtgc cttgtgatgg 1020  
tggtgcttca attaataatag atcgaaaaatc tttcaaaaac ttgacccaaac ttgcataacct 1080  
aaacctctct agcacttccc tcaggaagat taatgcgtcc tggTTTaaaa atatgcctca 1140  
tctgaagggtg ctggatctt aattcaacta ttttagtgggaa gaaatagcct ctggggcatt 1200  
tttaacgatg ctgccccgtt tagaaataact tgacttgtct ttttaactata taaaggggag 1260  
ttatccacag catattaataa tttccagaaa cttctctaaa cttttgtctc tacgggcatt 1320  
gcatttaaga gtttatgtgt tccaggaact cagagaagat gatttccagc ccctgtatgca 1380  
gttccaaac ttatcgacta tcaacttggg tattaatttt attaagcaaa tcgatttcaa 1440  
actttccaa aatttctcca atctggaaat tatttacttg tcagaaaaca gaatatcacc 1500  
gttggtaaaa gatacccgac agagttatgc aaatagttcc tctttcaac gtcatatccg 1560  
gaaacgacgc tcaacagatt ttgagttga cccacattcg aacttttatac atttcacccg 1620  
tccttaata aagccacaat gtgctgcttga tgaaaagcc ttagatttaa gcctcaacag 1680  
tattttcttc attggggccaa accaatttga aaatcttcct gacattgcct gtttaaatct 1740  
gtctgcaaat agcaatgctc aagtgttaag tggaactgaa ttttcagcca ttcctcatgt 1800  
caaataatttgc gatttgacaa acaatagact agactttgat aatgcgtatgc ctcttactga 1860  
attgtccgac ttggaagttc tagatctcag ctataattca cactattca gaatagcagg 1920  
cgtaacacat catctagaat ttattcaaaa ttccacaaat ctaaaaagtt taaacttgag 1980  
ccacaacaac atttataactt taacagataa gtataacctg gaaagcaagt ccctggtaga 2040

attagtttc agtggcaatc gccttgacat tttgtggaat gatgatgaca acaggtatat	2100
ctccattttc aaaggctctca agaatctgac acgtctggat ttatccctta ataggctgaa	2160
gcacatcccc aatgaagcat tccttaattt gccagcgagt ctcactgaac tacatataaa	2220
tgataatatg ttaaagtttt ttaactggac attactccag cagttccctc gtctcgagtt	2280
gcttgactta cgtggaaaca aactactctt ttaactgat agcctatctg actttacatc	2340
ttcccttcgg acactgctgc tgagtcataa caggattcc cacctaccct ctggctttct	2400
ttctgaagtc agtagtctga agcacctcga ttaagttcc aatctgctaa aaacaatcaa	2460
caaatccgca cttgaaaacta agaccaccac caaattatct atgttggAAC tacacggaaa	2520
cccctttgaa tgcacctgtg acattggaga tttccgaaga tggatggatg aacatctgaa	2580
tgtcaaaatt cccagactgg tagatgtcat ttgtgccagt cctggggatc aaagagggaa	2640
gagtattgtg agtctggagc taacaacttg ttttcagat gtcactgcag tgatattatt	2700
tttcttcacg ttctttatca ccaccatggt tatgttgct gccctggctc accatttgtt	2760
ttactggat gtttggttta tatataatgt gtgttagct aaggtaaaag gctacaggc	2820
tctttccaca tcccaaactt tctatgatgc ttacatttct tatgacacca aagatgcctc	2880
tgttactgac tgggtgataa atgagctgcg ctaccacctt gaagagagcc gagacaaaaaa	2940
cgttctcctt tgtcttagagg agagggattt ggatccggga ttggccatca tcgacaacct	3000
catgcagagc atcaacccaaa gcaagaaaac agtatttttt ttaacccaaa aatatgc	3060
aagcttggAAC tttaaaacag ctttttactt ggctttgcag aggctaatttgg atgagaacat	3120
ggatgtgatt atatttatcc tgctggagcc agtgttacag cattctcagt atttgggct	3180
acggcagcgg atctgttaga gctccatcct ccagtggcct gacaaccga aggcagaagg	3240
cttgggggg ccaaactctga gaaatgtggt ctgactgaa aatgattcac ggtataacaa	3300
tatgtatgtc gattccatTA agcaatacta actgacgtt agtcatgatt tcgcgccata	3360
ataaaagatgc aaaggaatga catttctgtt ttagttatct attgctatgt aacaaattat	3420
ccccaaaactt agtgggttAA aacaacacat ttgctggccc acagtttt	3468

<210> 50  
 <211> 1041  
 <212> PRT  
 <213> Homo sapiens

<400> 50

Met	Glu	Asn	Met	Phe	Leu	Gln	Ser	Ser	Met	Leu	Thr	Cys	Ile	Phe	Leu
1				5					10				15		

Leu	Ile	Ser	Gly	Ser	Cys	Glu	Leu	Cys	Ala	Glu	Glu	Asn	Phe	Ser	Arg
				20				25					30		

Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile Ala Glu  
35 40 45

Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly Lys Tyr  
50 55 60

Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile Thr Asn  
65 70 75 80

Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu Asn His  
85 90 95

Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln Ser Asn  
100 105 110

Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn Leu Arg  
115 120 125

Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser Gly Leu  
130 135 140

Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile Tyr Asn  
145 150 155 160

Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn Leu Tyr  
165 170 175

Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr Asn Ile  
180 185 190

Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu Ser Leu  
195 200 205

Ser Phe Asn Ser Leu Ser His Val Pro Pro Lys Leu Pro Ser Ser Leu  
210 215 220

Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser Glu Glu  
225 230 235 240

Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn  
245 250 255

Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys Asp Gly  
260 265 270

Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu Thr Gln  
275 280 285

Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile Asn Ala  
290 295 300

Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu Glu Phe  
305 310 315 320

Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr Met Leu  
325 330 335

Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys Gly Ser  
340 345 350

Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Leu Leu Ser

355                   360                   365  
Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu Arg Glu  
370                   375                   380

Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr Ile Asn  
385                   390                   395                   400

Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe Gln Asn  
405                   410                   415

Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile Ser Pro  
420                   425                   430

Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Ser Phe Gln  
435                   440                   445

Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp Pro His  
450                   455                   460

Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln Cys Ala  
465                   470                   475                   480

Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe Phe Ile  
485                   490                   495

Gly Pro Asn Gln Phe Glu Asn Leu Pro Asp Ile Ala Cys Leu Asn Leu  
500                   505                   510

Ser Ala Asn Ser Asn Ala Gln Val Leu Ser Gly Thr Glu Phe Ser Ala  
515                   520                   525

Ile Pro His Val Lys Tyr Leu Asp Leu Thr Asn Asn Arg Leu Asp Phe  
530                   535                   540

Asp Asn Ala Ser Ala Leu Thr Glu Leu Ser Asp Leu Glu Val Leu Asp  
545                   550                   555                   560

Leu Ser Tyr Asn Ser His Tyr Phe Arg Ile Ala Gly Val Thr His His  
565                   570                   575

Leu Glu Phe Ile Gln Asn Phe Thr Asn Leu Lys Val Leu Asn Leu Ser  
580                   585                   590

His Asn Asn Ile Tyr Thr Leu Thr Asp Lys Tyr Asn Leu Glu Ser Lys  
595                   600                   605

Ser Leu Val Glu Leu Val Phe Ser Gly Asn Arg Leu Asp Ile Leu Trp  
610                   615                   620

Asn Asp Asp Asp Asn Arg Tyr Ile Ser Ile Phe Lys Gly Leu Lys Asn  
625                   630                   635                   640

Leu Thr Arg Leu Asp Leu Ser Leu Asn Arg Leu Lys His Ile Pro Asn  
645                   650                   655

Glu Ala Phe Leu Asn Leu Pro Ala Ser Leu Thr Glu Leu His Ile Asn  
660                   665                   670

Asp Asn Met Leu Lys Phe Phe Asn Trp Thr Leu Leu Gln Gln Phe Pro  
675                   680                   685

Arg Leu Glu Leu Leu Asp Leu Arg Gly Asn Lys Leu Leu Phe Leu Thr

690	695	700
Asp Ser Leu Ser Asp Phe Thr Ser Ser Leu Arg Thr Leu Leu Leu Ser		
705	710	715
720		
His Asn Arg Ile Ser His Leu Pro Ser Gly Phe Leu Ser Glu Val Ser		
725	730	735
Ser Leu Lys His Leu Asp Leu Ser Ser Asn Leu Leu Lys Thr Ile Asn		
740	745	750
Lys Ser Ala Leu Glu Thr Lys Thr Thr Lys Leu Ser Met Leu Glu		
755	760	765
Leu His Gly Asn Pro Phe Glu Cys Thr Cys Asp Ile Gly Asp Phe Arg		
770	775	780
Arg Trp Met Asp Glu His Leu Asn Val Lys Ile Pro Arg Leu Val Asp		
785	790	795
800		
Val Ile Cys Ala Ser Pro Gly Asp Gln Arg Gly Lys Ser Ile Val Ser		
805	810	815
Leu Glu Leu Thr Thr Cys Val Ser Asp Val Thr Ala Val Ile Leu Phe		
820	825	830
Phe Phe Thr Phe Phe Ile Thr Thr Met Val Met Leu Ala Ala Leu Ala		
835	840	845
His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val Cys Leu		
850	855	860
860		
Ala Lys Val Lys Gly Tyr Arg Ser Leu Ser Thr Ser Gln Thr Phe Tyr		
865	870	875
880		
Asp Ala Tyr Ile Ser Tyr Asp Thr Lys Asp Ala Ser Val Thr Asp Trp		
885	890	895
Val Ile Asn Glu Leu Arg Tyr His Leu Glu Glu Ser Arg Asp Lys Asn		
900	905	910
910		
Val Leu Leu Cys Leu Glu Glu Arg Asp Trp Asp Pro Gly Leu Ala Ile		
915	920	925
925		
Ile Asp Asn Leu Met Gln Ser Ile Asn Gln Ser Lys Lys Thr Val Phe		
930	935	940
940		
Val Leu Thr Lys Tyr Ala Lys Ser Trp Asn Phe Lys Thr Ala Phe		
945	950	955
955		
960		
Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val Ile Ile		
965	970	975
975		
Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr Leu Arg Leu		
980	985	990
990		
Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln Trp Pro Asp Asn Pro		
995	1000	1005
1005		
Lys Ala Glu Gly Leu Phe Trp Gln Thr Leu Arg Asn Val Val Leu		
1010	1015	1020
1020		
Thr Glu Asn Asp Ser Arg Tyr Asn Asn Met Tyr Val Asp Ser Ile		

1025 Lys Gln Tyr 1040	1030	1035
<210> 51		
<211> 1059		
<212> PRT		
<213> Homo sapiens		
<400> 51		
Met Lys Glu Ser Ser Leu Gln Asn Ser Ser Cys Ser Leu Gly Lys Glu		
1	5	10
15		
Thr Lys Lys Glu Asn Met Phe Leu Gln Ser Ser Met Leu Thr Cys Ile		
20	25	30
Phe Leu Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe		
35	40	45
Ser Arg Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile		
50	55	60
Ala Glu Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly		
65	70	75
80		
Lys Tyr Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile		
85	90	95
Thr Asn Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu		
100	105	110
Asn His Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln		
115	120	125
Ser Asn Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn		
130	135	140
Leu Arg Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser		
145	150	155
160		
Gly Leu Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile		
165	170	175
Tyr Asn Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn		
180	185	190
Leu Tyr Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr		
195	200	205
Asn Ile Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu		
210	215	220
Ser Leu Ser Phe Asn Ser Leu Ser His Val Ser Pro Lys Leu Pro Ser		
225	230	235
240		
Ser Leu Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser		
245	250	255
Glu Glu Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser		
260	265	270

Gly Asn Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys  
275 280 285

Asp Gly Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu  
290 295 300

Thr Gln Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile  
305 310 315 320

Asn Ala Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu  
325 330 335

Glu Phe Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr  
340 345 350

Met Leu Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys  
355 360 365

Gly Ser Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Pro  
370 375 380

Leu Ser Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu  
385 390 395 400

Arg Glu Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr  
405 410 415

Ile Asn Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe  
420 425 430

Gln Asn Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile  
435 440 445

Ser Pro Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Ser  
450 455 460

Phe Gln Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp  
465 470 475 480

Pro His Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln  
485 490 495

Cys Ala Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe  
500 505 510

Phe Ile Gly Pro Asn Gln Phe Glu Asn Leu Pro Asp Ile Ala Cys Leu  
515 520 525

Asn Leu Ser Ala Asn Ser Asn Ala Gln Val Leu Ser Gly Thr Glu Phe  
530 535 540

Ser Ala Ile Pro His Val Lys Tyr Leu Asp Leu Thr Asn Asn Arg Leu  
545 550 555 560

Asp Phe Asp Asn Ala Ser Ala Leu Thr Glu Leu Ser Asp Leu Glu Val  
565 570 575

Leu Asp Leu Ser Tyr Asn Ser His Tyr Phe Arg Ile Ala Gly Val Thr  
580 585 590

His His Leu Glu Phe Ile Gln Asn Phe Thr Asn Leu Lys Val Leu Asn

595                    600                    605  
Leu Ser His Asn Asn Ile Tyr Thr Leu Thr Asp Lys Tyr Asn Leu Glu  
610                    615                    620

Ser Lys Ser Leu Val Glu Leu Val Phe Ser Gly Asn Arg Leu Asp Ile  
625                    630                    635                    640

Leu Trp Asn Asp Asp Asp Asn Arg Tyr Ile Ser Ile Phe Lys Gly Leu  
645                    650                    655

Lys Asn Leu Thr Arg Leu Asp Leu Ser Leu Asn Arg Leu Lys His Ile  
660                    665                    670

Pro Asn Glu Ala Phe Leu Asn Leu Pro Ala Ser Leu Thr Glu Leu His  
675                    680                    685

Ile Asn Asp Asn Met Leu Lys Phe Phe Asn Trp Thr Leu Leu Gln Gln  
690                    695                    700

Phe Pro Arg Leu Glu Leu Leu Asp Leu Arg Gly Asn Lys Leu Leu Phe  
705                    710                    715                    720

Leu Thr Asp Ser Leu Ser Asp Phe Thr Ser Ser Leu Arg Thr Leu Leu  
725                    730                    735

Leu Ser His Asn Arg Ile Ser His Leu Pro Ser Gly Phe Leu Ser Glu  
740                    745                    750

Val Ser Ser Leu Lys His Leu Asp Leu Ser Ser Asn Leu Leu Lys Thr  
755                    760                    765

Ile Asn Lys Ser Ala Leu Glu Thr Lys Thr Thr Lys Leu Ser Met  
770                    775                    780

Leu Glu Leu His Gly Asn Pro Phe Glu Cys Thr Cys Asp Ile Gly Asp  
785                    790                    795                    800

Phe Arg Arg Trp Met Asp Glu His Leu Asn Val Lys Ile Pro Arg Leu  
805                    810                    815

Val Asp Val Ile Cys Ala Ser Pro Gly Asp Gln Arg Gly Lys Ser Ile  
820                    825                    830

Val Ser Leu Glu Leu Thr Thr Cys Val Ser Asp Val Thr Ala Val Ile  
835                    840                    845

Leu Phe Phe Phe Thr Phe Ile Thr Thr Met Val Met Leu Ala Ala  
850                    855                    860

Leu Ala His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val  
865                    870                    875                    880

Cys Leu Ala Ile Lys Ile Lys Gly Tyr Arg Ser Leu Ser Thr Ser Gln Thr  
885                    890                    895

Phe Tyr Asp Ala Tyr Ile Ser Tyr Asp Thr Lys Asp Ala Ser Val Thr  
900                    905                    910

Asp Trp Val Ile Asn Glu Leu Arg Tyr His Leu Glu Glu Ser Arg Asp  
915                    920                    925

Lys Asn Val Leu Leu Cys Leu Glu Glu Arg Asp Trp Asp Pro Gly Leu

930	935	940
Ala Ile Ile Asp Asn Leu Met Gln Ser Ile Asn Gln Ser Lys Lys Thr		
945	950	955
		960
Val Phe Val Leu Thr Lys Lys Tyr Ala Lys Ser Trp Asn Phe Lys Thr		
965	970	975
Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val		
980	985	990
Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr Leu		
995	1000	1005
Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln Trp Pro		
1010	1015	1020
Asp Asn Pro Lys Ala Glu Gly Leu Phe Trp Gln Thr Leu Arg Asn		
1025	1030	1035
Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asn Asn Met Tyr Val		
1040	1045	1050
Asp Ser Ile Lys Gln Tyr		
1055		

<210> 52  
<211> 1041  
<212> PRT  
<213> *Homo sapiens*

<400> 52  
Met Glu Asp Met Phe Leu Gln Ser Ser Met Leu Thr Cys Ile Phe Leu

Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe Ser Arg

Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile Ala Glu

Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly Lys Tyr

Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile Thr Asn

Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu Asn His  
25 26 27 28 29 30 31 32 33 34 35

Asn Pro Asn Val Gln His Gln Asn Gly Asn-Phe-Gly Ile Gln Ser Asp  
100 105 110

Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn Leu Arg  
115 120 125

Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser Gly Leu  
130 135 140

Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile Tyr Asnn  
145 150 155 160

Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn Leu Tyr  
 165 170 175

Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr Asn Ile  
 180 185 190

Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu Ser Leu  
 195 200 205

Ser Phe Asn Ser Leu Ser His Val Pro Pro Lys Leu Pro Ser Ser Leu  
 210 215 220

Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser Glu Glu  
 225 230 235 240

Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn  
 245 250 255

Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys Asp Gly  
 260 265 270

Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu Thr Gln  
 275 280 285

Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile Asn Ala  
 290 295 300

Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu Glu Phe  
 305 310 315 320

Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr Met Leu  
 325 330 335

Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys Gly Ser  
 340 345 350

Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Leu Leu Ser  
 355 360 365

Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu Arg Glu  
 370 375 380

Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr Ile Asn  
 385 390 395 400

Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe Gln Asn  
 405 410 415

Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile Ser Pro  
 420 425 430

Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Phe Gln  
 435 440 445

Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp Pro His  
 450 455 460

Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln Cys Ala  
 465 470 475 480

Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe Phe Ile

	485	490	495
Gly Pro Asn Gln Phe Glu Asn Leu Pro Asp Ile Ala Cys Leu Asn Leu			
	500	505	510
Ser Ala Asn Ser Asn Ala Gln Val Leu Ser Gly Thr Glu Phe Ser Ala			
	515	520	525
Ile Pro His Val Lys Tyr Leu Asp Leu Thr Asn Asn Arg Leu Asp Phe			
	530	535	540
Asp Asn Ala Ser Ala Leu Thr Glu Leu Ser Asp Leu Glu Val Leu Asp			
	545	550	555
Leu Ser Tyr Asn Ser His Tyr Phe Arg Ile Ala Gly Val Thr His His			
	565	570	575
Leu Glu Phe Ile Gln Asn Phe Thr Asn Leu Lys Val Leu Asn Leu Ser			
	580	585	590
His Asn Asn Ile Tyr Thr Leu Thr Asp Lys Tyr Asn Leu Glu Ser Lys			
	595	600	605
Ser Leu Val Glu Leu Val Phe Ser Gly Asn Arg Leu Asp Ile Leu Trp			
	610	615	620
Asn Asp Asp Asp Asn Arg Tyr Ile Ser Ile Phe Lys Gly Leu Lys Asn			
	625	630	635
Leu Thr Arg Leu Asp Leu Ser Leu Asn Arg Leu Lys His Ile Pro Asn			
	645	650	655
Glu Ala Phe Leu Asn Leu Pro Ala Ser Leu Thr Glu Leu His Ile Asn			
	660	665	670
Asp Asn Met Leu Lys Phe Phe Asn Trp Thr Leu Leu Gln Gln Phe Pro			
	675	680	685
Arg Leu Glu Leu Leu Asp Leu Arg Gly Asn Lys Leu Leu Phe Leu Thr			
	690	695	700
Asp Ser Leu Ser Asp Phe Thr Ser Ser Leu Arg Thr Leu Leu Leu Ser			
	705	710	715
His Asn Arg Ile Ser His Leu Pro Ser Gly Phe Leu Ser Glu Val Ser			
	725	730	735
Ser Leu Lys His Leu Asp Leu Ser Ser Asn Leu Leu Lys Thr Ile Asn			
	740	745	750
Lys Ser Ala Leu Glu Thr Lys Thr Thr Lys Leu Ser Met Leu Glu			
	755	760	765
Leu His Gly Asn Pro Phe Glu Cys Thr Cys Asp Ile Gly Asp Phe Arg			
	770	775	780
Arg Trp Met Asp Glu His Leu Asn Val Lys Ile Pro Arg Leu Val Asp			
	785	790	795
Val Ile Cys Ala Ser Pro Gly Asp Gln Arg Gly Lys Ser Ile Val Ser			
	805	810	815
Leu Glu Leu Thr Thr Cys Val Ser Asp Val Thr Ala Val Ile Leu Phe			

Phe	Phe	Thr	Phe	Phe	Ile	Thr	Thr	Met	Val	Met	Leu	Ala	Ala	Leu	Ala
820															830
835								840							845
His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val Cys Leu															
850								855							860
Ala	Lys	Val	Lys	Gly	Tyr	Arg	Ser	Leu	Ser	Thr	Ser	Gln	Thr	Phe	Tyr
865								870							880
Asp Ala Tyr Ile Ser Tyr Asp Thr Lys Asp Ala Ser Val Thr Asp Trp															
885								890							895
Val Ile Asn Glu Leu Arg Tyr His Leu Glu Glu Ser Arg Asp Lys Asn															
900								905							910
Val	Leu	Leu	Cys	Leu	Glu	Glu	Arg	Asp	Trp	Asp	Pro	Gly	Leu	Ala	Ile
915								920							925
Ile	Asp	Asn	Leu	Met	Gln	Ser	Ile	Asn	Gln	Ser	Lys	Lys	Thr	Val	Phe
930								935							940
Val	Leu	Thr	Lys	Lys	Tyr	Ala	Lys	Ser	Trp	Asn	Phe	Lys	Thr	Ala	Phe
945								950							960
Tyr	Leu	Ala	Leu	Gln	Arg	Leu	Met	Asp	Glu	Asn	Met	Asp	Val	Ile	Ile
965								970							975
Phe	Ile	Leu	Leu	Glu	Pro	Val	Leu	Gln	His	Ser	Gln	Tyr	Leu	Arg	Leu
980								985							990
Arg	Gln	Arg	Ile	Cys	Lys	Ser	Ser	Ile	Leu	Gln	Trp	Pro	Asp	Asn	Pro
995								1000							1005
Lys	Ala	Glu	Gly	Leu	Phe	Trp		Gln	Thr	Leu	Arg	Asn	Val	Val	Leu
1010								1015							1020
Thr	Glu	Asn	Asp	Ser	Arg	Tyr	Asn	Asn	Met	Tyr	Val	Asp	Ser	Ile	
1025								1030							1035
Lys	Gln	Tyr													
1040															

<210> 53  
<211> 1041  
<212> PRT  
<213> Homo sapiens

<400> 53

Met Glu Asn Met Phe Leu Gln Ser Ser Met Leu Thr Cys Ile Phe Leu  
1 5 10 15

Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe Ser Arg  
20 25 30

Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile Ala Glu  
35 40 45

Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly Lys Tyr  
50 55 60

Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile Thr Asn  
65 70 75 80

Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu Asn His  
85 90 95

Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln Ser Asn  
100 105 110

Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn Leu Arg  
115 120 125

Glu Leu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser Gly Leu  
130 135 140

Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile Tyr Asn  
145 150 155 160

Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn Leu Tyr  
165 170 175

Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr Asn Ile  
180 185 190

Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu Ser Leu  
195 200 205

Ser Phe Asn Ser Leu Ser His Val Pro Pro Lys Leu Pro Ser Ser Leu  
210 215 220

Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser Glu Glu  
225 230 235 240

Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn  
245 250 255

Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys Asp Gly  
260 265 270

Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu Thr Gln  
275 280 285

Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile Asn Ala  
290 295 300

Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu Glu Phe  
305 310 315 320

Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr Met Leu  
325 330 335

Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys Gly Ser  
340 345 350

Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Leu Leu Ser  
355 360 365

Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu Arg Glu  
370 375 380

Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr Ile Asn

385	390	395	400												
Leu	Gly	Ile	Asn	Phe	Ile	Lys	Gln	Ile	Asp	Phe	Lys	Leu	Phe	Gln	Asn
405								410							415
Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile Ser Pro															
420								425							430
Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Phe Gln															
435								440							445
Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp Pro His															
450								455							460
Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln Cys Ala															
465								470							480
Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe Phe Ile															
485								490							495
Gly Pro Asn Gln Phe Glu Asn Leu Pro Asp Ile Ala Cys Leu Asn Leu															
500								505							510
Ser Ala Asn Ser Asn Ala Gln Val Leu Ser Gly Thr Glu Phe Ser Ala															
515								520							525
Ile Pro His Val Lys Tyr Leu Asp Leu Thr Asn Asn Arg Leu Asp Phe															
530								535							540
Asp Asn Ala Ser Ala Leu Thr Glu Leu Ser Asp Leu Glu Val Leu Asp															
545								550							560
Leu Ser Tyr Asn Ser His Tyr Phe Arg Ile Ala Gly Val Thr His His															
565								570							575
Leu Glu Phe Ile Gln Asn Phe Thr Asn Leu Lys Val Leu Asn Leu Ser															
580								585							590
His Asn Asn Ile Tyr Thr Leu Thr Asp Lys Tyr Asn Leu Glu Ser Lys															
595								600							605
Ser Leu Val Glu Leu Val Phe Ser Gly Asn Arg Leu Asp Ile Leu Trp															
610								615							620
Asn Asp Asp Asp Asn Arg Tyr Ile Ser Ile Phe Lys Gly Leu Lys Asn															
625								630							640
Leu Thr Arg Leu Asp Leu Ser Leu Asn Arg Leu Lys His Ile Pro Asn															
645								650							655
Glu Ala Phe Leu Asn Leu Pro Ala Ser Leu Thr Glu Leu His Ile Asn															
660								665							670
Asp Asn Met Leu Lys Phe Phe Asn Trp Thr Leu Leu Gln Gln Phe Pro															
675								680							685
Arg Leu Glu Leu Leu Asp Leu Arg Gly Asn Lys Leu Leu Phe Leu Thr															
690								695							700
Asp Ser Leu Ser Asp Phe Thr Ser Ser Leu Arg Thr Leu Leu Leu Ser															
705								710							720
His Asn Arg Ile Ser His Leu Pro Ser Gly Phe Leu Ser Glu Val Ser															

725	730	735
Ser Leu Lys His Leu Asp Leu Ser Ser Asn Leu Leu Lys Thr Ile Asn		
740	745	750
Lys Ser Ala Leu Glu Thr Lys Thr Thr Lys Leu Ser Met Leu Glu		
755	760	765
Leu His Gly Asn Pro Phe Glu Cys Thr Cys Asp Ile Gly Asp Phe Arg		
770	775	780
Arg Trp Met Asp Glu His Leu Asn Val Lys Ile Pro Arg Leu Val Asp		
785	790	795
795 800		
Val Ile Cys Ala Ser Pro Gly Asp Gln Arg Gly Lys Ser Ile Val Ser		
805	810	815
Leu Glu Leu Thr Thr Cys Val Ser Asp Val Thr Ala Val Ile Leu Phe		
820	825	830
Phe Phe Thr Phe Phe Ile Thr Thr Met Val Met Leu Ala Ala Leu Ala		
835	840	845
His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val Cys Leu		
850	855	860
Ala Lys Val Lys Gly Tyr Arg Ser Leu Ser Thr Ser Gln Thr Phe Tyr		
865	870	875
875 880		
Asp Ala Tyr Ile Ser Tyr Asp Thr Lys Asp Ala Ser Val Thr Asp Trp		
885	890	895
Val Ile Asn Glu Leu Arg Tyr His Leu Glu Glu Ser Arg Asp Lys Asn		
900	905	910
Val Leu Leu Cys Leu Glu Glu Arg Asp Trp Asp Pro Gly Leu Ala Ile		
915	920	925
Ile Asp Asn Leu Met Gln Ser Ile Asn Gln Ser Lys Lys Thr Val Phe		
930	935	940
Val Leu Thr Lys Lys Tyr Ala Lys Ser Trp Asn Phe Lys Thr Ala Phe		
945	950	955
955 960		
Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val Ile Ile		
965	970	975
Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr Leu Arg Leu		
980	985	990
Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln Trp Pro Asp Asn Pro		
995	1000	1005
Lys Ala Glu Gly Leu Phe Trp Gln Thr Leu Arg Asn Val Val Leu		
1010	1015	1020
Thr Glu Asn Asp Ser Arg Tyr Asn Asn Met Tyr Val Asp Ser Ile		
1025	1030	1035
Lys Gln Tyr		
1040		

<210> 54  
<211> 1059  
<212> PRT  
<213> Homo sapiens

<400> 54

Met Lys Glu Ser Ser Leu Gln Asn Ser Ser Cys Ser Leu Gly Lys Glu  
1 5 10 15

Thr Lys Lys Glu Asn Met Phe Leu Gln Ser Ser Met Leu Thr Cys Ile  
20 25 30

Phe Leu Leu Ile Ser Gly Ser Cys Glu Leu Cys Ala Glu Glu Asn Phe  
35 40 45

Ser Arg Ser Tyr Pro Cys Asp Glu Lys Lys Gln Asn Asp Ser Val Ile  
50 55 60

Ala Glu Cys Ser Asn Arg Arg Leu Gln Glu Val Pro Gln Thr Val Gly  
65 70 75 80

Lys Tyr Val Thr Glu Leu Asp Leu Ser Asp Asn Phe Ile Thr His Ile  
85 90 95

Thr Asn Glu Ser Phe Gln Gly Leu Gln Asn Leu Thr Lys Ile Asn Leu  
100 105 110

Asn His Asn Pro Asn Val Gln His Gln Asn Gly Asn Pro Gly Ile Gln  
115 120 125

Ser Asn Gly Leu Asn Ile Thr Asp Gly Ala Phe Leu Asn Leu Lys Asn  
130 135 140

Leu Arg Glu Leu Leu Glu Asp Asn Gln Leu Pro Gln Ile Pro Ser  
145 150 155 160

Gly Leu Pro Glu Ser Leu Thr Glu Leu Ser Leu Ile Gln Asn Asn Ile  
165 170 175

Tyr Asn Ile Thr Lys Glu Gly Ile Ser Arg Leu Ile Asn Leu Lys Asn  
180 185 190

Leu Tyr Leu Ala Trp Asn Cys Tyr Phe Asn Lys Val Cys Glu Lys Thr  
195 200 205

Asn Ile Glu Asp Gly Val Phe Glu Thr Leu Thr Asn Leu Glu Leu Leu  
210 215 220

Ser Leu Ser Phe Asn Ser Leu Ser His Val Pro Pro Lys Leu Pro Ser  
225 230 235 240

Ser Leu Arg Lys Leu Phe Leu Ser Asn Thr Gln Ile Lys Tyr Ile Ser  
245 250 255

Glu Glu Asp Phe Lys Gly Leu Ile Asn Leu Thr Leu Leu Asp Leu Ser  
260 265 270

Gly Asn Cys Pro Arg Cys Phe Asn Ala Pro Phe Pro Cys Val Pro Cys  
275 280 285

Asp Gly Gly Ala Ser Ile Asn Ile Asp Arg Phe Ala Phe Gln Asn Leu  
 290                    295                    300  
  
 Thr Gln Leu Arg Tyr Leu Asn Leu Ser Ser Thr Ser Leu Arg Lys Ile  
 305                    310                    315                    320  
  
 Asn Ala Ala Trp Phe Lys Asn Met Pro His Leu Lys Val Leu Asp Leu  
 325                    330                    335  
  
 Glu Phe Asn Tyr Leu Val Gly Glu Ile Ala Ser Gly Ala Phe Leu Thr  
 340                    345                    350  
  
 Met Leu Pro Arg Leu Glu Ile Leu Asp Leu Ser Phe Asn Tyr Ile Lys  
 355                    360                    365  
  
 Gly Ser Tyr Pro Gln His Ile Asn Ile Ser Arg Asn Phe Ser Lys Leu  
 370                    375                    380  
  
 Leu Ser Leu Arg Ala Leu His Leu Arg Gly Tyr Val Phe Gln Glu Leu  
 385                    390                    395                    400  
  
 Arg Glu Asp Asp Phe Gln Pro Leu Met Gln Leu Pro Asn Leu Ser Thr  
 405                    410                    415  
  
 Ile Asn Leu Gly Ile Asn Phe Ile Lys Gln Ile Asp Phe Lys Leu Phe  
 420                    425                    430  
  
 Gln Asn Phe Ser Asn Leu Glu Ile Ile Tyr Leu Ser Glu Asn Arg Ile  
 435                    440                    445  
  
 Ser Pro Leu Val Lys Asp Thr Arg Gln Ser Tyr Ala Asn Ser Ser Ser  
 450                    455                    460  
  
 Phe Gln Arg His Ile Arg Lys Arg Arg Ser Thr Asp Phe Glu Phe Asp  
 465                    470                    475                    480  
  
 Pro His Ser Asn Phe Tyr His Phe Thr Arg Pro Leu Ile Lys Pro Gln  
 485                    490                    495  
  
 Cys Ala Ala Tyr Gly Lys Ala Leu Asp Leu Ser Leu Asn Ser Ile Phe  
 500                    505                    510  
  
 Phe Ile Gly Pro Asn Gln Phe Glu Asn Leu Pro Asp Ile Ala Cys Leu  
 515                    520                    525  
  
 Asn Leu Ser Ala Asn Ser Asn Ala Gln Val Leu Ser Gly Thr Glu Phe  
 530                    535                    540  
  
 Ser Ala Ile Pro His Val Lys Tyr Leu Asp Leu Thr Asn Asn Arg Leu  
 545                    ...                550                    555                    560  
  
 Asp Phe Asp Asn Ala Ser Ala Leu Thr Glu Leu Ser Asp Leu Glu Val  
 565                    570                    575  
  
 Leu Asp Leu Ser Tyr Asn Ser His Tyr Phe Arg Ile Ala Gly Val Thr  
 580                    585                    590  
  
 His His Leu Glu Phe Ile Gln Asn Phe Thr Asn Leu Lys Val Leu Asn  
 595                    600                    605  
  
 Leu Ser His Asn Asn Ile Tyr Thr Leu Thr Asp Lys Tyr Asn Leu Glu

610	615	620
Ser Lys Ser Ile Val Glu Leu Val Phe Ser Gly Asn Arg Leu Asp Ile		
625	630	635
Leu Trp Asn Asp Asp Asp Asn Arg Tyr Ile Ser Ile Phe Lys Gly Leu		
645	650	655
Lys Asn Leu Thr Arg Leu Asp Leu Ser Leu Asn Arg Leu Lys His Ile		
660	665	670
Pro Asn Glu Ala Phe Leu Asn Leu Pro Ala Ser Leu Thr Glu Leu His		
675	680	685
Ile Asn Asp Asn Met Leu Lys Phe Phe Asn Trp Thr Leu Leu Gln Gln		
690	695	700
Phe Pro Arg Leu Glu Leu Leu Asp Leu Arg Gly Asn Lys Leu Leu Phe		
705	710	715
Leu Thr Asp Ser Leu Ser Asp Phe Thr Ser Ser Leu Arg Thr Leu Leu		
725	730	735
Leu Ser His Asn Arg Ile Ser His Leu Pro Ser Gly Phe Leu Ser Glu		
740	745	750
Val Ser Ser Leu Lys His Leu Asp Leu Ser Ser Asn Leu Leu Lys Thr		
755	760	765
Ile Asn Lys Ser Ala Leu Glu Thr Lys Thr Thr Lys Leu Ser Met		
770	775	780
Leu Glu Leu His Gly Asn Pro Phe Glu Cys Thr Cys Asp Ile Gly Asp		
785	790	795
Phe Arg Arg Trp Met Asp Glu His Leu Asn Val Lys Ile Pro Arg Leu		
805	810	815
Val Asp Val Ile Cys Ala Ser Pro Gly Asp Gln Arg Gly Lys Ser Ile		
820	825	830
Val Ser Leu Glu Leu Thr Thr Cys Val Ser Asp Val Thr Ala Val Ile		
835	840	845
Leu Phe Phe Thr Phe Ile Thr Thr Met Val Met Leu Ala Ala		
850	855	860
Leu Ala His His Leu Phe Tyr Trp Asp Val Trp Phe Ile Tyr Asn Val		
865	870	875
Cys Leu Ala Lys Val Lys Gly Tyr Arg Ser Leu Ser Thr Ser Gln Thr		
885	890	895
Phe Tyr Asp Ala Tyr Ile Ser Tyr Asp Thr Lys Asp Ala Ser Val Thr		
900	905	910
Asp Trp Val Ile Asn Glu Leu Arg Tyr His Leu Glu Ser Arg Asp		
915	920	925
Lys Asn Val Leu Leu Cys Leu Glu Glu Arg Asp Trp Asp Pro Gly Leu		
930	935	940
Ala Ile Ile Asp Asn Leu Met Gln Ser Ile Asn Gln Ser Lys Lys Thr		

945	950	955	960
Val Phe Val Leu Thr Lys Lys Tyr Ala Lys Ser Trp Asn Phe Lys Thr			
965	970	975	
Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp Glu Asn Met Asp Val			
980	985	990	
Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln His Ser Gln Tyr Leu			
995	1000	1005	
Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile Leu Gln Trp Pro			
1010	1015	1020	
Asp Asn Pro Lys Ala Glu Gly Leu Phe Trp Gln Thr Leu Arg Asn			
1025	1030	1035	
Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asn Asn Met Tyr Val			
1040	1045	1050	
Asp Ser Ile Lys Gln Tyr			
1055			

<210> 55  
<211> 3220  
<212> DNA  
<213> murine  
  
<400> 55  
attcagagtt ggatgttaag agagaaaacaa acgtttacc ttcccttgta tatagaacat 60  
ggaaaaacatg cccccctcagt catggattct gacgtgcctt tgtctgctgt cctctggAAC 120  
cagtGCCATC ttccataaaAG cgaactattc cagaagctat ccttgtgACG agataaggca 180  
caactccctt gtgattgcag aatgcaacca tcgtcaactg catgaagttc cccaaactat 240  
aggcaagtat gtgacAAACA tagacttgc agacaatgcc attacacata taacgaaaga 300  
gtccTTTCAA aagctgcaaa acctcactaa aatcgatctg aaccacaatg ccaaacaaca 360  
gcacCCAAAT gaaaataAAA atggtatgaa tattacagaa ggggcacttc tcagcctaAG 420  
aaatctaaca gtttactgc tggaagacAA ccagttatAT actatacctg ctgggttgCC 480  
tgagtCTTtG aaagaactta gcctaattca aaacaatATA tttcaggtAA ctAAAAACAA 540  
cactTTTGGG cttAGGAact tgGAAGAact ctatTTGGGc tgGAactGcT atTTAAATG 600  
taatcaaACC ttTAAGGTAG aagatGGGGc atTTAAAAT ctTatacACT tGAAGGTACT 660  
ctcattatCT ttCAATAACC ttTTCTATGT gccccccAAA ctaccaAGTT ctctAAggAA 720  
actTTTTCTG agtaatGCCA aaatcatgaa catcaCTcAg gaagacttca aaggactgga 780  
aaatTTAAACA ttactAGATC tgagtGGAAA ctgtCCAAGG tgTTACAATG ctccATTCC 840  
ttgcacacCT tgcaaggAAA actcatCCAT ccacataCAT cctctggCTT ttCAAAGTCT 900  
cacCCAACTT ctctatCTAA acCTTTCCAG cactCCCTC aggacGATTc cttctacCTG 960  
gtttgAAAAT ctgtCAAATC tGAAGGAact ccATCTTGAA ttCAACTATT taqTTCAAGA 1020

aattgcctcg gggcatttt taacaaaact acccagttt caaatccctg atttgcctt 1080  
caacttcaa tataaggaat atttacaatt tattaatatt tcctcaaatt tctctaagct 1140  
tcgttctctc aagaagttgc acttaagagg ctatgtgttc cgagaactta aaaagaagca 1200  
tttcgagcat ctccagagtc ttccaaactt ggcaaccatc aacttggca ttaactttat 1260  
tgagaaaatt gatttcaaag ctttccagaa ttttccaaa ctgcacgta tctatattc 1320  
aggaaatcgc atagcatctg tattagatgg tacagattat tccttgc gaaatcgtct 1380  
tcggaaacct ctctcaacag acgatgatga gtttgatcca cacgtgaatt tttaccatag 1440  
caccaaacct ttaataaagc cacagtgtac tgcttatggc aaggccttgg atttaagttt 1500  
gaacaatatt ttcattattt ggaaaagcca atttgaaggt tttcaggata tcgcctgctt 1560  
aaatctgtcc tc当地atgccca atactcaagt gtttaatggc acagaattct cctccatgcc 1620  
ccacattaaa tatttggatt taaccaacaa cagactagac tttgatgata acaatgcttt 1680  
cagtgatctt cacgatctg aagtgcgttgc cctgagccac aatgcacact atttcagttat 1740  
agcaggggta acgcaccgtc taggatttt ccagaactta ataaacctca ggggtttaaa 1800  
cctgagccac aatggcattt acaccctcac agaggaaagt gagctgaaaa gcatctcact 1860  
gaaagaattt gtttgcgtt gaaatcgtct tgaccattt tggaatgcaat atgatggcaat 1920  
atactggtcc atttttaaaa gtctccagaa tttgatacgc ctggacttt catacaataa 1980  
ccttcaacaa atccccaaatg gagcattcct caatttgcct cagagcctcc aagagttact 2040  
tatcagtggt aacaaattac gtttctttaa ttggacatta ctccagtatt ttcctcacct 2100  
tcacttgctg gatttatcga gaaatgagct gtattttcta cccaaattgcc tatctaagtt 2160  
tgcacattcc ctggagacac tgctactgag ccataatcat ttctctcacc taccctctgg 2220  
cttcctctcc gaagccagga atctggtgca cctggatcta agttcaaca caataaagat 2280  
gatcaataaa tcctccctgc aaaccaagat gaaaacgaac ttgtctattc tggagctaca 2340  
tgggaactat tttgactgca cgtgtgacat aagtgattt cgaagctggc tagatgaaaa 2400  
tctgaatatc acaattccta aattggtaaa tggatattgt tccaatccctg gggatcaaaa 2460  
atcaaagagt atcatgagcc tagatctcac gacttgcgtt tcggatcca ctgcagctgt 2520  
cctgttttc ctcacattcc ttaccaccc catggttatg ttggctgctc tggatccacca 2580  
cctgttttac tggatgttt ggttatcta tcacatgtgc tctgctaagt taaaaggcta 2640  
caggacttca tccacatccc aaactttcta tggatgtttt atttcttattt acaccaaaaga 2700  
tgcatctgtt actgactggg taatcaatga actgcgttac cacccgttgaag agatgtgaaga 2760  
caaaaatgttc ctccttgcgtt tagaggagag ggattggat ccaggattac ccatcattga 2820  
taacccatg cagagcataa accagagcaa gaaaacaatc tttgttttaa ccaagaaata 2880

tgccaaagagc tggaaacttta aaacagctt ctacttggcc ttgcagaggc taatggatga 2940  
 gaacatggat gtgattattt tcatcctcct ggaaccagtg ttacagtact cacagtacct 3000  
 gaggcttcgg cagaggatct gtaagagctc catcctccag tggcccaaca atccaaagc 3060  
 agaaaaacttg ttttggcaaa gtctgaaaaa tgtggtcttg actgaaaatg attcacggta 3120  
 tgacgatttg tacattgatt ccattaggca atactagtga tgggaagtca cgactctgcc 3180  
 atcataaaaa cacacagctt ctccttacaa tgaaccgaat 3220

<210> 56  
 <211> 3220  
 <212> DNA  
 <213> murine

<400> 56  
 attcagagtt ggatgttaag agagaaaacaa acgttttacc ttcccttgtc tatagaacat 60  
 ggaaaaacatg ccccctcagt catggattct gacgtgtttt tgtctgtgt cctctggAAC 120  
 cagtgcacatc ttccataaaag cgaactattc cagaagctat ctttgtgacg agataaggca 180  
 caactccctt gtgattgcag aatgcaacca tcgtcaactg catgaaggTC cccaaactat 240  
 aggcaagtat gtgacAAACA tagacttgc agacaatGCC attacacata taacgaaaga 300  
 gtcccttcaa aagctgcaaa acctcactaa aatcgatctg aaccacaatg ccaacaacAA 360  
 gcacccaaat gaaaataaaa atggtagaa tattacagaa gggcacttc tcagcctaAG 420  
 aaatctaaca gttttactgc tggaaagacAA ccagtttatAT actatacTG ctgggttgCC 480  
 tgagtctttg aaagaacttA gcctaattCA aaacaatATA ttccaggtaA ctAAAACAA 540  
 cactttggg cttaggaact tggAAAGACT ctatTTGGGc tggAACTGCT attttAAATG 600  
 taatcaaacc tttaaggtag aagatggggc attttAAAtC CTTATACACT tgaaggTACT 660  
 ctcattatCT ttcaataacc ttttctatgt gccccccAAAC ctaccaAGTT ctctAAGGAA 720  
 actttttCTG agtaatGCCA aaatcatgaa catcactcAG gaagacttCA aaggacttGGA 780  
 aaatttaaca ttactagatC tgagtggAAA ctgtccaagg tggtaAAATG ctccatttCC 840  
 ttgcacacCT tgcaaggAAA actcatCCAT ccacataCAT cctctggCTT ttCAAAGTCT 900  
 cacccAACTT ctctatCTAA acctttCCAG cacttCCCTC aggacgATTc ctttacCTG 960  
 gtttggAAAat ctgtCAAATC tgaaggAACT ccATCTTGAa ttcaacttatt tagttcaAGA 1020  
 aattgcctCG gggcatttt taacAAAact acccagttA caaatCCTTg atttgcctt 1080  
 caactttCAA tataaggaat atttacaatt tattaatatt tcctCAAATT tctctAAAGCT 1140  
 tcgttctCTC aagaagttGC acttaagagg ctatgtgttC cgagaacttA aaaagaAGCA 1200  
 ttgcagcat ctccagAGtC ttccAAactt ggcaaccatC aacttggcA ttaactttat 1260

tgagaaaatt gatttcaaag ctttccagaa ttttccaaa ctgcacgta tctatttac 1320  
aggaaatcgc atagcatctg tattagatgg tacagattat tcctcttggc gaaatcgct 1380  
tcggaaacct ctctcaacag acgatgatga gtttgatcca cacgtgaatt tttaccatag 1440  
caccaaacct ttaataaaagc cacagtgtac tgcttatggc aaggccttgg atttaagtt 1500  
gaacaatatt ttcattattt ggaaaagcca atttgaaggt tttcaggata tcgcctgctt 1560  
aaatctgtcc ttcaatgcc aatactcaagt gttaatggc acagaattct cctccatgcc 1620  
ccacattaaa tatttggatt taaccaaa cagactagac tttgatgata acaatgctt 1680  
cagtgatctt cacgatctag aagtgcgttga cctgagccac aatgcacact atttcagtt 1740  
agcaggggta acgcaccgtc taggatttat ccagaactta ataaacctca ggggtttaaa 1800  
cctgagccac aatggcattt acaccctcac agaggaaagt gagctgaaaa gcatctcact 1860  
gaaagaattt gttttcagtg gaaatcgct tgaccatttg tggaaatgcaa atgatggcaa 1920  
atactggtcc attttttaaaa gtctccagaa tttgatacgc ctggacttat catacaataa 1980  
ccttcaacaa atcccaaattt gaggatttcc caatttgcct cagagcctcc aagagttact 2040  
tatcagtggt aacaaattac gtttctttaa ttggacatta ctccagtatt ttcctcacct 2100  
tcacttgctg gatttacgta gaaatgagct gtatttcta cccaaattgcc tatctaagtt 2160  
tgcacattcc ctggagacac tgctactgag ccataatcat ttctctcacc taccctctgg 2220  
cttcctctcc gaagccagga atctggtgca cctggatcta agtttcaaca caataaagat 2280  
gatcaataaaa tcctccctgc aaaccaagat gaaaacgaac ttgtctattc tggagctaca 2340  
tgggaactat tttgactgca cgtgtgacat aagtgatttt cgaagctggc tagatgaaaa 2400  
tctgaatatc acaattccta aattggtaaa tggatgttgc tccaaatccctg gggatcaaaa 2460  
atcaaagagt atcatgagcc tagatctcac gacttgcgttgc tggatgatcca ctgcagctgt 2520  
cctgttttcc ctcacattcc ttaccaccc catggttatg ttggctgctc tggatcacc 2580  
cctgttttac tggatgttt ggttatcta tcacatgtgc tctgctaagt taaaaggcta 2640  
caggacttca tccacatccc aaactttcta tgatgcttattt atttctttagt acaccaaaga 2700  
tgcattctgtt actgactggg taatcaatga actgcgtac caccttgaag agagtgaaga 2760  
caaaagtgtc ctccttgc ttagaggagag ggattgggat ccaggattac ccatcattga 2820  
taacccatg cagacataa accagagcaa gaaaacaatc tttgtttaa ccaagaaata 2880  
tgccaagagc tggaaacttta aaacagctt ctacttggcc ttgcagagggc taatggatga 2940  
gaacatggat gtgatttattt tcattccctt ggaaccaggat ttacagtact cacagtaccc 3000  
gaggcttcgg cagaggatct gtaagagctc catcctccag tggcccaaca atcccaaagc 3060  
agaaaaacttgc ttttggcaaa gtctgaaaaa tggatgttttgc actgaaaaatg attcaggtt 3120  
tgacgatttgc tacatttgcattt ccattaggca atactgtga tggaaagtca cgactctgcc 3180

atcataaaaa cacacagctt ctccttacaa tgaaccgaat 3220

<210> 57  
<211> 1032  
<212> PRT  
<213> murine

<400> 57

Met Glu Asn Met Pro Pro Gln Ser Trp Ile Leu Thr Cys Phe Cys Leu  
1 5 10 15

Leu Ser Ser Gly Thr Ser Ala Ile Phe His Lys Ala Asn Tyr Ser Arg  
20 25 30

Ser Tyr Pro Cys Asp Glu Ile Arg His Asn Ser Leu Val Ile Ala Glu  
35 40 45

Cys Asn His Arg Gln Leu His Glu Val Pro Gln Thr Ile Gly Lys Tyr  
50 55 60

Val Thr Asn Ile Asp Leu Ser Asp Asn Ala Ile Thr His Ile Thr Lys  
65 70 75 80

Glu Ser Phe Gln Lys Leu Gln Asn Leu Thr Lys Ile Asp Leu Asn His  
85 90 95

Asn Ala Lys Gln Gln His Pro Asn Glu Asn Lys Asn Gly Met Asn Ile  
100 105 110

Thr Glu Gly Ala Leu Leu Ser Leu Arg Asn Leu Thr Val Leu Leu Leu  
115 120 125

Glu Asp Asn Gln Leu Tyr Thr Ile Pro Ala Gly Leu Pro Glu Ser Leu  
130 135 140

Lys Glu Leu Ser Leu Ile Gln Asn Asn Ile Phe Gln Val Thr Lys Asn  
145 150 155 160

Asn Thr Phe Gly Leu Arg Asn Leu Glu Arg Leu Tyr Leu Gly Trp Asn  
165 170 175

Cys Tyr Phe Lys Cys Asn Gln Thr Phe Lys Val Glu Asp Gly Ala Phe  
180 185 190

Lys Asn Leu Ile His Leu Lys Val Leu Ser Leu Ser Phe Asn Asn Leu  
195 200 205

Phe Tyr Val Pro Pro Lys Leu Pro Ser Ser Leu Arg Lys Leu Phe Leu  
210 215 220

Ser Asn Ala Lys Ile Met Asn Ile Thr Gln Glu Asp Phe Lys Gly Leu  
225 230 235 240

Glu Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn Cys Pro Arg Cys Tyr  
245 250 255

Asn Ala Pro Phe Pro Cys Thr Pro Cys Lys Glu Asn Ser Ser Ile His  
260 265 270

Ile His Pro Leu Ala Phe Gln Ser Leu Thr Gln Leu Leu Tyr Leu Asn  
 275                    280                    285  
 Leu Ser Ser Thr Ser Leu Arg Thr Ile Pro Ser Thr Trp Phe Glu Asn  
 290                    295                    300  
 Leu Ser Asn Leu Lys Glu Leu His Leu Glu Phe Asn Tyr Leu Val Gln  
 305                    310                    315                    320  
 Glu Ile Ala Ser Gly Ala Phe Leu Thr Lys Leu Pro Ser Leu Gln Ile  
 325                    330                    335  
 Leu Asp Leu Ser Phe Asn Phe Gln Tyr Lys Glu Tyr Leu Gln Phe Ile  
 340                    345                    350  
 Asn Ile Ser Ser Asn Phe Ser Lys Leu Arg Ser Leu Lys Lys Leu His  
 355                    360                    365  
 Leu Arg Gly Tyr Val Phe Arg Glu Leu Lys Lys Lys His Phe Glu His  
 370                    375                    380  
 Leu Gln Ser Leu Pro Asn Leu Ala Thr Ile Asn Leu Gly Ile Asn Phe  
 385                    390                    395                    400  
 Ile Glu Lys Ile Asp Phe Lys Ala Phe Gln Asn Phe Ser Lys Leu Asp  
 405                    410                    415  
 Val Ile Tyr Leu Ser Gly Asn Arg Ile Ala Ser Val Leu Asp Gly Thr  
 420                    425                    430  
 Asp Tyr Ser Ser Trp Arg Asn Arg Leu Arg Lys Pro Leu Ser Thr Asp  
 435                    440                    445  
 Asp Asp Glu Phe Asp Pro His Val Asn Phe Tyr His Ser Thr Lys Pro  
 450                    455                    460  
 Leu Ile Lys Pro Gln Cys Thr Ala Tyr Gly Lys Ala Leu Asp Leu Ser  
 465                    470                    475                    480  
 Leu Asn Asn Ile Phe Ile Ile Gly Lys Ser Gln Phe Glu Gly Phe Gln  
 485                    490                    495  
 Asp Ile Ala Cys Leu Asn Leu Ser Phe Asn Ala Asn Thr Gln Val Phe  
 500                    505                    510  
 Asn Gly Thr Glu Phe Ser Ser Met Pro His Ile Lys Tyr Leu Asp Leu  
 515                    520                    525  
 Thr Asn Asn Arg Leu Asp Phe Asp Asp Asn Asn Ala Phe Ser Asp Leu  
 530                    535                    540  
 His Asp Leu Glu Val Leu Asp Leu Ser His Asn Ala His Tyr Phe Ser  
 545                    550                    555                    560  
 Ile Ala Gly Val Thr His Arg Leu Gly Phe Ile Gln Asn Leu Ile Asn  
 565                    570                    575  
 Leu Arg Val Leu Asn Leu Ser His Asn Gly Ile Tyr Thr Leu Thr Glu  
 580                    585                    590  
 Glu Ser Glu Leu Lys Ser Ile Ser Leu Lys Glu Leu Val Phe Ser Gly

595	600	605
Asn Arg Leu Asp His Leu Trp	Asn Ala Asn Asp Gly Lys Tyr Trp Ser	
610	615	620
Ile Phe Lys Ser Leu Gln Asn Leu Ile Arg Leu Asp Leu Ser Tyr Asn		
625	630	640
Asn Leu Gln Gln Ile Pro Asn Gly Ala Phe Leu Asn Leu Pro Gln Ser		
645	650	655
Leu Gln Glu Leu Leu Ile Ser Gly Asn Lys Leu Arg Phe Phe Asn Trp		
660	665	670
Thr Leu Leu Gln Tyr Phe Pro His Leu His Leu Asp Leu Ser Arg		
675	680	685
Asn Glu Leu Tyr Phe Leu Pro Asn Cys Leu Ser Lys Phe Ala His Ser		
690	695	700
Leu Glu Thr Leu Leu Leu Ser His Asn His Phe Ser His Leu Pro Ser		
705	710	720
Gly Phe Leu Ser Glu Ala Arg Asn Leu Val His Leu Asp Leu Ser Phe		
725	730	735
Asn Thr Ile Lys Met Ile Asn Lys Ser Ser Leu Gln Thr Lys Met Lys		
740	745	750
Thr Asn Leu Ser Ile Leu Glu Leu His Gly Asn Tyr Phe Asp Cys Thr		
755	760	765
Cys Asp Ile Ser Asp Phe Arg Ser Trp Leu Asp Glu Asn Leu Asn Ile		
770	775	780
Thr Ile Pro Lys Leu Val Asn Val Ile Cys Ser Asn Pro Gly Asp Gln		
785	790	795
Lys Ser Lys Ser Ile Met Ser Leu Asp Leu Thr Thr Cys Val Ser Asp		
805	810	815
Thr Thr Ala Ala Val Leu Phe Phe Leu Thr Phe Leu Thr Thr Ser Met		
820	825	830
Val Met Leu Ala Ala Leu Val His His Leu Phe Tyr Trp Asp Val Trp		
835	840	845
Phe Ile Tyr His Met Cys Ser Ala Lys Leu Lys Gly Tyr Arg Thr Ser		
850	855	860
Ser Thr Ser Gln Thr Phe Tyr Asp Ala Tyr Ile Ser Tyr Asp Thr Lys		
865	870	880
Asp Ala Ser Val Thr Asp Trp Val Ile Asn Glu Leu Arg Tyr His Leu		
885	890	895
Glu Glu Ser Glu Asp Lys Ser Val Leu Leu Cys Leu Glu Glu Arg Asp		
900	905	910
Trp Asp Pro Gly Leu Pro Ile Ile Asp Asn Leu Met Gln Ser Ile Asn		
915	920	925
Gln Ser Lys Lys Thr Ile Phe Val Leu Thr Lys Lys Tyr Ala Lys Ser		

930	935	940
Trp Asn Phe Lys Thr Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp		
945	950	955
955	960	
Glu Asn Met Asp Val Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln		
965	970	975
Tyr Ser Gln Tyr Leu Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile		
980	985	990
Leu Gln Trp Pro Asn Asn Pro Lys Ala Glu Asn Leu Phe Trp Gln Ser		
995	1000	1005
Leu Lys Asn Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asp Asp		
1010	1015	1020
Leu Tyr Ile Asp Ser Ile Arg Gln Tyr		
1025	1030	
<210> 58		
<211> 1032		
<212> PRT		
<213> murine		
<400> 58		
Met Glu Asn Met Pro Pro Gln Ser Trp Ile Leu Thr Cys Phe Cys Leu		
1	5	10
		15
Leu Ser Ser Gly Thr Ser Ala Ile Phe His Lys Ala Asn Tyr Ser Arg		
20	25	30
Ser Tyr Pro Cys Asp Glu Ile Arg His Asn Ser Leu Val Ile Ala Glu		
35	40	45
Cys Asn His Arg Gln Leu His Glu Val Pro Gln Thr Ile Gly Lys Tyr		
50	55	60
Val Thr Asn Ile Asp Leu Ser Asp Asn Ala Ile Thr His Ile Thr Lys		
65	70	75
		80
Glu Ser Phe Gln Lys Leu Gln Asn Leu Thr Lys Ile Asp Leu Asn His		
85	90	95
Asn Ala Lys Gln Gln His Pro Asn Glu Asn Lys Asn Gly Met Asn Ile		
100	105	110
Thr Glu Gly Ala Leu Leu Ser Leu Arg Asn Leu Thr Val Leu Leu Leu		
115	120	125
Glu Asp Asn Gln Leu Tyr Thr Ile Pro Ala Gly Leu Pro Glu Ser Leu		
130	135	140
Lys Glu Leu Ser Leu Ile Gln Asn Asn Ile Phe Gln Val Thr Lys Asn		
145	150	155
		160
Asn Thr Phe Gly Leu Arg Asn Leu Glu Arg Leu Tyr Leu Gly Trp Asn		
165	170	175
Cys Tyr Phe Lys Cys Asn Gln Thr Phe Lys Val Glu Asp Gly Ala Phe		
180	185	190

Lys Asn Leu Ile His Leu Lys Val Leu Ser Leu Ser Phe Asn Asn Leu  
195 200 205

Phe Tyr Val Pro Pro Lys Leu Pro Ser Ser Leu Arg Lys Leu Phe Leu  
210 215 220

Ser Asn Ala Lys Ile Met Asn Ile Thr Gln Glu Asp Phe Lys Gly Leu  
225 230 235 240

Glu Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn Cys Pro Arg Cys Tyr  
245 250 255

Asn Ala Pro Phe Pro Cys Thr Pro Cys Lys Glu Asn Ser Ser Ile His  
260 265 270

Ile His Pro Leu Ala Phe Gln Ser Leu Thr Gln Leu Leu Tyr Leu Asn  
275 280 285

Leu Ser Ser Thr Ser Leu Arg Thr Ile Pro Ser Thr Trp Phe Glu Asn  
290 295 300

Leu Ser Asn Leu Lys Glu Leu His Leu Glu Phe Asn Tyr Leu Val Gln  
305 310 315 320

Glu Ile Ala Ser Gly Ala Phe Leu Thr Lys Leu Pro Ser Leu Gln Ile  
325 330 335

Leu Asp Leu Ser Phe Asn Phe Gln Tyr Lys Glu Tyr Leu Gln Phe Ile  
340 345 350

Asn Ile Ser Ser Asn Phe Ser Lys Leu Arg Ser Leu Lys Lys Leu His  
355 360 365

Leu Arg Gly Tyr Val Phe Arg Glu Leu Lys Lys Lys His Phe Glu His  
370 375 380

Leu Gln Ser Leu Pro Asn Leu Ala Thr Ile Asn Leu Gly Ile Asn Phe  
385 390 395 400

Ile Glu Lys Ile Asp Phe Lys Ala Phe Gln Asn Phe Ser Lys Leu Asp  
405 410 415

Val Ile Tyr Leu Ser Gly Asn Arg Ile Ala Ser Val Leu Asp Gly Thr  
420 425 430

Asp Tyr Ser Ser Trp Arg Asn Arg Leu Arg Lys Pro Leu Ser Thr Asp  
435 440 445

Asp Asp Glu Phe Asp Pro His Val Asn Phe Tyr His Ser Thr Lys Pro  
450 455 460

Leu Ile Lys Pro Gln Cys Thr Ala Tyr Gly Lys Ala Leu Asp Leu Ser  
465 470 475 480

Leu Asn Asn Ile Phe Ile Ile Gly Lys Ser Gln Phe Glu Gly Phe Gln  
485 490 495

Asp Ile Ala Cys Leu Asn Leu Ser Phe Asn Ala Asn Thr Gln Val Phe  
500 505 510

Asn Gly Thr Glu Phe Ser Ser Met Pro His Ile Lys Tyr Leu Asp Leu

515                        520                        525  
 Thr Asn Asn Arg Leu Asp Phe Asp Asp Asn Asn Ala Phe Ser Asp Leu  
 530                        535                        540  
  
 His Asp Leu Glu Val Leu Asp Leu Ser His Asn Ala His Tyr Phe Ser  
 545                        550                        555                        560  
  
 Ile Ala Gly Val Thr His Arg Leu Gly Phe Ile Gln Asn Leu Ile Asn  
 565                        570                        575  
  
 Leu Arg Val Leu Asn Leu Ser His Asn Gly Ile Tyr Thr Leu Thr Glu  
 580                        585                        590  
  
 Glu Ser Glu Leu Lys Ser Ile Ser Leu Lys Glu Leu Val Phe Ser Gly  
 595                        600                        605  
  
 Asn Arg Leu Asp His Leu Trp Asn Ala Asn Asp Gly Lys Tyr Trp Ser  
 610                        615                        620  
  
 Ile Phe Lys Ser Leu Gln Asn Leu Ile Arg Leu Asp Leu Ser Tyr Asn  
 625                        630                        635                        640  
  
 Asn Leu Gln Gln Ile Pro Asn Gly Ala Phe Leu Asn Leu Pro Gln Ser  
 645                        650                        655  
  
 Leu Gln Glu Leu Leu Ile Ser Gly Asn Lys Leu Arg Phe Phe Asn Trp  
 660                        665                        670  
  
 Thr Leu Leu Gln Tyr Phe Pro His Leu His Leu Leu Asp Leu Ser Arg  
 675                        680                        685  
  
 Asn Glu Leu Tyr Phe Leu Pro Asn Cys Leu Ser Lys Phe Ala His Ser  
 690                        695                        700  
  
 Leu Glu Thr Leu Leu Ser His Asn His Phe Ser His Leu Pro Ser  
 705                        710                        715                        720  
  
 Gly Phe Leu Ser Glu Ala Arg Asn Leu Val His Leu Asp Leu Ser Phe  
 725                        730                        735  
  
 Asn Thr Ile Lys Met Ile Asn Lys Ser Ser Leu Gln Thr Lys Met Lys  
 740                        745                        750  
  
 Thr Asn Leu Ser Ile Leu Glu Leu His Gly Asn Tyr Phe Asp Cys Thr  
 755                        760                        765  
  
 Cys Asp Ile Ser Asp Phe Arg Ser Trp Leu Asp Glu Asn Leu Asn Ile  
 770                        775                        780  
  
 Thr Ile Pro Lys Leu Val Asn Val Ile Cys Ser Asn Pro Gly Asp Gln  
 785                        790                        795                        800  
  
 Lys Ser Lys Ser Ile Met Ser Leu Asp Leu Thr Thr Cys Val Ser Asp  
 805                        810                        815  
  
 Thr Thr Ala Ala Val Leu Phe Phe Leu Thr Phe Leu Thr Thr Ser Met  
 820                        825                        830  
  
 Val Met Leu Ala Ala Leu Val His His Leu Phe Tyr Trp Asp Val Trp  
 835                        840                        845  
  
 Phe Ile Tyr His Met Cys Ser Ala Lys Leu Lys Gly Tyr Arg Thr Ser

850                    855                    860  
 Ser Thr Ser Gln Thr Phe Tyr Asp Ala Tyr Ile Ser Tyr Asp Thr Lys  
 865                    870                    875                    880  
  
 Asp Ala Ser Val Thr Asp Trp Val Ile Asn Glu Leu Arg Tyr His Leu  
 885                    890                    895  
  
 Glu Glu Ser Glu Asp Lys Ser Val Leu Leu Cys Leu Glu Glu Arg Asp  
 900                    905                    910  
  
 Trp Asp Pro Gly Leu Pro Ile Ile Asp Asn Leu Met Gln Ser Ile Asn  
 915                    920                    925  
  
 Gln Ser Lys Lys Thr Ile Phe Val Leu Thr Lys Lys Tyr Ala Lys Ser  
 930                    935                    940  
  
 Trp Asn Phe Lys Thr Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp  
 945                    950                    955                    960  
  
 Glu Asn Met Asp Val Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln  
 965                    970                    975  
  
 Tyr Ser Gln Tyr Leu Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile  
 980                    985                    990  
  
 Leu Gln Trp Pro Asn Asn Pro Lys Ala Glu Asn Leu Phe Trp Gln Ser  
 995                    1000                    1005  
  
 Leu Lys Asn Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asp Asp  
 1010                    1015                    1020  
  
 Leu Tyr Ile Asp Ser Ile Arg Gln Tyr  
 1025                    1030  
  
<210> 59  
<211> 1032  
<212> PRT  
<213> murine  
  
<400> 59  
  
Met Glu Asn Met Pro Pro Gln Ser Trp Ile Leu Thr Cys Phe Cys Leu  
1                        5                        10                        15  
  
Leu Ser Ser Gly Thr Ser Ala Ile Phe His Lys Ala Asn Tyr Ser Arg  
20                        25                        30  
  
Ser Tyr Pro Cys Asp Glu Ile Arg His Asn Ser Leu Val Ile Ala Glu  
35                        40                        45  
  
Cys Asn His Arg Gln Leu His Glu Val Pro Gln Thr Ile Gly Lys Tyr  
50                        55                        60  
  
Val Thr Asn Ile Asp Leu Ser Asp Asn Ala Ile Thr His Ile Thr Lys  
65                        70                        75                        80  
  
Glu Ser Phe Gln Lys Leu Gln Asn Leu Thr Lys Ile Asp Leu Asn His  
85                        90                        95  
  
Asn Ala Lys Gln Gln His Pro Asn Glu Asn Lys Asn Gly Met Asn Ile  
100                      105                        110

Thr Glu Gly Ala Leu Leu Ser Leu Arg Asn Leu Thr Val Leu Leu Leu  
 115 120 125  
 Glu Asp Asn Gln Leu Tyr Thr Ile Pro Ala Gly Leu Pro Glu Ser Leu  
 130 135 140  
 Lys Glu Leu Ser Leu Ile Gln Asn Asn Ile Phe Gln Val Thr Lys Asn  
 145 150 155 160  
 Asn Thr Phe Gly Leu Arg Asn Leu Glu Arg Leu Tyr Leu Gly Trp Asn  
 165 170 175  
 Cys Tyr Phe Lys Cys Asn Gln Thr Phe Lys Val Glu Asp Gly Ala Phe  
 180 185 190  
 Lys Asn Leu Ile His Leu Lys Val Leu Ser Leu Ser Phe Asn Asn Leu  
 195 200 205  
 Phe Tyr Val Pro Pro Lys Leu Pro Ser Ser Leu Arg Lys Leu Phe Leu  
 210 215 220  
 Ser Asn Ala Lys Ile Met Asn Ile Thr Gln Glu Asp Phe Lys Gly Leu  
 225 230 235 240  
 Glu Asn Leu Thr Leu Leu Asp Leu Ser Gly Asn Cys Pro Arg Cys Tyr  
 245 250 255  
 Asn Ala Pro Phe Pro Cys Thr Pro Cys Lys Glu Asn Ser Ser Ile His  
 260 265 270  
 Ile His Pro Leu Ala Phe Gln Ser Leu Thr Gln Leu Leu Tyr Leu Asn  
 275 280 285  
 Leu Ser Ser Thr Ser Leu Arg Thr Ile Pro Ser Thr Trp Phe Glu Asn  
 290 295 300  
 Leu Ser Asn Leu Lys Glu Leu His Leu Glu Phe Asn Tyr Leu Val Gln  
 305 310 315 320  
 Glu Ile Ala Ser Gly Ala Phe Leu Thr Lys Leu Pro Ser Leu Gln Ile  
 325 330 335  
 Leu Asp Leu Ser Phe Asn Phe Gln Tyr Lys Glu Tyr Leu Gln Phe Ile  
 340 345 350  
 Asn Ile Ser Ser Asn Phe Ser Lys Leu Arg Ser Leu Lys Lys Leu His  
 355 360 365  
 Leu Arg Gly Tyr Val Phe Arg Glu Leu Lys Lys Lys His Phe Glu His  
 370 375 380  
 Leu Gln Ser Leu Pro Asn Leu Ala Thr Ile Asn Leu Gly Ile Asn Phe  
 385 390 395 400  
 Ile Glu Lys Ile Asp Phe Lys Ala Phe Gln Asn Phe Ser Lys Leu Asp  
 405 410 415  
 Val Ile Tyr Leu Ser Gly Asn Arg Ile Ala Ser Val Leu Asp Gly Thr  
 420 425 430  
 Asp Tyr Ser Ser Trp Arg Asn Arg Leu Arg Lys Pro Leu Ser Thr Asp

435                    440                    445  
Asp Asp Glu Phe Asp Pro His Val Asn Phe Tyr His Ser Thr Lys Pro  
450                    455                    460  
  
Leu Ile Lys Pro Gln Cys Thr Ala Tyr Gly Lys Ala Leu Asp Leu Ser  
465                    470                    475                    480  
  
Leu Asn Asn Ile Phe Ile Ile Gly Lys Ser Gln Phe Glu Gly Phe Gln  
485                    490                    495  
  
Asp Ile Ala Cys Leu Asn Leu Ser Phe Asn Ala Asn Thr Gln Val Phe  
500                    505                    510  
  
Asn Gly Thr Glu Phe Ser Ser Met Pro His Ile Lys Tyr Leu Asp Leu  
515                    520                    525  
  
Thr Asn Asn Arg Leu Asp Phe Asp Asn Asn Ala Phe Ser Asp Leu  
530                    535                    540  
  
His Asp Leu Glu Val Leu Asp Leu Ser His Asn Ala His Tyr Phe Ser  
545                    550                    555                    560  
  
Ile Ala Gly Val Thr His Arg Leu Gly Phe Ile Gln Asn Leu Ile Asn  
565                    570                    575  
  
Leu Arg Val Leu Asn Leu Ser His Asn Gly Ile Tyr Thr Leu Thr Glu  
580                    585                    590  
  
Glu Ser Glu Leu Lys Ser Ile Ser Leu Lys Glu Leu Val Phe Ser Gly  
595                    600                    605  
  
Asn Arg Leu Asp His Leu Trp Asn Ala Asn Asp Gly Lys Tyr Trp Ser  
610                    615                    620  
  
Ile Phe Lys Ser Leu Gln Asn Leu Ile Arg Leu Asp Leu Ser Tyr Asn  
625                    630                    635                    640  
  
Asn Leu Gln Gln Ile Pro Asn Gly Ala Phe Leu Asn Leu Pro Gln Ser  
645                    650                    655  
  
Leu Gln Glu Leu Leu Ile Ser Gly Asn Lys Leu Arg Phe Phe Asn Trp  
660                    665                    670  
  
Thr Leu Leu Gln Tyr Phe Pro His Leu His Leu Leu Asp Leu Ser Arg  
675                    680                    685  
  
Asn Glu Leu Tyr Phe Leu Pro Asn Cys Leu Ser Lys Phe Ala His Ser  
690                    695                    700  
  
Leu Glu Thr Leu Leu Ser His Asn His Phe Ser His Leu Pro Ser  
705                    710                    715                    720  
  
Gly Phe Leu Ser Glu Ala Arg Asn Leu Val His Leu Asp Leu Ser Phe  
725                    730                    735  
  
Asn Thr Ile Lys Met Ile Asn Lys Ser Ser Leu Gln Thr Lys Met Lys  
740                    745                    750  
  
Thr Asn Leu Ser Ile Leu Glu Leu His Gly Asn Tyr Phe Asp Cys Thr  
755                    760                    765  
  
Cys Asp Ile Ser Asp Phe Arg Ser Trp Leu Asp Glu Asn Leu Asn Ile

770	775	780
Thr Ile Pro Lys Leu Val Asn Val Ile Cys Ser Asn Pro Gly Asp Gln		
785	790	795
800		
Lys Ser Lys Ser Ile Met Ser Leu Asp Leu Thr Thr Cys Val Ser Asp		
805	810	815
Thr Thr Ala Ala Val Leu Phe Phe Leu Thr Phe Leu Thr Thr Ser Met		
820	825	830
Val Met Leu Ala Ala Leu Val His His Leu Phe Tyr Trp Asp Val Trp		
835	840	845
Phe Ile Tyr His Met Cys Ser Ala Lys Leu Lys Gly Tyr Arg Thr Ser		
850	855	860
Ser Thr Ser Gln Thr Phe Tyr Asp Ala Tyr Ile Ser Tyr Asp Thr Lys		
865	870	875
880		
Asp Ala Ser Val Thr Asp Trp Val Ile Asn Glu Leu Arg Tyr His Leu		
885	890	895
Glu Glu Ser Glu Asp Lys Ser Val Leu Leu Cys Leu Glu Glu Arg Asp		
900	905	910
Trp Asp Pro Gly Leu Pro Ile Ile Asp Asn Leu Met Gln Ser Ile Asn		
915	920	925
Gln Ser Lys Lys Thr Ile Phe Val Leu Thr Lys Lys Tyr Ala Lys Ser		
930	935	940
Trp Asn Phe Lys Thr Ala Phe Tyr Leu Ala Leu Gln Arg Leu Met Asp		
945	950	955
960		
Glu Asn Met Asp Val Ile Ile Phe Ile Leu Leu Glu Pro Val Leu Gln		
965	970	975
Tyr Ser Gln Tyr Leu Arg Leu Arg Gln Arg Ile Cys Lys Ser Ser Ile		
980	985	990
Leu Gln Trp Pro Asn Asn Pro Lys Ala Glu Asn Leu Phe Trp Gln Ser		
995	1000	1005
Leu Lys Asn Val Val Leu Thr Glu Asn Asp Ser Arg Tyr Asp Asp		
1010	1015	1020
Leu Tyr Ile Asp Ser Ile Arg Gln Tyr		
1025	1030	

<210> 60  
<211> 3352  
<212> DNA  
<213> Homo sapiens

<400> 60  
aggctggtat aaaaatctta cttcctctat tctctgagcc gctgctgccc ctgtggaaag 60  
ggacctcgag tgtgaagcat cttccctgt agctgctgtc cagtctgccc gccagaccct 120  
ctggagaagc ccctgcccc cagcatgggt ttctgccgca ggcgcctgca cccgctgtct 180

ctcctggtgc aggccatcat gctggccatg accctggccc tgggtacctt gcctgccttc	240
ctaccctgtg agctccagcc caacggcctg gtgaactgca actggctgtt cctgaagtct	300
gtgccccact tctccatggc agcaccccggt ggcaatgtca ccagccttcc cttgtcctcc	360
aaccgcacatcc accacctcca tgattctgac tttgcccacc tgcccagcct gccgcacatcc	420
aacctcaagt ggaactgccc gccgggtggc ctcagcccca tgcacttccc ctgcacatg	480
accatcgagc ccagcacctt cttggctgtg cccaccctgg aagagctaaa cctgagctac	540
aacaacatca tgactgtgcc tgcgctgccc aaatccctca tatccctgtc cctcagccat	600
accaacatcc tgatgctaga ctctgcaggc ctgcggggcc tgcattgcctt ggcgttccta	660
ttcatggacg gcaactgtta ttacaagaac ccctgcaggc aggcactgga ggtggccccc	720
ggtgccctcc ttggcctggg caacctcacc cacctgtcac tcaagtacaa caacctcaact	780
gtgggtcccc gcaacactgcc ttccagcctg gagtatctgc tggatgtccta caaccgcata	840
gtcaaaactgg cgccctgagga cctggccaat ctgaccgccc tgcgtgtgct cgatgtggc	900
ggaaattgcc gccgctgcga ccacgcctcc aaccctgca tggagtgcct tcgtcacttc	960
ccccagctac atcccgatac ctgcaggccac ctgagccgtc ttgaaggcct ggtgttgaag	1020
gacagttctc tctctggct gaatgccagt tggttccgtg ggctggaaa cctccgagtg	1080
ctggacctga gtgagaactt cctctacaaa tgcattcaactt aaaccaaggc ctgcaggcc	1140
ctaacacagc tgcgcaagct taacctgtcc ttcaattacc aaaagagggt gtccttgc	1200
cacctgtctc tggcccccttc ctgcgggagc ctggcgtccc tgaaggagct ggacatgcac	1260
ggcatcttct tccgctcaact cgatgagacc acgctccggc cactggcccg cctgcccatt	1320
ctccagactc tgcgtctgca gatgaacttc atcaaccagg cccagctcgg catctcagg	1380
gccttccctg gcctgcgcta cgtggacctg tggacaacc gcatcagcgg agcttcggag	1440
ctgacagcca ccatggggga ggcagatgga gggagaagg tctggctgca gcctggggac	1500
cttgctccgg ccccagtggc cactcccagc tctgaagact tcaggccaa ctgcagcacc	1560
ctcaacttca ccttggatct gtcacggAAC aacctggtga ccgtgcagcc ggagatgttt	1620
gcccagctct cgcacctgca gtgcctgcgc ctgagccaca actgcacatc gcaggcagtc	1680
aatggctccc agttctgccc gctgaccggc ctgcagggtc tagacctgtc ccgcaataag	1740
ctggacctct accacgagca ctcattcactg gagctaccgc gactggagggc cctggacactc	1800
agctacaaca gccagccctt tggcatgcag ggcgtggcc acaacttcag ctgcgtggct	1860
cacctgcgca ccctgcgcca cctcagcctg gcccacaaca acatccacag ccaagtgtcc	1920
cagcagctct gcagtacgtc gctgcggggcc ctggacttca gcggcaatgc actggccat	1980
atgtggcccg agggagacct ctatctgcac ttcttccaag gcctgagcgg tttgatctgg	2040
ctggacttgt cccagaacccg cctgcacacc ctccctgcccc aaaccctgcg caacccccc	2100

aagagccctac aggtgctgcg tctccgtgac aattacctgg ctttctttaa gtgggtggagc	2160
ctccacttcc tgcccaaact ggaagtcctc gacctggcag gaaaccggct gaaggccctg	2220
accaatggca gcctgcctgc tggcacccgg ctccggaggc tggatgtcag ctgcaacagc	2280
atcagcttcg tggccccccgg cttctttcc aaggccaagg agctgcgaga gctcaacctt	2340
agcgccaaacg ccctcaagac agtggaccac tcctgggttg ggcccctggc gagtgccctg	2400
caaatactag atgtaagcgc caaccctctg cactgcgcct gtggggcggc ctttatggac	2460
ttcctgtctgg aggtgcaggc tgccgtgccc ggtctgcccc gcccgggtgaa gtgtggcagt	2520
ccgggcccagc tccagggcct cagcatctt gcacaggacc tgccgcctcg cctggatgag	2580
gccctctcct gggactgttt cgccctctcg ctgctggctg tggctctggg cctgggtgtg	2640
cccatgtcgc atcacctctg tggctggac ctctggtaact gttccacact gtgcctggcc	2700
tggcttcctt ggcggggggcg gcaaagtggg cgagatgagg atgcctgcct acgtatgcc	2760
ttcgtggctc tcgacaacaaac gcagagcgcga gtggcagact gggtgtacaa cgagcttcgg	2820
ggcagctgg aggagtgcgg tggcgctgg gcactccgcg tggctctggg ggaacgcgac	2880
tggctgcctg gcaaaaacctt ctggagaac ctgtggccct cggctatgg cagccgcaag	2940
acgctgtttg tgctggccca cacggaccgg gtcagtggtc tttgcgcgc cagttcctg	3000
ctggcccagc agcgccctgct ggaggaccgc aaggacgtcg tggctgtggt gatcctgagc	3060
cctgacggcc ggcgtccccg ctacgtgcgg ctgcgccagc gcctctggcc ccagagtgtc	3120
ctccctctggc cccaccagcc cagtggtcag cgccagttct gggcccgagct gggcatggcc	3180
ctgaccaggg acaaccacca cttctataac cggaaccttct gccaggacc cacggccgaa	3240
tagccgtgag ccggaatcct gcacggtgcc acctccacac tcacctcacc tctgcctgccc	3300
tggtctgacc ctcccctgct cgcctccctc accccacacc tgacacagag ca	3352

```
<210> 61
<211> 3257
<212> DNA
<213> Homo sapiens
```

```
<400> 61 ccgtcgctgc ccctgtggga agggacacctg agtgtgaagc atccctccct gtagctgctg 60  
tccagtctgc cggccagacc ctctggagaa gcccctgccc cccagcatgg gtttctgccc 120  
cagegccctg caccgcgtgt ctctcctggc gcaggccatc atgctggcca tgaccctggc 180  
cctgggttacc ttgcctgcct tcctacccttg tgagctccag cccccacggcc tggtaactg 240  
caactggctg ttccctgaagt ctgtgccccca cttctccatg gcagcaccccc gtggcaatgt 300  
caccagcctt tccttgtcct ccaaccgcattt ccaccacccatg catgattctg actttgcccc 360
```

cctgcccagc	ctgcggcatc	tcaaccaa	gtgaaactgc	ccggcggttgc	gcctcagcccc	420
catgacttc	ccctgccaca	tgaccatcga	gcccagcacc	ttttggctg	tgccaccct	480
ggaagagcta	aacctgagct	acaacaacat	catgactgtg	cctgcgctgc	ccaaatccct	540
catatccctg	tccctcagcc	ataccaacat	cctgatgcta	gactctgcca	gcctcgccgg	600
cctgcatgcc	ctgcgcttcc	tattcatgga	cggcaactgt	tattacaaga	accctgcag	660
gcaggcaactg	gagggtggccc	cgggtggccct	ccttggcctg	ggcaacctca	cccacctgtc	720
actcaagtac	aacaacctca	ctgtggtgcc	ccgcaacctg	ccttccagcc	tggagtatct	780
gctgttgtcc	tacaaccgca	tcgtcaaact	gggcgcctgag	gacctggcca	atctgaccgc	840
cctgcgtgtg	ctcgatgtgg	gcggaaatttgc	ccggccgctgc	gaccacgctc	ccaaacccctg	900
catggagtgc	cctcgtaact	tcccccagct	acatcccgtat	acttcagcc	acctgagccg	960
tcttgaaggc	ctgggtttga	aggacagttc	tcttccttgg	ctgaatgcca	gttggttccg	1020
tgggctggga	aacctccgag	tgctggacct	gagtgagaac	ttcccttata	aatgcatac	1080
taaaaaccaag	gccttccagg	gcctaacaca	gctgcgcaag	cttaacctgt	ccttcaatta	1140
ccaaaagagg	gtgtccttttgc	cccacctgtc	tctggcccttgc	tccttcggga	gcctggcgc	1200
cctgaaggag	ctggacatgc	acggcatcttgc	cttccgctca	ctcgatgaga	ccacgctccg	1260
gccactggcc	cgcctgccc	tgctccagac	tctgcgtctg	cagatgaact	tcatcaacca	1320
ggcccagctc	ggcatcttca	gggccttccc	tggcctgcgc	tacgtggacc	tgtcgacaa	1380
ccgcatcagc	ggagcttcgg	agctgacagc	caccatgggg	gaggcagatg	gagggagaa	1440
ggtctggctg	cagcctgggg	accttgc	ggcccccagtgc	gacactccca	gctctgaaga	1500
cttcaggccc	aactgcagca	ccctcaacttgc	cacccatggat	ctgtcacgg	acaacctgg	1560
gaccgtgcag	ccggagatgt	ttgcccagct	ctcgacactgc	cagtgcctgc	gcctgagcca	1620
caactgcata	tcgcaggcag	tcaatggctc	ccagttcctg	ccgctgaccgc	gtctgcaggt	1680
gctagacctg	tcccacaata	agctggacct	ctaccacgag	cactcattca	cgagactacc	1740
acgactggag	gccttggacc	tcagctacaa	cagccagccc	tttggcatgc	agggcgtgg	1800
ccacaacttc	agcttcgtgg	ctcacctgcg	cacccctgcgc	cacccatggcc	tggcccacaa	1860
caacatccac	agccaagtgt	cccagcagct	ctgcagta	tcgctgcggg	ccctggactt	1920
cagcggcaat	gcactggcc	atatgtggc	cgagggagac	ctctatctgc	acttcttcca	1980
aggcctgagc	ggtttgc	ggctggactt	gtcccagaac	cgccctgcaca	ccctcctgccc	2040
ccaaacccctg	cgcaacctcc	ccaagagcct	acaggtgctg	cgtctccgtg	acaattacct	2100
ggccttctt	aagtgggtg	gcctccactt	cctgccc	ctggaagtcc	tcgacactggc	2160
aggaaaccag	ctgaaggccc	tgaccaatgg	cagccctgcct	gctggcaccc	ggctccggag	2220
gctggatgtc	agctgcaaca	gcatcagctt	cgtggccccc	ggcttctttt	ccaggccaa	2280

ggagatgcga gagctcaacc	ttagcgccaa cgcctcaag acagtggacc actcctggtt	2340
tgggccccctg gcgagtgc	ccc tgcaaatact agatgttgc gccaaccctc tgcactgc	2400
ctgtggggcg gccttatgg	acttcctgt ggaggtgcag gctgccgtgc ccggctg	2460
cagccgggtg aagtgtggca	gtccgggcca gctccaggc ctcagcatct ttgcacagga	2520
cctgcgcctc tgcctggatg	aggccctc ctggactgt ttgcctctc cgctgctggc	2580
tgtggctctg ggcctgggtg	tgccatgt gcatcaccc tggctggg acctctggta	2640
ctgcttccac ctgtgcctgg	cctgggttcc ctgggggggg cggcaaagtg ggcgagatga	2700
ggatgcctg ccctacgtat	ccttcgttgtt ctccgacaaa acgcagagcg cagtggcaga	2760
ctgggtgtac aacgagctt	ggggggcagct ggaggagtgc cgtggcgct gggcactccg	2820
cctgtgcctg gaggaacgcg	actggctgcc tggcaaaacc ctcttgaga acctgtggc	2880
ctcggcttat ggcagccgca	agacgctgtt tggctggcc cacacggacc gggcactgg	2940
tctcttgcgc gca	ccagcttcc tgctggccca gcagcgcctg ctggaggacc gcaaggacgt	3000
cgtggcgttg	gtgatcctga gcccgtacgg ccggccgtcc cgctacgtgc ggctgcgcca	3060
gcgcctctgc	cgtccagatgt tccctcttg gccccaccag cccagtggc agcgcagatt	3120
ctggccca	ctggccatgg ccctgaccag ggacaaccac cacttctata accggactt	3180
ctgccaggaa	cccacggccg aatagccgtg agccgaaatc ctgcacggtg ccacctccac	3240
actcaccta cctctgc		3257

&lt;210&gt; 62

&lt;211&gt; 1032

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 62

Met	Gly	Phe	Cys	Arg	Ser	Ala	Leu	His	Pro	Leu	Ser	Leu	Leu	Val	Gln
1						5				10				15	

Ala	Ile	Met	Leu	Ala	Met	Thr	Leu	Ala	Leu	Gly	Thr	Leu	Pro	Ala	Phe
		20					25					30			

Leu	Pro	Cys	Glu	Leu	Gln	Pro	His	Gly	Leu	Val	Asn	Cys	Asn	Trp	Leu
						35		40				45			

Phe	Leu	Lys	Ser	Val	Pro	His	Phe	Ser	Met	Ala	Ala	Pro	Arg	Gly	Asn
						50			55			60			

Val	Thr	Ser	Leu	Ser	Leu	Ser	Ser	Asn	Arg	Ile	His	His	Leu	His	Asp
						65		70		75			80		

Ser	Asp	Phe	Ala	His	Leu	Pro	Ser	Leu	Arg	His	Leu	Asn	Leu	Lys	Trp
						85			90			95			

Asn	Cys	Pro	Pro	Val	Gly	Leu	Ser	Pro	Met	His	Phe	Pro	Cys	His	Met
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

100                    105                    110  
Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu  
115                    120                    125

Asn Leu Ser Tyr Asn Asn Ile Met Thr Val Pro Ala Leu Pro Lys Ser  
130                    135                    140

Leu Ile Ser Leu Ser Leu Ser His Thr Asn Ile Leu Met Leu Asp Ser  
145                    150                    155                    160

Ala Ser Leu Ala Gly Leu His Ala Leu Arg Phe Leu Phe Met Asp Gly  
165                    170                    175

Asn Cys Tyr Tyr Lys Asn Pro Cys Arg Gln Ala Leu Glu Val Ala Pro  
180                    185                    190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr  
195                    200                    205

Asn Asn Leu Thr Val Val Pro Arg Asn Leu Pro Ser Ser Leu Glu Tyr  
210                    215                    220

Leu Leu Leu Ser Tyr Asn Arg Ile Val Lys Leu Ala Pro Glu Asp Leu  
225                    230                    235                    240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg  
245                    250                    255

Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys Pro Arg His Phe  
260                    265                    270

Pro Gln Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly  
275                    280                    285

Leu Val Leu Lys Asp Ser Ser Leu Ser Trp Leu Asn Ala Ser Trp Phe  
290                    295                    300

Arg Gly Leu Gly Asn Leu Arg Val Leu Asp Leu Ser Glu Asn Phe Leu  
305                    310                    315                    320

Tyr Lys Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Thr Gln Leu  
325                    330                    335

Arg Lys Leu Asn Leu Ser Phe Asn Tyr Gln Lys Arg Val Ser Phe Ala  
340                    345                    350

His Leu Ser Leu Ala Pro Ser Phe Gly Ser Leu Val Ala Leu Lys Glu  
355                    360                    365

Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Asp Glu Thr Thr Leu  
370                    375                    380

Arg Pro Leu Ala Arg Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met  
385                    390                    395                    400

Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Arg Ala Phe Pro Gly  
405                    410                    415

Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ser Glu  
420                    425                    430

Leu Thr Ala Thr Met Gly Glu Ala Asp Gly Gly Glu Lys Val Trp Leu

435	440	445
Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu		
450	455	460
Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser		
465	470	475
		480
Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser		
485	490	495
His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val		
500	505	510
Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu		
515	520	525
Ser Arg Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu		
530	535	540
Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly		
545	550	555
		560
Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr		
565	570	575
Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser		
580	585	590
Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn		
595	600	605
Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe		
610	615	620
Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp Leu Ser Gln Asn Arg Leu		
625	630	635
		640
His Thr Leu Leu Pro Gln Thr Leu Arg Asn Leu Pro Lys Ser Leu Gln		
645	650	655
Val Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser		
660	665	670
Leu His Phe Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Arg		
675	680	685
Leu Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg		
690	695	700
Arg Leu Asp Val Ser Cys Asn Ser Ile Ser Phe Val Ala Pro Gly Phe		
705	710	715
		720
Phe Ser Lys Ala Lys Glu Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala		
725	730	735
Leu Lys Thr Val Asp His Ser Trp Phe Gly Pro Leu Ala Ser Ala Leu		
740	745	750
Gln Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala		
755	760	765
Ala Phe Met Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu		

770	775	780
Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Leu Ser		
785	790	795
800		
Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp		
805	810	815
Asp Cys Phe Ala Leu Ser Leu Leu Ala Val Ala Leu Gly Leu Gly Val		
820	825	830
Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His		
835	840	845
Leu Cys Leu Ala Trp Leu Pro Trp Arg Gly Arg Gln Ser Gly Arg Asp		
850	855	860
Glu Asp Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Thr Gln		
865	870	875
880		
Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Gly Gln Leu Glu		
885	890	895
Glu Cys Arg Gly Arg Trp Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp		
900	905	910
Trp Leu Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr		
915	920	925
Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser		
930	935	940
Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu		
945	950	955
960		
Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Ser Pro Asp Gly Arg		
965	970	975
Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val		
980	985	990
Leu Leu Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln		
995	1000	1005
Leu Gly Met Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg		
1010	1015	1020
Asn Phe Cys Gln Gly Pro Thr Ala Glu		
1025	1030	

<210> 63  
<211> 1032  
<212> PRT  
<213> Homo sapiens

<400> 63

Met Gly Phe Cys Arg Ser Ala Leu His Pro Leu Ser Leu Leu Val Gln		
1	5	10
15		
Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe		
20	25	30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu  
 35 40 45  
 Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly Asn  
 50 55 60  
 Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His His Leu His Asp  
 65 70 75 80  
 Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys Trp  
 85 90 95  
 Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met  
 100 105 110  
 Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu  
 115 120 125  
 Asn Leu Ser Tyr Asn Asn Ile Met Thr Val Pro Ala Leu Pro Lys Ser  
 130 135 140  
 Leu Ile Ser Leu Ser Leu Ser His Thr Asn Ile Leu Met Leu Asp Ser  
 145 150 155 160  
 Ala Ser Leu Ala Gly Leu His Ala Leu Arg Phe Leu Phe Met Asp Gly  
 165 170 175  
 Asn Cys Tyr Tyr Lys Asn Pro Cys Arg Gln Ala Leu Glu Val Ala Pro  
 180 185 190  
 Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr  
 195 200 205  
 Asn Asn Leu Thr Val Val Pro Arg Asn Leu Pro Ser Ser Leu Glu Tyr  
 210 215 220  
 Leu Leu Leu Ser Tyr Asn Arg Ile Val Lys Leu Ala Pro Glu Asp Leu  
 225 230 235 240  
 Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg  
 245 250 255  
 Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys Pro Arg His Phe  
 260 265 270  
 Pro Gln Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly  
 275 280 285  
 Leu Val Leu Lys Asp Ser Ser Leu Ser Trp Leu Asn Ala Ser Trp Phe  
 290 295 300  
 Arg Gly Leu Gly Asn Leu Arg Val Leu Asp Leu Ser Glu Asn Phe Leu  
 305 310 315 320  
 Tyr Lys Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Thr Gln Leu  
 325 330 335  
 Arg Lys Leu Asn Leu Ser Phe Asn Tyr Gln Lys Arg Val Ser Phe Ala  
 340 345 350  
 His Leu Ser Leu Ala Pro Ser Phe Gly Ser Leu Val Ala Leu Lys Glu

355                   360                   365  
Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Asp Glu Thr Thr Leu  
370                   375                   380

Arg Pro Leu Ala Arg Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met  
385                   390                   395                   400

Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Arg Ala Phe Pro Gly  
405                   410                   415

Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ser Glu  
420                   425                   430

Leu Thr Ala Thr Met Gly Glu Ala Asp Gly Gly Glu Lys Val Trp Leu  
435                   440                   445

Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu  
450                   455                   460

Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser  
465                   470                   475                   480

Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser  
485                   490                   495

His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val  
500                   505                   510

Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu  
515                   520                   525

Ser His Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu  
530                   535                   540

Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly  
545                   550                   555                   560

Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr  
565                   570                   575

Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser  
580                   585                   590

Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn  
595                   600                   605

Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe  
610                   615                   620

Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp Leu Ser Gln Asn Arg Leu  
625                   630                   635                   640

His Thr Leu Leu Pro Gln Thr Leu Arg Asn Leu Pro Lys Ser Leu Gln  
645                   650                   655

Val Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser  
660                   665                   670

Leu His Phe Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Gln  
675                   680                   685

Leu Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg

690	695	700
Arg Leu Asp Val Ser Cys Asn Ser Ile Ser Phe Val Ala Pro Gly Phe		
705	710	715
Phe Ser Lys Ala Lys Glu Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala		
725	730	735
Leu Lys Thr Val Asp His Ser Trp Phe Gly Pro Leu Ala Ser Ala Leu		
740	745	750
Gln Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala		
755	760	765
Ala Phe Met Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu		
770	775	780
Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Leu Ser		
785	790	795
Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp		
805	810	815
Asp Cys Phe Ala Leu Ser Leu Leu Ala Val Ala Leu Gly Leu Gly Val		
820	825	830
Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His		
835	840	845
Leu Cys Leu Ala Trp Leu Pro Trp Arg Gly Arg Gln Ser Gly Arg Asp		
850	855	860
Glu Asp Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Thr Gln		
865	870	875
Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Gly Gln Leu Glu		
885	890	895
Glu Cys Arg Gly Arg Trp Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp		
900	905	910
Trp Leu Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr		
915	920	925
Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser		
930	935	940
Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu		
945	950	955
Asp Arg Lys Asp Val Val Leu Val Ile Leu Ser Pro Asp Gly Arg		
965	970	975
Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val		
980	985	990
Leu Leu Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln		
995	1000	1005
Leu Gly Met Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg		
1010	1015	1020
Asn Phe Cys Gln Gly Pro Thr Ala Glu		

1025	1030
<210> 64	
<211> 333	
<212> PRT	
<213> Homo sapiens	
<400> 64	
Met Pro Met Lys Trp Ser Gly Trp Arg Trp Ser Trp Gly Pro Ala Thr	15
1 5 10	
His Thr Ala Leu Pro Pro Gln Gly Phe Cys Arg Ser Ala Leu His	30
20 25	
Pro Leu Ser Leu Leu Val Gln Ala Ile Met Leu Ala Met Thr Leu Ala	45
35 40	
Leu Gly Thr Leu Pro Ala Phe Leu Pro Cys Glu Leu Gln Pro His Gly	60
50 55	
Leu Val Asn Cys Asn Trp Leu Phe Leu Lys Ser Val Pro His Phe Ser	80
65 70 75	
Met Ala Ala Pro Arg Gly Asn Val Thr Ser Leu Ser Leu Ser Ser Asn	95
85 90	
Arg Ile His His Leu His Asp Ser Asp Phe Ala His Leu Pro Ser Leu	110
100 105	
Arg His Leu Asn Leu Lys Trp Asn Cys Pro Pro Val Gly Leu Ser Pro	125
115 120	
Met His Phe Pro Cys His Met Thr Ile Glu Pro Ser Thr Phe Leu Ala	140
130 135	
Val Pro Thr Leu Glu Glu Leu Asn Leu Ser Tyr Asn Asn Ile Met Thr	160
145 150 155	
Val Pro Ala Leu Pro Lys Ser Leu Ile Ser Leu Ser Leu Ser His Thr	175
165 170	
Asn Ile Leu Met Leu Asp Ser Ala Ser Leu Ala Gly Leu His Ala Leu	190
180 185	
Arg Phe Leu Phe Met Asp Gly Asn Cys Tyr Tyr Lys Asn Pro Cys Arg	205
195 200	
Gln Ala Leu Glu Val Ala Pro Gly Ala Leu Leu Gly Leu Gly Asn Leu	220
210 215	
Thr His Leu Ser Leu Lys Tyr Asn Asn Leu Thr Val Val Pro Arg Asn	240
225 230 235	
Leu Pro Ser Ser Leu Glu Tyr Leu Leu Leu Ser Tyr Asn Arg Ile Val	255
245 250	
Lys Leu Ala Pro Glu Asp Leu Ala Asn Leu Thr Ala Leu Arg Val Leu	270
260 265	
Asp Val Gly Gly Asn Cys Arg Arg Cys Asp His Ala Pro Asn Pro Cys	285
275 280	

Met Glu Cys Pro Arg His Phe Pro Gln Leu His Pro Asp Thr Phe Ser  
 290                    295                    300

His Leu Ser Arg Leu Glu Gly Leu Val Leu Lys Asp Ser Ser Leu Ser  
 305                    310                    315                    320

Trp Leu Asn Ala Ser Trp Phe Arg Gly Leu Gly Asn Leu  
 325                    330

<210> 65  
<211> 216  
<212> PRT  
<213> Homo sapiens

<400> 65

Met Leu Tyr Ser Ser Cys Lys Ser Arg Leu Leu Asp Ser Val Glu Gln  
 1                    5                    10                    15

Asp Phe His Leu Glu Ile Ala Lys Lys Gly Phe Cys Arg Ser Ala Leu  
 20                    25                    30

His Pro Leu Ser Leu Leu Val Gln Ala Ile Met Leu Ala Met Thr Leu  
 35                    40                    45

Ala Leu Gly Thr Leu Pro Ala Phe Leu Pro Cys Glu Leu Gln Pro His  
 50                    55                    60

Gly Leu Val Asn Cys Asn Trp Leu Phe Leu Lys Ser Val Pro His Phe  
 65                    70                    75                    80

Ser Met Ala Ala Pro Arg Gly Asn Val Thr Ser Leu Ser Leu Ser Ser  
 85                    90                    95

Asn Arg Ile His His Leu His Asp Ser Asp Phe Ala His Leu Pro Ser  
 100                    105                    110

Leu Arg His Leu Asn Leu Lys Trp Asn Cys Pro Pro Val Gly Leu Ser  
 115                    120                    125

Pro Met His Phe Pro Cys His Met Thr Ile Glu Pro Ser Thr Phe Leu  
 130                    135                    140

Ala Val Pro Thr Leu Glu Glu Leu Asn Leu Ser Tyr Asn Asn Ile Met  
 145                    150                    155                    160

Thr Val Pro Ala Leu Pro Lys Ser Leu Ile Ser Leu Ser Leu Ser His  
 165                    170                    175

Thr Asn Ile Leu Met Leu Asp Ser Ala Ser Leu Ala Gly Leu His Ala  
 180                    185                    190

Leu Arg Phe Leu Phe Met Asp Gly Asn Cys Tyr Tyr Lys Asn Pro Cys  
 195                    200                    205

Arg Gln Ala Leu Glu Val Ala Pro  
 210                    215

<210> 66

<211> 117  
<212> PRT  
<213> Homo sapiens

<400> 66

Met Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala  
1 5 10 15

Phe Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp  
20 25 30

Leu Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly  
35 40 45

Asn Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His  
50 55 60

Asp Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys  
65 70 75 80

Trp Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His  
85 90 95

Met Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu  
100 105 110

Leu Asn Leu Ser Tyr  
115

<210> 67  
<211> 1032  
<212> PRT  
<213> Homo sapiens

<400> 67

Met Gly Phe Cys Arg Ser Ala Leu His Pro Leu Ser Leu Leu Val Gln  
1 5 10 15

Ala Ile Met Leu Ala Met Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe  
20 25 30

Leu Pro Cys Glu Leu Gln Pro His Gly Leu Val Asn Cys Asn Trp Leu  
35 40 45

Phe Leu Lys Ser Val Pro His Phe Ser Met Ala Ala Pro Arg Gly Asn  
50 55 60

Val Thr Ser Leu Ser Leu Ser Ser Asn Arg Ile His His Leu His Asp  
65 70 75 80

Ser Asp Phe Ala His Leu Pro Ser Leu Arg His Leu Asn Leu Lys Trp  
85 90 95

Asn Cys Pro Pro Val Gly Leu Ser Pro Met His Phe Pro Cys His Met  
100 105 110

Thr Ile Glu Pro Ser Thr Phe Leu Ala Val Pro Thr Leu Glu Glu Leu  
115 120 125

Asn Leu Ser Tyr Asn Asn Ile Met Thr Val Pro Ala Leu Pro Lys Ser  
130 135 140

Leu Ile Ser Leu Ser Leu Ser His Thr Asn Ile Leu Met Leu Asp Ser  
145 150 155 160

Ala Ser Leu Ala Gly Leu His Ala Leu Arg Phe Leu Phe Met Asp Gly  
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Arg Gln Ala Leu Glu Val Ala Pro  
180 185 190

Gly Ala Leu Leu Gly Leu Gly Asn Leu Thr His Leu Ser Leu Lys Tyr  
195 200 205

Asn Asn Leu Thr Val Val Pro Arg Asn Leu Pro Ser Ser Leu Glu Tyr  
210 215 220

Leu Leu Leu Ser Tyr Asn Arg Ile Val Lys Leu Ala Pro Glu Asp Leu  
225 230 235 240

Ala Asn Leu Thr Ala Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg  
245 250 255

Arg Cys Asp His Ala Pro Asn Pro Cys Met Glu Cys Pro Arg His Phe  
260 265 270

Pro Gln Leu His Pro Asp Thr Phe Ser His Leu Ser Arg Leu Glu Gly  
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu Ser Trp Leu Asn Ala Ser Trp Phe  
290 295 300

Arg Gly Leu Gly Asn Leu Arg Val Leu Asp Leu Ser Glu Asn Phe Leu  
305 310 315 320

Tyr Lys Cys Ile Thr Lys Thr Lys Ala Phe Gln Gly Leu Thr Gln Leu  
325 330 335

Arg Lys Leu Asn Leu Ser Phe Asn Tyr Gln Lys Arg Val Ser Phe Ala  
340 345 350

His Leu Ser Leu Ala Pro Ser Phe Gly Ser Leu Val Ala Leu Lys Glu  
355 360 365

Leu Asp Met His Gly Ile Phe Phe Arg Ser Leu Asp Glu Thr Thr Leu  
370 375 380

Arg Pro Leu Ala Arg Leu Pro Met Leu Gln Thr Leu Arg Leu Gln Met  
385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Gly Ile Phe Arg Ala Phe Pro Gly  
405 410 415

Leu Arg Tyr Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Ala Ser Glu  
420 425 430

Leu Thr Ala Thr Met Gly Glu Ala Asp Gly Gly Glu Lys Val Trp Leu  
435 440 445

Gln Pro Gly Asp Leu Ala Pro Ala Pro Val Asp Thr Pro Ser Ser Glu

450                    455                    460  
Asp Phe Arg Pro Asn Cys Ser Thr Leu Asn Phe Thr Leu Asp Leu Ser  
465                    470                    475                    480  
  
Arg Asn Asn Leu Val Thr Val Gln Pro Glu Met Phe Ala Gln Leu Ser  
485                    490                    495  
  
His Leu Gln Cys Leu Arg Leu Ser His Asn Cys Ile Ser Gln Ala Val  
500                    505                    510  
  
Asn Gly Ser Gln Phe Leu Pro Leu Thr Gly Leu Gln Val Leu Asp Leu  
515                    520                    525  
  
Ser His Asn Lys Leu Asp Leu Tyr His Glu His Ser Phe Thr Glu Leu  
530                    535                    540  
  
Pro Arg Leu Glu Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe Gly  
545                    550                    555                    560  
  
Met Gln Gly Val Gly His Asn Phe Ser Phe Val Ala His Leu Arg Thr  
565                    570                    575  
  
Leu Arg His Leu Ser Leu Ala His Asn Asn Ile His Ser Gln Val Ser  
580                    585                    590  
  
Gln Gln Leu Cys Ser Thr Ser Leu Arg Ala Leu Asp Phe Ser Gly Asn  
595                    600                    605  
  
Ala Leu Gly His Met Trp Ala Glu Gly Asp Leu Tyr Leu His Phe Phe  
610                    615                    620  
  
Gln Gly Leu Ser Gly Leu Ile Trp Leu Asp Leu Ser Gln Asn Arg Leu  
625                    630                    635                    640  
  
His Thr Leu Leu Pro Gln Thr Leu Arg Asn Leu Pro Lys Ser Leu Gln  
645                    650                    655  
  
Val Leu Arg Leu Arg Asp Asn Tyr Leu Ala Phe Phe Lys Trp Trp Ser  
660                    665                    670  
  
Leu His Phe Leu Pro Lys Leu Glu Val Leu Asp Leu Ala Gly Asn Gln  
675                    680                    685  
  
Leu Lys Ala Leu Thr Asn Gly Ser Leu Pro Ala Gly Thr Arg Leu Arg  
690                    695                    700  
  
Arg Leu Asp Val Ser Cys Asn Ser Ile Ser Phe Val Ala Pro Gly Phe  
705                    710                    715                    720  
  
Phe Ser Lys Ala Lys Glu Leu Arg Glu Leu Asn Leu Ser Ala Asn Ala  
725                    730                    735  
  
Leu Lys Thr Val Asp His Ser Trp Phe Gly Pro Leu Ala Ser Ala Leu  
740                    745                    750  
  
Gln Ile Leu Asp Val Ser Ala Asn Pro Leu His Cys Ala Cys Gly Ala  
755                    760                    765  
  
Ala Phe Met Asp Phe Leu Leu Glu Val Gln Ala Ala Val Pro Gly Leu  
770                    775                    780  
  
Pro Ser Arg Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Leu Ser

785	790	795	800
Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Ala Leu Ser Trp			
805	810	815	
Asp Cys Phe Ala Leu Ser Leu Leu Ala Val Ala Leu Gly Leu Gly Val			
820	825	830	
Pro Met Leu His His Leu Cys Gly Trp Asp Leu Trp Tyr Cys Phe His			
835	840	845	
Leu Cys Leu Ala Trp Leu Pro Trp Arg Gly Arg Gln Ser Gly Arg Asp			
850	855	860	
Glu Asp Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Thr Gln			
865	870	875	880
Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Gly Gln Leu Glu			
885	890	895	
Glu Cys Arg Gly Arg Trp Ala Leu Arg Leu Cys Leu Glu Glu Arg Asp			
900	905	910	
Trp Leu Pro Gly Lys Thr Leu Phe Glu Asn Leu Trp Ala Ser Val Tyr			
915	920	925	
Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser			
930	935	940	
Gly Leu Leu Arg Ala Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu			
945	950	955	960
Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Ser Pro Asp Gly Arg			
965	970	975	
Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val			
980	985	990	
Leu Leu Trp Pro His Gln Pro Ser Gly Gln Arg Ser Phe Trp Ala Gln			
995	1000	1005	
Leu Gly Met Ala Leu Thr Arg Asp Asn His His Phe Tyr Asn Arg			
1010	1015	1020	
Asn Phe Cys Gln Gly Pro Thr Ala Glu			
1025	1030		
<210> 68			
<211> 3200			
<212> DNA			
<213> murine			
<400> 68			
tgtcagaggg	agcctcgaaa	gaatccctcca	tctcccaaca
		tggttctccg	tcgaaggact
ctgcacccct	tgtccctcct	ggtacaggct	gcagtgtctgg
		ctgagactct	ggccctgggt
accctgcctg	cttccttacc	ctgtgagctg	aagcctcatg
		gcctggtgaa	ctgcaattgg
ctgttcctga	agtctgtacc	ccgtttctct	gcggcagcat
		cctgttccaa	catcacccgc
ctctcccttga	tctccaaccg	tatccaccac	ctgcacaact
		ccgacttcgt	ccacctgtcc
			300

aacctgcggc agctgaacct caagtggAAC tgtccaccca ctggccttag cccccctgcac 360  
ttctcttgcc acatgaccat tgagcccaga accttcctgg ctatgcgtac actggaggag 420  
ctgaacctga gctataatgg tatcaccact gtgccccgac tgcccagctc cctggtgaat 480  
ctgagcctga gccacaccaa catcctggtt ctagatgcta acagcctcgc cgccctatac 540  
agcctgcggcg ttctcttcat ggacgggAAC tgctactaca agaaccctg cacaggagcg 600  
gtgaagggtga ccccaggcgc ctcctgggc ctgagcaatc tcacccatct gtctctgaag 660  
tataacaacc tcacaaagggt gccccgccaa ctgccccca gcctggagta ctcctggtg 720  
tcctataacc tcattgtcaa gctggggcct gaagacctgg ccaatctgac ctcccttcga 780  
gtacttgatg tgggtggaa ttgccgtcgc tgcgaccatg cccccaatcc ctgtatagaa 840  
tgtggccaaa agtccctcca cctgcacccct gagaccttcc atcacctgag ccacatggaa 900  
ggcctggtgc tgaaggacag ctctctccat acactgaact cttcctggtt ccaaggctcg 960  
gtcaacctct cggtgctgga cctaagcggag aactttctct atgaaagcat caaccacacc 1020  
aatgccttc agaacctaac ccgcctgcgc aagctcaacc tgtccttcaa ttaccgcaag 1080  
aaggatcct ttgcccgcct ccacctggca agttccttca agaacctggt gtcactgcag 1140  
gagctgaaca tgaacggcat cttctccgc tegctcaaca agtacacgct cagatggctg 1200  
gccgatctgc ccaaactcca cactctgcat cttcaaattga acttcatcaa ccaggcacag 1260  
ctcagcatct ttgggtacctt cegagccctt cgctttgtgg acttgcaga caatcgcatc 1320  
agtgggcctt caacgctgtc agaagccacc cctgaagagg cagatgtgc agagcaggag 1380  
gagctgttgt ctgcggatcc tcacccagct ccactgagca cccctgcttc taagaacttc 1440  
atggacaggt gtaagaactt caagttcacc atggacctgt ctcggAACAA cctggtgact 1500  
atcaagccag agatgttgtt caatctctca cgccctccagt gtcttagcct gagccacaac 1560  
tccattgcac aggctgtcaa tggctctcag ttccgtccgc tgactaatct gcaggctgc 1620  
gacctgtccc ataacaaact ggacttgtac cactggaaat cgttcagtga gctaccacag 1680  
ttgcaggccc tggacctgag ctacaacagc cagccctta gcatgaaggg tataggccac 1740  
aatttcagtt ttgtggccca tctgtccatg ctacacagcc ttagcctggc acacaatgac 1800  
attcataaccc gtgtgtccct acatctcaac agcaactcag tgaggttct tgacttcagc 1860  
ggcaacggta tggccgcatt gtggatgag gggggcctt atctccattt cttccaaggc 1920  
ctgagtgccc tgctgaagct ggacctgtct caaaataacc tgcatatatct ccggccccag 1980  
aaccttgaca acctccccaa gagcctgaag ctgctgagcc tccgagacaa ctacccatct 2040  
ttctttaact ggaccagtct gtccttcctg cccaaacctgg aagtccctaga cctggcaggc 2100  
aaccagctaa aggccctgac caatggcacc ctgcctaatg gcaccctcct ccagaaactg 2160

gatgtcagca gcaacagtat cgtctctgtg gtcccagcct tcttcgcct ggcggtcgag	2220
ctgaaaagg tcaacctcag ccacaacatt ctcaagacgg tggatcgctc ctggtttggg	2280
cccatgtga tgaacctgac agttcttagac gtgagaagca accctctgca ctgtgcctgt	2340
ggggcagcct tcgttagactt actgttggag gtgcagacca aggtgcctgg cctggctaata	2400
ggtgtgaagt gtggcagccc cggccagctg cagggccgta gcacatctcgc acaggacctg	2460
cggctgtgcc tggatgaggt cctcttttg gactgctttg gccttcact cttggctgtg	2520
gccccggca tgggtgggcc tataactgcac catctctgctg gctgggacgt ctggactgt	2580
tttcatctgt gcctggcatg gctaccccttg ctggcccgca gccgacgcag cgcccaagct	2640
ctcccctatg atgccttcgt ggtgttcgt aaggcacaga ggcgcgttgc ggactgggtg	2700
tataacgagc tgcgggtgcg gctggaggag cggcgccgc gccgagccct acgcttgcgt	2760
ctggaggacc gagattggct gcctggccag acgctttcg agaacctctg ggcttccatc	2820
tatggagcc gcaagactct atttgtgtcg gcccacacgg accgcgtcag tggcctcctg	2880
cgcaccagct tcctgctggc tcagcagcgc ctgttggaaag accgcaagga cgtgggttg	2940
ttgggtatcc tgcgtccggc tgcccaccgc tcccgctatg tgcgcactgcg ccagcgtctc	3000
tgccgccaga gtgtgtcttt ctggcccccag cagcccaacg ggcagggggg cttctggcc	3060
cagctgagta cagccctgac tagggacaac cgcacattct ataaccagaa cttctggcc	3120
ggacctacag cagaatagct cagagcaaca gctggaaaca gctgcatactt catgcctgg	3180
tcccgagttg ctctgcctgc	3200

<210> 69  
<211> 3471  
<212> DNA  
<213> murine

<400> 69	
tgaaagtgtc acttcctcaa ttctctgaga gaccctggtg tggAACATCA ttctctgccg	60
cccagttgt cagagggagc ctggggagaa tcctccatct cccaacatgg ttctccgtcg	120
aaggactctg cacccttgt ccctcctggt acaggctgca gtgctggctg agactctggc	180
cctgggtacc ctgcctgcct tcctaccctg tgagctgaag cctcatggcc tggggactg	240
caattggctg ttccctgaagt ctgtaccccg tttctctgcg gcagcatctt gctccaacat	300
caccgcctc tccttgatct ccaaccgtat ccaccacctg cacaactccg acttcgtcca	360
cctgtccaac ctgcggcagc tgaacctcaa gtggaactgt ccacccactg gccttagccc	420
cctgcacttc tcttgccaca tgaccattga gcccagaacc ttctggcta tgcgtacact	480
ggaggagctg aacctgagct ataatggtat caccactgtg ccccgactgc ccagctccct	540

ggtaatctg agcctgagcc acaccaacat cctggttcta gatgctaaca gcctcgccgg	600
cctatacagc ctgcgcgttc tttcatgga cgggaactgc tactacaaga acccctgcac	660
aggagcggtg aaggtgaccc caggcgccct cctgggcctg agcaatctca cccatctgtc	720
tctgaagtat aacaacctca caaaggtgcc cggccaactg cccccccagcc tggagtacct	780
cctgggtgtcc tataacctca ttgtcaagct ggggcctgaa gacctggcca atctgaccc	840
ccttcgagta cttgtatgtgg gtggaaattt ccgtcgctgc gaccatgccc ccaatccctg	900
tatagaatgt ggccaaaagt ccctccaccc gcaccctgag accttccatc acctgagcca	960
tctggaaaggc ctggtgctga aggacagctc tctccatata ctgaacttt cctggttcca	1020
aggctggtc aacctctcg tgctggacct aagcgagaac tttctctatg aaagcatcaa	1080
ccacaccaat gccttcaga acctaaccgg cctgcgcaag ctcaacctgt cttcaatta	1140
ccgcaagaag gtatcctttg cccgcctcca cctggcaagt tccttcaaga acctgggtgc	1200
actgcaggag ctgaacatga acggcatctt cttccgctcg ctcaacaatg acacgctcag	1260
atggctggcc gatctgccc aactccacac tctgcattttt caaatgaact tcatacaacca	1320
ggcacagctc agcatctttg gtacccctcg agcccttcgc tttgtggact tgcagacaa	1380
tcgcatttcgt gggccttcaa cgctgtcaga agccacccct gaagaggcag atgatgcaga	1440
gcaggaggag ctgttgcgtc cggatccctca cccagctcca ctgagcaccc ctgcttctaa	1500
gaacttcattt gacaggtgttta agaacttcaa gttcaccatg gacctgtctc ggaacaacct	1560
ggtgactatc aagccagaga tgtttgcattt tcttcacgc ctccagtgtc ttagccttag	1620
ccacaactcc attgcacagg ctgtcaatgg ctctcaggatc ctggcgctga ctaatctgca	1680
ggtgctggac ctgtccata acaaactgga cttgtaccac tggaaatcgt tcagttagct	1740
accacagttt caggccctgg acctgagcta caacagccag cccttttagca tgaagggtat	1800
aggccacaat ttcatgtttt tgaccatct gtccatgcta cagagcctta gcctggcaca	1860
caatgacatt cataccctgt tgcctcaca tctcaacagc aactcagtgttga gtttcttgc	1920
cttcagcggc aacggtatgg gccgcattgtt ggatgagggg ggcctttatc tccatttttt	1980
ccaaaggcctg agtggcctgc tgaagctgga cctgtctcaa aataacctgc atatccctcg	2040
gccccagaac ctgacaacc tccccaaagag cctgaagctg ctgagcctcc gagacaacta	2100
cctatcttc tttaactgga ccagtctgtc cttccatacc aacctggaaag tcctagaccc	2160
ggcaggcaac cagctaaagg ccctgaccaaa tggcaccctg cctaatggca ccctccctca	2220
gaaactcgat gtcagtagca acagtatcgt ctctgtggc ccagccttct tcgcctggc	2280
ggtcgagctg aaagaggtca acctcagcca caacattctc aagacggtgg atcgctcctg	2340
gtttggggccatttgtatga acctgacagt tctagacgtg agaagcaacc ctctgcactg	2400
tgcctgtggc gcagccttcg tagacttact gttggaggtg cagaccaagg tgcctggcc	2460

ggctaatggt gtgaagtgtg gcagccccgg ccagctgcag gcccgtagca tcttcgcgca 2520  
 ggacctgcgg ctgtgcctgg atgaggctct ctcttggac tgctttggcc tttcaacttt 2580  
 ggctgtggcc gtgggcattgg tggtcctat actgcaccat ctctgcggct gggacgtctg 2640  
 gtactgtttt catctgtgcc tggcatggct acctttgtg gcccgcagcc gacgcagcgc 2700  
 ccaaactctc ccttatgatg ccttcgtggt gttcgataag gcacagagcg cagttgccga 2760  
 ctgggtgtat aacgagctgc gggtgccggct ggaggagcgg cgccgtcgcc gagccctacg 2820  
 cttgtgtctg gaggaccgag attggctgcc tggccagacg ctcttcgaga acctctggc 2880  
 ttccatctat gggagccgca agactctatt tgtgctggcc cacacggacc gcgtcagtgg 2940  
 cctcctgcgc accagcttcc tgctggctca gcagcgcctg ttggaaagacc gcaaggacgt 3000  
 ggtgggtttg gtgatcctgc gtccggatgc ccacccgtcc cgctatgtgc gactgcgc 3060  
 gcgtctctgc cgccagagtg tgctttctg gccccagcag cccaaacgggc aggggggctt 3120  
 ctgggcccag ctgagttacag ccctgactag ggacaaccgc cacttctata accagaactt 3180  
 ctgcggggga cctacagcag aatagcttag agcaacacgt ggaaacacgt gcatcttcat 3240  
 gcctggttcc cgagttgctc tgctgcctt gctctgtctt actacaccgc tatttggcaa 3300  
 gtgcgcata tatgctacca agccaccagg cccacggagc aaagggtggc agtaaagggt 3360  
 agttttcttc ccatgcatct ttcaggagag tgaagataga caccagaccc acacagaaca 3420  
 ggactggagt tcattctctg cccctccacc ccactttgcc tgtctctgta t 3471

<210> 70  
 <211> 3340  
 <212> DNA  
 <213> murine

<400> 70  
 tctctgagag accctgggtgt ggaacatcat tctctgcgc ccagtttgtc agagggagcc 60  
 tcgggagaat cctccatctc ccaacatggt tctccgtcga aggactctgc accccttgc 120  
 cctctggta caggctgcag tgctggctga gactctggcc ctgggtaccc tgccgcctt 180  
 cctaccctgt gagctgaagc ctcatggct ggtggactgc aattggctgt tcctgaagtc 240  
 tgtacccctgt ttctctgcgg cagcatctg ctccaacatc accccgcctt ctttgatctc 300  
 caaccgtatc caccacactgc acaactccga cttcgccac ctgtccaacc tgccgcagct 360  
 gaacctcaag tggaaactgtc cacccactgg ccttagcccc ctgcaacttct cttgccacat 420  
 gaccattgag cccagaacact tcctggctat gcgtacactg gaggagctga acctgagcta 480  
 taatggtatac accactgtgc cccgactgcc cagctccctg gtgaatctga gcctgagcca 540  
 caccaacatc ctgggtcttag atgctaacag cctcgccggc ctatacagcc tgccgcgttct 600

cttcatggac gggaaactgtc actacaagaa cccctgcaca ggagcggtga aggtgaccac	660
aggcgccctc ctgggcctga gcaatctcac ccatactgtct ctgaagtata acaacctcac	720
aaaggtgccc cgccaactgc cccccagcct ggagtacctc ctggtgtcct ataacctcat	780
tgtcaagctg gggctgaag acctggccaa tctgacctcc cttcgagtagtac ttgatgtggg	840
tgggaattgc cgtcgctgct accatgcccc caatccctgt atagaatgtg gccaaaagtc	900
cctccacctg caccctgaga cttccatca cctgagccat ctgaaaggcc tggtgctgaa	960
ggacagctct ctccatacac tgaactcttc ctggttccaa ggtctggtca acctctcggt	1020
gctggaccta agcgagaact ttctctatga aagcatcaac cacaccaatg ctttcagaa	1080
cctaaccgc ctgcgcaagc tcaaccctgtc cttcaattac cgcaagaagg tatcctttgc	1140
ccgcctccac ctggcaagtt cttcaagaa cctgggtgtca ctgcaggagc tgaacatgaa	1200
cggcatcttc ttccgctcgc tcaacaagta cacgctcaga tggctggccg atctgccccaa	1260
actccacact ctgcatcttc aaatgaactt catcaaccag gcacagctca gcatctttgg	1320
tacctccga gcccttcgct ttgtggactt gtcagacaat cgcatcagtg ggccttcaac	1380
gtgtcagaa gccacccctg aagaggcaga tgatgcagag caggaggagc tgggtctgc	1440
ggatcctcac ccagctccac tgagcacccc tgcttctaag aacttcatgg acaggtgtaa	1500
gaacttcaag ttccacatgg acctgtctcg gaacaacctg gtgactatca agccagagat	1560
gtttgtcaat ctctcacgco tccagtgtct tagcctgagc cacaactcca ttgcacaggc	1620
tgtcaatggc tctcagtctc tgccgctgac taatctgcag gtgctggacc tgtccataaa	1680
caaactggac ttgttaccact ggaaatcggt cagttagtca ccacagttgc aggccctgga	1740
cctgggctac aacagccagc ctttagcat aaagggtata ggccacaatt tcagtttgt	1800
ggcccatctg tccatgctac acagccttag cctggcacac aatgacattc ataccgtgt	1860
gtcctcacat ctcaacagca actcagttag gtttcttgac ttcagcggca acggatggg	1920
ccgcatgtgg gatgaggggg gccttatct ccatttcttc caaggcctga gtggcctgct	1980
gaagctggac ctgtctcaaa ataacctgca tattctccgg ccccagaacc ttgacaacct	2040
ccccaaagagc ctgaagctgc tgagcctccg agacaactac ctatcttct ttaactggac	2100
cagtctgtcc ttctgccccca acctggaaatg cctagacctg gcaggcaacc agctaaaggc	2160
cctgaccaat ggcacccctgc ctaatggcac cttccctccag aaactggatg tcagcagcaa	2220
cagtatcgtc tctgtggtcc cagccttctt cgctctggcg gtcgagctga aagaggtcaa	2280
cctcagccac aacattctca agacggtgga tcgctctgg tttggccca ttgtgatgaa	2340
cctgacagtt ctagacgtga gaagcaaccc tctgcactgt gcctgtgggg cagccttcgt	2400
agacttactg ttggaggtgc agaccaaggt gcctggcctg gctaattggtg tgaagtgtgg	2460
cagccccggc cagctgcagg gcccgtacat cttcgacacag gacctgcggc tggcctgga	2520

tgaggtcctc	tcttggact	gctttggcct	ttcaactcttg	gctgtggccg	tgggcattgt	2580
gggcctata	ctgcaccatc	tctgcggctg	ggacgtctgg	tactgtttc	atctgtgcct	2640
ggcatggcta	cctttgctgg	cccgcaagccg	acgcagcgcc	caagctctcc	cctatgatgc	2700
cttcgtggtg	ttcgataagg	cacagagcgc	agttgcggac	tgggtgtata	acgagctgcf	2760
ggtgcggctg	gaggggcggc	gcccgtcccg	agccctacgc	ttgtgtctgg	aggaccgaga	2820
ttggctgcct	ggccagacgc	tcttcgagaa	cctctggct	tccatctatg	ggagccgcaa	2880
gactctat	ttgtgcgtcc	acacggaccg	cgtcagtggc	ctccctgcga	ccagcttcct	2940
gctggctcag	cagcgcctgt	tggaagaccc	caaggacgtg	gtgggtgtgg	tgatcctgcg	3000
tccggatgcc	caccgctccc	gctatgtgcg	actgcgcacag	cgtctctgcc	gccagagtgt	3060
gctctttgg	ccccagcagc	ccaacgggca	ggggggcttc	tgggcccagc	tgagtagcagc	3120
cctgactagg	gacaacccgccc	acttctataa	ccagaacttc	tgccggggac	ctacagcaga	3180
atagctcaga	gcaacagctg	gaaacagctg	catcttcatg	cctgggttccc	gagttgtct	3240
gcctgcctt	ctctgtctta	ctacaccgct	atttggcaag	tgcgcaatat	atgctaccaa	3300
gccaccgggc	ccacggagca	aagggtggct	gtaaaagggt			3340

<210> 71  
<211> 3471  
<212> DNA  
<213> murine

<400> 71						
tgaaaagtgtc	acttcctcaa	ttctctgaga	gaccctggtg	tggAACATCA	ttctctgcgg	60
cccagtttgt	cagagggagc	ctcgggagaa	tcctccatct	cccaacatgg	ttctccgtcg	120
aaggactctg	cacccttgt	ccctcctggt	acaggctgca	gtgctggctg	agactctggc	180
cctgggtacc	ctgcctgcct	tcctaccctg	tgagctgaag	cctcatggcc	tgggtggactg	240
caattggctg	ttcctgaagt	ctgtaccccg	tttctctgcg	gcagcatcct	gctccaacat	300
cacccgcctc	tccttgatct	ccaaaccttat	ccaccacctg	cacaactccg	acttgcgtcca	360
cctgtccaac	ctgcggcagc	tgaacctcaa	gtggaactgt	ccacccactg	gccttagccc	420
cctgcacttc	tcttgcacaca	tgaccattga	gcccagaacc	ttcctggcta	tgcgtacact	480
ggaggagctg	aacctgagct	ataatggtat	caccactgtg	ccccgactgc	ccagctccct	540
ggtaaatctg	agcctgagcc	acaccaacat	cctgggttcta	gatgctaaca	gcctgcggg	600
cctatacagc	ctgcgcgttc	tcttcatgga	cgggaactgc	tactacaaga	acccctgcac	660
aggagcggtg	aagggtgaccc	caggcgcct	cctgggcctg	agcaatctca	cccatctgtc	720
tctgaagtat	aacaacctca	caaaggtgcc	ccgccaactg	ccccccagcc	tggagtacct	780

cctggtgtcc tataaccta ttgtcaagct gggcctgaa gacctggcca atctgaccc 840  
ccttcgagta cttgtatgtgg gtggaaatttgc cgctcgctgc gaccatgccccc 900  
tatagaatgt ggccaaaagt ccctccaccc gcacccttag accttccatc acctgagcca 960  
tctggaaaggc ctggtgctga aggacagctc tctccataca ctgaactctt cctggttcca 1020  
aggctggtc aacctctcggtg tgctggacct aagcgagaac tttctctatg aaagcatcaa 1080  
ccacaccaat gccttcaga acctaaccgg cctgcgcag ctcaacctgt ccttcattaa 1140  
ccgcaagaag gtatcctttg cccgcctcca cctggcaagt tccttcaga acctgggtgc 1200  
actgcaggag ctgaacatga acggcatctt ctccgcctcg ctcaacaatgt acacgctcag 1260  
atggctggcc gatctgccc aactccacac tctgcattttt caaatgaact tcatcaacca 1320  
ggcacagctc agcatctttg gtaccttccg agcccttcgc tttgtggact tgtcagacaa 1380  
tcgcattcgt gggcattcaa cgctgtcaga agccacccct gaagaggcag atgatgcaga 1440  
gcaggaggag ctgttgcgtcg cggatcctca cccagctcca ctgagcaccc ctgcttctaa 1500  
gaacttcattt gacagggtgttta agaacttcaa gttcaccatg gacctgtctc ggaacaacct 1560  
ggtgactatc aagccagaga tgggttgcattt tctctcacgc ctccagtgtc ttagcctgag 1620  
ccacaactcc attgcacagg ctgtcaatgg ctctcagttc ctgcccgttca ctaatctgca 1680  
ggtgcgtggac ctgtccata acaaacttggat cttgttccac tggaaatctgt tcagtggact 1740  
accacagttt caggccctgg acctgagcta caacagccag cccttttagca tgaagggtat 1800  
aggccacaat ttcatgttttgc tgaccatct gtccatgttca cagagcctta gcctggcaca 1860  
caatgacatt catacccggtg tggcctcaca tctcaacagc aactcagtgttca ggtttcttgc 1920  
cttcagcggc aacggtatgg gcccgtatgttca cttgttccac tggaaatctgt tcagtggact 1980  
ccaaaggcctg agtggcctgc tgaagcttggat cctgtctcaa aataacctgc atatcctccg 2040  
gccccagaac cttgacaacc tccccaaagag cctgaagctg ctgagcctcc gagacaacta 2100  
cctatcttcc tttaacttggat cctgttccac aaccttggaaatcccttgc tccatcttgc 2160  
ggcaggcaac cagctaaagg ccctgaccaa tggcaccctg cctaatggca ccctcccttca 2220  
gaaactcgat gtcagtagca acagtatctgt ctctgtggat ccagccttgc tccatcttgc 2280  
ggtcgagctg aaagaggtca acctcagcca caacattctc aagacgggtgg atcgttccctg 2340  
gtttggccccc attgtatgttca acctgacagt tcttagacgttca agaagcaacc ctctgcactg 2400  
tgcctgtggat gcagccttcgttca tagacttact gttggaggttca cagaccaagg tgcctggat 2460  
ggctaatggat gtgaagttgttca gcaagccccgg ccagctgcag ggccgttca tcttcgttgc 2520  
ggacctgcgg ctgtgcctgg atgaggatctt ctcttggat tgccttggat tttcaatcttgc 2580  
ggctgtggcc gtggggcatgg tggcgttgcatttactgcaccat ctctgcggat gggacgttgc 2640  
gtactgtttt catctgtgcc tggcgttgcatttactgcaccat ctctgcggat gggacgttgc 2700

ccaaactctc ccttatgatg cttcggtggt gttcgataag gcacagagcg cagttgccga 2760  
 ctgggtgtat aacgagctgc gggtgccgct ggaggagcgg cgccgtcgcc gagccctacg 2820  
 cttgtgtctg gaggaccgag attggctgcc tggccagacg ctcttcgaga acctctggc 2880  
 ttccatctat gggagccgca agactctatt tgtgctggcc cacacggacc gcgtcagtgg 2940  
 cctcctgcgc accagcttcc tgctggctca gcagcgcctg ttgaaagacc gcaaggacgt 3000  
 ggtgggtttg gtgatcctgc gtccggatgc ccacccgtcc cgctatgtgc gactgcgc 3060  
 ggtctctgc cgccagagtg tgctcttcg gccccagcag cccaacggc aggggggctt 3120  
 ctggcccag ctgagtagcag ccctgactag ggacaaccgc cacttctata accagaactt 3180  
 ctgcggggga cctacagcag aatagctcag agcaacagct ggaaacagct gcatcttcat 3240  
 gcctggttcc cgagttgctc tgcctgcctt gctctgtctt actacaccgc tatggcaa 3300  
 gtgcgcata tatgctacca agccaccagg cccacggagc aaaggttgc agtaaagggt 3360  
 agtttcttc ccatgcacat ttcaggagag tgaagataga caccagaccc acacagaaca 3420  
 ggactggagt tcattctctg cccctccacc ccactttgcc tgtctctgta t 3471

<210> 72  
 <211> 1032  
 <212> PRT  
 <213> murine

<400> 72

Met Val Leu Arg Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln  
 1 5 10 15

Ala Ala Val Leu Ala Glu Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe  
 20 25 30

Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu  
 35 40 45

Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ser Cys Ser Asn  
 50 55 60

Ile Thr Arg Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asn  
 65 70 75 80

Ser Asp Phe Val His Leu Ser Asn Leu Arg Gln Leu Asn Leu Lys Trp  
 85 90 95

Asn Cys Pro Pro Thr Gly Leu Ser Pro Leu His Phe Ser Cys His Met  
 100 105 110

Thr Ile Glu Pro Arg Thr Phe Leu Ala Met Arg Thr Leu Glu Glu Leu  
 115 120 125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser  
 130 135 140

Leu Val Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala  
145 150 155 160

Asn Ser Leu Ala Gly Leu Tyr Ser Leu Arg Val Leu Phe Met Asp Gly  
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Thr Gly Ala Val Lys Val Thr Pro  
180 185 190

Gly Ala Leu Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr  
195 200 205

Asn Asn Leu Thr Lys Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr  
210 215 220

Leu Leu Val Ser Tyr Asn Leu Ile Val Lys Leu Gly Pro Glu Asp Leu  
225 230 235 240

Ala Asn Leu Thr Ser Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg  
245 250 255

Arg Cys Asp His Ala Pro Asn Pro Cys Ile Glu Cys Gly Gln Lys Ser  
260 265 270

Leu His Leu His Pro Glu Thr Phe His His Leu Ser His Leu Glu Gly  
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu His Thr Leu Asn Ser Ser Trp Phe  
290 295 300

Gln Gly Leu Val Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu  
305 310 315 320

Tyr Glu Ser Ile Asn His Thr Asn Ala Phe Gln Asn Leu Thr Arg Leu  
325 330 335

Arg Lys Leu Asn Leu Ser Phe Asn Tyr Arg Lys Lys Val Ser Phe Ala  
340 345 350

Arg Leu His Leu Ala Ser Ser Phe Lys Asn Leu Val Ser Leu Gln Glu  
355 360 365

Leu Asn Met Asn Gly Ile Phe Phe Arg Ser Leu Asn Lys Tyr Thr Leu  
370 375 380

Arg Trp Leu Ala Asp Leu Pro Lys Leu His Thr Leu His Leu Gln Met  
385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala  
405 410 415

Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr  
420 425 430

Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Gln Glu Glu  
435 440 445

Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser  
450 455 460

Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu

465                  470                  475                  480  
Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu  
485                  490                  495  
  
Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala  
500                  505                  510  
  
Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp  
515                  520                  525  
  
Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu  
530                  535                  540  
  
Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe  
545                  550                  555                  560  
  
Ser Met Lys Gly Ile Gly His Asn Phe Ser Phe Val Ala His Leu Ser  
565                  570                  575  
  
Met Leu His Ser Leu Ser Leu Ala His Asn Asp Ile His Thr Arg Val  
580                  585                  590  
  
Ser Ser His Leu Asn Ser Asn Ser Val Arg Phe Leu Asp Phe Ser Gly  
595                  600                  605  
  
Asn Gly Met Gly Arg Met Trp Asp Glu Gly Gly Leu Tyr Leu His Phe  
610                  615                  620  
  
Phe Gln Gly Leu Ser Gly Leu Leu Lys Leu Asp Leu Ser Gln Asn Asn  
625                  630                  635                  640  
  
Leu His Ile Leu Arg Pro Gln Asn Leu Asp Asn Leu Pro Lys Ser Leu  
645                  650                  655  
  
Lys Leu Leu Ser Leu Arg Asp Asn Tyr Leu Ser Phe Phe Asn Trp Thr  
660                  665                  670  
  
Ser Leu Ser Phe Leu Pro Asn Leu Glu Val Leu Asp Leu Ala Gly Asn  
675                  680                  685  
  
Gln Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu  
690                  695                  700  
  
Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Ser Val Val Pro Ala  
705                  710                  715                  720  
  
Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn  
725                  730                  735  
  
Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn  
740                  745                  750  
  
Leu Thr Val Leu Asp Val Arg Ser Asn Pro Leu His Cys Ala Cys Gly  
755                  760                  765  
  
Ala Ala Phe Val Asp Leu Leu Glu Val Gln Thr Lys Val Pro Gly  
770                  775                  780  
  
Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg  
785                  790                  795                  800  
  
Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Val Leu Ser

385	390	395	400
Asn Phe Ile Asn Gln Ala Gln Leu Ser	Ile Phe Gly Thr Phe Arg Ala		
405	410	415	
Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr			
420	425	430	
Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Gln Glu Glu			
435	440	445	
Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser			
450	455	460	
Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu			
465	470	475	480
Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu			
485	490	495	
Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala			
500	505	510	
Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp			
515	520	525	
Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu			
530	535	540	
Leu Pro Gln Leu Gln Ala Leu Asp Leu Gly Tyr Asn Ser Gln Pro Phe			
545	550	555	560
Ser Ile Lys Gly Ile Gly His Asn Phe Ser Phe Val Ala His Leu Ser			
565	570	575	
Met Leu His Ser Leu Ser Leu Ala His Asn Asp Ile His Thr Arg Val			
580	585	590	
Ser Ser His Leu Asn Ser Asn Ser Val Arg Phe Leu Asp Phe Ser Gly			
595	600	605	
Asn Gly Met Gly Arg Met Trp Asp Glu Gly Gly Leu Tyr Leu His Phe			
610	615	620	
Phe Gln Gly Leu Ser Gly Leu Leu Lys Leu Asp Leu Ser Gln Asn Asn			
625	630	635	640
Leu His Ile Leu Arg Pro Gln Asn Leu Asp Asn Leu Pro Lys Ser Leu			
645	650	655	
Lys Leu Leu Ser Leu Arg Asp Asn Tyr Leu Ser Phe Phe Asn Trp Thr			
660	665	670	
Ser Leu Ser Phe Leu Pro Asn Leu Glu Val Leu Asp Leu Ala Gly Asn			
675	680	685	
Gln Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu			
690	695	700	
Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Ser Val Val Pro Ala			
705	710	715	720
Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn			

	725	730	735
Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn			
740	745		750
Leu Thr Val Leu Asp Val Arg Ser Asn Pro Leu His Cys Ala Cys Gly			
755	760		765
Ala Ala Phe Val Asp Leu Leu Glu Val Gln Thr Lys Val Pro Gly			
770	775		780
Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg			
785	790		795
Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Val Leu Ser			
805	810		815
Trp Asp Cys Phe Gly Leu Ser Leu Leu Ala Val Ala Val Gly Met Val			
820	825		830
Val Pro Ile Leu His His Leu Cys Gly Trp Asp Val Trp Tyr Cys Phe			
835	840		845
His Leu Cys Leu Ala Trp Leu Pro Leu Leu Ala Arg Ser Arg Arg Ser			
850	855		860
Ala Gln Ala Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln			
865	870		875
Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu			
885	890		895
Gly Arg Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Asp Arg Asp			
900	905		910
Trp Leu Pro Gly Gln Thr Leu Phe Glu Asn Leu Trp Ala Ser Ile Tyr			
915	920		925
Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser			
930	935		940
Gly Leu Leu Arg Thr Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu			
945	950		955
Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Arg Pro Asp Ala His			
965	970		975
Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val			
980	985		990
Leu Phe Trp Pro Gln Gln Pro Asn Gly Gln Gly Gly Phe Trp Ala Gln			
995	1000		1005
Leu Ser Thr Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln			
1010	1015		1020
Asn Phe Cys Arg Gly Pro Thr Ala Glu			
1025	1030		

<210> 74  
<211> 1032  
<212> PRT

<213> murine  
<400> 74

Met Val Leu Arg Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln  
1 5 10 15

Ala Ala Val Leu Ala Glu Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe  
20 25 30

Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu  
35 40 45

Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ser Cys Ser Asn  
50 55 60

Ile Thr Arg Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asn  
65 70 75 80

Ser Asp Phe Val His Leu Ser Asn Leu Arg Gln Leu Asn Leu Lys Trp  
85 90 95

Asn Cys Pro Pro Thr Gly Leu Ser Pro Leu His Phe Ser Cys His Met  
100 105 110

Thr Ile Glu Pro Arg Thr Phe Leu Ala Met Arg Thr Leu Glu Glu Leu  
115 120 125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser  
130 135 140

Leu Val Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala  
145 150 155 160

Asn Ser Leu Ala Gly Leu Tyr Ser Leu Arg Val Leu Phe Met Asp Gly  
165 170 175

Asn Cys Tyr Tyr Lys Asn Pro Cys Thr Gly Ala Val Lys Val Thr Pro  
180 185 190

Gly Ala Leu Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr  
195 200 205

Asn Asn Leu Thr Lys Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr  
210 215 220

Leu Leu Val Ser Tyr Asn Leu Ile Val Lys Leu Gly Pro Glu Asp Leu  
225 230 235 240

Ala Asn Leu Thr Ser Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg  
245 250 255

Arg Cys Asp His Ala Pro Asn Pro Cys Ile Glu Cys Gly Gln Lys Ser  
260 265 270

Leu His Leu His Pro Glu Thr Phe His His Leu Ser His Leu Glu Gly  
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu His Thr Leu Asn Ser Ser Trp Phe  
290 295 300

Gln Gly Leu Val Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu  
305 310 315 320

Tyr Glu Ser Ile Asn His Thr Asn Ala Phe Gln Asn Leu Thr Arg Leu  
325 330 335

Arg Lys Leu Asn Leu Ser Phe Asn Tyr Arg Lys Lys Val Ser Phe Ala  
340 345 350

Arg Leu His Leu Ala Ser Ser Phe Lys Asn Leu Val Ser Leu Gln Glu  
355 360 365

Leu Asn Met Asn Gly Ile Phe Phe Arg Ser Leu Asn Lys Tyr Thr Leu  
370 375 380

Arg Trp Leu Ala Asp Leu Pro Lys Leu His Thr Leu His Leu Gln Met  
385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala  
405 410 415

Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr  
420 425 430

Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Gln Glu Glu  
435 440 445

Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser  
450 455 460

Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu  
465 470 475 480

Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu  
485 490 495

Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala  
500 505 510

Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp  
515 520 525

Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu  
530 535 540

Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe  
545 550 555 560

Ser Met Lys Gly Ile Gly His Asn Phe Ser Phe Val Thr His Leu Ser  
565 570 575

Met Leu Gln Ser Leu Ser Leu Ala His Asn Asp Ile His Thr Arg Val  
580 585 590

Ser Ser His Leu Asn Ser Asn Ser Val Arg Phe Leu Asp Phe Ser Gly  
595 600 605

Asn Gly Met Gly Arg Met Trp Asp Glu Gly Gly Leu Tyr Leu His Phe  
610 615 620

Phe Gln Gly Leu Ser Gly Leu Leu Lys Leu Asp Leu Ser Gln Asn Asn  
625 630 635 640

Leu His Ile Leu Arg Pro Gln Asn Leu Asp Asn Leu Pro Lys Ser Leu

645                    650                    655  
Lys Leu Leu Ser Leu Arg Asp Asn Tyr Leu Ser Phe Phe Asn Trp Thr  
660                    665                    670

Ser Leu Ser Phe Leu Pro Asn Leu Glu Val Leu Asp Leu Ala Gly Asn  
675                    680                    685

Gln Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu  
690                    695                    700

Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Ser Val Val Pro Ala  
705                    710                    720

Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn  
725                    730                    735

Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn  
740                    745                    750

Leu Thr Val Leu Asp Val Arg Ser Asn Pro Leu His Cys Ala Cys Gly  
755                    760                    765

Ala Ala Phe Val Asp Leu Leu Glu Val Gln Thr Lys Val Pro Gly  
770                    775                    780

Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg  
785                    790                    800

Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Val Leu Ser  
805                    810                    815

Trp Asp Cys Phe Gly Leu Ser Leu Leu Ala Val Ala Val Gly Met Val  
820                    825                    830

Val Pro Ile Leu His His Leu Cys Gly Trp Asp Val Trp Tyr Cys Phe  
835                    840                    845

His Leu Cys Leu Ala Trp Leu Pro Leu Leu Ala Arg Ser Arg Arg Ser  
850                    855                    860

Ala Gln Thr Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln  
865                    870                    880

Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu  
885                    890                    895

Glu Arg Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Asp Arg Asp  
900                    905                    910

Trp Leu Pro Gly Gln Thr Leu Phe Glu Asn Leu Trp Ala Ser Ile Tyr  
915                    920                    925

Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser  
930                    935                    940

Gly Leu Leu Arg Thr Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu  
945                    950                    960

Asp Arg Lys Asp Val Val Val Leu Val Ile Leu Arg Pro Asp Ala His  
965                    970                    975

Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val

980                    985                    990  
 Leu Phe Trp Pro Gln Gln Pro Asn Gly Gln Gly Gly Phe Trp Ala Gln  
 995                    1000                    1005

Leu Ser Thr Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln  
 1010                    1015                    1020

Asn Phe Cys Arg Gly Pro Thr Ala Glu  
 1025                    1030

<210> 75  
<211> 1032  
<212> PRT  
<213> murine

<400> 75

Met Val Leu Arg Arg Arg Thr Leu His Pro Leu Ser Leu Leu Val Gln  
 1                    5                    10                    15

Ala Ala Val Leu Ala Glu Thr Leu Ala Leu Gly Thr Leu Pro Ala Phe  
 20                    25                    30

Leu Pro Cys Glu Leu Lys Pro His Gly Leu Val Asp Cys Asn Trp Leu  
 35                    40                    45

Phe Leu Lys Ser Val Pro Arg Phe Ser Ala Ala Ala Ser Cys Ser Asn  
 50                    55                    60

Ile Thr Arg Leu Ser Leu Ile Ser Asn Arg Ile His His Leu His Asn  
 65                    70                    75                    80

Ser Asp Phe Val His Leu Ser Asn Leu Arg Gln Leu Asn Leu Lys Trp  
 85                    90                    95

Asn Cys Pro Pro Thr Gly Leu Ser Pro Leu His Phe Ser Cys His Met  
 100                    105                    110

Thr Ile Glu Pro Arg Thr Phe Leu Ala Met Arg Thr Leu Glu Glu Leu  
 115                    120                    125

Asn Leu Ser Tyr Asn Gly Ile Thr Thr Val Pro Arg Leu Pro Ser Ser  
 130                    135                    140

Leu Val Asn Leu Ser Leu Ser His Thr Asn Ile Leu Val Leu Asp Ala  
 145                    150                    155                    160

Asn Ser Leu Ala Gly Leu Tyr Ser Leu Arg Val Leu Phe Met Asp Gly  
 165                    170                    175

Asn Cys Tyr Tyr Lys Asn Pro Cys Thr Gly Ala Val Lys Val Thr Pro  
 180                    185                    190

Gly Ala Leu Leu Gly Leu Ser Asn Leu Thr His Leu Ser Leu Lys Tyr  
 195                    200                    205

Asn Asn Leu Thr Lys Val Pro Arg Gln Leu Pro Pro Ser Leu Glu Tyr  
 210                    215                    220

Leu Leu Val Ser Tyr Asn Leu Ile Val Lys Leu Gly Pro Glu Asp Leu  
 225                    230                    235                    240

Ala Asn Leu Thr Ser Leu Arg Val Leu Asp Val Gly Gly Asn Cys Arg  
245 250 255

Arg Cys Asp His Ala Pro Asn Pro Cys Ile Glu Cys Gly Gln Lys Ser  
260 265 270

Leu His Leu His Pro Glu Thr Phe His His Leu Ser His Leu Glu Gly  
275 280 285

Leu Val Leu Lys Asp Ser Ser Leu His Thr Leu Asn Ser Ser Trp Phe  
290 295 300

Gln Gly Leu Val Asn Leu Ser Val Leu Asp Leu Ser Glu Asn Phe Leu  
305 310 315 320

Tyr Glu Ser Ile Asn His Thr Asn Ala Phe Gln Asn Leu Thr Arg Leu  
325 330 335

Arg Lys Leu Asn Leu Ser Phe Asn Tyr Arg Lys Lys Val Ser Phe Ala  
340 345 350

Arg Leu His Leu Ala Ser Ser Phe Lys Asn Leu Val Ser Leu Gln Glu  
355 360 365

Leu Asn Met Asn Gly Ile Phe Phe Arg Ser Leu Asn Lys Tyr Thr Leu  
370 375 380

Arg Trp Leu Ala Asp Leu Pro Lys Leu His Thr Leu His Leu Gln Met  
385 390 395 400

Asn Phe Ile Asn Gln Ala Gln Leu Ser Ile Phe Gly Thr Phe Arg Ala  
405 410 415

Leu Arg Phe Val Asp Leu Ser Asp Asn Arg Ile Ser Gly Pro Ser Thr  
420 425 430

Leu Ser Glu Ala Thr Pro Glu Glu Ala Asp Asp Ala Glu Gln Glu Glu  
435 440 445

Leu Leu Ser Ala Asp Pro His Pro Ala Pro Leu Ser Thr Pro Ala Ser  
450 455 460

Lys Asn Phe Met Asp Arg Cys Lys Asn Phe Lys Phe Thr Met Asp Leu  
465 470 475 480

Ser Arg Asn Asn Leu Val Thr Ile Lys Pro Glu Met Phe Val Asn Leu  
485 490 495

Ser Arg Leu Gln Cys Leu Ser Leu Ser His Asn Ser Ile Ala Gln Ala  
500 505 510

Val Asn Gly Ser Gln Phe Leu Pro Leu Thr Asn Leu Gln Val Leu Asp  
515 520 525

Leu Ser His Asn Lys Leu Asp Leu Tyr His Trp Lys Ser Phe Ser Glu  
530 535 540

Leu Pro Gln Leu Gln Ala Leu Asp Leu Ser Tyr Asn Ser Gln Pro Phe  
545 550 555 560

Ser Met Lys Gly Ile Gly His Asn Phe Ser Phe Val Thr His Leu Ser

	565	570	575
Met Leu Gln Ser	Leu Ser Leu Ala His Asn Asp Ile His Thr Arg Val		
580	585	590	
Ser Ser His Leu Asn Ser Asn Ser Val Arg Phe Leu Asp Phe Ser Gly			
595	600	605	
Asn Gly Met Gly Arg Met Trp Asp Glu Gly Gly Leu Tyr Leu His Phe			
610	615	620	
Phe Gln Gly Leu Ser Gly Leu Leu Lys Leu Asp Leu Ser Gln Asn Asn			
625	630	635	640
Leu His Ile Leu Arg Pro Gln Asn Leu Asp Asn Leu Pro Lys Ser Leu			
645	650	655	
Lys Leu Leu Ser Leu Arg Asp Asn Tyr Leu Ser Phe Phe Asn Trp Thr			
660	665	670	
Ser Leu Ser Phe Leu Pro Asn Leu Glu Val Leu Asp Leu Ala Gly Asn			
675	680	685	
Gln Leu Lys Ala Leu Thr Asn Gly Thr Leu Pro Asn Gly Thr Leu Leu			
690	695	700	
Gln Lys Leu Asp Val Ser Ser Asn Ser Ile Val Ser Val Val Pro Ala			
705	710	715	720
Phe Phe Ala Leu Ala Val Glu Leu Lys Glu Val Asn Leu Ser His Asn			
725	730	735	
Ile Leu Lys Thr Val Asp Arg Ser Trp Phe Gly Pro Ile Val Met Asn			
740	745	750	
Leu Thr Val Leu Asp Val Arg Ser Asn Pro Leu His Cys Ala Cys Gly			
755	760	765	
Ala Ala Phe Val Asp Leu Leu Leu Glu Val Gln Thr Lys Val Pro Gly			
770	775	780	
Leu Ala Asn Gly Val Lys Cys Gly Ser Pro Gly Gln Leu Gln Gly Arg			
785	790	795	800
Ser Ile Phe Ala Gln Asp Leu Arg Leu Cys Leu Asp Glu Val Leu Ser			
805	810	815	
Trp Asp Cys Phe Gly Leu Ser Leu Leu Ala Val Ala Val Gly Met Val			
820	825	830	
Val Pro Ile Leu His His Leu Cys Gly Trp Asp Val Trp Tyr Cys Phe			
835	840	845	
His Leu Cys Leu Ala Trp Leu Pro Leu Leu Ala Arg Ser Arg Arg Ser			
850	855	860	
Ala Gln Thr Leu Pro Tyr Asp Ala Phe Val Val Phe Asp Lys Ala Gln			
865	870	875	880
Ser Ala Val Ala Asp Trp Val Tyr Asn Glu Leu Arg Val Arg Leu Glu			
885	890	895	
Glu Arg Arg Gly Arg Arg Ala Leu Arg Leu Cys Leu Glu Asp Arg Asp			

900	905	910
Trp Leu Pro Gly Gln Thr Leu Phe Glu Asn Leu Trp Ala Ser Ile Tyr		
915	920	925
Gly Ser Arg Lys Thr Leu Phe Val Leu Ala His Thr Asp Arg Val Ser		
930	935	940
Gly Leu Leu Arg Thr Ser Phe Leu Leu Ala Gln Gln Arg Leu Leu Glu		
945	950	955
Asp Arg Lys Asp Val Val Leu Val Ile Leu Arg Pro Asp Ala His		
965	970	975
Arg Ser Arg Tyr Val Arg Leu Arg Gln Arg Leu Cys Arg Gln Ser Val		
980	985	990
Leu Phe Trp Pro Gln Gln Pro Asn Gly Gln Gly Gly Phe Trp Ala Gln		
995	1000	1005
Leu Ser Thr Ala Leu Thr Arg Asp Asn Arg His Phe Tyr Asn Gln		
1010	1015	1020
Asn Phe Cys Arg Gly Pro Thr Ala Glu		
1025	1030	

<210> 76  
 <211> 3002  
 <212> DNA  
 <213> Homo sapiens

<400> 76		
gtggcttgggt attcaactggc aggtttcaga catttagatc tttcttttaa tgactaacac	60	
catgcctatc tgtggagaag ctggcaacat gtcacacctg gaaattgttt ttcaacatta	120	
atactattat ttggcagtaa tccagattgc tttgccacc aacctgaaga catatagagg	180	
cagaaggaca ggaataattc tatttgttgc ctgtttgaa acttccatct gtaaggctat	240	
caaaaggaga tgtgagagag ggtattgagt ctggcctgac aatgcagttc ttaaacaaaa	300	
ggtccattat gcttctcctc tctgagaatc ctgacttacc tcaacaacgg agacatggca	360	
cagtagccag cttggagact tctcagccaa tgctctgaga tcaagtcgaa gaccaatat	420	
acagggtttt gagctcatct tcattcattca tatgaggaaa taagtggtaa aatccttgaa	480	
aatacaatga gactcatcag aaacatttac atattttgtta gtattgttat gacagcagag	540	
ggtgatgctc cagagctgcc agaagaaaagg gaactgatga ccaactgctc caacatgtct	600	
ctaagaaaagg ttcccgcaga cttgacccca gccacaacga cactggattt atccataac	660	
ctcccttttc aactccagag ttcagatttt cattctgtct ccaaactgag agttttgatt	720	
ctatgccata acagaattca acagctggat ctc当地acct ttgaattcaa caaggagtt	780	
agatatttag atttgtctaa taacagactg aagagtgtaa cttggatattt actggcaggt	840	
ctcaggtatt tagatcttcc tttaatgac tttgacacca tgcctatctg tgaggaagct	900	

ggcaacatgt cacacctgga aatccatgtt ttgagtgggg caaaaataca aaaatcgat	960
ttccagaaaa ttgcctatct gcatctaaat actgtcttct taggattcag aactcttcct	1020
cattatgaag aaggtagcct gcccatctta aacacaacaa aactgcacat tgttttacca	1080
atggacacaa atttctgggt tctttgcgt gatggaatca agacttcaa aatattagaa	1140
atgacaaata tagatggcaa aagccaattt gtaagttatg aaatgcaacg aaatcttagt	1200
ttagaaaatg ctaagacatc ggttcttattt cttataaaag ttgatttact ctgggacgac	1260
cttttcctta tcttacaatt tgtttggcat acatcagtgg aacacttca gatccgaaat	1320
gtgacttttg gtggtaaggc ttatcttgc cacaattcat ttgactactc aaatactgtt	1380
atgagaacta taaaattgga gcatgtacat ttcagagtgt tttacattca acaggataaa	1440
atctatttgc ttttgaccaa aatggacata gaaaacctga caatatcaaa tgcacaaatg	1500
ccacacatgc ttttccccaa ttatcctacg aaattccaat atttaaattt tgccaataat	1560
atcttaacag acgagttgtt taaaagaact atccaaactgc ctcacttcaa aactctcatt	1620
ttgaatggca ataaaactgga gacactttct ttagtaagtt gctttgctaa caacacaccc	1680
ttggaacact tggatcttag tcaaaatcta ttacaacata aaaatgtga aaattgctca	1740
tggccagaaa ctgtggtcaa tatgaatctg tcatacataa aattgtctga ttctgtcttc	1800
aggtgcttgc caaaaagtat tcaaatactt gacctaata ataaccaaata ccaaactgtt	1860
cctaaagaga ctattcatct gatggcctta cgagaactaa atattgcatt taattttcta	1920
actgatctcc ctggatgcag tcatttcagt agactttcag ttctgaacat tgaaatgaac	1980
ttcattctca gcccattctct ggattttgtt cagagctgcc aggaagttaa aactctaaat	2040
gcgggaagaa atccattccg gtgtacctgt gaattaaaaa atttcattca gcttgaacaa	2100
tattcagagg tcatgatgggt tggatggtca gattcataca cctgtgaata ccctttaaac	2160
ctaaaggaa ttaggtaaa agacgttcat ctccacgaat tatcttgc当地 cacagctctg	2220
ttgattgtca ccattgtgggt tattatgcta gttctgggggt tggctgtggc cttctgctgt	2280
ctccacttttgc atctgccttg gtatctcagg atgcttaggtc aatgcacaca aacatggcac	2340
agggttagga aaacaacccaa agaacaactc aagagaaatg tccgattcca cgcatttatt	2400
tcatacagtgc aacatgatttgc tctgtgggtg aagaatgaat tgatccccaa tctagagaag	2460
gaagatgggtt ctatcttgat ttgcctttat gaaagctact ttgaccctgg caaaagcatt	2520
agtggaaaata ttgtaagctt cattgagaaa agctataagt ccattttgtt tttgtctccc	2580
aactttgtcc agaatgagtg gtgccattat gaattttact ttgcccacca caatcttcc	2640
catggaaaattt ctgatcatat aattcttatac ttactggaaac ccattccatt ctattgcatt	2700
cccaccaggt atcataaact gaaagcttc ctggaaaaaaa aagcataactt ggaatggccc	2760
aaggataggtt gtaaatgtgg gctttctgg gcaaaccttc gagctgctat taatgttaat	2820

gtattagcca ccagagaaaat gtatgaactg cagacattca cagagttaaa tgaagagtct	2880
cgaggttcta caatctctct gatgagaaca gattgtctat aaaatcccac agtccttggg	2940
aagttgggga ccacatacac tggatc tacattgata caacctttat gatggcaatt	3000
tg	3002

<210> 77  
<211> 811  
<212> PRT  
<213> Homo sapiens

<400> 77

Met Arg Leu Ile Arg Asn Ile Tyr Ile Phe Cys Ser Ile Val Met Thr			
1	5	10	15
Ala Glu Gly Asp Ala Pro Glu Leu Pro Glu Glu Arg Glu Leu Met Thr			
20	25	30	
Asn Cys Ser Asn Met Ser Leu Arg Lys Val Pro Ala Asp Leu Thr Pro			
35	40	45	
Ala Thr Thr Thr Leu Asp Leu Ser Tyr Asn Leu Leu Phe Gln Leu Gln			
50	55	60	
Ser Ser Asp Phe His Ser Val Ser Lys Leu Arg Val Leu Ile Leu Cys			
65	70	75	80
His Asn Arg Ile Gln Gln Leu Asp Leu Lys Thr Phe Glu Phe Asn Lys			
85	90	95	
Glu Leu Arg Tyr Leu Asp Leu Ser Asn Asn Arg Leu Lys Ser Val Thr			
100	105	110	
Trp Tyr Leu Leu Ala Gly Leu Arg Tyr Leu Asp Leu Ser Phe Asn Asp			
115	120	125	
Phe Asp Thr Met Pro Ile Cys Glu Glu Ala Gly Asn Met Ser His Leu			
130	135	140	
Glu Ile Leu Gly Leu Ser Gly Ala Lys Ile Gln Lys Ser Asp Phe Gln			
145	150	155	160
Lys Ile Ala His Leu His Leu Asn Thr Val Phe Leu Gly Phe Arg Thr			
165	170	175	
Leu Pro His Tyr Glu Glu Gly Ser Leu Pro Ile Leu Asn Thr Thr Lys			
180	185	190	
Leu His Ile Val Leu Pro Met Asp Thr Asn Phe Trp Val Leu Leu Arg			
195	200	205	
Asp Gly Ile Lys Thr Ser Lys Ile Leu Glu Met Thr Asn Ile Asp Gly			
210	215	220	
Lys Ser Gln Phe Val Ser Tyr Glu Met Gln Arg Asn Leu Ser Leu Glu			
225	230	235	240

Asn Ala Lys Thr Ser Val Leu Leu Leu Asn Lys Val Asp Leu Leu Trp  
245 250 255

Asp Asp Leu Phe Leu Ile Leu Gln Phe Val Trp His Thr Ser Val Glu  
260 265 270

His Phe Gln Ile Arg Asn Val Thr Phe Gly Gly Lys Ala Tyr Leu Asp  
275 280 285

His Asn Ser Phe Asp Tyr Ser Asn Thr Val Met Arg Thr Ile Lys Leu  
290 295 300

Glu His Val His Phe Arg Val Phe Tyr Ile Gln Gln Asp Lys Ile Tyr  
305 310 315 320

Leu Leu Leu Thr Lys Met Asp Ile Glu Asn Leu Thr Ile Ser Asn Ala  
325 330 335

Gln Met Pro His Met Leu Phe Pro Asn Tyr Pro Thr Lys Phe Gln Tyr  
340 345 350

Leu Asn Phe Ala Asn Asn Ile Leu Thr Asp Glu Leu Phe Lys Arg Thr  
355 360 365

Ile Gln Leu Pro His Leu Lys Thr Leu Ile Leu Asn Gly Asn Lys Leu  
370 375 380

Glu Thr Leu Ser Leu Val Ser Cys Phe Ala Asn Asn Thr Pro Leu Glu  
385 390 395 400

His Leu Asp Leu Ser Gln Asn Leu Leu Gln His Lys Asn Asp Glu Asn  
405 410 415

Cys Ser Trp Pro Glu Thr Val Val Asn Met Asn Leu Ser Tyr Asn Lys  
420 425 430

Leu Ser Asp Ser Val Phe Arg Cys Leu Pro Lys Ser Ile Gln Ile Leu  
435 440 445

Asp Leu Asn Asn Asn Gln Ile Gln Thr Val Pro Lys Glu Thr Ile His  
450 455 460

Leu Met Ala Leu Arg Glu Leu Asn Ile Ala Phe Asn Phe Leu Thr Asp  
465 470 475 480

Leu Pro Gly Cys Ser His Phe Ser Arg Leu Ser Val Leu Asn Ile Glu  
485 490 495

Met Asn Phe Ile Leu Ser Pro Ser Leu Asp Phe Val Gln Ser Cys Gln  
500 505 510

Glu Val Lys Thr Leu Asn Ala Gly Arg Asn Pro Phe Arg Cys Thr Cys  
515 520 525

Glu Leu Lys Asn Phe Ile Gln Leu Glu Thr Tyr Ser Glu Val Met Met  
530 535 540

Val Gly Trp Ser Asp Ser Tyr Thr Cys Glu Tyr Pro Leu Asn Leu Arg  
545 550 555 560

Gly Ile Arg Leu Lys Asp Val His Leu His Glu Leu Ser Cys Asn Thr

565	570	575
Ala Leu Leu Ile Val Thr Ile Val Val Ile Met Leu Val Leu Gly Leu		
580	585	590
Ala Val Ala Phe Cys Cys Leu His Phe Asp Leu Pro Trp Tyr Leu Arg		
595	600	605
Met Leu Gly Gln Cys Thr Gln Thr Trp His Arg Val Arg Lys Thr Thr		
610	615	620
Gln Glu Gln Leu Lys Arg Asn Val Arg Phe His Ala Phe Ile Ser Tyr		
625	630	635
Ser Glu His Asp Ser Leu Trp Val Lys Asn Glu Leu Ile Pro Asn Leu		
645	650	655
Glu Lys Glu Asp Gly Ser Ile Leu Ile Cys Leu Tyr Glu Ser Tyr Phe		
660	665	670
Asp Pro Gly Lys Ser Ile Ser Glu Asn Ile Val Ser Phe Ile Glu Lys		
675	680	685
Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro Asn Phe Val Gln Asn Glu		
690	695	700
Trp Cys His Tyr Glu Phe Tyr Phe Ala His His Asn Leu Phe His Glu		
705	710	720
Asn Ser Asp His Ile Ile Leu Ile Leu Glu Pro Ile Pro Phe Tyr		
725	730	735
Cys Ile Pro Thr Arg Tyr His Lys Leu Lys Ala Leu Leu Glu Lys Lys		
740	745	750
Ala Tyr Leu Glu Trp Pro Lys Asp Arg Arg Lys Cys Gly Leu Phe Trp		
755	760	765
Ala Asn Leu Arg Ala Ala Ile Asn Val Asn Val Leu Ala Thr Arg Glu		
770	775	780
Met Tyr Glu Leu Gln Thr Phe Thr Glu Leu Asn Glu Glu Ser Arg Gly		
785	790	800
Ser Thr Ile Ser Leu Met Arg Thr Asp Cys Leu		
805	810	

<210> 78  
<211> 2760  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<222> (2529)..(2529)  
<223> n is a, c, g, or t

<400> 78  
aagaatttgg actcatatca agatgctctg aagaagaaca accctttagg atagccactg 60  
caacatcatg accaaagaca aagaacctat tgtaaaagc ttccattttg tttgccttat 120

gatcataata gttggAACCA gaatccAGTT ctccgACGGA aatgaATTG cagtagACAA	180
gtcaaaaAGA ggtcttATTc atgttccAAA agacctACCG ctgaaaACCA aagtctTAGA	240
 tatgtctcag aactacatcg ctgagcttca ggtctctgac atgagcttc tatcagAGTT	300
gacagTTTtg agactttccc ataacagaAT ccagctactt gatttaAGTG ttttcaAGTT	360
caaccaggat ttAgaaTATT tggatttATC tcataatcAG ttgcaAAAGA tatcctGCCA	420
tcctattGTG agtttcAGGC atttagatCT ctcattCAAT gatttcaAGG ccctGCCAT	480
ctgtAAggAA ttggcaACT tatcacaACT gaatttcttG ggattgAGTG ctatGAAGCT	540
gcaaaaATTA gatttGCTGc caattGCTcA cttGcatcta agttataTCC ttctGGATT	600
aagaaaATTAT tatataAAAG aaaatgAGAC agaaaAGTcTA caaattCTGA atgcaAAAC	660
ccttcacCTT gttttcACC caactAGTTT attcgCTATC caagtGAACA tatcAGTTA	720
tactttAGGG tgcttacaAC tgactaATA taaattGAAT gatgacaACT gtcaAGTTT	780
cattaaATTt ttatcAGAAc tcaccAGGG tccAAcCTTA ctgaaTTTA ccctcaACCA	840
catagAAACG acttggAAAT gcctggTCAG agtcttCAA tttcttGGC ccaaACCTGT	900
ggaatatCTC aatatttACa atttaACAt aattgAAAGC attcgtGAAG aagattttAC	960
ttattctAAA acgacATTGA aagcATTGAC aatAGAACAT atcAcGAACc aagttttCT	1020
gttttcACAG acagcttGt acaccGtGTT ttctGAGATG aacatttATGA tGTTAACCAT	1080
ttcagatacA cttttatac acatGCTGTG tcctcatGcA ccaAGCACAT tcaAGTTT	1140
gaactttacc cagaACGTT tcacAGATAG tattttGAA aaatGTTCCA cgtagttaA	1200
attggagaca cttatcttAC AAAAGAATGG attaaaAGAC ctTTCAAAAG taggtctcat	1260
gacgaaggat atgcTTCTT tggAAataCT ggatGTTAGC tggAAattCTT tggAAatCTGG	1320
tagacataAA gaaaACTGcA cttgggttGA gagtataGtG gtgttaAAtt tGtcttCAA	1380
tatgcttACT gactctGTT tcagatGTT acctcccAGG atcaaggTAC ttGatCTCA	1440
cagcaataAA ataaAGAGCG ttccTAAACA agtcgtAAAA ctggAAAGCTT tgcaAGAACT	1500
caatgttgCT ttcaattCTT taactGACCT tcctggatGT ggcagCTTtA gcagcTTtC	1560
tgtattgATC attgatcACA attcAGTTc ccacCCATCG gctgatttCT tccAGAGCTG	1620
ccagaAGATG aggtcaATAA aagcAGGGGA caatCCATTC caatgtACCT gtgAGCTAAG	1680
agaatttGTC AAAAATATAG accaAGTATC aagtGAAGTG ttagAGGGCT ggcctGATTc	1740
ttataAGTGT gactACCCAG aaagttaTAG aggaAGCCCAtA ctaaaggACT ttcACATGTC	1800
tgaattatCC tgcaACATAA ctctGCTGAT cgtcAccATC ggtGCCACCA tgctGGTGTt	1860
ggctGtGACT gtgacCTCCC tctGcatCTA cttggatCTG ccctGGTATC tcaggatGgt	1920
gtgccAGTGG acccAGACTC ggcgcAGGGC cagGAACATA cccttagAAAG aactccAAAG	1980
aaacCTCCAG tttcatGCTT ttatTCATA tagtGAACAT gattctGCCT gggtgAAAAG	2040

tgaattggta ccttacctag	aaaaagaaga tatacagatt	tgtcttcatg agaggaactt	2100
tgtccctggc aagagcattg	tggaaaatat catcaactgc	attgagaaga gttacaagtc	2160
catctttgtt ttgtctccc	actttgtcca gagtgagtgg	tgccattacg aactctat	2220
tgcccatcac aatctcttc	atgaaggatc taataactta	atcctcatct tactggaacc	2280
cattccacag aacagcattc	ccaacaagta ccacaagctg	aaggctctca tgacgcagcg	2340
gacttatttgc	cagtgccca aggagaaaag	caaacgtggg ctctttggg ctaacattag	2400
agccgc	tttt aatatgaaat taacactagt	cactgaaaac aatgatgtga	2460
aaattttagga aattcaactt	aagaaaccat tatttacttg	gatgatggg aatagtacag	2520
tcgtaa	gttgatgna ctgtctggag	gtgcctccat tatcctcatg	2580
aaaacaatgt	ttcatctggg gaactgagct	aggcggtgag gttgcctgc	2640
cagcccagtc	tcttctgggtt taatcattat	gtttcaaatt gaaacagtct	2700
aatgctcagt	tttcagctc ctctccactc	tgcttccc aatggattct	2760

<210> 79  
<211> 2753  
<212> DNA  
<213> Homo sapiens

<400> 79	agaatttggta ctcataatcaa	gatgctctga agaagaacaa	cccttttagga tagccactgc	60
	aacatcatga ccaaagacaa	agaacctatt	gttaaaagct tccattttgt ttgccttat	120
	atcataatag ttggaaccag	aatccagttc	tccgacggaa atgaatttgc	180
	tcaaaaagag gtcttattca	tgttccaaaa	gacctaccgc tgaaaaccaa	240
	atgtctcaga actacatcgc	tgagcttcag	gtctctgaca tgagcttct	300
	acagtttga gactttccca	taacagaatc	cagctacttg atttaagtgt	360
	aaccaggatt tagaatattt	ggatttatct	cataatcgt tgcaaaagat	420
	cctattgtga gtttcaggca	tttagatctc	tcattcaatg atttcaaggc	480
	tgtaa	ggttcaactt atcacaactg	aatttcttgg gattgagtgc	540
	aaaaattag atttgctgcc	aattgctcac	ttgcatctaa gttatatcct	600
	agaaattatt atataaaaga	aatgagaca	gaaagtctac aaattctgaa	660
	cttcaccc	tttttccacc	aactagtttta ttgcgtatcc	720
	acttttagggt	gcttacaact	gactaatatt	780
	ataaaatttt	tatcagaact	caccagaggt	840
	atagaaacga	cttggaaatg	cctggtcaga gtcttcaat	900

gaatatctca atatttacaa tttaacaata attgaaagca ttcgtgaaga agatttact 960  
tattctaaaa cgacattgaa agcattgaca atagaacata tcacgaacca agttttctg 1020  
ttttcacaga cagcttgta caccgtgtt tctgagatga acattatgtat gtaaccatt 1080  
tcagatacac cttttataca catgctgtgt cctcatgcac caagcacatt caagttttg 1140  
aactttaccc agaacgttt cacagatgt attttgaaa aatgttccac gtagttaaa 1200  
ttggagacac ttatcttaca aaaaaatgga ttaaaagacc ttttcaaagt aggtctcatg 1260  
acgaaggata tgcccttctt ggaaatactg gatgttagct ggaattctt ggaatctgg 1320  
agacataaaag aaaactgcac ttgggttgag agtatagtgg tgtaaattt gtctcaaatt 1380  
atgcttactg actctgtttt cagatgtta cctcccagga tcaaggtaact tgatcttac 1440  
agcaataaaa taaagagcgt tcctaaacaa gtcgtaaaac tggaaagctt gcaagaactc 1500  
aatgttgcct tcaattctt aactgacctt cctggatgtg gcagctttag cagccttct 1560  
gtattgatca ttgatcacaa tttagttcc caccatcg ctgattctt ccagagctgc 1620  
cagaagatga ggtcaataaa agcaggggac aatccattcc aatgtacctg tgagctaaga 1680  
gaatttgcataaaaataga ccaagtatca agtgaagtgt tagagggctg gcctgattct 1740  
tataagtgtg actacccaga aagttataga ggaagcccac taaaggactt tcacatgtct 1800  
gaattatcct gcaacataac tctgctgatc gtcaccatcg gtgccaccat gctgggttg 1860  
gctgtgactg tgacctccct ctgcatactac ttggatctgc cctggtatct caggatggtg 1920  
tgccagtggaa cccagactcg gcgcaggggcc aggaacatac ctttagaaga actccaaaga 1980  
aacctccagt ttcatgcttt tatttcatat agtgaacatg attctgcctg ggtgaaaagt 2040  
gaatttgcataaaaataga aaaaagat atacagattt gtcttcatga gaggaacttt 2100  
gtccctggca agagcattgt ggaaaatatc atcaactgca ttgagaagag ttacaagtcc 2160  
atctttgttt tgtctccaa ctttgtccag agtgagtggt gccattacga actctatttt 2220  
gcccatcaca atctctttca tgaaggatct aataacttaa tcctcatctt actggAACCC 2280  
attccacaga acagcattcc caacaagttac cacaagctga aggctctcat gacgcagcgg 2340  
acttatttgc agtggcccaa ggagaaaagc aaacgtggc tctttggc taacattaga 2400  
gccgcctttta atatgaaatt aacactagtc actgaaaaca atgatgtgaa atcttaaaaa 2460  
aatttaggaa attcaactta agaaaccatt atttacttgg atgatggtga atagtagt 2520  
cgtaagtaac tgtctggagg tgcctccatt atcctcatgc cttcagggaa gacttaacaa 2580  
aaacaatgtt tcattctgggg aactgagctt ggcggtgagg tttagcctgcc agtttagagac 2640  
agcccaatgtt cttctgggtt aatcattatg tttcaaattt aaacagtctc ttttggatgaa 2700  
atgctcagtt tttagctcc tctccactct gctttcccaa atggattctg ttg 2753

<210> 80  
<211> 796  
<212> PRT  
<213> Homo sapiens

<400> 80

Met Thr Lys Asp Lys Glu Pro Ile Val Lys Ser Phe His Phe Val Cys  
1 5 10 15

Leu Met Ile Ile Ile Val Gly Thr Arg Ile Gln Phe Ser Asp Gly Asn  
20 25 30

Glu Phe Ala Val Asp Lys Ser Lys Arg Gly Leu Ile His Val Pro Lys  
35 40 45

Asp Leu Pro Leu Lys Thr Lys Val Leu Asp Met Ser Gln Asn Tyr Ile  
50 55 60

Ala Glu Leu Gln Val Ser Asp Met Ser Phe Leu Ser Glu Leu Thr Val  
65 70 75 80

Leu Arg Leu Ser His Asn Arg Ile Gln Leu Leu Asp Leu Ser Val Phe  
85 90 95

Lys Phe Asn Gln Asp Leu Glu Tyr Leu Asp Leu Ser His Asn Gln Leu  
100 105 110

Gln Lys Ile Ser Cys His Pro Ile Val Ser Phe Arg His Leu Asp Leu  
115 120 125

Ser Phe Asn Asp Phe Lys Ala Leu Pro Ile Cys Lys Glu Phe Gly Asn  
130 135 140

Leu Ser Gln Leu Asn Phe Leu Gly Leu Ser Ala Met Lys Leu Gln Lys  
145 150 155 160

Leu Asp Leu Leu Pro Ile Ala His Leu His Leu Ser Tyr Ile Leu Leu  
165 170 175

Asp Leu Arg Asn Tyr Tyr Ile Lys Glu Asn Glu Thr Glu Ser Leu Gln  
180 185 190

Ile Leu Asn Ala Lys Thr Leu His Leu Val Phe His Pro Thr Ser Leu  
195 200 205

Phe Ala Ile Gln Val Asn Ile Ser Val Asn Thr Leu Gly Cys Leu Gln  
210 215 220

Leu Thr Asn Ile Lys Leu Asn Asp Asp Asn Cys Gln Val Phe Ile Lys  
225 230 235 240

Phe Leu Ser Glu Leu Thr Arg Gly Pro Thr Leu Leu Asn Phe Thr Leu  
245 250 255

Asn His Ile Glu Thr Thr Trp Lys Cys Leu Val Arg Val Phe Gln Phe  
260 265 270

Leu Trp Pro Lys Pro Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile  
275 280 285

Ile Glu Ser Ile Arg Glu Glu Asp Phe Thr Tyr Ser Lys Thr Thr Leu  
290 295 300

Lys Ala Leu Thr Ile Glu His Ile Thr Asn Gln Val Phe Leu Phe Ser  
305 310 315 320

Gln Thr Ala Leu Tyr Thr Val Phe Ser Glu Met Asn Ile Met Met Leu  
325 330 335

Thr Ile Ser Asp Thr Pro Phe Ile His Met Leu Cys Pro His Ala Pro  
340 345 350

Ser Thr Phe Lys Phe Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser  
355 360 365

Ile Phe Glu Lys Cys Ser Thr Leu Val Lys Leu Glu Thr Leu Ile Leu  
370 375 380

Gln Lys Asn Gly Leu Lys Asp Leu Phe Lys Val Gly Leu Met Thr Lys  
385 390 395 400

Asp Met Pro Ser Leu Glu Ile Leu Asp Val Ser Trp Asn Ser Leu Glu  
405 410 415

Ser Gly Arg His Lys Glu Asn Cys Thr Trp Val Glu Ser Ile Val Val  
420 425 430

Leu Asn Leu Ser Ser Asn Met Leu Thr Asp Ser Val Phe Arg Cys Leu  
435 440 445

Pro Pro Arg Ile Lys Val Leu Asp Leu His Ser Asn Lys Ile Lys Ser  
450 455 460

Val Pro Lys Gln Val Val Lys Leu Glu Ala Leu Gln Glu Leu Asn Val  
465 470 475 480

Ala Phe Asn Ser Leu Thr Asp Leu Pro Gly Cys Gly Ser Phe Ser Ser  
485 490 495

Leu Ser Val Leu Ile Ile Asp His Asn Ser Val Ser His Pro Ser Ala  
500 505 510

Asp Phe Phe Gln Ser Cys Gln Lys Met Arg Ser Ile Lys Ala Gly Asp  
515 520 525

Asn Pro Phe Gln Cys Thr Cys Glu Leu Arg Glu Phe Val Lys Asn Ile  
530 535 540

Asp Gln Val Ser Ser Glu Val Leu Glu Gly Trp Pro Asp Ser Tyr Lys  
545 550 555 560

Cys Asp Tyr Pro Glu Ser Tyr Arg Gly Ser Pro Leu Lys Asp Phe His  
565 570 575

Met Ser Glu Leu Ser Cys Asn Ile Thr Leu Leu Ile Val Thr Ile Gly  
580 585 590

Ala Thr Met Leu Val Leu Ala Val Thr Val Thr Ser Leu Cys Ile Tyr  
595 600 605

Leu Asp Leu Pro Trp Tyr Leu Arg Met Val Cys Gln Trp Thr Gln Thr

610                615                620  
Arg Arg Arg Ala Arg Asn Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu  
625                630                635                640  
  
Gln Phe His Ala Phe Ile Ser Tyr Ser Glu His Asp Ser Ala Trp Val  
645                650                655  
  
Lys Ser Glu Leu Val Pro Tyr Leu Glu Lys Glu Asp Ile Gln Ile Cys  
660                665                670  
  
Leu His Glu Arg Asn Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile  
675                680                685  
  
Ile Asn Cys Ile Glu Lys Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro  
690                695                700  
  
Asn Phe Val Gln Ser Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His  
705                710                715                720  
  
His Asn Leu Phe His Glu Gly Ser Asn Asn Leu Ile Leu Ile Leu Leu  
725                730                735  
  
Glu Pro Ile Pro Gln Asn Ser Ile Pro Asn Lys Tyr His Lys Leu Lys  
740                745                750  
  
Ala Leu Met Thr Gln Arg Thr Tyr Leu Gln Trp Pro Lys Glu Lys Ser  
755                760                765  
  
Lys Arg Gly Leu Phe Trp Ala Asn Ile Arg Ala Ala Phe Asn Met Lys  
770                775                780  
  
Leu Thr Leu Val Thr Glu Asn Asn Asp Val Lys Ser  
785                790                795  
  
  
<210> 81  
<211> 796  
<212> PRT  
<213> Homo sapiens  
  
<400> 81  
  
Met Thr Lys Asp Lys Glu Pro Ile Val Lys Ser Phe His Phe Val Cys  
1                5                10                15  
  
Leu Met Ile Ile Ile Val Gly Thr Arg Ile Gln Phe Ser Asp Gly Asn  
20                25                30  
  
Glu Phe Ala Val Asp Lys Ser Lys Arg Gly Leu Ile His Val Pro Lys  
35                40                45  
  
Asp Leu Pro Leu Lys Thr Lys Val Leu Asp Met Ser Gln Asn Tyr Ile  
50                55                60  
  
Ala Glu Leu Gln Val Ser Asp Met Ser Phe Leu Ser Glu Leu Thr Val  
65                70                75                80  
  
Leu Arg Leu Ser His Asn Arg Ile Gln Leu Leu Asp Leu Ser Val Phe  
85                90                95  
  
Lys Phe Asn Gln Asp Leu Glu Tyr Leu Asp Leu Ser His Asn Gln Leu  
100                105                110

Gln Lys Ile Ser Cys His Pro Ile Val Ser Phe Arg His Leu Asp Leu  
115 120 125

Ser Phe Asn Asp Phe Lys Ala Leu Pro Ile Cys Lys Glu Phe Gly Asn  
130 135 140

Leu Ser Gln Leu Asn Phe Leu Gly Leu Ser Ala Met Lys Leu Gln Lys  
145 150 155 160

Leu Asp Leu Leu Pro Ile Ala His Leu His Leu Ser Tyr Ile Leu Leu  
165 170 175

Asp Leu Arg Asn Tyr Tyr Ile Lys Glu Asn Glu Thr Glu Ser Leu Gln  
180 185 190

Ile Leu Asn Ala Lys Thr Leu His Leu Val Phe His Pro Thr Ser Leu  
195 200 205

Phe Ala Ile Gln Val Asn Ile Ser Val Asn Thr Leu Gly Cys Leu Gln  
210 215 220

Leu Thr Asn Ile Lys Leu Asn Asp Asp Asn Cys Gln Val Phe Ile Lys  
225 230 235 240

Phe Leu Ser Glu Leu Thr Arg Gly Ser Thr Leu Leu Asn Phe Thr Leu  
245 250 255

Asn His Ile Glu Thr Thr Trp Lys Cys Leu Val Arg Val Phe Gln Phe  
260 265 270

Leu Trp Pro Lys Pro Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile  
275 280 285

Ile Glu Ser Ile Arg Glu Glu Asp Phe Thr Tyr Ser Lys Thr Thr Leu  
290 295 300

Lys Ala Leu Thr Ile Glu His Ile Thr Asn Gln Val Phe Leu Phe Ser  
305 310 315 320

Gln Thr Ala Leu Tyr Thr Val Phe Ser Glu Met Asn Ile Met Met Leu  
325 330 335

Thr Ile Ser Asp Thr Pro Phe Ile His Met Leu Cys Pro His Ala Pro  
340 345 350

Ser Thr Phe Lys Phe Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser  
355 360 365

Ile Phe Glu Lys Cys Ser Thr Leu Val Lys Leu Glu Thr Leu Ile Leu  
370 375 380

Gln Lys Asn Gly Leu Lys Asp Leu Phe Lys Val Gly Leu Met Thr Lys  
385 390 395 400

Asp Met Pro Ser Leu Glu Ile Leu Asp Val Ser Trp Asn Ser Leu Glu  
405 410 415

Ser Gly Arg His Lys Glu Asn Cys Thr Trp Val Glu Ser Ile Val Val  
420 425 430

Leu Asn Leu Ser Ser Asn Met Leu Thr Asp Ser Val Phe Arg Cys Leu

435                    440                    445  
Pro Pro Arg Ile Lys Val Leu Asp Leu His Ser Asn Lys Ile Lys Ser  
450                    455                    460

Val Pro Lys Gln Val Val Lys Leu Glu Ala Leu Gln Glu Leu Asn Val  
465                    470                    475                    480

Ala Phe Asn Ser Leu Thr Asp Leu Pro Gly Cys Gly Ser Phe Ser Ser  
485                    490                    495

Leu Ser Val Leu Ile Ile Asp His Asn Ser Val Ser His Pro Ser Ala  
500                    505                    510

Asp Phe Phe Gln Ser Cys Gln Lys Met Arg Ser Ile Lys Ala Gly Asp  
515                    520                    525

Asn Pro Phe Gln Cys Thr Cys Glu Leu Arg Glu Phe Val Lys Asn Ile  
530                    535                    540

Asp Gln Val Ser Ser Glu Val Leu Glu Gly Trp Pro Asp Ser Tyr Lys  
545                    550                    555                    560

Cys Asp Tyr Pro Glu Ser Tyr Arg Gly Ser Pro Leu Lys Asp Phe His  
565                    570                    575

Met Ser Glu Leu Ser Cys Asn Ile Thr Leu Leu Ile Val Thr Ile Gly  
580                    585                    590

Ala Thr Met Leu Val Leu Ala Val Thr Val Thr Ser Leu Cys Ile Tyr  
595                    600                    605

Leu Asp Leu Pro Trp Tyr Leu Arg Met Val Cys Gln Trp Thr Gln Thr  
610                    615                    620

Arg Arg Arg Ala Arg Asn Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu  
625                    630                    635                    640

Gln Phe His Ala Phe Ile Ser Tyr Ser Glu His Asp Ser Ala Trp Val  
645                    650                    655

Lys Ser Glu Leu Val Pro Tyr Leu Glu Lys Glu Asp Ile Gln Ile Cys  
660                    665                    670

Leu His Glu Arg Asn Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile  
675                    680                    685

Ile Asn Cys Ile Glu Lys Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro  
690                    695                    700

Asn Phe Val Gln Ser Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His  
705                    710                    715                    720

His Asn Leu Phe His Glu Gly Ser Asn Asn Leu Ile Leu Ile Leu  
725                    730                    735

Glu Pro Ile Pro Gln Asn Ser Ile Pro Asn Lys Tyr His Lys Leu Lys  
740                    745                    750

Ala Leu Met Thr Gln Arg Thr Tyr Leu Gln Trp Pro Lys Glu Lys Ser  
755                    760                    765

Lys Arg Gly Leu Phe Trp Ala Asn Ile Arg Ala Ala Phe Asn Met Lys

770                    775                    780  
Leu Thr Leu Val Thr Glu Asn Asn Asp Val Lys Ser  
785                    790                    795

<210> 82  
<211> 796  
<212> PRT  
<213> Homo sapiens

<400> 82

Met Thr Lys Asp Lys Glu Pro Ile Val Lys Ser Phe His Phe Val Cys  
1                    5                    10                    15

Leu Met Ile Ile Ile Val Gly Thr Arg Ile Gln Phe Ser Asp Gly Asn  
20                    25                    30

Glu Phe Ala Val Asp Lys Ser Lys Arg Gly Leu Ile His Val Pro Lys  
35                    40                    45

Asp Leu Pro Leu Lys Thr Lys Val Leu Asp Met Ser Gln Asn Tyr Ile  
50                    55                    60

Ala Glu Leu Gln Val Ser Asp Met Ser Phe Leu Ser Glu Leu Thr Val  
65                    70                    75                    80

Leu Arg Leu Ser His Asn Arg Ile Gln Leu Leu Asp Leu Ser Val Phe  
85                    90                    95

Lys Phe Asn Gln Asp Leu Glu Tyr Leu Asp Leu Ser His Asn Gln Leu  
100                    105                    110

Gln Lys Ile Ser Cys His Pro Ile Val Ser Phe Arg His Leu Asp Leu  
115                    120                    125

Ser Phe Asn Asp Phe Lys Ala Leu Pro Ile Cys Lys Glu Phe Gly Asn  
130                    135                    140

Leu Ser Gln Leu Asn Phe Leu Gly Leu Ser Ala Met Lys Leu Gln Lys  
145                    150                    155                    160

Leu Asp Leu Leu Pro Ile Ala His Leu His Leu Ser Tyr Ile Leu Leu  
165                    170                    175

Asp Leu Arg Asn Tyr Tyr Ile Lys Glu Asn Glu Thr Glu Ser Leu Gln  
180                    185                    190

Ile Leu Asn Ala Lys Thr Leu His Leu Val Phe His Pro Thr Ser Leu  
195                    200                    205

Phe Ala Ile Gln Val Asn Ile Ser Val Asn Thr Leu Gly Cys Leu Gln  
210                    215                    220

Leu Thr Asn Ile Lys Leu Asn Asp Asp Asn Cys Gln Val Phe Ile Lys  
225                    230                    235                    240

Phe Leu Ser Glu Leu Thr Arg Gly Pro Thr Leu Leu Asn Phe Thr Leu  
245                    250                    255

Asn His Ile Glu Thr Thr Trp Lys Cys Leu Val Arg Val Phe Gln Phe  
260                    265                    270

Leu Trp Pro Lys Pro Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile  
275 280 285

Ile Glu Ser Ile Arg Glu Glu Asp Phe Thr Tyr Ser Lys Thr Thr Leu  
290 295 300

Lys Ala Leu Thr Ile Glu His Ile Thr Asn Gln Val Phe Leu Phe Ser  
305 310 315 320

Gln Thr Ala Leu Tyr Thr Val Phe Ser Glu Met Asn Ile Met Met Leu  
325 330 335

Thr Ile Ser Asp Thr Pro Phe Ile His Met Leu Cys Pro His Ala Pro  
340 345 350

Ser Thr Phe Lys Phe Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser  
355 360 365

Ile Phe Glu Lys Cys Ser Thr Leu Val Lys Leu Glu Thr Leu Ile Leu  
370 375 380

Gln Lys Asn Gly Leu Lys Asp Leu Phe Lys Val Gly Leu Met Thr Lys  
385 390 395 400

Asp Met Pro Ser Leu Glu Ile Leu Asp Val Ser Trp Asn Ser Leu Glu  
405 410 415

Ser Gly Arg His Lys Glu Asn Cys Thr Trp Val Glu Ser Ile Val Val  
420 425 430

Leu Asn Leu Ser Ser Asn Met Leu Thr Asp Ser Val Phe Arg Cys Leu  
435 440 445

Pro Pro Arg Ile Lys Val Leu Asp Leu His Ser Asn Lys Ile Lys Ser  
450 455 460

Val Pro Lys Gln Val Val Lys Leu Glu Ala Leu Gln Glu Leu Asn Val  
465 470 475 480

Ala Phe Asn Ser Leu Thr Asp Leu Pro Gly Cys Gly Ser Phe Ser Ser  
485 490 495

Leu Ser Val Leu Ile Ile Asp His Asn Ser Val Ser His Pro Ser Ala  
500 505 510

Asp Phe Phe Gln Ser Cys Gln Lys Met Arg Ser Ile Lys Ala Gly Asp  
515 520 525

Asn Pro Phe Gln Cys Thr Cys Glu Leu Arg Glu Phe Val Lys Asn Ile  
530 535 540

Asp Gln Val Ser Ser Glu Val Leu Glu Gly Trp Pro Asp Ser Tyr Lys  
545 550 555 560

Cys Asp Tyr Pro Glu Ser Tyr Arg Gly Ser Pro Leu Lys Asp Phe His  
565 570 575

Met Ser Glu Leu Ser Cys Asn Ile Thr Leu Leu Ile Val Thr Ile Gly  
580 585 590

Ala Thr Met Leu Val Leu Ala Val Thr Val Thr Ser Leu Cys Ile Tyr

595	600	605
Leu Asp Leu Pro Trp Tyr	Leu Arg Met Val Cys Gln Trp Thr Gln Thr	
610	615	620
Arg Arg Arg Ala Arg Asn Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu		
625	630	635
640		
Gln Phe His Ala Phe Ile Ser Tyr Ser Glu His Asp Ser Ala Trp Val		
645	650	655
Lys Ser Glu Leu Val Pro Tyr Leu Glu Lys Glu Asp Ile Gln Ile Cys		
660	665	670
Leu His Glu Arg Asn Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile		
675	680	685
Ile Asn Cys Ile Glu Lys Ser Tyr Lys Ser Ile Phe Val Leu Ser Pro		
690	695	700
Asn Phe Val Gln Ser Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His		
705	710	715
720		
His Asn Leu Phe His Glu Gly Ser Asn Asn Leu Ile Leu Ile Leu Leu		
725	730	735
Glu Pro Ile Pro Gln Asn Ser Ile Pro Asn Lys Tyr His Lys Leu Lys		
740	745	750
Ala Leu Met Thr Gln Arg Thr Tyr Leu Gln Trp Pro Lys Glu Lys Ser		
755	760	765
Lys Arg Gly Leu Phe Trp Ala Asn Ile Arg Ala Ala Phe Asn Met Lys		
770	775	780
Leu Thr Leu Val Thr Glu Asn Asn Asp Val Lys Ser		
785	790	795

<210> 83  
<211> 2604  
<212> DNA  
<213> murine

<400> 83	
aagtaaaaat gctgtgaaga atggtaaagt ccctctggga tagcctctgc aacatgagcc	60
aagacagaaa acccategtg gggagtttcc actttgttg cgcctggcc ttaatagtcg	120
gaagcatgac cccgttctct aatgaacttg agtctatggc agactattca aacaggaacc	180
ttactcatgt ccccaaagac ctgccaccaa gaacaaaagc cctgagtctg tctaaaact	240
ctatatctga gcttcggatg cctgatatac gctttctgtc agagctgaga gttctgagac	300
tctcccacaa caggatacgg agccttgatt tccatgtatt cttgttcaat caggacttag	360
aataacctgga tgtctcacac aatcggttgc aaaacatctc ttgctgccct atggcgagcc	420
tgaggcatct agacctctca ttcaatgact ttgatgtact gcctgtgtgt aaggaatttg	480
gcaaccctgac gaagctgact ttccctggat taagtgtgc caagttccga caactggatc	540

tgctccagt tgctcaacttgcatctaagct gcatctttctggacttagtg agtcatcataaaaaaggcgggaaacacagaa agtcttcaga ttcccaataccaccgttctc catttggtct	600 660
ttcatccaaa tagcttggttc tctgttcaag tgaacatgtctgtaaacgcctttaggacatt	720
tacaactgag taatattaaa ttgaatgtatg aaaactgtca aaggtaatg acattttat	780
cagaactcac cagagggtcca accttattga atgtgaccct ccagcacata gaaacaacct	840
ggaagtgctc ggttaaactt ttccaaatttcttggccccg accgggtggag tacctcaata	900
tttacaactt aacgataact gagagaatcg acagggaaaga atttacttac tcggagacag	960
cactgaagtc actgatgata gagcacgtca aaaaccaagt gttccctttt tcaaaggagg	1020
cgctataactc ggtgtttgtc gagatgaaca tcaagatgtctctatctca gacacccctt	1080
tcatccacat ggtgtgccccg ccattccaa gctcatttac atttctgaac ttacccaga	1140
atgttttac tgacagtgtt ttcaaggctt gttccacctt aaagagatttgcagacactta	1200
tcttacaaag gaatggtttgaagaactttt ttaaagttagc tctcatgact aagaatatgt	1260
cctctctgga aactttggat gttagtttga attctttgaa ctctcatgca tatgacagga	1320
catgcgcctg ggctgagagc atattgggtt gtaatttgccttcaaatatg cttacaggct	1380
ctgtcttcag atgcttaccccaagggtca aggtcccttga ctttcacaac aacaggataa	1440
tgagcatccc taaagatgtc acccacctgc aggctttgca ggaactcaat gtacatcca	1500
actccttaac tgaccttccctt ggggtggggcccttcagcag ctttcgttgc ctggcatcg	1560
accataactc agtttccat ccctctgagg atttcttcca gagctgtcag aatattagat	1620
ccctaacagc gggaaacaac ccattccaaat gcacatgtga gctgagggac ttgtcaaga	1680
acataggctg gtagcaaga gaagtgggttggaggcttgc tgactcttac aggtgtgact	1740
acccagaaag ctctaaggga actgcactga gggacttcca catgtctcca ctgtcctgt	1800
atactgttct gctgactgtc accatggggccactatgtctgtgttgcactgggg	1860
ctttcctctg tctctactttt gacctggccctt ggtatgtgag gatgtgtgtt cagtgacac	1920
agaccaggca cagggccagg cacatcccctt tagaggaact ccagagaaac ctccagttcc	1980
atgctttgtt ctcatacagt gagcatgattt ctgcctgggtt gaagaacgaa ttactaccac	2040
acctagagaa agatgacatc cgggttgcc tccatgagag gaactttgtc cctggcaaga	2100
gcatttgttga gaacatcatc aatttcatttga agaagagttt caaggccatc tttgtgtt	2160
ctccccactt catccagagt gagtgggttgccttattatgtacttcttgc catcataatc	2220
tcttccatgttga aggctctgtt aacttaatcc tcatcttgc ggaacccattt ctacagaaca	2280
acattcccag tagataccac aagctgcggg ctctcatggc acagcggact tacttggaaat	2340
ggcctacttga gaagggcaaaa cgtgggtgtt tttggggccaa ccttagagct tcatatttata	2400
tgaagtttagc cttagtcaat gaggatgttgc taaaacttgc aaacttgggtt ttctaaactt	2460

ataaaactgtc aacctggct ctcatgaaca ctgtggttt cagttcctac ctggaggtac 2520  
ttctgttgtg gtgtcttagt ttgctctgtg cttatgataa ataacatgtt tagaagttagt 2580  
ttatgaaggt gctaagttca ttaa 2604

<210> 84  
<211> 2604  
<212> DNA  
<213> murine

<400> 84  
aagtaaaaat gctgtgaaga atggtaaagt ccctctggga tagcctctgc aacatgagcc 60  
aagacagaaa acccatcgta gggagttcc actttgttg cgccctggcc ttaatagtcg 120  
gaagcatgac cccgttctct aatgaacttg agtctatggt agactattca aacaggaacc 180  
ttactcatgt ccccaaagac ctgccaccaa gaacaaaagc cctgagtctg tctcaaaact 240  
ctatatctga gcttcggatg cctgatatac gcttctgtc agagctgaga gttctgagac 300  
tctccacaa caggatacgg agccttgatt tccatgtatt cttgttcaat caggacttag 360  
aatacctgga tgtctcacac aatcggttgc aaaacatctc ttgctgcct atggcgagcc 420  
tgaggcatct agacctctca ttcaatgact ttgatgtact gctgtgtgt aaggaatttg 480  
gcaacctgac gaagctgact ttcctggat taagtgtgc caagttccga caactggatc 540  
tgctcccagt tgctcacttg catctaagct gcattctct ggacttagtg agtcatcata 600  
taaaaggcgg gaaaaacagaa agtcttcaga ttcccaatac caccgttctc cattggct 660  
ttcatccaaa tagcttggtc tctgttcaag tgaacatgtc tgtaaacgct ttaggacatt 720  
tacaactgag taatattaaa ttgaatgatg aaaactgtca aaggttaatg acattttat 780  
cagaactcac cagaggtcca accttattga atgtgaccct ccagcacata gaaacaacct 840  
ggaagtgtc gtttaaactt ttccaaattct tttggccccg accggtgag tacctaata 900  
tttacaactt aacgataact gagagaatcg acagggaaaga atttacttac tcggagacag 960  
caactgaagtc actgatgata gagcacgtca aaaaccaagt gttcctcttt tcaaaggagg 1020  
cgctataactc ggtgtttgtc gagatgaaca tcaagatgtc ctctatctca gacaccctt 1080  
tcatccacat ggtgtgccccg ccatccccaa gtcatttac atttctgaac tttacccaga 1140  
atgtttttac tgacagtgtt tttcaaggct gttccacctt aaagagattg cagacactta 1200  
tcttacaaag gaatggttt aagaactttt taaaagtagc tctcatgact aagaatatgt 1260  
cctctctgga aactttggat gttagttga attctttgaa ctctcatgca tatgacagga 1320  
catgcgcctg ggctgagagc atattgggt tgaatttgc ttcgaatatg cttacaggct 1380  
ctgtcttcag atgcttaccc cccaaggtca aggtccttga ctttcacaac aacaggataa 1440

tgagcatccc taaagatgtc acccacctgc aggcttgca ggaactcaat gtagcatcca	1500
actcctaac tgacettccct gggtgtggg ctttcagcag ctttctgtg ctggcatcg	1560
accataactc agtttccat ccctctgagg atttcttcca gagctgtcag aatattagat	1620
ccctaacaac gggaaacaac ccattccaat gcacatgtga gctgagggac tttgtcaaga	1680
acataggctg gtagcaaga gaagtggtgg agggctggcc tgactcttac aggtgtgact	1740
acccagaaag ctctaaggga actgcactga gggacttcca catgtctcca ctgtcctgtg	1800
atactgttct gctgactgtc accatcgaaa ccactatgct ggtgctggct gtcactgggg	1860
ctttcctctg tctctacttt gacctgcctt ggtatgtgag gatgctgtgt cagtggacac	1920
agaccaggca cagggccagg cacatccct tagaggaact ccagagaaac ctccagttcc	1980
atgctttgt ctcatacagt gagcatgatt ctgcctgggt gaagaacgaa ttactaccca	2040
acctagagaa agatgacatc cgggtttgcc tccatgagag gaactttgtc cctggcaaga	2100
gcatttgga gaacatcatc aatttcattt agaagagttt caaggccatc tttgtgtgt	2160
ctccccactt catccagagt gagtggtgcc attatgaact ctatggcc catcataatc	2220
tcttccatga aggctctgat aacttaatcc tcatcttgc ggaacccatt ctacagaaca	2280
acattcccg tagataccac aagctgcggg ctctcatggc acagcggact tacttggaaat	2340
ggcctactga gaagggcaaa cgtggcgtgt tttggccaa ctttagagct tcatttatta	2400
tgaagttagc cttagtcaat gaggatgatg tgaaaacttg aaacttgggt ttcttaactta	2460
ataaaactgtc aacctggct ctcatgaaca ctgtggttt cagttcctac ctggaggtac	2520
ttctgttggc gtgtcttagt ttgctctgtg cttatgataa ataacatgtt tagaagtagt	2580
ttatgaaggt gctaagttca tttaa	2604

<210> 85  
<211> 2421  
<212> DNA  
<213> murine

<400> 85 atggtaaagt ccctctggga tagcctctgc aacatgagcc aagacagaaaa acccatcg	60
gggagttcc actttgtttg cgccctggcc ttaatagtgc gaagcatgac cccgttctct	120
aatgaacttg agtctatggt agactattca aacaggaacc ttactcatgt ccccaaagac	180
ctgccaccaa gaacaaaagc cctgagtctg tctaaaaact ctatatctga gtttcggatg	240
cctgatatca gctttctgtc agagctgaga gttctgagac tttccaccaa caggatacgg	300
agccttgatt tccatgtatt cttgttcaat caggacttag aataacctgga tgttcacac	360
aatcggttgc aaaacatetc ttgctccct atggcgagcc tgaggcatct agacactctca	420
ttcaatgact ttgatgtact gcctgtgtgt aaggaatttg gcaacctgac gaagctgact	480

ttcctggat taagtgctgc aaagttccga caactggatc tgctcccagt tgctcaacttgc 540  
catctaagct gcattttct ggacttagtg agttatcata taaaaggcgg ggaaacagaa 600  
agtcttcaga ttcccaatac caccgttctc catttggctc ttcatccaaa tagttgttc 660  
tctgtcaag tgaacatgtc tgtaaacgct ttaggacatt tacaactgag taatattaaa 720  
ttgaatgtatg aaaactgtca aaggtaatg acattttat cagaactcac cagaggtcca 780  
accttattga atgtgaccct ccagcacata gaaacaacct ggaagtgcgc ggttaaactt 840  
ttccaaattct tttggccccg accgggtggag tacctcaata tttacaactt aacgataact 900  
gagagaatcg acagggaaaga atttacttac tcggagacag cactgaagtc actgatgata 960  
gagcacgtca aaaaccaagt gttcctcttt tcaaaggagg cgctataactc ggtgtttgtc 1020  
gagatgaaca tcaagatgtct ctctatctca gacaccctt tcatccacat ggtgtgcccgg 1080  
ccatccccaa gtcattttac atttctgaac tttacccaga atgttttac tgacagtgtt 1140  
tttcaaggct gttccacctt aaagagattg cagacactta tcttacaaag gaatggtttgc 1200  
aagaactttt ttaaaagtagc tctcatgact aagaatatgt cctctctggaa aactttggat 1260  
gttagtttga attctttgaa ctctcatgca tatgacagga catgcgcctg ggctgagagc 1320  
atattgggt tgaatttgc ttcgaatatg cttacaggct ctgtcttcag atgcttacct 1380  
cccaagggtca aggtccttgc ggaactcaat gtacatcca actccttaac tgaccttcct 1440  
gggtgtgggg ctttcagcag ctttctgtg ctggtcatcg accataactc agttcccat 1560  
ccctctgagg atttcttcca gagctgtcag aatatttagat ccctaacagc gggaaacaac 1620  
ccattccaat gcacatgtga gctgaggac tttgtcaaga acataggctg ggtagcaaga 1680  
gaagtggtgg agggctggcc tgactttac aggtgtgact acccagaaaag ctctaaggga 1740  
actgcactga gggacttcca catgtctcca ctgtcctgtg atactgtct gctgactgtc 1800  
accatcgggg ccactatgct ggtgctggct gtcactgggg ctttcctctg tctctacttt 1860  
gacctgccct ggtatgtgag gatgctgtgt cagtggacac agaccaggca cagggccagg 1920  
cacatccccct tagaggaact ccagagaaac ctccagttcc atgctttgt ctcatacagt 1980  
gagcatgatt ctgcctgggt gaagaacgaa ttactaccca acctagagaa agatgacatc 2040  
cgggttgcc tccatgagag gaactttgc cctggcaaga gcattgtgga gaacatcatc 2100  
aatttcattt agaagagttt caaggccatc tttgtgtgt ctccccactt catccagagt 2160  
gagtggtgcc attatgaact ctatttgc catcataatc tcttccatga aggctctgat 2220  
aacttaatcc tcattttgtt ggaaccattt ctacagaaca acattccag tagataaccac 2280  
aagctgcggg ctctcatggc acagcggact tacttggat ggcctactga gaagggcaaa 2340  
cgtggctgt tttggccaa ctttagagct tcatttatta tgaagttagc cttagtcaat 2400

gaggatgatg tgaaaacttg a

2421

<210> 86  
<211> 806  
<212> PRT  
<213> murine

&lt;400&gt; 86

Met Val Lys Ser Leu Trp Asp Ser Leu Cys Asn Met Ser Gln Asp Arg  
1 5 10 15

Lys Pro Ile Val Gly Ser Phe His Phe Val Cys Ala Leu Ala Leu Ile  
20 25 30

Val Gly Ser Met Thr Pro Phe Ser Asn Glu Leu Glu Ser Met Val Asp  
35 40 45

Tyr Ser Asn Arg Asn Leu Thr His Val Pro Lys Asp Leu Pro Pro Arg  
50 55 60

Thr Lys Ala Leu Ser Leu Ser Gln Asn Ser Ile Ser Glu Leu Arg Met  
65 70 75 80

Pro Asp Ile Ser Phe Leu Ser Glu Leu Arg Val Leu Arg Leu Ser His  
85 90 95

Asn Arg Ile Arg Ser Leu Asp Phe His Val Phe Leu Phe Asn Gln Asp  
100 105 110

Leu Glu Tyr Leu Asp Val Ser His Asn Arg Leu Gln Asn Ile Ser Cys  
115 120 125

Cys Pro Met Ala Ser Leu Arg His Leu Asp Leu Ser Phe Asn Asp Phe  
130 135 140

Asp Val Leu Pro Val Cys Lys Glu Phe Gly Asn Leu Thr Lys Leu Thr  
145 150 155 160

Phe Leu Gly Leu Ser Ala Ala Lys Phe Arg Gln Leu Asp Leu Leu Pro  
165 170 175

Val Ala His Leu His Leu Ser Cys Ile Leu Leu Asp Leu Val Ser His  
180 185 190

His Ile Lys Gly Gly Glu Thr Glu Ser Leu Gln Ile Pro Asn Thr Thr  
195 200 205

Val Leu His Leu Val Phe His Pro Asn Ser Leu Phe Ser Val Gln Val  
210 215 220

Asn Met Ser Val Asn Ala Leu Gly His Leu Gln Leu Ser Asn Ile Lys  
225 230 235 240

Leu Asn Asp Glu Asn Cys Gln Arg Leu Met Thr Phe Leu Ser Glu Leu  
245 250 255

Thr Arg Gly Pro Thr Leu Leu Asn Val Thr Leu Gln His Ile Glu Thr  
260 265 270

Thr Trp Lys Cys Ser Val Lys Leu Phe Gln Phe Phe Trp Pro Arg Pro  
275 280 285

Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile Thr Glu Arg Ile Asp  
290 295 300

Arg Glu Glu Phe Thr Tyr Ser Glu Thr Ala Leu Lys Ser Leu Met Ile  
305 310 315 320

Glu His Val Lys Asn Gln Val Phe Leu Phe Ser Lys Glu Ala Leu Tyr  
325 330 335

Ser Val Phe Ala Glu Met Asn Ile Lys Met Leu Ser Ile Ser Asp Thr  
340 345 350

Pro Phe Ile His Met Val Cys Pro Pro Ser Pro Ser Ser Phe Thr Phe  
355 360 365

Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser Val Phe Gln Gly Cys  
370 375 380

Ser Thr Leu Lys Arg Leu Gln Thr Leu Ile Leu Gln Arg Asn Gly Leu  
385 390 395 400

Lys Asn Phe Phe Lys Val Ala Leu Met Thr Lys Asn Met Ser Ser Leu  
405 410 415

Glu Thr Leu Asp Val Ser Leu Asn Ser Leu Asn Ser His Ala Tyr Asp  
420 425 430

Arg Thr Cys Ala Trp Ala Glu Ser Ile Leu Val Leu Asn Leu Ser Ser  
435 440 445

Asn Met Leu Thr Gly Ser Val Phe Arg Cys Leu Pro Pro Lys Val Lys  
450 455 460

Val Leu Asp Leu His Asn Asn Arg Ile Met Ser Ile Pro Lys Asp Val  
465 470 475 480

Thr His Leu Gln Ala Leu Gln Glu Leu Asn Val Ala Ser Asn Ser Leu  
485 490 495

Thr Asp Leu Pro Gly Cys Gly Ala Phe Ser Ser Leu Ser Val Leu Val  
500 505 510

Ile Asp His Asn Ser Val Ser His Pro Ser Glu Asp Phe Phe Gln Ser  
515 520 525

Cys Gln Asn Ile Arg Ser Leu Thr Ala Gly Asn Asn Pro Phe Gln Cys  
530 535 540

Thr Cys Glu Leu Arg Asp Phe Val Lys Asn Ile Gly Trp Val Ala Arg  
545 550 555 560

Glu Val Val Glu Gly Trp Pro Asp Ser Tyr Arg Cys Asp Tyr Pro Glu  
565 570 575

Ser Ser Lys Gly Thr Ala Leu Arg Asp Phe His Met Ser Pro Leu Ser  
580 585 590

Cys Asp Thr Val Leu Leu Thr Val Thr Ile Gly Ala Thr Met Leu Val

595                    600                    605  
 Leu Ala Val Thr Gly Ala Phe Leu Cys Leu Tyr Phe Asp Leu Pro Trp  
 610                    615                    620  
  
 Tyr Val Arg Met Leu Cys Gln Trp Thr Gln Thr Arg His Arg Ala Arg  
 625                    630                    635                    640  
  
 His Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu Gln Phe His Ala Phe  
 645                    650                    655  
  
 Val Ser Tyr Ser Glu His Asp Ser Ala Trp Val Lys Asn Glu Leu Leu  
 660                    665                    670  
  
 Pro Asn Leu Glu Lys Asp Asp Ile Arg Val Cys Leu His Glu Arg Asn  
 675                    680                    685  
  
 Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile Ile Asn Phe Ile Glu  
 690                    695                    700  
  
 Lys Ser Tyr Lys Ala Ile Phe Val Leu Ser Pro His Phe Ile Gln Ser  
 705                    710                    715                    720  
  
 Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His His Asn Leu Phe His  
 725                    730                    735  
  
 Glu Gly Ser Asp Asn Leu Ile Leu Leu Leu Glu Pro Ile Leu Gln  
 740                    745                    750  
  
 Asn Asn Ile Pro Ser Arg Tyr His Lys Leu Arg Ala Leu Met Ala Gln  
 755                    760                    765  
  
 Arg Thr Tyr Leu Glu Trp Pro Thr Glu Lys Gly Lys Arg Gly Leu Phe  
 770                    775                    780  
  
 Trp Ala Asn Leu Arg Ala Ser Phe Ile Met Lys Leu Ala Leu Val Asn  
 785                    790                    795                    800  
  
 Glu Asp Asp Val Lys Thr  
 805

<210> 87  
 <211> 806  
 <212> PRT  
 <213> murine

<400> 87

Met Val Lys Ser Leu Trp Asp Ser Leu Cys Asn Met Ser Gln Asp Arg  
 1                    5                    10                    15

Lys Pro Ile Val Gly Ser Phe His Phe Val Cys Ala Leu Ala Leu Ile  
 20                    25                    30

Val Gly Ser Met Thr Pro Phe Ser Asn Glu Leu Glu Ser Met Val Asp  
 35                    40                    45

Tyr Ser Asn Arg Asn Leu Thr His Val Pro Lys Asp Leu Pro Pro Arg  
 50                    55                    60

Thr Lys Ala Leu Ser Leu Ser Gln Asn Ser Ile Ser Glu Leu Arg Met  
 65                    70                    75                    80

Pro Asp Ile Ser Phe Leu Ser Glu Leu Arg Val Leu Arg Leu Ser His  
85 90 95

Asn Arg Ile Arg Ser Leu Asp Phe His Val Phe Leu Phe Asn Gln Asp  
100 105 110

Leu Glu Tyr Leu Asp Val Ser His Asn Arg Leu Gln Asn Ile Ser Cys  
115 120 125

Cys Pro Met Ala Ser Leu Arg His Leu Asp Leu Ser Phe Asn Asp Phe  
130 135 140

Asp Val Leu Pro Val Cys Lys Glu Phe Gly Asn Leu Thr Lys Leu Thr  
145 150 155 160

Phe Leu Gly Leu Ser Ala Ala Lys Phe Arg Gln Leu Asp Leu Leu Pro  
165 170 175

Val Ala His Leu His Leu Ser Cys Ile Leu Leu Asp Leu Val Ser Tyr  
180 185 190

His Ile Lys Gly Gly Glu Thr Glu Ser Leu Gln Ile Pro Asn Thr Thr  
195 200 205

Val Leu His Leu Val Phe His Pro Asn Ser Leu Phe Ser Val Gln Val  
210 215 220

Asn Met Ser Val Asn Ala Leu Gly His Leu Gln Leu Ser Asn Ile Lys  
225 230 235 240

Leu Asn Asp Glu Asn Cys Gln Arg Leu Met Thr Phe Leu Ser Glu Leu  
245 250 255

Thr Arg Gly Pro Thr Leu Leu Asn Val Thr Leu Gln His Ile Glu Thr  
260 265 270

Thr Trp Lys Cys Ser Val Lys Leu Phe Gln Phe Phe Trp Pro Arg Pro  
275 280 285

Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile Thr Glu Arg Ile Asp  
290 295 300

Arg Glu Glu Phe Thr Tyr Ser Glu Thr Ala Leu Lys Ser Leu Met Ile  
305 310 315 320

Glu His Val Lys Asn Gln Val Phe Leu Phe Ser Lys Glu Ala Leu Tyr  
325 330 335

Ser Val Phe Ala Glu Met Asn Ile Lys Met Leu Ser Ile Ser Asp Thr  
340 345 350

Pro Phe Ile His Met Val Cys Pro Pro Ser Pro Ser Ser Phe Thr Phe  
355 360 365

Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser Val Phe Gln Gly Cys  
370 375 380

Ser Thr Leu Lys Arg Leu Gln Thr Leu Ile Leu Gln Arg Asn Gly Leu  
385 390 395 400

Lys Asn Phe Phe Lys Val Ala Leu Met Thr Lys Asn Met Ser Ser Leu

	405	410	415												
Glu	Thr	Leu	Asp	Val	Ser	Leu	Asn	Ser	Leu	Asn	Ser	His	Ala	Tyr	Asp
				420				425					430		
Arg	Thr	Cys	Ala	Trp	Ala	Glu	Ser	Ile	Leu	Val	Leu	Asn	Leu	Ser	Ser
						435			440			445			
Asn	Met	Leu	Thr	Gly	Ser	Val	Phe	Arg	Cys	Leu	Pro	Pro	Lys	Val	Lys
						450			455			460			
Val	Leu	Asp	Leu	His	Asn	Asn	Arg	Ile	Met	Ser	Ile	Pro	Lys	Asp	Val
						465			470			475			480
Thr	His	Leu	Gln	Ala	Leu	Gln	Glu	Leu	Asn	Val	Ala	Ser	Asn	Ser	Leu
						485			490			495			
Thr	Asp	Leu	Pro	Gly	Cys	Gly	Ala	Phe	Ser	Ser	Leu	Ser	Val	Leu	Val
						500			505			510			
Ile	Asp	His	Asn	Ser	Val	Ser	His	Pro	Ser	Glu	Asp	Phe	Phe	Gln	Ser
						515			520			525			
Cys	Gln	Asn	Ile	Arg	Ser	Leu	Thr	Ala	Gly	Asn	Asn	Pro	Phe	Gln	Cys
						530			535			540			
Thr	Cys	Glu	Leu	Arg	Asp	Phe	Val	Lys	Asn	Ile	Gly	Trp	Val	Ala	Arg
						545			550			555			560
Glu	Val	Val	Glu	Gly	Trp	Pro	Asp	Ser	Tyr	Arg	Cys	Asp	Tyr	Pro	Glu
						565			570			575			
Ser	Ser	Lys	Gly	Thr	Ala	Leu	Arg	Asp	Phe	His	Met	Ser	Pro	Leu	Ser
						580			585			590			
Cys	Asp	Thr	Val	Leu	Leu	Thr	Val	Thr	Ile	Gly	Ala	Thr	Met	Leu	Val
						595			600			605			
Leu	Ala	Val	Thr	Gly	Ala	Phe	Leu	Cys	Leu	Tyr	Phe	Asp	Leu	Pro	Trp
						610			615			620			
Tyr	Val	Arg	Met	Leu	Cys	Gln	Trp	Thr	Gln	Thr	Arg	His	Arg	Ala	Arg
						625			630			635			640
His	Ile	Pro	Leu	Glu	Glu	Leu	Gln	Arg	Asn	Leu	Gln	Phe	His	Ala	Phe
						645			650			655			
Val	Ser	Tyr	Ser	Glu	His	Asp	Ser	Ala	Trp	Val	Lys	Asn	Glu	Leu	Leu
						660			665			670			
Pro	Asn	Leu	Glu	Lys	Asp	Asp	Ile	Arg	Val	Cys	Leu	His	Glu	Arg	Asn
						675			680			685			
Phe	Val	Pro	Gly	Lys	Ser	Ile	Val	Glu	Asn	Ile	Ile	Asn	Phe	Ile	Glu
						690			695			700			
Lys	Ser	Tyr	Lys	Ala	Ile	Phe	Val	Leu	Ser	Pro	His	Phe	Ile	Gln	Ser
						705			710			715			720
Glu	Trp	Cys	His	Tyr	Glu	Leu	Tyr	Phe	Ala	His	His	Asn	Leu	Phe	His
						725			730			735			
Glu	Gly	Ser	Asp	Asn	Leu	Ile	Leu	Ile	Leu	Glu	Pro	Ile	Leu	Gln	

	740	745	750
Asn Asn Ile Pro Ser Arg Tyr His Lys Leu Arg Ala Leu Met Ala Gln			
	755	760	765
Arg Thr Tyr Leu Glu Trp Pro Thr Glu Lys Gly Lys Arg Gly Leu Phe			
	770	775	780
Trp Ala Asn Leu Arg Ala Ser Phe Ile Met Lys Leu Ala Leu Val Asn			
	785	790	795
			800
Glu Asp Asp Val Lys Thr			
	805		

<210> 88  
<211> 806  
<212> PRT  
<213> murine

<400> 88

Met Val Lys Ser Leu Trp Asp Ser Leu Cys Asn Met Ser Gln Asp Arg			
1	5	10	15

Lys Pro Ile Val Gly Ser Phe His Phe Val Cys Ala Leu Ala Leu Ile			
	20	25	30

Val Gly Ser Met Thr Pro Phe Ser Asn Glu Leu Glu Ser Met Val Asp			
35	40	45	

Tyr Ser Asn Arg Asn Leu Thr His Val Pro Lys Asp Leu Pro Pro Arg			
50	55	60	

Thr Lys Ala Leu Ser Leu Ser Gln Asn Ser Ile Ser Glu Leu Arg Met			
65	70	75	80

Pro Asp Ile Ser Phe Leu Ser Glu Leu Arg Val Leu Arg Leu Ser His			
85	90	95	

Asn Arg Ile Arg Ser Leu Asp Phe His Val Phe Leu Phe Asn Gln Asp			
100	105	110	

Leu Glu Tyr Leu Asp Val Ser His Asn Arg Leu Gln Asn Ile Ser Cys			
115	120	125	

Cys Pro Met Ala Ser Leu Arg His Leu Asp Leu Ser Phe Asn Asp Phe			
130	135	140	

Asp Val Leu Pro Val Cys Lys Glu Phe Gly Asn Leu Thr Lys Leu Thr			
145	150	155	160

Phe Leu Gly Leu Ser Ala Ala Lys Phe Arg Gln Leu Asp Leu Leu Pro			
165	170	175	

Val Ala His Leu His Leu Ser Cys Ile Leu Leu Asp Leu Val Ser His			
180	185	190	

His Ile Lys Gly Gly Glu Ser Leu Gln Ile Pro Asn Thr Thr			
195	200	205	

Val Leu His Leu Val Phe His Pro Asn Ser Leu Phe Ser Val Gln Val			
210	215	220	

Asn Met Ser Val Asn Ala Leu Gly His Leu Gln Leu Ser Asn Ile Lys  
225 230 235 240

Leu Asn Asp Glu Asn Cys Gln Arg Leu Met Thr Phe Leu Ser Glu Leu  
245 250 255

Thr Arg Gly Pro Thr Leu Leu Asn Val Thr Leu Gln His Ile Glu Thr  
260 265 270

Thr Trp Lys Cys Ser Val Lys Leu Phe Gln Phe Trp Pro Arg Pro  
275 280 285

Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile Thr Glu Arg Ile Asp  
290 295 300

Arg Glu Glu Phe Thr Tyr Ser Glu Thr Ala Leu Lys Ser Leu Met Ile  
305 310 315 320

Glu His Val Lys Asn Gln Val Phe Leu Phe Ser Lys Glu Ala Leu Tyr  
325 330 335

Ser Val Phe Ala Glu Met Asn Ile Lys Met Leu Ser Ile Ser Asp Thr  
340 345 350

Pro Phe Ile His Met Val Cys Pro Pro Ser Pro Ser Ser Phe Thr Phe  
355 360 365

Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser Val Phe Gln Gly Cys  
370 375 380

Ser Thr Leu Lys Arg Leu Gln Thr Leu Ile Leu Gln Arg Asn Gly Leu  
385 390 395 400

Lys Asn Phe Phe Lys Val Ala Leu Met Thr Lys Asn Met Ser Ser Leu  
405 410 415

Glu Thr Leu Asp Val Ser Leu Asn Ser Leu Asn Ser His Ala Tyr Asp  
420 425 430

Arg Thr Cys Ala Trp Ala Glu Ser Ile Leu Val Leu Asn Leu Ser Ser  
435 440 445

Asn Met Leu Thr Gly Ser Val Phe Arg Cys Leu Pro Pro Lys Val Lys  
450 455 460

Val Leu Asp Leu His Asn Asn Arg Ile Met Ser Ile Pro Lys Asp Val  
465 470 475 480

Thr His Leu Gln Ala Leu Gln Glu Leu Asn Val Ala Ser Asn Ser Leu  
485 490 495

Thr Asp Leu Pro Gly Cys Gly Ala Phe Ser Ser Leu Ser Val Leu Val  
500 505 510

Ile Asp His Asn Ser Val Ser His Pro Ser Glu Asp Phe Phe Gln Ser  
515 520 525

Cys Gln Asn Ile Arg Ser Leu Thr Ala Gly Asn Asn Pro Phe Gln Cys  
530 535 540

Thr Cys Glu Leu Arg Asp Phe Val Lys Asn Ile Gly Trp Val Ala Arg

545	550	555	560
Glu Val Val Glu Gly Trp Pro Asp Ser Tyr Arg Cys Asp Tyr Pro Glu			
565		570	575
Ser Ser Lys Gly Thr Ala Leu Arg Asp Phe His Met Ser Pro Leu Ser			
580		585	590
Cys Asp Thr Val Leu Leu Thr Val Thr Ile Gly Ala Thr Met Leu Val			
595		600	605
Leu Ala Val Thr Gly Ala Phe Leu Cys Leu Tyr Phe Asp Leu Pro Trp			
610		615	620
Tyr Val Arg Met Leu Cys Gln Trp Thr Gln Thr Arg His Arg Ala Arg			
625		630	635
His Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu Gln Phe His Ala Phe			
645		650	655
Val Ser Tyr Ser Glu His Asp Ser Ala Trp Val Lys Asn Glu Leu Leu			
660		665	670
Pro Asn Leu Glu Lys Asp Asp Ile Arg Val Cys Leu His Glu Arg Asn			
675		680	685
Phe Val Pro Gly Lys Ser Ile Val Glu Asn Ile Ile Asn Phe Ile Glu			
690		695	700
Lys Ser Tyr Lys Ala Ile Phe Val Leu Ser Pro His Phe Ile Gln Ser			
705		710	720
Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His His Asn Leu Phe His			
725		730	735
Glu Gly Ser Asp Asn Leu Ile Leu Ile Leu Leu Glu Pro Ile Leu Gln			
740		745	750
Asn Asn Ile Pro Ser Arg Tyr His Lys Leu Arg Ala Leu Met Ala Gln			
755		760	765
Arg Thr Tyr Leu Glu Trp Pro Thr Glu Lys Gly Lys Arg Gly Leu Phe			
770		775	780
Trp Ala Asn Leu Arg Ala Ser Phe Ile Met Lys Leu Ala Leu Val Asn			
785		790	800
Glu Asp Asp Val Lys Thr			
	805		

<210> 89  
<211> 795  
<212> PRT  
<213> murine

<400> 89

Met Ser Gln Asp Arg Lys Pro Ile Val Gly Ser Phe His Phe Val Cys		
1	5	10
Ala Leu Ala Leu Ile Val Gly Ser Met Thr Pro Phe Ser Asn Glu Leu		
20		25
30		

Glu Ser Met Val Asp Tyr Ser Asn Arg Asn Leu Thr His Val Pro Lys  
35 40 45

Asp Ile Pro Pro Arg Thr Lys Ala Leu Ser Leu Ser Gln Asn Ser Ile  
50 55 60

Ser Glu Leu Arg Met Pro Asp Ile Ser Phe Leu Ser Glu Leu Arg Val  
65 70 75 80

Leu Arg Leu Ser His Asn Arg Ile Arg Ser Leu Asp Phe His Val Phe  
85 90 95

Leu Phe Asn Gln Asp Leu Glu Tyr Leu Asp Val Ser His Asn Arg Leu  
100 105 110

Gln Asn Ile Ser Cys Cys Pro Met Ala Ser Leu Arg His Leu Asp Leu  
115 120 125

Ser Phe Asn Asp Phe Asp Val Leu Pro Val Cys Lys Glu Phe Gly Asn  
130 135 140

Leu Thr Lys Leu Thr Phe Leu Gly Leu Ser Ala Ala Lys Phe Arg Gln  
145 150 155 160

Leu Asp Leu Leu Pro Val Ala His Leu His Leu Ser Cys Ile Leu  
165 170 175

Asp Leu Val Ser Tyr His Ile Lys Gly Gly Glu Thr Glu Ser Leu Gln  
180 185 190

Ile Pro Asn Thr Thr Val Leu His Leu Val Phe His Pro Asn Ser Leu  
195 200 205

Phe Ser Val Gln Val Asn Met Ser Val Asn Ala Leu Gly His Leu Gln  
210 215 220

Leu Ser Asn Ile Lys Leu Asn Asp Glu Asn Cys Gln Arg Leu Met Thr  
225 230 235 240

Phe Leu Ser Glu Leu Thr Arg Gly Pro Thr Leu Leu Asn Val Thr Leu  
245 250 255

Gln His Ile Glu Thr Thr Trp Lys Cys Ser Val Lys Leu Phe Gln Phe  
260 265 270

Phe Trp Pro Arg Pro Val Glu Tyr Leu Asn Ile Tyr Asn Leu Thr Ile  
275 280 285

Thr Glu Arg Ile Asp Arg Glu Glu Phe Thr Tyr Ser Glu Thr Ala Leu  
290 295 300

Lys Ser Leu Met Ile Glu His Val Lys Asn Gln Val Phe Leu Phe Ser  
305 310 315 320

Lys Glu Ala Leu Tyr Ser Val Phe Ala Glu Met Asn Ile Lys Met Leu  
325 330 335

Ser Ile Ser Asp Thr Pro Phe Ile His Met Val Cys Pro Pro Ser Pro  
340 345 350

Ser Ser Phe Thr Phe Leu Asn Phe Thr Gln Asn Val Phe Thr Asp Ser

355	360	365
Val Phe Gln Gly Cys Ser Thr Leu Lys Arg Leu Gln Thr Leu Ile Leu		
370	375	380
385	390	395
Gln Arg Asn Gly Leu Lys Asn Phe Phe Lys Val Ala Leu Met Thr Lys		
400		
Asn Met Ser Ser Leu Glu Thr Leu Asp Val Ser Leu Asn Ser Leu Asn		
405	410	415
420	425	430
Ser His Ala Tyr Asp Arg Thr Cys Ala Trp Ala Glu Ser Ile Leu Val		
435	440	445
450	455	460
Pro Pro Lys Val Lys Val Leu Asp Leu His Asn Asn Arg Ile Met Ser		
465	470	475
Ile Pro Lys Asp Val Thr His Leu Gln Ala Leu Gln Glu Leu Asn Val		
480		
485	490	495
Ala Ser Asn Ser Leu Thr Asp Leu Pro Gly Cys Gly Ala Phe Ser Ser		
500	505	510
515	520	525
Asp Phe Phe Gln Ser Cys Gln Asn Ile Arg Ser Leu Thr Ala Gly Asn		
530	535	540
545	550	555
Gly Trp Val Ala Arg Glu Val Val Glu Gly Trp Pro Asp Ser Tyr Arg		
560		
565	570	575
Cys Asp Tyr Pro Glu Ser Ser Lys Gly Thr Ala Leu Arg Asp Phe His		
580	585	590
595	600	605
Ala Thr Met Leu Val Leu Ala Val Thr Gly Ala Phe Leu Cys Leu Tyr		
610	615	620
625	630	635
Arg His Arg Ala Arg His Ile Pro Leu Glu Glu Leu Gln Arg Asn Leu		
640		
645	650	655
Gln Phe His Ala Phe Val Ser Tyr Ser Glu His Asp Ser Ala Trp Val		
660	665	670
Lys Asn Glu Leu Leu Pro Asn Leu Glu Lys Asp Asp Ile Arg Val Cys		
675	680	685
Ile Asn Phe Ile Glu Lys Ser Tyr Lys Ala Ile Phe Val Leu Ser Pro		

690 695 700  
His Phe Ile Gln Ser Glu Trp Cys His Tyr Glu Leu Tyr Phe Ala His  
705 710 715 720

His Asn Leu Phe His Glu Gly Ser Asp Asn Leu Ile Leu Ile Leu Leu  
725 730 735

Glu Pro Ile Leu Gln Asn Asn Ile Pro Ser Arg Tyr His Lys Leu Arg  
740 745 750

Ala Leu Met Ala Gln Arg Thr Tyr Leu Glu Trp Pro Thr Glu Lys Gly  
755 760 765

Lys Arg Gly Leu Phe Trp Ala Asn Leu Arg Ala Ser Phe Ile Met Lys  
770 775 780

Leu Ala Leu Val Asn Glu Asp Asp Val Lys Thr  
785 790 795

<210> 90

<211> 10

<212> DNA

<213> artificial sequence

<220>

<223> consensus p50 subunit

<220>

<221> misc\_feature

<222> (7)..(7)

<223> N = c or t

<400> 90

ggggatnccc

10

<210> 91

<211> 10

<212> DNA

<213> artificial sequence

<220>

<223> consensus p65 subunit

<220>

<221> misc\_feature

<222> (4)..(4)

<223> N = a or g

<220>

<221> misc\_feature

<222> (5)..(5)

<223> N = a, c, g, or t

<400> 91

gggnntttcc

10

<210> 92

<211> 22  
<212> DNA  
<213> artificial sequence

<220>

<223> consensus subunit

<400> 92  
agttgagggg actttcccag gc

22

<210> 93  
<211> 27  
<212> DNA  
<213> artificial sequence

<220>

<223> CREB binding site

<400> 93  
agagattgcc tgacgtcaga gagctag

27

<210> 94  
<211> 21  
<212> DNA  
<213> artificial sequence

<220>

<223> AP-1 binding site

<400> 94  
cgcttgatga gtcagccgga a

21

<210> 95  
<211> 15  
<212> DNA  
<213> artificial sequence

<220>

<223> AP-1 binding site

<400> 95  
cgcattgatgc agaca

15

<210> 96  
<211> 19  
<212> DNA  
<213> artificial sequence

<220>

<223> ISRE

<400> 96

19

tgcagaagtg aaactgagg  
<210> 97  
<211> 11  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

&lt;223&gt; ISRE

<400> 97  
agaacgaaac a

11

<210> 98  
<211> 15  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

&lt;223&gt; ISRE

<400> 98  
gagaagtcaa agtgg

15

<210> 99  
<211> 18  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

&lt;223&gt; ISRE

<400> 99  
taagaacatg aaactgaa

18

<210> 100  
<211> 15  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

&lt;223&gt; ISRE

<400> 100  
atgaaaactgaa aagta

15

<210> 101  
<211> 16  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

&lt;223&gt; ISRE

<400> 101  
tgaaaaccga aagcgc

16

<210> 102  
<211> 13  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

&lt;223&gt; ISRE

<400> 102  
agaaaatggaa agt

13

<210> 103  
<211> 9  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

&lt;223&gt; SRE

<400> 103  
tcaccccac

9

<210> 104  
<211> 10  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

&lt;223&gt; SRE

<400> 104  
ctcaccccac

10

<210> 105  
<211> 10  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

&lt;223&gt; SRE

<400> 105  
gccaccctac

10

<210> 106  
<211> 17  
<212> DNA  
<213> artificial sequence

<220>  
<223> NFAT

<400> 106  
tatgaaacag ttttcc

17

<210> 107  
<211> 9  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

&lt;223&gt; NFAT

<400> 107  
aggaaaactc

9

<210> 108  
<211> 10  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

&lt;223&gt; NFAT

<220>  
<221> misc\_feature  
<222> (2)..(2)  
<223> N = a or g

<220>  
<221> misc\_feature  
<222> (5)..(5)  
<223> N = a or g

<400> 108  
anganattcc

10

<210> 109  
<211> 16  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

&lt;223&gt; NFAT

<400> 109  
ccagttgagc cagaga

16

<210> 110  
<211> 30  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

<223> GAS

<400> 110

ctttcagttt catattactc taaatccatt

30

<210> 111

<211> 10

<212> DNA

<213> artificial sequence

<220>

<223> p53 consensus site

<220>

<221> misc\_feature

<222> (1)..(3)

<223> N = a or g

<220>

<221> misc\_feature

<222> (5)..(6)

<223> N = a or t

<220>

<221> misc\_feature

<222> (8)..(10)

<223> N = c or t

<400> 111

nnncnngnnn

10

<210> 112

<211> 10

<212> DNA

<213> artificial sequence

<220>

<223> p53 consensus site

<400> 112

aggcatgcct

10

<210> 113

<211> 10

<212> DNA

<213> artificial sequence

<220>

<223> p53 consensus site

<400> 113

gggcttgccc

10

<210> 114

<211> 10  
<212> DNA  
<213> artificial sequence  
  
<220>  
  
<223> p53 consensus site  
  
<400> 114  
gggcttgctt 10  
  
<210> 115  
<211> 13  
<212> DNA  
<213> artificial sequence  
  
<220>  
  
<223> p53 consensus site  
  
<400> 115  
gcctggactt gcc 13  
  
<210> 116  
<211> 20  
<212> DNA  
<213> artificial sequence  
  
<220>  
  
<223> p53 consensus site  
  
<400> 116  
ggacatgccc gggcatgtcc 20  
  
<210> 117  
<211> 23  
<212> DNA  
<213> artificial sequence  
  
<220>  
  
<223> p53 consensus site  
  
<400> 117  
gtagcattag cccagacatg tcc 23  
  
<210> 118  
<211> 36  
<212> DNA  
<213> artificial sequence  
  
<220>  
  
<223> TARE  
  
<400> 118  
gaggtatgca gacaagagtc agagttccc cttgaa 36

<210> 119  
<211> 10  
<212> DNA  
<213> artificial sequence

<220>

<223> SRF

<220>

<221> misc\_feature  
<222> (3)..(8)  
<223> N = a or t

<400> 119  
ccnnnnnnngg 10

<210> 120  
<211> 11  
<212> DNA  
<213> artificial sequence

<220>

<223> SRF

<400> 120  
ccaaataagg c 11

<210> 121  
<211> 670  
<212> DNA  
<213> Homo sapiens

<400> 121  
agaaaaattt taaaaaatta ttcatcata ttttaggag tttgaatga ttggatatgt 60  
aattatatttc atattattaa tgtgtatcta tatagatttt tattttgcattt atgtactttg 120  
atacaaaaatt tacatgaaca aattacacta aaagttattc cacaaatata cttatcaaatt 180  
taagttaaat gtcaatagct tttaaactta aatttttagtt taactttctt gtcattttt 240  
actttgaata aaaagagcaa actttgttgtt ttttatctgtt gaagtagagg tatacgtaat 300  
atacataaaat agatatgccaa aatctgtgtt attaaaattt catgaagatt tcaatttagaa 360  
aaaaataacca taaaaggctt tgagtgcagg tgaaaaatag gcaatgatga aaaaaaatga 420  
aaaactttttt aaacacatgtt agagagtgcgtt taaaagaaagc aaaaacagag atagaaaatgtt 480  
caacttaggaa atttagaaaaa tggaaatttag tatgttcaactt atttaaagacc tatgcacaga 540  
gcaaagtctt cagaaaaacctt agaggccgaa gttcaagggtt atccatctca agtagccttag 600  
caatatttgc aacatcccaa tggccctgtc cttttcttta ctgatggccg tgctggtgct 660  
cagctacaaa 670

<210> 122  
<211> 207  
<212> DNA  
<213> Homo sapiens

<400> 122  
aggttctctg aaggccttgc ttccctgcaga tgccttaaat aggaaacata ctgattcca 60  
ctttcttaat gcttctggac catttccatt tctgttttg ctttccttct taactctta 120  
catgagtttga gagccgtgtt tctcaaatga tgggcttagca cgcgtaagag ctcggtacct 180  
atcgatagag aaatgttctg gcacactg 207

<210> 123  
<211> 161  
<212> DNA  
<213> Homo sapiens

<400> 123  
aggttctctg aaggccttgc ttccctgcaga tgccttaaat aggaaacata ctgattcca 60  
ctttcttaat gcttctggac cactttccat ttctgtttt gcttccttc ttgaactctt 120  
tacatgagtt tagagccgtg tttctcaacc attttgttt t 161

<210> 124  
<211> 300  
<212> DNA  
<213> Homo sapiens

<400> 124  
ttctcaggcgttgc gtttgctttc ctttgcttgc tcccaagtct tgttttacaa tttgcttttag 60  
tcatttcactg aaactttaaa aaacattttaga aaaccttcaca gtttgtaaat ctttttcctt 120  
attatatata tcataagata ggagcttaaa taaagagttt tagaaaactac taaaatgtaa 180  
atgacatagg aaaactgaaa gggagaagtg aaagtggaa attcctctga atagagagag 240  
gaccatctca tataaatagg ccatacccac ggagaaagga cattctaact gcaaccttgc 300

<210> 125  
<211> 401  
<212> DNA  
<213> Homo sapiens

<400> 125  
gatctgtaat gaataagcag gaactttgaa gactcagtga ctcagtgagt aataaaagact 60  
cagtgacttc tgatcctgtc ctaactgcca ctccctgttgc tcccaagaaaa gcccgttcc 120  
gctctctgag gaggaccct tccctggaag gtaaaactaa ggatgtcagc agagaaattt 180  
ttccaccatt ggtgcttggt caaagaggaa actgatgagc tcactctaga tgagagagca 240  
gtgagggaga gacagagact cgaatttccg gagctatttc agttttctt tccgtttgt 300

gcaatttcac ttatgatacc ggccaatgct tgggtgctat tttggaaact ccccttaggg	360
gatccccctc aactggccct ataaaaggcc agcctgagct g	401

<210> 126  
<211> 781  
<212> DNA  
<213> Homo sapiens

<400> 126	
ggttgtctgt atgcctccct gagggtattt cactttctgc tcccatccgc ccctatgagc	60
gagtacctat gagcacagga tgtgcacata tttgagtctt attagtggta cacgcagttt	120
tatcatctcc ccaggtctgt gtctgtatga aatgtgcatg ggtgtgtgtg tgcacgcgtg	180
tgttcccact cggggaatgt ggggagaggt gcatggagcc aagatgggtg gtaaatagta	240
tgtttctgaa attaaaggac taatgtggag gaaggcgccc cagatgtact aaaccctttg	300
ccttcatctc atcctctctg acttgggaag aaccaggatt ttgttttaa gcccttggc	360
atacagttgt tccatcccgaa catgaactca gcctcccgtc tgaccgcccc ttggccttcc	420
ttcttcctcg atctgtggaa cccagggaaat ctgcctagtg ctgtctccaa gcaccttggc	480
catgatgtaa acccagagaa attagcatct ccacatccctt ccttattccccc cacccaaag	540
tcatttcctc ttagttcatt acctgggatt ttgatgtcta tgttccctcc tcgttattga	600
tacacacaca gagagagaca aacaaaaaag gaacttcttg aaattcccccc agaaggtttt	660
gagagttgtt ttcaatgttg caacaagtca gtttctagtt taagtttcca tcagaaagga	720
gtagagtata taagttccag taccagcaac agcagcagaa gaaacaacat ctgttcagg	780
g	781

<210> 127  
<211> 277  
<212> DNA  
<213> Homo sapiens

<400> 127	
gcatctccat ctcccttcattt attccccacc caaaaagtcat ttcccttttag ttcattacct	60
gggattttga tgtctatgtt ccctcctcgt tattgataca cacacagaga gagacaaaca	120
aaaaaggaac ttcttgaaat tccccccagaa gtttttgaga gttgtttca atgttgcaac	180
aagtcaagttt ctatgttaag tttccatcag aaaggagtag agtatataag ttccagtacc	240
agcaacagca gcagaagaaa caacatctgt ttcaagg	277

<210> 128  
<211> 305  
<212> DNA  
<213> Homo sapiens

<400> 128

caagacatgc caagtgctga gtcactaata aagaaaaaaag aagtaaagga agagtggttc	60
tgccttcttag cgctaggctc aatgacgacc taagctgcac ttttccccct agttgtgtct	120
tgcgatgcta aaggacgtca ttgcacaatc ttaataaggt ttccaatcag ccccacccgc	180
tctggcccca ccctcaccct ccaacaaaga tttatcaaat gtgggatttt cccatgagtc	240
tcaatattag agtctcaacc cccaataaaat ataggactgg agatgtctct gaggctcatt	300
ctgcc	305

<210> 129  
<211> 1181  
<212> DNA  
<213> Homo sapiens

<400> 129	
cctgcaagag acaccatcct gaggggaaga gggcttctga accagcttga cccaaataaga	60
aattcttggg tgccgacggg gacagcagat tcagagccta gagccgtgcc tgcgccgt	120
gtttccttct agcttcttt tgatttcaaa tcaagactta cagggagagg gagcgataaa	180
cacaaactct gcaagatgcc acaaggctt ccttgacat ccccaacaaa gaaggtgagt	240
agtaatctcc ccctttctgc cctgaaccaa gtggcttcag taagtttcag ggctccagga	300
gacctgggca tgcaggtgcc gatgaaacag tggtaagag actcagtgcc agtggcagt	360
gggagagcac tcgcagcaca ggcaaacctc tggcacaaga gcaaagtctt cactggagga	420
ttcccaaggg tcacttggga gagggcaggc agcagccaaac ctccctctaag tgggctgaag	480
caggtgaaga aatggcagaa gacgcgtgg tggcaaaaag gagtcacaca ctccacactgg	540
agacgccttg aagtaactgc acgaaatttg agggtggcca ggcagttcta caacagccgc	600
ctcacagggc gagccagaac acagcaagaa ctcagatgac tggtagtatt acttcttca	660
taatcccagg cttggggggc tgcgatggag tcagaggaaa ctcagtttcag aacatcttg	720
gtttttacaa tacaattaa ctggAACGCT aaattcttagc ctgttaatct ggtcaactgaa	780
aaaaaaaaaaa tttttttttt ttcaaaaaac atagctttag cttatTTTT ttttctcttt	840
gtaaaaacttc gtgcattgact tcagcttac tcttgtcaag acatgccaag tgctgagtca	900
ctaataaaga aaaaagaagt aaaggaagag tggttctgct tcttagcgct agcctcaatg	960
acgacctaag ctgcactttt ccccctagtt gtgtcttgcg atgctaaagg acgtcattgc	1020
acaatcttaa taaggTTTCC aatcagcccc acccgctctg gccccacccct caccctccaa	1080
caaagattta tcaaattgtgg gatTTTCCCA tgagtctcaa tatttagagtc tcaacccccc	1140
ataaaatata tag gactggagat gtctctgagg ctcattctgc c	1181

<210> 130  
<211> 778  
<212> DNA

<213> Homo sapiens  
<400> 130  
ctaccacttg tctattctgc tatatagtca gtccttacat tgctttcttc ttctgataga 60  
ccaaactctt taaggacaag tacctagtct tatctatssc tagatcccc acattactca 120  
gaaagttact ccataaatgt ttgtggaact gatttctatg tgaagacatg tgcccctca 180  
ctctgttaac tagcattaga aaaacaaaatc ttttggaaaag ttgttagtatg cccctaagag 240  
cagtaacagt tcctagaaac tctctaaaat gcttagaaaa agatttattt taaattacct 300  
ccccaaataaa atgattggct ggcttatctt caccatcatg atagcatctg taattaactg 360  
aaaaaaaaata attatgccat taaaagaaaa tcatccatga tcttgttcta acacctgcca 420  
ctctagtaact atatctgtca catggcttat gataaagtta tctagaaaata aaaaagcata 480  
caattgataa ttcaccaaat tgtggagctt cagttttta aatgtatatt aaaattaaat 540  
tattttaaag atcaaagaaa actttcgta tactccgtat ttgataagga acaaataagga 600  
agtgtgtatga ctcagggtttc ccctgaggggg atggccatc agttgcaaat cgtggattt 660  
cctctgacat aatgaaaaga tgagggtgca taagttctct agtagggtgta tgatataaaa 720  
agccaccgga gcactccata aggcacaaac tttcagagac agcagagcac acaagctt 778

<210> 131  
<211> 207  
<212> DNA  
<213> Homo sapiens  
  
<400> 131  
actccgtatt tgataaggaa caaataggaa gtgtgtatgac tcaggtttgc cctgagggga 60  
tggggccatca gttgcaaatc gtggaaatttc ctctgacata atgaaaagat gaggggtgcat 120  
aagttctcta gtaggggtgat gatataaaaa gccaccggag cactccataa ggcacaaact 180  
ttcagagaca gcagagcaca caagctt 207

<210> 132  
<211> 645  
<212> DNA  
<213> Homo sapiens  
  
<400> 132  
gggggtgatt tcactccccg gggctgtccc aggcttgtcc ctgctacccg caccctggct 60  
ttcctgaggc ctcaaggcctg ccaccaagcc cccagctcct tctcccccgc gggcccaaac 120  
acaggcctca ggactcaaca cagctttcc ctccaaacccc gttttctctc cctcaacgg 180  
ctcagcttcc tgaagccct cccagttcta gttctatctt tttcctgcat cctgtctgga 240  
agttagaagg aaacagacca cagacctggc cccaaaaga aatggaggca ataggtttg 300  
aggggcattgg ggacgggggtt cagcctccag ggtcctacac acaaattcagt cagtggccca 360

gaagaccccc ctccgaatcg gagcaggagg gatggggagt gtgaggggta tccttgatgc 420  
ttgtgtgtcc ccaacttccaaatccccgc cccgcgatg gagaagaaac cgagacagaa 480  
ggtgcagggc ccactaccgc ttccctccaga tgagctcatg ggtttctcca ccaaggaagt 540  
tttccgctgg ttgaatgatt ctttccccgc cctcctctcg ccccagggac atataaaggc 600  
agttgttggc acacccagcc agcagacgct ccctcagcaa ggaca 645

<210> 133  
<211> 457  
<212> DNA  
<213> Homo sapiens

<400> 133  
gcctgtactc agccaagggt gcagagatgt tatatatgtat tgcttttag ggaaccgggc 60  
ctccagctca caccccaagct gctcaaccac ctcctctctg aattgactgt cccttctttg 120  
gaactctagg cctgacccca ctccctggcc ctcccagccc acgattcccc tgacccgact 180  
cccttccca gaactcagtc gcctgaaccc ccagcctgtg gttctctctt aggcttcagc 240  
cttcctgcc tttgactgaa acagcagttat cttctaagcc ctgggggatt cccggggccc 300  
cagcccccac ctagaaccccg cccgcgtcct gccacgcgtc cactgcccgt tccttataa 360  
agggacctga gcgtccgggc ccaggggctc cgcacagcag gtgaggctct cctggcccat 420  
ctccttggc tgccctgtct tcgtgtttt gactacc 457

<210> 134  
<211> 973  
<212> DNA  
<213> Homo sapiens

<400> 134  
gcagcaaatc agaatggcag tttgattcat ggtgctgaga ctggagggttc ctctgtgtat 60  
ggctcagaat atgtctaagc aattgaggaa tgtctcagaa aacgtggggc tagtgtgc 120  
tatttatctg caaagccatt ttccctccct aattctgatt ggataagggc attacagttg 180  
acttagcaaa acctgctggc tgttcctggg gaagtcccat gttgcagact cgaaggtatt 240  
atttattgtt gcctccaagt tacggaattt ccctctgctc ctctttttt ggtaatagt 300  
aatttagttt cactttccaa aacatgaact gtttctgaa aaaaagaact tcattgcata 360  
tagaaaaaaaaa caaagggtgc aatccattct aactataatg cttttctca acactaaac 420  
ttttacagtt actttcagag gttatttttc aaaatatccc cagtaataga aattttcat 480  
cctttatagg taaacctaatttttggtaa cagcaagttg tgcctgatta tttagaacagt 540  
gatttacctg gacagtccctc cttgatcaaa tactataaag taataggact ggcctgctt 600  
gacagggtca aagatctgga actggcaagt tttaaataat tcaataaataatg ctttgcatt 660  
tcataacacc attagattaa gtaaatagcc tccaacataa ctattttag gaaaaacatt 720

gctcatttgg gtagatctgatt tgtggtgtgt taaaacaagt ttcacgtctt atagcagtcc 780  
ctgaatgaaa acatcataag atggtatcta gaatggtgtg agaaaaggat tcatacgat 840  
cctagggtta ttgtaaaaaaaaaa caaagggtgc ttttgagga aatgaattta aaagcggggg 900  
ggcacgcata gagacagacc ttgggaaagt agcttgagac agaaggaaaa caggttgatt 960  
tacgatgggg ttc 973

<210> 135  
<211> 333  
<212> DNA  
<213> Homo sapiens

<400> 135  
gctacacctaa gaaggctgg taccatctgg gtttgcacag tgctttcaca ttcttatcac 60  
tttcaacact actgcaaata ggaaggaca gtaacattta gaagagaaca aaacagaaac 120  
tcttggaaagc aggaaagggtg catgactcaa agagggaaat tcctgtgccca taaaaggatt 180  
gctgggttat aaaatgctct atatatgccca attatcaatt tccttcatg ttcatgtt 240  
ctactccttc caagaagagc agcaaagctg aagtttagcag cagcagcacc agcagcaaca 300  
gcaaaaaaca aacatgagtg tgaagggcat ggc 333

<210> 136  
<211> 1048  
<212> DNA  
<213> Homo sapiens

<400> 136  
ggtgaccaag aatgtgagca agcccaggca cagccactgt gggcgccctga ccaaacagca 60  
ctaaatttgt gtgggacatg atcccagagg tgtgtggctt cacccctcaa cgagtggcgt 120  
ggcatggagt tactgaatct ccaaggtcaa acaggccctc aaattcatca agaaaagggt 180  
agggacaaac atctgtacca agagaaggca ggaggagctg agcaacgtcc tgctgccatg 240  
aggaaagcag ctgccaagaa ggactgagcc cctgccccatct gcctataatg aaagctttgc 300  
aaaataaaaat aaatataaaa taaagtaata aaattaaatt aaatttaaaa ataaaataaa 360  
gcaaaaacaaa ataaaatata taaagtaaaa attgttaaaa tgcaaaaacaa tatggacata 420  
aatacagaaaa cacagggaaa cttctttagg cactcattta caggtaaaaa tatgaaattg 480  
aataaaaggta atctgggtgtc aaataatata ggccttatct attataagag tttggactga 540  
aaagcaaaaag tgagataaca aaaaaaaagct tttcagaata ttatTTTgt tagatatgtg 600  
aaggatgaag ggtgggtgaa aggaccaaaa acagaaaacac agtcttcctg aatgaatgac 660  
aatcagaatt ccgctgcccc aagttagtccg acaattaaat ggatttcttag gaaaagctac 720  
cttaagaagg ctggttacca tctgggttt cacagtgtt tcacattctt atcactttca 780

acactactgc aaataggaag ggacagtaac atttagaaga gaacaaaaca gaaactcttg 840  
 gaaggcggaa aggtgcatga ctcaaagagg gaaattcctg tgccataaaa ggattgctgg 900  
 tgtataaaat gctcttatata tgccaattat caatttcctt tcatgttcag catttctact 960  
 cttccaaga agagcagcaa agctgaagtt agcagcagca gcaccagcag caacagcaaa 1020  
 aaacaaacat gagtgtgaag ggcatggc 1048

<210> 137  
 <211> 504  
 <212> DNA  
 <213> Homo sapiens

<400> 137  
 agggggcccc gcagcagccc cttggcttcc cttctccctt gcctccctc cggggctccg 60  
 gttcagaggc actctggcg cctgctacag cttccaaact gcgccgcttc cttcttcggc 120  
 agaaaaggac tttcagatgc ggccggcgccg gggccggcga ctcaggacag cgcccccctcc 180  
 cctaacggcc gcctctccct ctccccctcg cccgccccgg ctccccccacc tctgggaagg 240  
 cgctgggggt gtggccaggg accggtataa agtccggggg agccggtccc gggcagccgc 300  
 tcagccccct gccccctcgcc gcccccccgcc tgccctggcc gggccgagga tgcggcgcag 360  
 cgccctggcg gccaggcttg ctccccccgg cacgcctgct aacttccccc gctacgtccc 420  
 cgttcggcccg ccgggcccgc ccgtctcccc gcgcctccg gtcgggtcc tccaggagcg 480  
 ccaggcgctg ccggccgtgtg ccct 504

<210> 138  
 <211> 1042  
 <212> DNA  
 <213> Homo sapiens

<400> 138  
 gatcacacaaca gctctacaaa tacacaatga ttacaaggaa tggtgcccca ctggagttgt 60  
 tcaacgcaaa acttgcacat tgcaagtggc aatctccag gcctgcctcc ctccacgagt 120  
 gggctgaat gggcctgaga ggcaaacatc caagaaggag gaagaggctc ggcggcacct 180  
 ccctccccgg gagttctgct gattccatct tggggaaagca gggtggacca gggcccaaat 240  
 ggcgcctggg gagattgcgg gggcgggaga gttgcaagg ggcaagtggc aagagcctgt 300  
 taacgtctta gggcctccag gccttctgt gcccctagct gtgcctgtac gctttacccc 360  
 acctcaggag gcttggtctc cagcggttga ggctggaagc accggggtgc ggtggaaagg 420  
 gctctgtcca ggaagaccgg atccgcagag cggggagtcc gggcttagaa gtccctttct 480  
 cggtgtggaga ctgaggccgc cttggcgaaaa cgggacgaga ctccctccgag gtcgggaaag 540  
 gggggcccccgc agcagccct tggctccct tctcccttgc ctccctccg gggctcccggt 600

tcagaggcac tctggcgcc tgctacagct tccaaactgc gccgcttcct tttcggcag 660  
aaaaggactt tcagatgcgg cggcgccggc gcggcgact caggacagcg ccccccccc 720  
taacggccgc ctctccctct cccccctcgcc cgccccggct ccccccacctc tgggaaggcg 780  
ctgggggtgt ggccagggac cggtataaag tccggggag ccggtcccgg gcagccgctc 840  
agccccctgc ccctcgccgc cggccgcctg cctggccgg gccgaggatg cggcgcagcg 900  
ccctcgccggc caggcttgct ccctccggca cgccctgctaa ctccccccgc tacgtccccg 960  
ttcgccccgcc gggccgcccc gtctccccgc gcctccggg tcgggtcctc caggagcgcc 1020  
aggcgctgcc gccgtgtgcc ct 1042

<210> 139  
<211> 24  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 139  
tcgtcgaaaa gacgttttgt cgtt 24

<210> 140  
<211> 24  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 140  
tcgtcgaaaa gtcgtttttt tcga 24

<210> 141  
<211> 24  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 141  
tcgtcgaaaa gtcgtttcgt cgtt 24

<210> 142  
<211> 24  
<212> DNA  
<213> artificial sequence

<220>  
<223> Immunostimulatory nucleic acid

<400> 142  
tcgtcgttc gtcgtttgt cgtt

24

<210> 143  
<211> 21  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

<223> Immunostimulatory nucleic acid

<400> 143  
tcgtcgaaaa tcggtcgaaa t

21

<210> 144  
<211> 22  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

<223> Immunostimulatory nucleic acid

<400> 144  
tcgtcgaaaa tcgtgcgttt tt

22

<210> 145  
<211> 22  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

<223> Immunostimulatory nucleic acid

<400> 145  
tcgtcgaaaa cggcgccgcg cg

22

<210> 146  
<211> 24  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

<223> Immunostimulatory nucleic acid

<400> 146  
tcgtcgaaaa acggcgccgt gccg

24

<210> 147  
<211> 24  
<212> DNA

<213> artificial sequence  
<220>  
<223> Immunostimulatory nucleic acid  
  
<220>  
<221> misc\_feature  
<222> (2)..(2)  
<223> N = 5-methylcytosine  
  
<220>  
<221> misc\_feature  
<222> (5)..(5)  
<223> N = 5-methylcytosine  
  
<220>  
<221> misc\_feature  
<222> (13)..(13)  
<223> N = 5-methylcytosine  
  
<220>  
<221> misc\_feature  
<222> (21)..(21)  
<223> N = 5-methylcytosine  
  
<400> 147  
tngtngtttt gtngtttgt ngtt

24

<210> 148  
<211> 27  
<212> DNA  
<213> artificial sequence  
  
<220>  
<223> Immunostimulatory nucleic acid  
  
<220>  
<221> misc\_feature  
<222> (2)..(2)  
<223> N = 5-methylcytosine  
  
<220>  
<221> misc\_feature  
<222> (5)..(5)  
<223> N = 5-methylcytosine  
  
<220>  
<221> misc\_feature  
<222> (7)..(7)  
<223> N = 5-methylcytosine  
  
<220>  
<221> misc\_feature  
<222> (11)..(11)  
<223> N = 5-methylcytosine  
  
<220>  
<221> misc\_feature  
<222> (13)..(14)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (16)..(16)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (19)..(19)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (22)..(22)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (26)..(27)  
<223> N = 5-methylcytosine

<400> 148  
tngtngntgt ntngntttnt tnttgmn

27

<210> 149  
<211> 21  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<220>  
<221> misc\_feature  
<222> (2)..(2)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (8)..(8)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (10)..(10)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (13)..(13)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (16)..(16)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (20)..(20)

<223> N = 5-methylcytosine  
<400> 149  
gmgtttgntn ttnttnttgn g

21

<210> 150  
<211> 20  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

<223> Immunostimulatory nucleic acid

<220>  
<221> misc\_feature  
<222> (2)..(4)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (8)..(8)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (12)..(12)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (15)..(16)  
<223> N = 5-methylcytosine

<220>  
<221> misc\_feature  
<222> (19)..(19)  
<223> N = 5-methylcytosine

<400> 150  
gnnnnaagntg gnatnngtna

20

<210> 151  
<211> 15  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

<223> Immunostimulatory nucleic acid

<400> 151  
tcctggcgaaat

15

<210> 152  
<211> 42  
<212> DNA  
<213> artificial sequence

&lt;220&gt;

<400> 152  
gaaactcgag ccaccatgag acagactttg ccttgtatct ac

42

<210> 153  
<211> 37  
<212> DNA  
<213> artificial sequence

<220>

<223> Oligonucleotide

<400> 153  
gaaagaattc ttaatgtaca gagttttgg atccaag

37

<210> 154  
<211> 24  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 154  
tgctgctttt gtgctttgt gctt

24

<210> 155  
<211> 20  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 155  
tccatgacgt tcctgatgct

20

<210> 156  
<211> 20  
<212> DNA  
<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 156  
tccatgagct tcctgatgct

20

<210> 157  
<211> 20  
<212> DNA  
<213> artificial sequence

WO 2004/094671

PCT/US2004/012788

<223> Immunostimulatory nucleic acid

<220>

<221> misc\_feature

<222> (8)..(8)

<223> N = 5-methylcytosine

<400> 157

tccatgangt tcctgatgct

20

<210> 158

<211> 22

<212> DNA

<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 158

tcgtcgttt cggcgccgcg cg

22

<210> 159

<211> 21

<212> DNA

<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 159

ggggacgacg tcgtgggggg g

21

<210> 160

<211> 22

<212> DNA

<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 160

tgctgctttt cggcgccgcg cg

22

<210> 161

<211> 21

<212> DNA

<213> artificial sequence

<220>

<223> Immunostimulatory nucleic acid

<400> 161

ggggagcgc tgctgggggg g

21

This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record

## BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
-  **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)

THIS PAGE BLANK (USPTO)